Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2022

Detailing the Genetic and Environmental Influences Shared
between Conventional and Electronic Cigarette Use Across
Measures of Initiation and Past 12-Month Use
James Clifford
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Epidemiology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/6950

This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars
Compass. For more information, please contact libcompass@vcu.edu.

Detailing the Genetic and Environmental Influences Shared Between
Conventional and Electronic Cigarette Use Across Measures of Initiation and Past
12-Month Use
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
James Samuel Clifford
Bachelor of Science, Psychology, Virginia Tech, 2005
Master of Science, Experimental Psychology, Radford University, 2007

Director:
Elizabeth C. Prom-Wormley, MPH PhD
Assistant Professor
Division of Epidemiology
Department of Family Medicine and Population Health

Virginia Commonwealth University
Richmond, VA
April 2022
© James Clifford, 2022

Dissertation Committee:
Elizabeth Prom-Wormley, MPH PhD (Committee Chair)
Assistant Professor
Division of Epidemiology
Department of Family Medicine and Population Health
Virginia Commonwealth University, Richmond, VA
Juan Lu, MPH MD PhD
Associate Professor
Division of Epidemiology
Department of Family Medicine and Population Health
Virginia Commonwealth University, Richmond, VA
Silviu Bacanu, PhD
Associate Professor
Department of Psychiatry
Virginia Commonwealth University, Richmond, VA
Alexis Edwards, PhD
Associate Professor
Department of Psychiatry
Virginia Commonwealth University, Richmond, VA
Alison Breland, PhD
Assistant Professor
Department of Psychology
Virginia Commonwealth University, Richmond, VA

ii

ACKNOWLEDGEMENTS
I would like to thank my exceptional Advisor, Dr Elizabeth Prom-Wormley for giving me
this opportunity. It has been rough at times, it has been excellent at times, but I can’t
say thank you enough for teaching me, tutoring me, and believing in me even when I
didn’t believe in myself. I appreciate all that you’ve done for me and know that you have
been, and are, the best role model that I could have ever imagined.
I’d also like to thank my committee members: Dr Juan Lu, Dr Alexis Edwards, Dr Alison
Breland, and Dr Silviu Bacanu for all your dedication, patience, and tutelage. Know that
every time you read something and gave me comments, I took them to heart and am
happy that you have given me your time and energy over the last five years.
I thank everyone in the Division of Epidemiology, from the faculty members who taught
classes to the staff who have assisted me in every way. Thank you!
To the students from Epidemiology and beyond, I appreciate you all. Thank you for
always making it fun to learn with you. A big thank you to Dr Courtney Blondino who
always pushed me to go a little further when I thought I was done. Mariam Sankoh who
took up that torch after Courtney graduated, you taught me so much about
perseverance and I appreciate our writing sessions.
I’d also like to thank individuals from other places: Dr Hermine Maes and Dr Roseann
Peterson for looking over work and making me uncomfortable in meetings. That made
me learn all that much harder. Dr Elizabeth Do for always being there when I needed
something, even to talk about twin models. Dr Jeffrey Aspelmeier from Radford
University, my first mentor; thank you. Drs George Kenna, Bob Swift, and Peter Monti
from Brown University, along with Dr Lorenzo Leggio now at NIH, thank you for giving
me a chance.
Dr Megan Cooke, who always has a smile and is one of the warmest colleagues I could
ever hope for. It’s been a long time coming, but I have arrived and I thank you for your
help in getting here.
My family who have been supportive of their “professional student” for many years,
thank you for sticking it out with me.
Ana Gordon, who has helped prop me up during my studies, I couldn’t have done it
without your love and support, thank you. Also to Hank, Lucille, and Pierce, thanks for
the pets and listening to me rant during the writing process.
Finally, to my dog Scully. She has seen more ups and downs than anyone else and has
never faltered in her support. You are truly my best friend, and I thank you.
There are too many people to thank to be listed, so let me close by saying that I am
sorry if I missed you, but know that I am grateful.

iii

TABLE OF CONTENTS
List of Tables and Figures
Glossary of Abbreviations
Abstracts
Chapter 1: INTRODUCTION
Chapter 2: USE OF A TWIN STUDY TO QUANTIFY THE
GENETIC AND ENVIRONMENTAL INFLUENCES SHARED
BETWEEN ELECTRONIC CIGARETTE AND CIGARETTE
INITIATION
Introduction
Methods
Results
Discussion
Chapter 3: SCOPING REIVEW OF TOBACCO USE
MEASURES IN GENETICALLY INFORMATIVE SAMPLES:
RECOMMENDATIONS FOR FUTURE TOBACCO
RESEARCH
Introduction
Methods
Results
Discussion
Chapter 4: ELECTRONIC CIGARETTE GENOME-WIDE
ASSOCIATION AND POLYGENIC SCORES AMONG SELFIDENTIFIED WHITE PARTICIPANTS: TEST OF
OVERLAPPING GENETIC INFLUENCES WITH
CONVENTIONAL CIGARETTE INITIATION
Introduction
Methods
Results
Discussion
Chapter 5: THE EFFECT OF COUPON RECEIPT ON THE
RELATIONSHIP BETWEEN INCOME AND PAST 12-MONTH
ELECTRONIC AND CONVENTIONAL CIGARETTE USE IN
ADULTS
Introduction
Methods
Results
Discussion
Chapter 6: DISCUSSION
Appendices
References
Statistical Code
Chapter 2
Chapter 4
Chapter 5
Vita

v-vi
vii
viii – xvi
17 – 32
33-59
33-40
40-46
47-55
55-59

60-124
60-63
63-68
68-116
117-124

125-155
125-133
134-143
143-151
151-155

156-176
156-158
159-162
163-168
168-176
177-190
191
192-219
220-309
220-271
272-299
300-309
310-319

iv

LIST OF TABLES AND FIGURES
Figure 1.1. Common ECIG Devices Showing the Evolution from First
Generation (Cig-A-Likes) to Fourth Generation Cartridge Devices (JUUL)
Figure 1.2. Stages of Commonly Measured Smoking Behaviors
Corresponding to the Development of Nicotine Dependence and Smoking
Abstinence
Table 1.1. Common Measures of Cigarette Use Behaviors
Table 1.2. Common Measures of Electronic Cigarette Use Behaviors
Table 1.3. Knowledge Gaps, Research Questions, and the Chapters
Addressed in the Dissertation
Figure 2.1. Univariate classical twin model used to estimate additive genetic
(A), shared environmental (C), and unique environmental (E) influences
Figure 2.3. Bivariate genetic model used to estimate genetic and
environmental contributions. a11 and a22 represent unique sources of additive
genetic variance for electronic and conventional cigarette initiation
respectively. a21 represents the overlapping additive genetic variance. ECI =
ECIG Initiation, CCI = CIG Initiation
Table 2.1. Summary Statistics of AYATS Sample
Table 2.2. Summary of Tests of Twin Model Assumptions
Figure 2.3. Bivariate Models of Sex-Specific Models, Panel A Shows Male
Pairs, Panel B Shows Female Pairs, Panel C Shows Opposite Sex Pairs
Table 2.3. Summary of Tests of Genetic Effects Within the Twin Model
Table 2.4. Bivariate Modeling Fit Statistics
Table 2.5. Standardized Genetic and Environmental Parameter Estimates for
Electronic (ECIG) and Conventional Cigarette (CIG) Initiation
Table 3.1. DAVID-Identified Gene Clusters and Biological Systems for
Smoking Initiation
Figure 3.1. Nicotine Metabolism Pathway with Enzymes Responsible for the
Pathways.
Table 3.2. DAVID-Identified Gene Clusters and Biological Systems for
Quantitative Smoking
Table 3.3. DAVID-Identified Gene Clusters and Biological Systems for
Nicotine Dependence
Table 3.4. DAVID-Identified Gene Clusters and Biological Systems
forSmoking Cessation
Figure 4.1. Nicotine Acts as an Agonist for Acetylcholine Receptors. Nicotine
binds to and stimulates the acetylcholine receptor (1), which allows sodium
(Na+) into the presynaptic neuronal cell (2), which stimulations the calcium
ion channel to open (3) releasing Ca2+, potentiating the cell to release
neurotransmitters (4) into the synapse. Figure adapted from Price &
Martinez, 2019
Figure 4.2. Flowchart of Quality Control Procedures and Number of SNPs
and Individuals Removed

19

Figure 4.3. Three-dimensional plot of the first three principle components for
SIA White participants
Figure 4.4. Scree plot showing the proportion of variance (y-axis) explained
by the SIA White Principle Components (x-axis)

141

22

23
25
30
43
44

47
50
52
53
54
55
85-87
89
97-98
105-107
111-114
128

138

142

v

Table 4.1. Descriptive Statistics for Genotyped vs Not Genotyped
Participants
Table 4.2. Descriptive Statistics of CIG Lifetime Initiators
Table 4.3. Descriptive Statistics of ECIG Lifetime Initiators
Table 4.4. Distribution of Tobacco Lifetime Initiation Among Self-Identified
White Participants with Genotypic Data
Figure 4.5 Manhattan Plot of CIG Initiation Adjusted for Covariates
Figure 4.6. Manhattan Plot of ECIG Initiation Adjusted for Covariates
Figure 4.7. Distribution of Raw (Panel A) and Transformed (Panel B)
Genome-wide Polygenic Scores
Figure 4.8. Receiver Operator Curve from the Full Model, Including Genomewide Polygenic Score
Figure 5.1. Conceptual Model of Moderation Analysis Framework
Table 5.1. Summary Statistics for PATH Wave 3
Table 5.2 Description of PATH Coupon Receivers
Table 5.3. Distribution of Tobacco Use and Coupon Receipt by Income
Category
Table 5.4. Parameter Estimates for Association between income and Past
12-Month Tobacco Use by ECIG and CIG Coupon Receipt
Table 5.5. Parameter Estimates of Past 12-Month CIG Use by ECIG Coupon
Receipt Stratified by Income Level
Figure 5.2. Proportion of CIG-Exclusive Users by Income Level and ECIG
Coupon Receipt

144
145
146
147
148
149
150
151
162
163
164
165
167
168
168

vi

GLOSSARY OF ABBREVIATIONS
A – Additive Genetic effects
ALSPAC – Avon Longitudinal Study of Parents And Children
AUC – Area Under the Curve
C – Shared Environmental effects
CI – Confidence Interval
CIG – Conventional Cigarette
DAVID - The Database for Annotation, Visualization, and Integrated
Discovery
E – Unique Environmental effects
ECIG – Electronic Cigarette
G4G – Genes for Good
GPS – Genome-Wide Polygenic Score
GSCAN – GWAS and Sequencing Consortium of Alcohol and Nicotine
GWAS – Genome Wide Association Study
GxE – Gene by Environment Interaction
HWE – Hardy-Weinberg Equilibrium
ISC - International Schizophrenia Consortium
LD – Linkage Disequilibrium
MAF – Minor Allele Frequency
MGS - Molecular Genetics of Schizophrenia
ND – Nicotine Dependence
OR – Odds Ratio
PC – Principal Component
PCA – Principal Components Analysis
PRS-CS – Polygenic Risk Score with Continuous Shrinkage
QC – Quality Control
ROC – Receiver Operating Characteristic
S4S – Spit for Science
SI – Smoking Initiation
SIA – Self Identified Ancestry
SNP – Single Nucleotide Polymorphism
TAG - Tobacco Genetics Consortium

vii

ABSTRACT
Detailing the Genetic and Environmental Influences Shared Between
Conventional and Electronic Cigarette Use Across Measures of Initiation and Past
12-Month Use
By James Samuel Clifford, MS, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University
Virginia Commonwealth University 2021
Director: Elizabeth Prom-Wormley, MPH, Ph.D.
Assistant Professor
Division of Epidemiology
Department of Family Medicine and Population Health
Introduction. Tobacco use continues to be a public health crisis with nearly 500,000
Americans suffering premature mortality directly attributable to tobacco use in 2014.
Tobacco use, particularly among those who are nicotine dependent, has been
associated with a host of negative health outcomes such as various cancers and
cardiovascular system deficits. New research and development efforts have created
new nicotine delivery systems whose health consequences are not yet fully understood
such as electronic cigarettes. It is possible there are shared genetic and environmental
factors that influence an individual’s liability to initiate cigarette or electronic cigarette
use, as both systems are designed to deliver nicotine.
Objective. The purpose of this study is to detail the shared genetic and environmental
liability toward electronic and conventional cigarette initiation, or current use, and how to
best measure these concepts to ensure consistency and reliability of results.
Methods. Four studies were used to help resolve the genetic and environmental
influences that underlie cigarette and electronic cigarette initiation. The first study
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(Adolescents and Young Adult Twin Study) to estimate the degree to which genetic and
environmental factors for ECIG and CIG initiation were shared. Chapter 4 examined
specific variants in the form of genome-wide association analysis (Genes for Good).
Chapter 4 also addressed overlap via the use of genome-wide polygenic scores to
quantify the degree of molecular overlap between these phenotypes (GWAS and
Sequencing Consortia of Alcohol and Nicotine). The third study quantified a known
environmental exposure for both CIG and ECIG use while also probing a potential
environmental moderator (Population Assessment of Tobacco and Health). Meanwhile,
the fourth study examines how genetically informative samples have measured
cigarette use and shows the heterogeneity of results as a function of measure used.
Further, this fourth study offers advice for future studies of electronic cigarettes and how
best to quantify electronic cigarette use.
Results. The first study detected significant contributions of shared genetic and
environmental factors shared between CIG and ECIG initiation. The twin study
suggested there was significant overlap between cigarette and electronic cigarette
initiation in regards to additive genetic variance. The scoping review of tobacco use
measures in genetically informative samples reported that how individual studies
measured different aspects of tobacco use lead to different genome-wide significant
results. Aggregating genetic effects by biological function lead to greater consistency of
results. Replication of GWAS results at a gene or biological function level rather than
replicating individual SNPs lead to more consistent results. The third study did not
detect any genome-wide significant association for ECIG initiation in self-identified white
participants. Genome-wide polygenic scores reported no association between

ix

conventional cigarette initiation and electronic cigarette initiation. Statistical evidence of
a weak interaction between electronic cigarette coupon receipt, income level, and
conventional cigarette use was reported.
Conclusions. These analyses showed there is genetic and environmental overlap
between CIG and ECIG initiation.
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CHAPTER 2: USE OF A TWIN STUDY TO QUANTIFY THE GENETIC AND
ENVIRONMENTAL INFLUENCES SHARED BETWEEN ELECTRONIC CIGARETTE
AND CIGARETTE INITIATION
Introduction. The use of electronic cigarettes (ECIG) continues to rise in the United
States, especially among adolescents and young adults. Therefore, it is necessary to
better understand factors associated with ECIG initiation. However, it is unclear whether
genetic and environmental factors influence the initiation of ECIGs. Further, the degree
to which genetic and environmental factors influences are shared between ECIG
initiation and conventional cigarette (CIG) initiation is unknown.
Methods. A sample of young adult twins ages 15-20 (N = 858 individuals; 421 complete
twin pairs) was used to estimate the genetic and environmental influences on the
liability of initiation unique to ECIG and CIG as well as the degree to which these factors
are shared between the two. Approximately 20% of participants ever initiated ECIG use
and 19% initiated CIG. 11% of the sample had initiated dual use of both products.
Results. The combined contributions of additive genetic and shared environmental
influences were non-significant, while unique environmental influences were significant,
for CIG (ACC = 0.19 [95% CI = 0-0.79], p = 0.57; CCC = 0.42 [95% CI = 0-0.70], p = 0.13;
ECC = 0.39 [95% CI = 0.18-0.57], p < 0.001) and ECIG (AEC = 0.25 [95% CI = 0-0.83, p
= 0.44; CEC = 0.42 [95% CI = 0-0.73], p = 0.12; EEC = 0.32 [95% CI = 0.14-0.56], p <
0.001). There was a significant phenotypic correlation between ECIG and CIG initiation
(r = 0.72, p < 0.001). This correlation was due to significant contributions due to unique
environmental factors shared between ECIG and CIG initiation (re = 0.87, p = 0.01, 95%
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CI = 0.50-0.99). However, genetic factors shared between ECIG and CIG initiation were
not statistically significant.
Conclusions. These results suggest that both genetic and environmental influences are
important for ECIG initiation among adolescents and young adults.
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CHAPTER 3: TOBACCO USE MEASURES IN GENETICALLY INFORMATIVE
SAMPLES: HETEROGENITY AND RECOMMENDATIONS FOR FUTURE STUDIES
Introduction. Many genetically-informative studies, (e.g., twin study designs and
genome-wide association studies [GWAS}), have been conducted to examine a variety
of phenotypes. Though twin studies consistently report significant additive genetic
effects for tobacco use, GWAS have been plagued with inconsistent results. This may
be due in part to the heterogeneity of measures for tobacco use. A scoping review was
evaluated how tobacco use has been measured in previously published studies using
genetically-informative samples.
Methods. Four databases (PubMed, EMBASE, PsychINFO, and CINAHL) were
searched with terms from three concepts (tobacco use, genetically-informative designs,
tobacco measurement), producing 310 articles. Of those, 87 directly used a twin design
or GWAS (or a variation of GWAS) to examine tobacco use. Articles were then
classified as one of five tobacco use classifications: initiation, quantitative measures of
smoking, nicotine metabolism, nicotine dependence, or smoking cessation. Biological
relevance of significant GWAS results was assessed and summarized using the
Database for Annotation, Visualization, and Integrated Discovery (DAVID).
Results. Variants within genes responsible for nicotinic acetylcholine receptor function
(e.g., CHRNA3, CHRNB4, CHRNA5) as well as nicotine metabolism (CYP2A6) were
consistently associated with most measures of tobacco use.
Conclusions. Although GWAS results were highly variable, gene-level reporting of results
informed by biological function produced greater consistency and improved interpretation across
studies.
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CHAPTER 4: ELECTRONIC CIGARETTE GENOME-WIDE ASSOCIATION AND
POLYGENIC SCORES AMONG SELF-IDENTIFIED WHITE PARTICIPANTS: TEST
OF OVERLAPPING GENETIC INFLUENCES WITH CONVENTIONAL CIGARETTE
INITIATION
Introduction. Three studies have used genome-wide association data to produce
polygenic scores (GPS) or CIG initiation to test its relationship with ECIG use. However,
these studies have mainly focused on young adults (age 18-25 years old).
Nevertheless, ECIG initiation occurs across adulthood, but the role of genetic factors
associated with this outcome remains inconsistent. Some of the genetic variants
associated with CIG initiation are also expected to influence ECIG initiation since both
products contain nicotine. Tests for genetic association of ECIG initiation that take
advantage of the genetic factors associated with CIG initiation may help to clarify the
etiology of nicotine dependence which begins with initiation of products containing
nicotine. In particular, specific genetic variants associated with ECIG initiation in adults
have not yet been identified. Similarly, genetic variants contributing to ECIG and CIG
initiation across adulthood have also not been identified although this information is
needed to understand the etiology of nicotine dependence.
Methods. Data from the Genes for Good (G4G) study, a population-based sample of
American adults aged 18-93 (N =15,881) were used. Two GWAS were conducted on
lifetime CIG and ECIG initiation to test for genetic associations across all loci in the
genome. Additionally, a GPS for CIG initiation was generated and used to test the
degree to which there was polygenic overlap between CIG and ECIG initiation.
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Results. No genome-wide significant associations were detected for ECIG or CIG
lifetime initiation. However, there were four SNPs for ECIG lifetime initiation which
approached genome-wide significance (locations summarized as chromosome number:
base pair number- 13:32403784, OR = 0.62, p = 7.49 x 10-7; 2:115364757, OR = 1.28, p
= 5.19 x10-7; 15:49010393, OR = 0.44, p = 8.01 x 10-7; 6:33902823, OR = 0.79, p = 1.75
x 10-7). No significant polygenic association was detected between polygenic scores
calculated for CIG lifetime initiation in GSCAN with ECIG lifetime initiation as measured
in G4G.
Conclusions. This first-ever GWAS of ECIG lifetime initiation identified two SNPs in
novel genes for tobacco use. There was no evidence for overlapping genetic factors for
CIG and ECIG lifetime initiation. Replication is strongly encouraged because these
results have low power to detect statistically significant genetic effects.
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CHAPTER 5: THE EFFECT OF COUPON RECEIPT ON THE RELATIONSHIP
BETWEEN INCOME AND PAST 12-MONTH ELECTRONIC AND CONVENTIONAL
CIGARETTE USE IN ADULTS
Introduction. Lower household income levels have been associated with electronic
cigarette (ECIG) or conventional cigarette (CIG) use. However, it is unclear whether this
relationship changes with the receipt of ECIG or CIG coupons in adults.
Methods. Data from Wave 3 of the Population Assessment of Tobacco and Health (N =
28,148) was used to test the association between tobacco use and income in adults.
Associations were tested using multinomial logistic regression.
Results. Income level was significantly associated with CIG-exclusive and dual use, but
not ECIG-exclusive use. Receipt of ECIG coupons was associated with past 12-month
ECIG use (aOR = 1.40; 95% CI = 1.05-1.88), CIG use (aOR = 5.69; 95% CI = 5.086.38), and dual use (aOR = 7.61; 95% CI = 6.75-8.58). Receipt of CIG coupons was an
independent risk factor for ECIG-exclusive (aOR = 2.32, 95% CI = 1.74-3.10) or dual
use (aOR = 2.62, 95% CI = 2.10-3.28), but protective against CIG-exclusive use (aOR =
0.74, 95% CI = 0.59-0.92). There was evidence of weak moderation between receipt of
ECIG coupons and CIG-exclusive use. Individuals with household incomes between
$50,000 and $99,999 (aOR = 2.51; 95% CI = 1.50-4.16) were more likely to be CIG
users if they received ECIG coupons relative to those who do not receive ECIG
coupons.
Conclusions. Individuals with lower levels of income may be at greater risk for dual use
of ECIG and CIG as well as CIG-exclusive use. Additionally, receipt of CIG and ECIG
coupons appears to be an independent risk factor for past 12-month use of tobacco.
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Chapter 1: General introduction
The Importance of the Problem
Nicotine consumption through electronic cigarette (ECIG) use is an ongoing public
health issue in adults that contributes to morbidity and premature mortality. In 2014,
there were 500,000 American adults ages 18 and over whose deaths were attributed to
nicotine use 1. ECIG use is also associated with mortality and morbidity 2. From 2015 to
2017, 2,035 emergency room visits were due to explosions or burns from ECIGs 3.
Further, 68 deaths have been attributed to the e-cigarette, or vaping, product use
associated lung injury (EVALI) as of 2020 4. ECIGs contain many chemicals including
propylene glycol (a respiratory irritant), volatile organic compounds (VOC, associated
with greater cancer risk) 5, and polycyclic aromatic hydrocarbons (PAH, mutagenic and
carcinogenic properties) 6. Compared to CIG users, ECIG-exclusive users showed lower
levels of the 5 major classes of tobacco product constituents (tobacco-specific
nitrosamines, metals, PAHs, VOCs, and nicotine) though still more than non-smokers 7.
Nevertheless, epidemiologic studies of ECIGs have reported that the odds of chronic
obstructive pulmonary disease (COPD) and asthma increase with ECIG use 8. ECIGs
also contain nicotine, which has been associated with many negative health outcomes
cardiovascular disease 9, psychiatric disorder 10, and substance use disorder 11.
Nicotine may also be associated with numerous types of cancers (e.g., gastrointestinal,
pancreatic, breast, and lung) 12–15. Further, nicotine is an addictive substance, which
encourages continued use of ECIGs. 7

17

What are Electronic Cigarettes and How Do They Work?
ECIGs are a nicotine delivery system that aerosolizes an e-liquid cartridge containing
nicotine and a flavor (such as mint, tobacco, or candy) using a power source and an
electronic heating element 16. An ECIG is activated by pulling air through the
mouthpiece or pressing an activation button. Upon activation, a battery engages the
electronic heating element which aerosolizes the e-liquid. Therefore, ECIGs were
previously marketed and are sometimes considered by conventional cigarette (CIG)
users as “healthier” products because additional chemicals such as tar are not
produced or are present in lower concentrations compared to CIGs 17,18.
ECIGs have undergone several alterations since they were first sold in the United
States in 2007 (Figure 1.1). First generation ECIGs were designed to have the look and
feel of a conventional cigarette, leading to the term “cig-a-like”. Most of these firstgeneration devices were designed to be used once and then discarded 19. Second
generation devices allowed users to refill the tanks for additional e-liquid, leading to
reusable ECIGs. Third generation ECIGs were designed to be the most accessible and
allow the user to have the greatest opportunity for personalization and customization.
Users can vary the voltage, wattage, and power of the device along with additional
peripheral enhancements such as being able to charge a cell phone with the device 19.
The most recent version of ECIG devices, the fourth generation, are designed to use
pods (i.e., cartridges containing e-liquid) and dock with the device (i.e., adjoining the eliquid containing pod with the mouthpiece).
ECIG devices are broken down into two general categories of devices, open and
closed systems (Figure 1.1) 20. Open system devices allow the user to reload the device
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with their choice of e-liquid, which may contain different levels of nicotine (including
having no nicotine) and flavors. Importantly, open systems allow for additional user
modifications. Batteries can also be modified creating more aerosolization per pull (i.e.,
low-ohm device) 21. These modifications make it harder to standardize the amount of
nicotine consumed in open systems. Therefore, open system ECIG use may lead to
greater nicotine consumption and an increased likelihood of nicotine dependence 22.
Closed systems cannot generally be modified by the user. Generally, these are single
use products designed to be discarded after use and not refilled with new liquids. Single
use, preloaded, “cig-a-likes” are examples of closed systems (Figure 1.1). Many firstgeneration devices are closed systems, though closed systems are not limited to firstgeneration, having gained in popularity in recent years. The most popular closed
system ECIG to date in the United States is JUUL (Figure 1.1). JUUL administers
nicotine through “pods”, small cartridges that contain standardized amounts of nicotine
and a heating coil that cannot be replaced 23. JUUL use has increased dramatically,
doubling from 2018 to 2019, and several reports of harmful use in adolescents and
young adults were reported at that time 24. Further, some reports indicate the average
JUUL user was exposed to much larger amounts of nicotine compared to CIG users 25,
leading the CDC and FDA to carefully review the product in 2019 26.

Figure 1.1. Common ECIG Devices Showing the Evolution from First Generation
(Cig-A-Likes) to Fourth Generation Cartridge Devices (JUUL).
19

The Etiology of Nicotine Dependence for Combustible Cigarette Use Motivates Study of
Initiation and Dependence due to Electronic Cigarette Use
The Diagnostic and Statistical Manual, 4th Edition (DSM-IV) defines nicotine
dependence (ND) as a maladaptive pattern of nicotine use that leads to clinically
relevant impairment or distress. There were four criteria that contributed to ND: 1)
tolerance, 2) withdrawal, 3) consuming a larger amount of nicotine than originally
planned, and 4) difficulty in quitting use 27. The DSM-5 was released in 2013 and
renamed ND as tobacco use disorder (TUD) 28. The DSM-5 definition of TUD, while
significantly overlapping with the DSM-IV definition of ND, removed the criteria of
“difficulty in quitting” while adding an item related to craving 11. As there is significant
overlap between these definitions, and most research to date has been conducted using
the DSM-IV definition, this dissertation will continue to use the term “nicotine
dependence” rather than the updated “tobacco use disorder”.
Nicotine dependence is considered an acquired disease of the brain since
nicotine can cross the blood brain barrier 29. Further, nicotine can activate several
neurobiological pathways that function across several brain structures once in the brain,
including: reward/saliency, inhibitory control and executive function, and motivation
(Volkow 2014). Nicotine activates the dopaminergic pathway which has been reported
to be associated with craving as well as activates the reward pathway associated with
dopamine leading to feelings of euphoria. Rewarding feelings created via activation of
this pathway create a feedback loop as the use of nicotine increases to create
pleasurable feelings, which leads to increased use of nicotine.
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Several additional neurotransmitters contribute to nicotine dependence. Nicotine
activates neurotransmitters that influence arousal, attention, and motivations, including
acetylcholine 30 and norepinephrine 31 which explains the motivating aspects of nicotine
use. Neurotransmitters that engage the learning and memory systems are also
influenced by nicotine. These neurotransmitters including serotonin 32, glutamate 33, and
gamma-aminobutyric acid (GABA) 34, influence ND by helping the body remember the
rewarding feelings from nicotine use.
The development of ND has generally been studied across several stages of CIG
use behaviors (Figure 1.2). All stages of smoking behaviors and the development of ND
require an individual to engage in smoking initiation before transitioning to other stages.
After initiation, individuals may transition into regular smoking wherein they smoke
consistently. Regular smoking has many definitions with some definitions being tied to
the number of cigarettes smoked in one’s lifetime, daily cigarette use, or most
commonly asking participants to self-identify as a regular or current smoker 35,36. Some
regular smokers become nicotine dependent, as defined above and indicated via
reliable and validated measures of ND, from CIG use due to consistent exposure to
nicotine. Finally, individuals may transition to smoking cessation, a process whereby a
smoker transitions into becoming a non-smoker. Successful cessation is defined as the
abstinence of further tobacco use. As cessation is a process, individuals can relapse
and return to regular smoking or nicotine dependence. Cessation is typically defined in
research studies via self-identified smoking status (i.e., current or former smoker) 37. A
time frame is sometimes attached to smoking status (e.g., “Have you smoked a
cigarette in the past 6 months?”) 38. Individuals who achieve cessation may relapse into
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CIG use after abstaining for a period of time and then begin the cessation process
again. Common measures of these nicotine phenotypes are presented in Table 1.1.
Each phenotype has multiple measures which are used to assess these conceptual
behaviors.

Figure 1.2. Stages of Commonly Measured Smoking Behaviors Corresponding to
the Development of Nicotine Dependence and Smoking Abstinence
Nicotine dependence is common in American adults. A study of the NESARC-III
(National Epidemiologic Survey on Alcohol and Related Conditions, 3rd Wave; data
collected 2012-2013) estimated that 14% of Americans were currently nicotine
dependent 39. NESARC-III did not include questions on ECIGs, but rather exposure to
nicotine via combustible (CIG or cigar use) or oral administration (e.g., snuff, dip) only.
To date, most work detailing the progression of nicotine use and dependence has been
conducted on CIG use behaviors 40–45. However, the prevalence of CIG use is at its
lowest point among American adults and is increasing for ECIGs. Between 2010 and
2013, the prevalence of adult CIG initiation decreased from 8.9% to 5.4% and ECIG
initiation rates increased from 1.8% to 13% 46. Rates of ND have been stable over the
same time frame. These trends suggest that any population-level reduction in CIG use
may reflect a shift to ECIG use.

22

Table 1.1. Common Measures of Cigarette Use Behaviors
Conceptual Measure
Operational Measures
• “Have you ever smoked cigarettes?” (Rhee, 2003)
Initiation
• “At what age did you start smoking?” (Heath, 1999)
Regular or Current
Smoking

Nicotine Dependence

Smoking Cessation &
Abstinence

• “Do you smoke cigarettes now?” (True 1997
• “During the last 30 days, how many (if any) have you
used electronic cigarettes?” (McCabe, 2017)
• “During the past 30 days, on how many days did you use
e-cigarettes?” (Selya, 2017)
•
•
•

Fagerström Test for Nicotine Dependence (FTND)
Nicotine Dependence Syndrome Scale (NDSS)
DSM-III/DSM-IV Nicotine Dependence Symptom Count
or Diagnosis

•
•
•

Current smoking status (Current vs former)
eCO (expired carbon monoxide) verified
Abstinence for a period of time (e.g., 6 months)

ECIG use is also associated ND, although there are currently few studies that
have established this conclusion in comparison with CIG use 47. The prevalence of ND
due specifically to ECIG use in adults is currently unclear in the US. However, a study of
twelfth-grade students in Los Angeles, California reported that 16.7% of ECIG-exclusive
users reported some level of ND dependence arising from ECIG use 48. Additionally, a
recent study of ND using a measure of “time to first cigarette” reported that ND in
participants who use ECIGs was less than that of CIG users (i.e., participants could wait
longer to use their ECIG than those who used CIGs). Past 30-day JUUL use was
associated with at least some level of dependence in a sample of college students 22.
The mean score for nicotine dependence, using the Penn State Electronic Cigarette
Dependence Index (PSECDI), was 7.8. Individuals who score below a 4 on the PSECDI
are not considered to be nicotine dependent. Most individuals in this study had at least
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low levels (i.e., scores greater than 4) of dependence. This study also reported that the
level of dependence was unrelated to other tobacco product use, such as CIGs.
Further, replacing CIG use with ECIG did not change the overall dependence level of
the user among dual users 49. A systematic review reported increased levels of ND in
adolescent participants who used fourth generation pod-based ECIGs. While these
studies report lower levels of ND are associated with ECIG use compared to CIG use,
other work has suggested ECIGs are as addictive, if not more so, as CIGs 50. These
results highlight the inconsistency of research results for ND as arises from ECIG use.
The most common ECIG use measurement that parallel those of CIG use and
relate to the development of ND are summarized in Table 1.2. ECIG initiation is
measured similarly to CIG initiation, by asking participants if they have ever used an
ECIG. One notable difference is in asking individuals if they own an ECIG, as users
must purchase a device to use (though this method does not capture individuals who
may have used a peer’s device). Current ECIG use is also measured similarly to CIG
use. Most often this is accomplished by asking participants to report if they had used
ECIGs in the past 30 days. However, ECIGs present novel challenges compared to CIG
measurement. CIGs are unable to be user modified so there is less variability, whereas
ECIG measurement should consider characteristics of the device as well as nicotine
concentration of e-liquid used. Utilizing standardized ECIGs (i.e., giving research
participants the same device and e-liquid) will reduce variability due to user
modifications, particularly in randomized controlled trials. Further, puffing behaviors may
be investigated with attachable mouthpieces for ECIGs which measure puff duration,
volume, puff count, flow rate, and inter-puff intervals. These measurements require
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additional hardware and software to gather data. While measurement of ND due to
ECIG use is still being investigated, several measures (e.g., PSECDI, e-FTND) have
been validated.
Table 1.2. Common Measures of Electronic Cigarette Use Behaviors
Conceptual Measure
Operational Measures
Lifetime ECIG Initiation
• “Have you ever used an electronic cigarette, even one or
two puffs?” (O’Loughlin 2017)
• “Have you ever tried one of the following substances,
devices, etc.?” followed by a list, including ECIG
(Hammond 2017)
Regular or Current ECIG
Use

• “In the last 30 days, did you use any of the following?
(Mark all that apply)” (Hammond, 2017)
• “During the last 30 days, how many (if any) have you
used electronic cigarettes?” (McCabe, 2017)
• “During the past 30 days, on how many days did you use
e-cigarettes?” (Selya, 2017)

Nicotine Dependence

•
•
•
•

Penn State Electronic Cigarette Dependency Index
(PSECDI)
Electronic Wisconsin Inventory of Smoking Dependence
Motives (eWISDM)
Electronic Fagerström Test for Nicotine Dependence
(eFTND)
E-Cigarette Dependence Scale (EDS) (Morean, 2018)

The Epidemiology of Adult ECIG Initiation Emphasizes the Need for Study with CIG
Initiation
This dissertation focuses on the study of ECIG and CIG initiation for several
reasons. First, ECIG initiation often co-occurs with CIG initiation in adults. In 2017,
20.3% of US adults (aged 18+) initiated ECIG use 51. Of those individuals, 21.6%
reported currently using ECIGs at least some days 52. Daily ECIG use has increased
between 2016 (6.8%) and 2017 (7.5%) among adults in the United States 52. Further,
the lifetime prevalence of ECIG initiation among young adults (18-24) doubled between
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2013 and 2014 from roughly 7% to nearly 14%. ECIG initiation is associated with
subsequent CIG initiation among never smokers (OR = 3.62, 95%CI = 2.42-5.41) 46,53,
and the reverse is also true: previous CIG initiation is associated with subsequent ECIG
initiation (OR = 3.54, 95% CI = 1.68-7.45) 54.
Second, there are yet undetailed dynamic patterns related to the dual use of
ECIG and CIGs. These two products are commonly used together, and users may
switch between the two products. Consequently, current studies of ECIG use
necessitate the inclusion of CIG use and vice versa. Similarly, studies that have not
modeled dual use accurately may have produced biased estimates, limiting the
knowledge of studies that have examined these phenotypes. Further, it is unclear if
ECIGs are used by individuals who would have otherwise remained tobacco-naïve.
Third, as summarized above there is substantial overlap in the associations
between ND with ECIG and CIG initiation. This is likely due to an etiology that is shared
between ECIG and CIG that begins with the initiation of these products and that may
continue into the development of ND. Consequently, it is important to first detail the
factors involved with ECIG initiation and to identify those factors that may overlap with
CIG initiation to fully understand the etiology of ND resulting from ECIG use in the
future. Understanding the genetic and environmental influences that are shared
between CIG and ECIGs will ensure a greater understanding of why they are used
together.
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Environmental and Genetic Factors Associated with CIG Use May Also Influence ECIG
Use
To date, genome-wide association studies report significant genetic associations
between multiple CIG use behaviors with loci in several genes. One set of genes, the
nicotinic acetylcholine receptor gene cluster (e.g., CHRNA2, CHRNA5, CHRNB4), are
consistently associated with multiple phenotypes of smoking behavior including CIG
initiation, cigarettes per day (CPD), current smoking, and ND 55. These genes encode
for receptor polypeptides that respond to acetylcholine, but for which nicotine is also an
agonist. In addition, CYP2A6 is often associated with quantitative measures of smoking
(e.g., CPD) and is involved with the metabolism of nicotine via oxidation 56. The
serotonin transporter genes (e.g., SLC03A1) are also associated with ND. These genes
are responsible for transporting serotonin from the synaptic cleft back into the
presynaptic neuron 57. Further, preliminary evidence from polygenic association studies
of ECIG and CIG initiation in young adults (aged 18 to 25 years) suggests that similar
genes impact ECIG and CIG initiation. Genome-wide polygenic scores (i.e., the
aggregate molecular genetic effect from measured and imputed markers) associated
with CIG initiation were also associated with ECIG initiation (OR = 1.24, 95% CI = 1.141.34, p < 0.001) 58. Thus, identifying the genetic factors and biological pathways
associated with ECIG initiation could guide future studies on ECIG behaviors including
ND.
Several environmental factors have also been implicated in increasing the risk of
CIG initiation. These include positive peer opinions towards smoking 59,60, income levels
61

, low parental monitoring 62,63, and high exposure to tobacco advertising 64,65. These

factors have also been reported to increase the likelihood of ECIG initiation 66–68.

27

Economic factors are particularly important in the development of CIG and ECIG
initiation. Economic factors such as income, educational attainment, and health
insurance status may disproportionately impact individuals in society, causing more
harm to individuals with fewer resources 69,70. For instance, tobacco users with less
income spend a larger portion of their resources on tobacco compared to people with
more income. Consequently, the economic factors of household income and coupon
use are particularly useful for understanding ECIG and CIG initiation.
Income has previously been associated with CIG use 46. Previous research
suggests that the association between ECIG and income is similar. ECIG initiation is
more expensive than CIG initiation as one must purchase the device prior to initiating
use, which may prevent some lower income individuals from starting to use the device.
However, mediating or moderating factors may impact this relationship, such as coupon
receipt or use to reduce the initial cost burden.
There are several avenues tobacco companies use to increase the usage of their
products. Coupons are a known method to reduce the cost of cigarette use. Previous
research indicates that individuals who receive coupons are more likely to start using
CIGs and ECIGs 71. Further studies have reported that possessing any type of
promotional material (e.g., ball caps, t-shirts, or posters) for alternative tobacco
products, such as ECIGs, is associated with increased odds of initiation of those
products 72. However, it remains unclear how coupon receipt of tobacco products
impacts the initiation of different tobacco products (i.e., is receipt of CIG coupons
associated with ECIG initiation and vice versa).
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Knowledge Gaps
To date, there are two important gaps in knowledge that are necessary to reduce
the impact of ECIGs on ND. First, the relative degree to which genetic and
environmental influences ECIG lifetime initiation is currently unknown, particularly
among adults. Preliminary research has shown there may be genetic overlap between
CIG and ECIG initiation using genome-wide association data, but this work has only
been performed in young adults (those aged 24 or younger). It remains unknown if
these influences are also relevant for a sample of adults. Adults remain an understudied
population in genetically-informed studies as well as epidemiological studies of ECIG or
CIG initiation. Prior studies of ECIG or CIG initiation have only assessed age of
initiation. Further, most studies of ECIG and CIG use/initiation focus on adolescent
samples, perhaps due to the more malleable nature of this stage of development (i.e.,
environmental factors are more influential for younger ages compared to older ages
when genetic factors are more influential). However, the rates of tobacco naïve adults
CIG and ECIG initiation remain above 10% for those aged 18-21. In contrast, there has
been a slight increase in the prevalence in initiation those between the ages of 20-29
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indicating that individuals will still initiate use beyond adolescence. Further, many adults
who initiate ECIGs may do so to address and reduce CIG use. Consequently, factors
that influence ECIG initiation in adulthood may likely be similar to those of CIG initiation.
Second, few specific genetic and environmental factors influencing CIG and
ECIG lifetime initiation have been identified. This is in part due to: 1) inconsistency of
genetic epidemiology studies for CIG use, 2) a lack of synthesis of results across these
study designs, and 3) few genetic epidemiology studies of tobacco products beyond
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CIGs. Operational measures of tobacco use vary between studies, which contributes to
the inconsistency of results. Without a synthesis of the available results, it is unknown
which specific genetic variants are relevant for CIG and ECIG initiation. Additionally,
specific environmental factors also remain undetailed for ECIG and CIG initiation.

Using Multiple Study Designs to Detail the Shared Genetic and Environmental Factors
for ECIG and CIG Lifetime Initiation
Table 1.3. Knowledge Gaps, Research Questions, and the Chapters Addressed
in the Dissertation
• Chapter 2: Are there shared latent
genetic and environmental factors for
CIG and ECIG initiation in a sample
Knowledge Gap 1: Quantify the relative
of twins?
contribution of genetic and environmental
factors toward ECIG and CIG initiation
• Chapter 4: Are the genetic factors
that are associated with CIG initiation
also associated with ECIG initiation?

Knowledge Gap 2: Which specific genetic
and environmental factors are associated
with CIG and ECIG initiation

•

Chapter 3: Are there overlapping
results in genetically informed studies
of tobacco use? Are there ways to
synthesize results which will lead to
more consistent results?

•

Chapter 5: To what degree are
environmental factors (receipt of
coupons and income) associated with
CIG use also associated with ECIG
and dual use?

This dissertation will address the aforementioned knowledge gaps by
characterizing the relative contribution of genetic and environmental factors associated
with lifetime ECIG initiation as well as those shared with lifetime CIG initiation using
three different study designs. For this dissertation lifetime CIG and ECIG initiation is
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defined as having ever used either product at any time throughout an individual’s life.
These studies utilized secondary data and therefore, operationalization of these
conceptual variables may differ between original studies (i.e., ever use may actually
have been assessed with, “Have you smoked at least 100 cigarettes in your lifetime?”).
A summary of the knowledge gaps as well as specific research questions and the
chapters where they are addressed are summarized in Table 1.3.
Chapter 2 uses a sample of adolescent and young adult twins (mean age = 19.2,
SD = 1.3, age range = 17.6-22.4) to assess the degree to which genetic and
environmental effects influence ECIG initiation and to what degree are these influences
shared with CIG initiation. Chapter 4 expands on results from Chapter 2 by testing for
genetic association with CIG and ECIG initiation across loci through the genome using
genome-wide polygenic scores in a community-based sample of adults (ages 18-93).
This chapter uses a genome-wide association study (GWAS) approach to study ECIG
and CIG initiation and answer the following questions: 1) Are there any genetic loci that
are associated with ECIG initiation? and 2) Do the genetic factors that contribute to CIG
initiation also contribute to ECIG initiation in a sample of adults? A GWAS is a study
design that utilizes genetic data from a genetic marker to test for a statistical association
between the marker and a phenotype. A significant association suggests that the
genotype co-occurs with the phenotype more often than expected by chance41. Chapter
5 also builds on results from Chapter 2 by estimating the degree to which environmental
factors (e.g., income and coupon use) are associated with CIG and ECIG past 12month use. Past 12-month use is a relevant phenotype to study due to its proximity to
CIG initiation as shown in figure 1.2. Chapter 5 uses an epidemiological sample of
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American adults (age: 18-99) to detail a shared environmental factor (income). Chapter
5 answers the questions: 1) are ECIG-exclusive and dual users similar to CIG-exclusive
users in terms of income and tobacco use? and 2) do coupons, a known method for
reducing the cost of tobacco use, moderate the relationship between income and
tobacco use? Taken together, these results will begin to detail the etiology of CIG and
ECIG use in developmental stages beyond adolescence.
To address the second knowledge gap, Chapter 3 uses a scoping review
approach to reflect on the current state of measurement and conclusions on tobacco
products for use in genetic epidemiology studies. A scoping review is a review designed
to examine the body of literature. This aim will also address gaps in environmental
influences toward ECIG initiation in Chapter 5. Accurately modeling the outcome
variable will detail how this environment changes across products. A potential
moderator will further characterize how this environmental influence changes across a
second environmental factor. This knowledge is expected to make the production of
knowledge for ECIG use more efficient in the future.
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CHAPTER 2: USE OF A TWIN STUDY TO QUANTIFY THE GENETIC AND
ENVIRONMENTAL INFLUENCES SHARED BETWEEN ELECTRONIC CIGARETTE
AND CIGARETTE INITIATION1

INTRODUCTION
Electronic cigarette (ECIG) initiation is associated with conventional cigarette
(CIG) initiation in adolescents and young adults 74–77. A recent meta-analysis reported
that individuals who engaged in any ECIG use were 3.5 times more likely to initiate CIG
use compared to those who did not use ECIG 53. This is a major public health concern
as both CIG and ECIG use exposes individuals to nicotine, the addictive component of
both smoke and ECIG aerosol, which may lead to nicotine dependence. In addition to
the addictive nature of nicotine, tobacco use is also associated with several negative
health outcomes such as cancer and cardiovascular impairments 78.
Epidemiological studies have identified several factors, such as peer group use,
that are associated with both CIG initiation 79 and ECIG initiation 80. However, the
degree to which these factors are shared between ECIG and CIG initiation remains
unresolved. If overlap exists in risk factors for CIG and ECIG initiation, similar public
health messaging and interventions may influence the initiation of both products.
Genetic epidemiological study designs have the potential to provide clarity on the
influence of shared risk factors for CIG and ECIG initiation.

1

1 This chapter has been modified from the original manuscript published in Nicotine and Tobacco
Research, DOI: 10.1093/ntr/ntaa201
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Genetic Epidemiology of Electronic Cigarette and Conventional Cigarette Initiation
Twin Concordance Studies and Adoption Studies. Early studies of twins
calculated twin concordance rates to quantify familial aggregation of smoking.
Concordance rates are a measure of probability, asking the question if one twin starts
smoking, what is the probability that the other twin begins using 81? Early twin studies
on smoking initiation (SI) reported higher concordance rates in monozygotic (MZ;
identical) twin pairs compared to dizygotic (DZ; fraternal) pairs, which suggested that
genetic influences play a role in SI 82. However, the degree to which these factors
influenced smoking was not able to be estimated.
Two adoption studies have examined smoking initiation 83,84. Adoption studies
use data from adoptive children and examine their similarity to biological parents versus
adoptive parents. Another possible comparison is between adoptees and their biological
or adoptive siblings. Children adopted away from biological parents still resembled their
biological parents (r = 0.21) more closely than their adoptive parents (r = -0.02) in
regard to smoking behaviors. While these designs are powerful to untangle genetic and
shared environmental effects, a major limitation of these early studies was their small
sample size 83. Furthermore, it may be difficult to ascertain biological parents for
participation. Therefore, while these study designs are powerful, it is unlikely they will
have appropriate sample sizes to provide stable estimates.

Classical Twin Studies. Since the 1970s, the “classical twin study design” (CTD)
has been used to estimate the magnitude of genetic and environmental effects on SI of
CIG. The CTD uses data from monozygotic (MZ) and dizygotic (DZ) twin pairs to
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partition the total variance of a phenotype into the proportion of the contribution due to
genetic and environmental influences. MZ twins share 100% of their genes while DZ
twins share, on average, 50% of their segregating genes. This design can be used to
estimate additive genetic influences (A - effects of alleles at every contributing locus);
shared environmental effects (C - influence of all the environmental effects shared by
twin pairs); and unique environmental effects (E - influence of all the environmental
effects not shared by members of twin pair, which make the twins less similar and
includes measurement error) 85.
The CTD is subject to the following conceptual assumptions. First, twins are
assumed to be subject to the equal environments assumptions (i.e., both twins
experience the environment in the same manner) 86,87. Second, the CTD assumes
random mating of adults in the population. Random mating is defined as choosing a
partner not based on any sort of identifying characteristic (such as political preference)
that may also be due to genetic factors 81. Third, the CTD assumes that there is no
influence due to gene by environment interaction or gene-environment correlation 88.
To date, 16 twin studies have investigated the genetic and environmental
contributions toward smoking initiation of CIG.

Lifetime Ever Smoking Initiation. Twin studies most consistently (8 out of 16)
studied SI, by asking participants to self-identify as initiators (e.g., “Have you ever tried
a cigarette”). These studies reported a significant contribution of A to the total variance
of SI (36-78%). However, when asked whether they smoked one or two puffs (e.g.,
“Have you ever tried a cigarette, even one or two puffs”) in addition to the ever use
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question, the estimate of A dropped to 15%. Shared environmental effects (C) ranged
from 7% to 24% of the total variance when measured with a self-reported ever use
question. If ‘even one or two puffs’ was added to the question probing lifetime ever use,
the estimate for C increased to 70% of the total variance.

Initiation of Regular Smoking. Three twin studies examined the initiation of
regular smoking via self-report (3/16). Overall, there was a significant effect of A on the
initiation of regular smoking. One estimate of A was 49% of the total variance when
measuring initiation of regular smoking as self-reported regular smoking initiation (e.g.,
“Have you ever been a regular smoker?”). Two twin studies89,90 examined SI by asking
if participants identified as a regular smoker (“Have you smoked cigarettes regularly for
at least one month?”), which reported A to be between 62%-72%, slightly higher than
the previous estimate, but still within the 95% confidence interval of the first estimate.

Age of Smoking Initiation. Four additional studies examined the age of SI. These
studies estimated substantial contribution due to A, ranging between 51% and 62% 91–
94

. Further, estimates of C were between 31% to 53%.

Genetic and Environmental Influences on Smoking Initiation Vary Over Time.
Twin studies of CIG tobacco, and other substances, have shown that the effect of
additive genetic and shared environmental factors changes over time 95,96. In general,
shared environmental factors played a large role in SI during adolescence, and were
less of a factor in young adulthood (i.e. college-aged individuals, 18-22), and even less

36

of a factor as one entered adulthood (age 23+) suggesting that genetic influences may
be more prominent in young adults. In one of the first studies to examine this effect,
Tully and colleagues reported a five-fold reduction in the proportion of variance due to C
in nicotine dependence symptoms while the proportions due to A increased by a factor
of two between the ages of 15 and 21 97. Other mega-analyses have reported C was
most influential around ages 14-15 with A steadily increasing from age 15 onwards 95.

Sex Differences in Smoking Initiation. There are consistent sex differences in the
prevalence of CIG initiation which may be due in part to sex differences in the
contribution of genetic and environmental factors. There are differences by sex in the
prevalence of SI 98–100. Phenotypically, women over the age of 16 more often initiate
cigarette use (59.8%) compared to men (50.3%) 101. Additionally, prior twin studies
indicate genetic and environmental differences also exist by sex. A meta-analysis of 17
twin studies reported a larger contribution of additive genetic effects in women
compared to men (Awomen =0.55, Amen = 0.37). This study reported a significantly larger
contribution of shared environmental factors in men compared to women (Amen = 0.49,
Awomen = 0.24)

102

. These estimates were significantly different from one another,

suggesting quantitative sex differences (i.e., the magnitude of the effect of additive
genetic influence differs between men and women) in sources of variation for SI.
Additional studies also report differences in the magnitude of ACE estimates for
SI by sex. A study of Australian twins reported similar results with smaller estimates of A
for men (Amen = 0.22) compared to women (Awomen = 0.63 for women; at the same time,
C was larger for men (Cmen = 0.42) compared to women (Cwomen = 0.11) 103. In another
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study of Australian adult twins, Morley and colleagues estimated similar estimates of A
for men (Amen = 0.63) and women (Awomen = 0.54) for SI 104. Research utilizing adults
from the United States has also provided additional evidence of the sex differences
(Amen ranging 0.48-0.72, while Awomen estimates ranged from 0.32-0.63), continuing to
suggest there are differences between men and women in the US 105–107. This pattern is
also present in other countries as reported by a study of Finish adult twins which
reported larger estimates of A for men (Amen = 0.59) compared to women (Awomen =
0.35) 108. More recent mega-analysis of 11 studies consisting of data from 19,313 twin
pairs analyses have reported sex differences for genetic and environmental effects (for
age 12 twins, Awomen = 0.60, Amen = 0.40; Cwomen = 0.05, Cmen = 0.10). However, these
estimates were not statistically significant (18-year olds Awomen = 0.30, Amen = 0.45;
Cwomen = 0.10, Cmen = 0.10) until after puberty (i.e., ages 15 and older). Consequently,
although there are sex differences in estimates of genetic and environmental effects,
they are only significant at later ages. Estimates of genetic and environmental
contributions at young ages (ages 12, 13, and 15) produced non-significant estimates
while older teens (14-18, excluding age 15) reported significant effects. Further
complicating the results, this sex difference is no longer present as teens transition into
young adulthood (age = 19)

Genetic and Environmental Factors Are Shared Between Initiation of CIG and
Other Substances. Twin studies of SI and the use of other tobacco products report
significant genetic overlap. When examining SI and the initiation of snus (a variant of
dry snuff popular in parts of Europe where it is legal, similar to dipping tobacco in
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America) data from Norwegian twins suggested similar, but not identical, genetic
influences for both delivery systems (rg = 0.82, ACIG = 0.77 ASNU = 0.54) 109. CIG use
has also been associated with other substances beyond tobacco. Alcohol and SI have
been identified as sharing genetic overlap with the genetic correlation being estimated
at 0.68 (95% CI = 0.61-0.74) in one study of adult twins 110,111. Additional studies
reported a significant genetic correlation between ND and cannabis use, such that
roughly 50% of the genetic variance was shared between those phenotypes 112.
Therefore, these studies suggest the importance of genetic and environmental factors
shared across tobacco products and possibly other substances, suggesting there may
be common factors for substance use, in addition to unique factors for each substance.
In all, prior studies on the genetic and environmental contributions toward CIG
initiation indicated: (1) significant additive genetic (i.e., the effect of alleles at every
contributing locus) and shared environmental influences (i.e., the effect of
environmental factors that increase similarity between members of twin pairs), (2) the
magnitude of these influences changed across development (i.e., shared environmental
influences have substantial contributions during adolescence and young adulthood
which decrease into older adulthood), and (3) the presence of significant sex differences
in genetic and environmental contributions 8-11.
To date, most twin studies of tobacco products focus on CIG use; however,
recent population-level studies indicate that more adolescents and young adults using
ECIGs over CIGs 5. These tobacco products are often used together suggesting that
using one product will increase the odds of using another product 113. Not every
individual who uses ECIGs will use CIGs, thus it is currently unclear whether different
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genetic and environmental influences contribute to CIG and ECIG initiation or whether
risk factors are shared between ECIG and CIG. We address this knowledge gap in a
twin study of adolescents and young adults. Specifically, we explore: (1) the degree to
which there is a correlation between ECIG and CIG initiation, (2) the degree to which
the correlation between ECIG and CIG initiation is due to shared genetic and
environmental influences, and (3) the degree to which genetic and environmental
influences are specific to ECIG initiation.

METHODS
Data and Study Population.
Data were obtained from participants in the Adolescent and Young Adult Twin
Study (AYATS), a US longitudinal cohort study of twins aged 15-20 (average age at
wave 1 = 17.22, SD = 1.28; wave 2 = 19.23, SD = 1.33). Data were collected on 860
individuals via web-based questionnaires over two waves (Wave 1: March 2012 –
December 2016; Wave 2: May 2016 – November 2019). A total of 858 individuals (421
complete twin pairs: 160 MZ pairs, 261 DZ pairs) who had tobacco use data were
included in the analysis. The majority of the sample was female (56%), EuropeanAmerican (90%), had an average annual parental income greater than $35,000 per year
(60%), and most parents (68%) had earned a Bachelor’s degree or higher.
Tobacco Use Measures. Lifetime ECIG initiation was measured at both waves
using a 4-item ordinal variable which asked, “On how many occasions, in your lifetime,
have you used an e-cigarette (assume one use is about 15 puffs or lasts around 10
minutes)?” Participants indicating any level of use during Wave 1 or Wave 2 were

40

considered to have initiated ECIG at some point in their lifetime and were coded as 1.
Participants who did not initiate in Wave 1 and Wave 2 were considered not to have
engaged in lifetime initiation and were coded as 0. Lifetime CIG initiation was a binary
variable that asked, “Do you currently or have you ever smoked cigarettes?”
Participants indicating initiation during either Wave 1 or Wave 2 were considered to
have initiated CIG at some point in their lifetime and were coded as 1. Participants who
did not initiate in Wave 1 and Wave 2 were coded as 0.

Statistical Analysis. A CTD was used to study the contribution of genetic and
environmental influences for binary traits. Twin modeling for binary traits builds on the
principles of model development using continuous data. In a univariate genetic analysis
of continuous data, the total phenotypic variance underlying the liability (VP) of an
outcome.
The expectations of twin member resemblance for MZ and DZ pairs can be
summarized as a path diagram which can be used for the calculation of the phenotypic
variance and variances due to genetic and environmental influences as well as the
covariances between individual twins within pairs (Figure 2.1). The expected covariance
in a twin model can be summarized with “Wright’s Rules” for path analysis114,115. There
are six rules: 1) the covariance is calculated as the sum of all possible paths between
two variables, where each path represents the product of all path coefficients in the
chain, 2) after moving forward along a single-headed arrow, moving backward is illegal,
3) a path can contain at most one double-headed arrow, 4) each variable can be
crossed only once per path, 5) whenever changing direction (from upstream to
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downstream) multiply the path by the variance of the upstream variable (in Figure 2.1,
all variances are set to 1 and denoted with a double-headed arrow that returns to the
latent variable), and 6) loops are not allowed.
The latent influences due to A, C, and E are represented by circles, which have a
variance of one (denoted by double headed arrows above each circle). The paths a11,
c11, and e11 represent the paths from the latent influences that contribute to the
measured total phenotypic variance for each of the twins (represented as squares). The
genetic correlation between members of an MZ pair is equal to 1 because MZ twin on
average share 100% of their genetic material. The genetic correlation between
members of DZ pair is equal to 0.5 because they share, on average, 50% of their
genetic material. Therefore, the genetic covariance shared between members of a twin
pair (represented as the double headed arrow between the A latent influences) is given
a value of either 1 for MZ twins or 0.5 for DZ twins. Members of MZ and DZ twin pairs
are assumed to share the same degree of common environmental influences and as
such the correlation for C latent influences is one. Path tracing rules can be used to
translate the path diagram into formulas to calculate means, variances, and covariances
that can be used to estimate A, C, and E. First, the estimate of VA for a single member
of a twin pair is represented using the a11 path as: a*1* a, which is equal to a2. VC and
VE are similarly estimated as c2 and e2, respectively. The total phenotypic variance (VP)
is decomposed as the sum of the variances due to additive genetic (VA), common
environmental (VC), and unique environmental (VE) influences (Equation 2.1).

!"# = %& + %) + %*

Eq. 2.1

42

1

1

1

1

E

C

A

c
e

MZ = 1
DZ = 0.5

a

Phenotype
X
Twin 1

1

1

1

A

C

E

a

c
e

Phenotype
X
Twin 2

Figure 2.1. Univariate classical twin model used to estimate additive genetic (A),
shared environmental (C), and unique environmental (E) influences.
The covariances between members of twin pairs are estimated as:
covMZ = a2 + c2

(2.2)

covDZsame-sex = 0.5a2 + c2

(2.3)

covDZopposite-sex = 0.5rga2 + c2

(2.4)

Estimation of A, C, and E from the CTD model using continuous data was
modified for the study of the binary measures ECIG and CIG initiation. Such models
adopt a threshold model approach, which describes discrete traits to have an underlying
normal distribution of liability (e.g., susceptibility for endorsing an item measured as a
probability with a Z-score distribution). Liability is measured as a series of ordered
categories characterized by phenotypic discontinuities that occur when the liability
reaches a given threshold. In other words, the thresholds differentiate those with and
without the trait. Since the underlying trait is continuous in nature, the prevalence of the
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trait under study can be used to estimate the threshold. For instance, if 1000 individuals
were sampled and 120 had the trait of interest, a threshold could be put on the normal
distribution so the area under the curve to the right of the threshold would be equal to
12% (120/1000; the prevalence of the trait in the sample). Therefore, modeling
thresholds allows binary or ordinal data to be treated as continuous data 116.
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Figure 2.2. Bivariate genetic model used to estimate genetic and environmental
contributions. a11 and a22 represent unique sources of additive genetic variance
for electronic and conventional cigarette initiation respectively. a21 represents the
overlapping additive genetic variance. ECI = ECIG Initiation, CCI = CIG Initiation.

Bivariate Genetic Modeling. The univariate twin model (Figure 2.1) was extended
to evaluate two phenotypes simultaneously (a bivariate model; Figure 2.2). A bivariate
model allows for possible overlap in genetic (A) and common (C) and unique (E)
environmental factors between two traits and the estimation of genetic or environmental
correlations.
A bivariate genetic model was implemented using a Cholesky factorization to
determine how much of the covariance between ECIG and CIG initiation could be
explained by shared genetic and environmental factors 85 (Figure 2.3). This is a method
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of triangular decomposition of the genetic and environmental sources of variance where
the first variable is assumed to be influenced by a latent factor that also explains some
or all of the variance in the second variable. For each source of variance, the second
variable is also explained by a latent factor that is uncorrelated with the first factor (path
a22; Figure 2.2). The diagonal elements in the genetic matrix (e.g., paths a11 and a22;
Figure 2.2) in a Cholesky factorization estimate the variances of a specific variable while
the off-diagonal element (path a21; Figure 2.2) estimates how much of the variance of
the second variable is shared with the first variable.
The same path rules that guided the covariance in a univariate model apply in
the bivariate model. Using Figure 2.3 as a guide, the expectation of A is slightly
changed. Instead of one path to get between both latent additive genetic variables there
are two. The first comes from the additive genetic variance alone: a11*1*a11 = a112 (in the
case of MZ twins). However, there is now a secondary pathway starting from the
second phenotype of twin 1 (here CCI – T1). Pathway a21 leads from CCI – T1 to A for
ECI, then around the covariance between twin 1 and twin 2 and back down pathway
a11, leading to a total expectation for MZ twins of a112 +a11*a21. Similarly, the effect of C
can be expected to consist of c112 +c11*c21 for both MZ and DZ twins.
Genetic and environmental correlations between ECIG and CIG initiation were
estimated to evaluate the degree to which genetic and environmental factors overlap
between the initiation of ECIG and CIG. Standardized genetic and environmental
covariances (covA, covC, covE) were also estimated to detail the degree to which genetic
or environmental factors contributed to the phenotypic correlation (rp) between ECIG
and CIG initiation. The phenotypic correlation is equal to the sum of the standardized
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genetic (covA) and environmental (covC and covE) covariances (+,-./0 = 1234 + 1235 +
1236). The standardized genetic correlation between two measures is defined in
equation 2.5:
+7,9 =

479
:47 × 49

Eq. 2.5

where Axy is the genetic covariance between ECIG ever use and CIG ever use,
and Ax and Ay represent the genetic variances of ECIG and CIG ever use.
The statistical significance of the genetic and environmental covariances was
assessed by comparing the model fit of the full bivariate model to that of three
submodels in which the genetic (pathway a21) or environmental (pathway c21 or pathway
e21) paths between ECIG and CIG initiation were separately set to zero (difference in df
= 1). Under certain conditions, such differences are asymptotically distributed as a chisquare distribution with one degree of freedom 85. A fourth sub-model tested the
significance of the phenotypic correlation by setting all genetic and environmental cross
paths between ECIG and CIG initiation to zero (difference in df = 3).
All analyses were performed in R 3.4.1 117 using the OpenMx package 2.8.3 118,
and missing data were addressed using full-information maximum-likelihood estimation.
We chose a priori to retain and report all parameters in the model. Estimates from a full
ACE model will be more accurate than simplified models. Further, attempts at
parsimony result in oversimplification of the models rather than a more accurate
representation of the data. Consequently, reporting a potentially oversimplified model
might result in future research that may ignore an important source of variance 119.

46

RESULTS
Descriptive Statistics
Approximately 24% of the sample had initiated ECIG use while 19% had initiated
CIG use, and 11% had initiated dual use. Males had a significantly higher prevalence of
CIG (23.9%) and ECIG (22.5%) initiation compared to females (CIG- 14.2% and ECIG12.5%). There was a moderate to large cross-twin correlation for ECIG initiation (rMZ =
0.65, 95% CI = 0.42-0.89; rDZ = 0.55, 95% CI = 0.33-0.77). A similar pattern was
observed for CIG initiation (rMZ = 0.62, 95% CI = 0.38-0.86; rDZ = 0.52, 95% CI = 0.300.74).

Table 2.1. Summary Statistics of AYATS Sample
Males
Females
N (%)
N (%)
Tobacco Initiation
ECIG
51 (22.5)
42 (12.5)
CIG
88 (23.9)
70 (14.2)
Race
African-American
24 (6.4)
40 (8.0)
European-American
340 (90.4) 435 (87.3)
Latino
12 (3.2)
23 (4.6)
Parental Education
HS/GED
47 (12.7)
85 (17.6)
Associate’s
35 (9.5)
68 (14.1)
Bachelor’s
145 (39.2) 182 (37.8)
Master’s
111 (30.0) 105 (21.8)
Doctorate
16 (4.3)
24 (5.0)
Other
16 (4.3)
18 (3.7)

Total
N (%)
92 (20.2)
159 (18.5)
64 (7.3)
775 (88.7)
35 (4.0)
132 (15.5)
103 (12.1)
327 (38.4)
216 (25.4)
40 (4.7)
34 (4.0)

Tests of Twin Model Assumptions
Prior to genetic analysis, several data-related assumptions were tested to
ensure that such genetic modeling would be plausible. Assumptions were tested to
ensure that there were no significant differences in thresholds by twin order, zygosity
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and sex prior to genetic modeling. Model assumptions were tested by equating
threshold estimates to be the same for twin one and twin two, then equating threshold
estimates to be the same for MZ and DZ twins, and finally making the thresholds
equivalent between males and females. Each of these models was tested against a
saturated model, or the model where all parameters could be estimated.
Submodel expectations were evaluated through a series of model fit
comparisons against the saturated bivariate model. First, measures of model fit were
estimated between the saturated model and each submodel. Model fit is measured by
comparing measures of likelihood (i.e., negative two log-likelihood, -2LL). Model fit
represents a measure of how well the model tested explains the data collected. Model
fit comparisons between models are assessed by estimating the difference in model fit
between two models, which produces a value that can be interpreted as a test with a
Chi-square distribution and having degrees of freedom equal to the difference between
the number of parameters between the two. A non-significant result would be
interpreted as the submodel fitting the data equally well as the full model (i.e., there is
no significant difference between the two models). The model with fewer parameters
would be retained as this fits the criteria laid forth by Neale and Cardon for the best
model. Second, a value of model parsimony estimated as AIC (Akaike Information
Criterion) was used to examine which model is the most parsimonious 85. The model
with the lowest AIC value is considered to be the simplest model.
Evaluating models by comparing model fit and parsimony applies the four
criteria of a good model as summarized by Neale and Cardon (1992): 1) a model
provides a good fit to the data, 2) the model is consistent, 3) the model is simple, and 4)
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the model has statistically significant parameter estimates. If the model does not provide
a good fit to the data, then the model needs to be modified 85. Further, a model that is
not consistent with biometrical theory (such as a model that has dominance effects, but
not additive genetic effects, Falconer 1990) may not be a good model. Simple models
are easier to falsify and are more informative than complex models. Finally, any nonsignificant parameter should be removed from the model as it does not add to the
model’s ability to explain the data.
A saturated bivariate model was used as the base comparison model. A
saturated model estimates the means, variances, and covariances for all variables (CIG
and ECIG initiation in both members of a twin pair, both zygosity groups, and for males
and females), and therefore each possible pathway is estimated in a saturated model.
Three bivariate models were fit to test the assumptions inherent in the twin study
(Table 2.2). Model 1 tested a saturated model where all parameters were free to vary
across twin order, zygosity, and sex. Model 2 equated the thresholds across twin order
as a test of birth order (i.e., whether thresholds could be equated across twin order to
assess the randomness of assigning twins to be the first or second twin). There was no
significant difference in model fit between this model and the saturated model (p =
0.42). Model 3 equated the thresholds across the zygosities as a test of consistency
between MZ and DZ twins on their ECIG and CIG initiation (i.e., whether thresholds
could be equated across zygosity in same sex pairs). There was no significant
difference between this model and the saturated model (p = 0.07).
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Table 2.2. Summary of Tests of Twin Model Assumptions
Model
Model
EP
DF
-2LL
AIC
Δ-2LL
p
Number
Comparison
1
50
1385
1110.16
-1659.84
2
2 vs 1
40
1395
1120.40
-1669.60
10.15
0.42
3
3 vs 1
32
1403
1137.71
-1668.29
27.55
0.07
Model 1- Saturated
Model 2- Equate Twin 1/Twin 2 Thresholds
Model 3- Equate Twin1/Twin 2 Thresholds and MZ/DZ Thresholds
EP = Estimated Number of Model Parameters; DF = Degrees of Freedom; -2LL =
Model Fit as Measured by the Negative Two Log Likelihood; AIC = Model Parsimony
as Measured by Akaike Information Criteria
Tests of Sex Differences. A series of models were fitted to test the significance of
sex differences in the magnitude and nature of genetic and environmental factors (Table
2.3). A full model included separate parameter estimates for each sex, as well as a
parameter for the correlation between factors in males and females (Figure 2.3). There
was no significant loss of model fit when the bivariate genetic model with all sources of
genetic and environmental sex differences was compared to the saturated model (Table
2.3, Model 4, p = 0.51). Therefore, all subsequent tests of genetic and environmental
influences were compared against this model. Model 5 (Table 2.3) tested the
equivalence of thresholds across sex (i.e., male threshold is equal to the female
threshold). The fit of Model 5 was not significantly different from that of Model 4 (p =
0.63). Model 7 tested the significance of the genetic correlation between additive
genetic factors in males and females (rg) by fixing it to 1, thus testing qualitative sex
differences or whether the same set of genes contributes to liability in males and
females. The fit of Model 7 was not statistically different from Model 4 (p = 0.11). Model
6 tested whether the A, C and E parameters could be equated for females and males as
a test of quantitative sex differences to determine whether the magnitude of genetic and
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environmental influences is the same across the sexes. There was no significant loss of
fit using this model (Table 2.3, p = 0.06) compared to a model that did estimate the
sexes separately (Model 4). Finally, Model 8 tested the bivariate ACE model without any
additional genetic and environmental sex differences (Figure 2.2). No significant
differences in model fit were detected between Model 8 and either Model 4 (Table 2.3, p
= 0.51) or Model 1 (saturated model, Table 2.3, p = 0.20). Consequently, a model
without any sex differences was used to assess the magnitude of genetic and
environmental effects on CIG and ECIG intiation.
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Figure 2.3. Bivariate Models of Sex-Specific Models, Panel A Shows Male Pairs,
Panel B Shows Female Pairs, Panel C Shows Opposite Sex Pairs
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Table 2.3. Summary of Tests of Genetic and Environmental Sex Differences
Model
Model
EP
DF
-2LL
AIC
Δ-2LL
p
Number
Comparison
4
4 vs 1
23
1412 1136.35
-1687.65
26.19
0.51
5
5 vs 4
21
1414 1137.27
-1690.73
0.92
0.63
6
6 vs 4
12
1423 1155.65
-1690.35
19.31
0.06
7
7 vs 4
11
1424 1154.68
-1693.32
18.33
0.11
8
8 vs 1
13
1422 1154.03
-1689.97
43.87
0.20
Model 4: Bivariate genetic model estimating all sources of genetic and environmental sex
differences
Model 5: Equate thresholds by sex
Model 6: Test of Quantiative Sex Differences- Equate path estimates by sex
(Am/Cm/Em = Af/Cf/Ef)
Model 7: Test of Qualitative Sex Differences- Set rg to 1
Model 8: Bivariate ACE model without any genetic and environmental sex differences
EP = Estimated Number of Model Parameters; DF = Degrees of Freedom; -2LL = Model Fit
as Measured by the Negative Two Log Likelihood; AIC = Model Parsimony as Measured by
Akaike Information Criteria

Bivariate Genetic Model Testing. Tests of genetic and environmental covariance
between CIG and ECIG initiation indicated no significant differences in models where
a21 to zero (Model 2, Table 2.4, Figure 2.2) or setting c21 to zero (Model 3, Table 2.4,
Figure 2.2). However, setting the e21 cross path to zero did result in a significant
difference in model fit (Model 4, Table 2.4, p = 0.01). There was no significant difference
when dropping either all A or all C influences (i.e., Models 5, paths a11, a21, and a22
were set to zero, for Model 6 paths c11, c21, and c22 were set to zero, Table 2.4).
However, when both A and C influences were dropped simultaneously (i.e., all a and c
paths were set to 0, Model 7), the models fit significantly worse when compared to the
full bivariate ACE model (Model 1, Table 2.4; p < 0.001).
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Table 2.4. Bivariate Modeling Fit Statistics
Model
Model Name EP
DF
-2LL
AIC
Δ-2LL
p
Number
1
Bivariate ACE 13
1422
1154.03
-1689.97
2
Test of CovA 12
1423
1155.18
-1690.82
1.15
0.28
3
Test of CovC 12
1423
1156.97
-1689.03
2.95
0.09
4
Test of CovE 12
1423
1160.46
-1685.54
6.43
0.01
5
CE Model
10
1425
1155.18
-1694.82
1.15
0.76
6
AE Model
10
1425
1159.71
-1690.29
5.68
0.13
7
E Model
7
1428
1213.18
-1642.82
59.15
< 0.001
Note. EP = number of estimate parameters; df = degrees of freedom; -2LL = negative two
log likelihood, a measure of model fit; AIC = Akaike Information Criteria; Δ-2LL = difference
of -2LL
Common environmental influences accounted for a non-significant proportion of
the variance in the liability of ECIG and CIG initiation (ECIG: C = 0.42, 95% CI = 0-0.73,
p = 0.12; CIG: C = 0.42, 95% CI = 0-0.70, p = 0.13). In addition, the contribution of
additive genetic influences on the initiation of both delivery systems was non-significant
(ECIG: A = 0.25, 95% CI = 0-0.83, p = 0.44; CIG: A = 0.19, 95% CI = 0-0.79, p = 0.57)
(Table 2.4).
There was a strong phenotypic correlation between ECIG and CIG initiation (r =
0.77, p < 0.001). This phenotypic correlation was due to non-significant common
environmental covariance (covC = 0.23, p = 0.32), non-significant additive genetic
covariance (covA = 0.23, p = 1), and significant unique environmental covariance (covE
= 0.31, p = 0.01). The unique environmental correlation (rE = 0.87, p = 0.01) was
significant between both delivery systems (Table 2.5)
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Table 2.5. Standardized Genetic and Environmental Parameter Estimates
for Electronic (ECIG) and Conventional Cigarette (CIG) Initiation
Parameter
ECIG Initiation
A
C
E
CIG Initiation
A
C
E

Estimate (95% CI)

p-value

0.25 (0 – 0.83)
0.42 (0 – 0.73)
0.32 (0.14 – 0.56)

0.44
0.12
< 0.001

0.19 (0 – 0.79)
0.42 (0 – 0.70)
0.39 (0.18 – 0.57)

0.57
0.13
< 0.001

Shared Parameters
covA
0.23 (0 – 0.43)
1
covC
0.23 (0 – 0.52)
0.32
covE
0.31 (0.14 – 0.45)
0.01
rg
0.76 (0 – 0.99)
1
rc
0.68 (0 - 1.0)
0.32
re
0.87 (0.50 – 0.99)
0.01
covA- genetic covariance; covC- shared environmental covariance; covE- unique
environmental covariance; rg – genetic correlation; rc- shared environmental
correlation; re- unique environmental correlation
DISCUSSION
This is the first study to investigate the genetic and environmental contributions
to the liability for ECIG initiation and explore the degree to which genetic and
environmental factors influencing ECIG initiation are shared with CIG initiation. There
was evidence for familial resemblance - likely a combination of additive genetic and
shared environmental effects - on ECIG initiation. Additionally, there was substantial
shared influences of unique environmental factors shared between both delivery
systems.
The prevalence of ECIG initiation (~24%) in the current study was similar to
those reported in other studies collected during a similar time frame (18.7% in 2014) 75.
However, the prevalence of CIG initiation was higher compared to national estimates
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(19% vs. an average prevalence of 9.9% during 2011-2015) and may reflect regional
preferences for CIG use (e.g., Virginia, North Carolina). There was also a strong
association between ECIG and CIG initiation, which is supported by prior research
which indicates that ECIG users are more likely to engage in CIG use 53,77,120.

Genetic and Environmental Factors Influence ECIG as well as CIG Initiation.
The magnitude of the estimates for the genetic and environmental contributions
toward CIG initiation were similar to those previously reported in a mega-study of
adolescents 95. The magnitude of A from prior studies are generally smaller (range: 0.10
– 0.40) than estimates of C (range: 0.40 – 0.80) 95. There was a similar pattern in the
magnitude of genetic and environmental influences (A = 0.19 and C = 0.42) for CIG as
well as ECIG initiation (A = 0.25 and C = 0.42).
Additionally, although genetic and shared environmental correlations (i.e. rG, rC)
across ECIG and CIG initiation were individually not significant, their combined effects
were. Similarly, though estimates of A and C were non-significant, models which did not
include both sources of variance fit significantly worse than models that did, suggesting
that both A and C are important factors of ECIG and CIG initiation.

Unique Environmental Factors Influence Electronic Cigarette Initiation and Have
Overlap with Conventional Cigarette Initiation.
There were significant contributions of unique environmental factors specific to
ECIG initiation, as well as significant shared influences of unique environmental factors
contributing to ECIG and CIG initiation. Possible factors include peer smoking and
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opinions towards nicotine products 62 as well as exposure to tobacco marketing 64.
Consequently, unique environmental factors are important for tobacco initiation and may
be shared across delivery systems.
GWAS of CIG initiation has provided many insights into the molecular genetic
architecture of CIG use. A recent meta-analysis of 1.2 million individuals reported 378
variants that were associated with CIG initiation 121. However, a more recent GWAS of
smoking initiation in ~800,000 individuals only reported 12 loci that were associated with
CIG initiation 122. There are several genes that are consistently reported in the
molecular genetics literature of tobacco use. The nicotinic acetylcholine receptor
(nAChR) genes (e.g., CHRNA4, CHRNB2) have consistently shown a significant
association with SI 123. These genes are able to be bound to and excited by nicotine,
mimicking the action of choline.
Recent results using polygenic scores of cigarette use suggest that there is
significant overlap in the genetic influences of ECIG and CIG initiation. For example,
one study of participants in the Netherlands Twin Registry, reported a significant
association between a polygenic risk score (PRS) for cigarettes per day, as calculated
by summary statistics from the Tobacco and Genetics Consortium (TAG) and lifetime
use of ECIGs such that ex-smokers had roughly 43% greater odds of initiating ECIGs
124

. Further investigation using the Avon Longitudinal Study of Parents and Children

(ALSPAC) reported a positive association between a PRS for CIG initiation (as
calculated from the GWAS and Sequencing Consortia for Alcohol and Nicotine) and
ECIG ever use such that individuals were 24% more likely to be an ECIG initiator based
on their PRS 58. Both of these samples utilized adults (Allegrini mean age = 45; Khouja
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age of data collection = 24) rather than adolescents or blended samples. There should
be no bias for the changing effects of A and C across age due to the retrospective
nature of the data (i.e., reporting on childhood behaviors as an adult). By reporting
significant associations between PRS generated from CIG use and ECIG initiation,
there appears to be confirmation that there is some genetic overlap between CIG and
ECIG use.
These results should be evaluated in light of the following limitations. First, the
majority of participants identified as European-American race/ethnicity, and results from
this study may not generalize to other racial/ethnic populations. Second, this study used
self-report data which may be subject to reporter bias. Third, we used measures of
lifetime ECIG and CIG initiation which do not capture the complexities of long-term use
(e.g., quantity/frequency). Nevertheless, many genetic epidemiological studies have
focused on CIG initiation and have consistently identified similar results regarding the
factors involved with this first step in nicotine dependence. Fourth, the power to detect
significant additive genetic effects and genetic correlations was limited as a result of
sample size and prevalence of ECIG/CIG initiation.
These results provide preliminary evidence for genetic and environmental
influences involved in ECIG initiation as well as significant shared influences between
ECIG and CIG initiation. More recent research has provided additional evidence from
molecular genetics regarding the shared influences in genetic factors between ECIG
and CIG. Two recent papers have reported the use of polygenic risk scores (PRS)
generated for CIG initiation, that are significantly associated with ECIG initiation 58,124.
Thus, the evidence is mounting that genetic factors that influence the liability toward
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CIG initiation may also play a role in ECIG initiation. However, there is not one hundred
percent shared influences in the genetic variants that influence these phenotypes.
Further research is needed to characterize which variants are unique and shared
between ECIG and CIG initiation.
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CHAPTER 3: SCOPING REIVEW OF TOBACCO USE MEASURES IN
GENETICALLY-INFORMATIVE SAMPLES: RECOMMENDATIONS FOR FUTURE
TOBACCO RESEARCH

INTRODUCTION
Tobacco use is a significant risk factor for several chronic conditions (e.g., lung cancer
and cardiovascular disease) and remains a global public health concern 78. Many
individuals continue to engage in CIG use. However, the rates of CIG use in the US
population have reached their lowest ever level125. CIG use often leads to the
development of Tobacco Use Disorder (TUD), defined as tobacco use leading to
dependence on nicotine—the addictive chemical in tobacco 126.
There is a large amount of heterogeneity in tobacco use measures.
Several different instruments have measured the several stages of tobacco use:
initiation of use, progression to regular smoking, and nicotine dependence 27. The
variation of measurement within a stage has led to several gaps in understanding
across the etiology and remission of TUD as well as for each smoking behavior. In
particular, measurement variation for tobacco product use is likely to have implications
in the conclusions of recent and future genetic epidemiologic studies of tobacco use and
TUD particularly for new and emerging tobacco products (such as electronic cigarettes,
ECIGs). As inconsistent findings for CIG use may be due in part to measurement
issues, future work in ECIGs (and other novel tobacco use products) should anticipate
these concerns. Genetic epidemiology results may be inconsistent because of the
measurement heterogeneity of tobacco use across studies. Meta-analysis of published
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studies produces standardized results across studies. However, they have the potential
to mask the degree of measurement variability and may not motivate careful
consideration of the kinds of results that are produced specifically for a given measure.
This concern is particularly important for researchers as they consider new data
collection and are faced with making choices of the types of measurements to include in
a study. Therefore, it is necessary to systematically evaluate the magnitude and quality
of study results produced using genetic epidemiology study designs. Although some
prior meta-analysis and systematic reviews of CIG use have been reported using twin
studies, the most recent was conducted in 2017 95 and have not evaluated genetic and
environmental influences for other tobacco products.
The issue of measurement heterogeneity leading to variation in results may also
have important implications for genome-wide association studies (GWAS). If the
outcome, or phenotype of interest, is poorly defined two problems may occur. First, the
parameter estimates of the magnitude of associations generated from GWAS may be
biased. This would lead to differences in estimates of heritability from GWAS compared
to those generated from twin studies. Second, heterogeneity in outcome measurement
may lead to inconsistent results across GWAS. Further, this would lead to an inability to
replicate GWAS results.
This study seeks to aggregate and summarize results across two sets of results.
The first set focuses on results from specific studies of tobacco use. These studies
include variance component estimates from twin studies, and single marker variants
from GWAS. This will provide insight into the range of the influence of genetic factors
across tobacco use phenotypes. The second set focuses on summarizing the biological
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relevance of GWAS results. It is possible that conclusions about biological function
derived from GWAS results may be dependent on phenotype measure. However, to
date, there has been relatively little effort to broadly aggregate and reflect on the
functional relevance of GWAS results across published studies of tobacco use.
Consequently, it may be helpful to aggregate GWAS results by summarizing the known
downstream biological products of genetic variants to establish the functional relevance
of GWAS results for genetic variants (e.g., mRNA production, gene expression, and
protein). Functional relevance may provide novel insights into the treatment of disorders
by pharmacological means. Aggregating and synthesizing GWAS results within the
context of functional relevance does not rely on the consistent replication of specific
genetic variants of the genome. Instead, a summary of results related to functional
relevance produces detail on biological pathways. For example, a study examined
GWAS results for childhood onset asthma, reporting biological pathways involved with
the immune system 127. This type of information produces biological context to motivate
future pathways for study.
There is fair amount of heterogeneity in the results of genetic epidemiologic
studies of tobacco use because the measurement of tobacco use is heterogeneous.
However, it is unclear if different operational measures of the same conceptual variable
will lead to differing results (i.e., the detection of significant results across different SNPs
or genes). Thus, the goal of this chapter is to summarize the genetic epidemiology
results for two major study designs—twin studies and genome-wide association studies.
These study designs were prioritized because twin studies provide the rationale for
continuing to examine a phenotype for genetic variants. This will be done via first
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providing twin study results as a basis for proceeding to GWAS designs. Secondly,
functional relevance will be reported for significant published GWAS results.
Recommendations for future studies will be outlined to conclude this chapter.

METHODS
A series of searches in four databases was performed (PubMed, EMBASE, PsychINFO,
and CINAHL) to identify potential articles of interest. Article requirements included: (1)
published in English, (2) published between the years 1982 (the first year a geneticallyinformative analysis was performed for tobacco use) and 2020, and (3) conducted using
human subjects. The search was performed on 20 May 2020. Searches focused on
articles satisfying three different concepts were created, each with unique search terms
(tobacco product, tobacco use measurement, and genetically-informative studies).
The tobacco product concept reflects the different types of tobacco products that
could be used by individuals. We wanted to capture all studies that examined tobacco
products. The purpose of this concept was to capture each tobacco product to ensure
that lesser known or used products (e.g., snus, hookahs, chewing tobacco) were
included and not the most often studied products (e.g., combustible or conventional
cigarettes). Tobacco products were searched using the following search terms:
cigarette, conventional cigarette, combustible cigarette, electronic cigarette, chewing
tobacco, hookah, cigar, snus, polytobacco use, comorbidity, and polysubstance. These
terms returned 345,709 potential articles.
A tobacco use measurement concept was used to quantify the behaviors that
are related to tobacco use. This concept was used to define the way researchers
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previously conceptualized tobacco use behaviors to ensure all possible studies that may
have studied tobacco use as an outcome measure (not a covariate) were found and
included in the search. The search for this concept utilized the following terms:
cigarettes per day, cessation, pack-years, initiation, ever use, current use, age of
initiation, nicotine dependence, withdrawal symptoms, former smokers, current smoker,
withdrawal, cravings, heaviness of smoking index, initial subjective experiences with
tobacco use, number of puffs, over 100 cigarettes, smoking status, cotinine level, NNAL
(4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol) level, and Fägerström Test for Nicotine
Dependence. This concept lead to 482,151 potential articles.
A genetically-informed studies concept was used to reflect studies that utilized
genetically informative study designs, either through molecular, familial, or statistical
genetic methods. This review is only interested in studies that addressed genetic
influences (with or without environmental influences). Therefore, the search addressing
this concept focused on the following terms: twin, family-based, genetic association,
candidate gene, genotype, GWAS, co-twin design, consortia-based GWAS, genome
wide association, genome wide, PheWAS, adoption studies, gene-environment
interaction, epigenetic – methylation, epigenetic – miRNA, epigenetic – acetylation,
heritability, multivariate, development. This concept returned 608,086 potential articles
of interest. This study further focused on GWAS and twin studies for two reasons. First,
twin studies are the first step for genetic epidemiologic studies, with results informing
the degree to which latent genetic factors are associated with a phenotype. GWAS then
examines measured genetic effects in an effort to pinpoint where in the genome the
association comes from. Thus, these two designs form a logical dyad. Secondly,
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tobacco use needed to be an outcome rather than an exposure or covariate. Many
studies of more recent technologies (e.g., methylation or epigenetic studies) consider
tobacco as an exposure rather than an outcome and are therefore not relevant for this
review.
Utilizing the Concepts
While each concept returned hundreds of thousands of potential articles, they only
returned articles based on their individual concept (e.g., the tobacco product concept
only returned articles that addressed tobacco products). However, this strategy did not
account for the overlap with the genetically-informative concept. Therefore, we
combined each of the results from the three previous concepts and retained only those
articles that were present in each of the concept searches. We retained 16,778 articles
that were focused on tobacco products (i.e., from the tobacco product concept) and
were genetically informed. Of those, 6,096 articles were present in all three concepts.
The resulting 6,096 articles were then uploaded to the Rayyan application to facilitate
the review of abstracts 128.
Article inclusion criteria included: written in the English language, use of a
genetically-informative study design, and a tobacco use measure as the outcome (i.e.,
not as a covariate or main exposure variable). Agreement across two out of three
research assistants was required to include an article into this review. Any disputes that
could not be resolved by those authors were decided upon by the lead author (JSC).
This resulted in 492 articles deemed relevant for data extraction. Fifty-five articles were
removed from the data extraction process (Figure 1) as a result of duplications (i.e.,
published online the year prior to journal publication and were erroneously counted as
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separate articles). An additional set of 127 articles were removed because they were
abstracts from conference proceedings, were not available in English, or were
review/commentary articles. This resulted in 310 articles relevant for data extraction
(Figure 1). Some studies measured tobacco use multiple ways (e.g., initiation and
cigarette quantity), therefore a single article may be referenced several times
throughout this review. Further, results were limited to those articles that utilized a
genome-wide association analysis or some variation of that design, leaving 87 articles.
Data Extraction
Data from the 87 articles were extracted with a team of researchers including
undergraduate and graduate students. Articles were binned into sets of 20 by year of
publication and disseminated to team members. In consultation with colleagues who
had previously conducted systematic reviews, a data extraction spreadsheet was
designed (Appendix S3.1) which detailed various aspects of the articles such as sample
size, age range, any subsamples the study examined, the conceptual variable, and the
operational variable. The spreadsheet was then refined to only include relevant
information for this review (Appendix S3.2). After data extraction was completed,
another team member reviewed to ensure all relevant data were captured during the
extraction process. Finally, data were summarized based on the conceptual measure of
nicotine use. In other words, all studies that examined smoking initiation were collated
into a separate spreadsheet from studies that examined nicotine dependence. These
conceptual measures are not mutually exclusive, and studies could be represented in
multiple tobacco use behaviors.
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Aggregating and Translating GWAS Results to Understand Biological Relevance
Following the extraction of relevant markers from the GWAS studies, gene lists were
run through DAVID (The Database for Annotation, Visualization, and Integrated
Discovery) to extract biological pathways which appeared more often than expected as
denoted by Fisher’s Exact test 129–131. DAVID is a data-mining tool which extracts the
biological pathways that are represented by the genes with which DAVID is given from
the GWAS results. This organization of biological pathways is accomplished by
examining the co-occurrences across multiple bioinformatic platforms that curate details
on the functional annotation of genes relevant to a SNP-based result (i.e., gene
name/aliases, molecular function, and biological role).
DAVID results produce four different classes of results. The first class is a
“Category”. This class provides information on the bioinformatic platforms from which
the results were extracted. DAVID probes publically available bioinformatic platforms
including (but not limited to): BioCarta
(https://www.hsls.pitt.edu/obrc/index.php?page=URL1151008585), Kyoto Encyclopedia
of Genes and Genomes (KEGG; https://www.genome.jp/kegg/), GO (GOTERM;
http://geneontology.org), and UniProtKB keyword (UP_KEYWORD; UniProtKB
keyword). The second class is “Term”, which describes the actual functional relevance
within the pathway, such as “cell signaling”. Term details the pathway’s relevance based
on evaluation of results across bioinformatic platforms which are not mutally exlcusive
(i.e., the term could appear in multiple platforms). The third class of results is “Genes”.
This column provides the genes that enriched, or occur more often than expected by
chance, for that particular term, such as cell signaling. The final class for the results is
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the p value calculated for the Fisher’s Exact Test to determine if a gene or gene list is
significantly associated with a term.
GWAS results for phenotypes were submitted to DAVID analysis if they were
either (1) conducted in at least three independent published GWAS studies or (2)
conducted in GWAS consortia consisting of at least three separate samples. DAVID
reported pathways that were significant at 0.05 using a Benjamini-Hochberg False
Disovery Rate. Single nucleotide polymorphisms (SNPs) that were reported to be
genome-wide significant (p < 10-8) in the original GWASs were included in DAVID
analyses.

RESULTS
1. Smoking Initiation
Twin Studies
Twin studies give a broad estimate of the extent to which a phenotype is
influenced by genetic variants. In brief (see Chapter 2), twin studies estimate additive
genetic (A), shared environmental (C), and unique environmental (E) effects by
decomposing the covariance shared between two twins. As monozygotic (MZ, or
identical) twins are presumed to shared 100% of their genetic effects, as well as 100%
of the shared environmental influences, the only differences that could arise between
these twins are due to unique environmental influences or measurement error.
However, dizygotic (DZ, or fraternal) twins are assumed to only share, on average, 50%
of their genomes but 100% of the shared environment. Thus, any differences in DZ
twins could arise from either genetic or unique environmental influences. Comparison of
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the covariances from the different zygosity groups allows the decomposition of variance
into A, C, and E estimates. Twin models may also be extended to model non-additive
genetic variance (D) in lieu of C influences as D and C are confounded 132. The choice
to model C or D is driven by the correlation pattern of MZ and DZ twins 133. An rMZ
greater than two times that of rDZ would necessitate modeling D rather than C. In total,
14 studies examined smoking initiation (SI) within a twin design.
Lifetime Ever Smoking Initiation. A common way used to measure SI is by asking
if the participant has ever smoked. Rhee and colleagues reported if 1,062 twin and
sibling pairs had ever used cigarettes and reported significant additive genetic (A =
0.24), non-additive genetic (D = 0.08), and shared environmental influences (C = 0.34)
134

. Similarly, Maes et al. (2004) used data from 6,805 twins from the Virginia Twin

Registry focused on whether they had ever used a cigarette 135. They reported
significant genetic effects (A = 0.75) and unique environmental effects (E = 0.25). Vink
and colleagues also asked a sample of Finnish twins (N = 10,063) if they had ever
smoked a cigarette 135,136. They reported significant genetic (A = 0.36), shared
environmental (C = 0.56), and unique environmental influences (E = 0.07) in this
European sample.
Further research has examined SI through the use of lifetime ever smoking but
stratified the results by different self-reported race/ethnicity groups. Sartor and
colleagues studied SI from an American sample of 3,553 twins of European descent
and 945 twins of African descent 137. They reported significant genetic (A = 0.50) and
unique environmental influences (E = 0.46) and nonsignificant shared environmental
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effects (C = 0.04) in twins of African descent. In the twins of European descent, there
were significant influences of A (0.51) and E (0.12) but nonsignificant C (0.24).
Some researchers examined lifetime ever smoking by adding a threshold of the
number of cigarettes a participant needed to have smoked in their lifetime before
classifying them as initiating smoking. Hamilton and colleagues asked if participants in
their study had smoked more than 100 cigarettes in their lifetime, meaning if an
individual had smoked less than 100 cigarettes they would be considered a non-smoker
107

. In this study of 32,359 American twin pairs, male pairs were reported to have

significant genetic (A = 0.71), shared environmental (C = 0.12) and unique
environmental influences (E = 0.17). Female twin pairs also reported significant genetic
(A = 0.32), shared environmental (C = 0.48) and unique environmental influences (E =
0.21). Similarly, McCaffery, examining a group of 9,414 American twins who had served
in the Vietnam War, categorized individuals as initiators if they had smoked more than
100 cigarettes in their lifetime 138. They reported significant genetic (A = 0.49), shared
environmental (C = 0.29) and unique environmental effects (E = 0.22) in this sample.
Finally, in a mega-analysis using raw data from multiple samples, Maes and
colleagues defined SI as having ever had a cigarette, even one or two puffs 95. In this
multi-country study of adolescent (aged 10-19) twins (N = 19,313), the researchers
reported changing impacts of additive genetic and shared environmental influences of
the developmental period. Specifically, shared environmental influences played a larger
role at younger ages (C = 0.70 at age 13 and 0.40 at age 19) while additive genetic
influences played less of a role at younger ages (A = 0.15 at age 13 and 0.45 at age
19).
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Initiation of Regular Smoking. One of the first twin studies of SI derived smoking
initiation by asking an individual to categorize themselves as ever being a smoker or
not. The research aggregated three twin cohorts (Australian twins, 3,808 pairs; Virginia
twins, 2,145 pairs; and a study from the AARP consisting of 3,620 twin pairs) 139.
Researchers reported significant genetic effects (A for men = 0.83; for women A = 0.50)
and nonsignificant shared environmental effects for men (C = 0.01), but significant for
women (C = 0.29). A different study in 2006 examined SI as individuals having been a
regular smoker (self-identified) versus those who did not identify as a regular smoker in
14,472 Australian twins and siblings 90. Similar to the aforementioned study, Morley
reported significant genetic effects (A = 0.59 for females; A = 0.63 for males) and
unique environmental effects (E = 0.17 for female; E = 0.19 for males), as well as small
but significant shared environmental effects (C = 0.04 for females; C = 0.07 for males).
Finally, Kendler and colleagues asked participants to identify themselves as regular
smokers by asking if they had regularly smoked for at least one month in their lifetime
109

. In this sample of 1,103 Norwegian twin pairs, there were significant additive genetic

(A = 0.79) and unique environmental influences (E = 0.21) to the initiation of regular
smoking.
Smoking Initiation Derived from Smoking Status. An initial study of SI used
whether an individuals, 7,375 male-male twin pairs who served in the Vietnam War, was
a current smoker or not as their initiation variable 92. Participants were classified as
smokers if they currently smoked, and had smoked at least 100 cigarettes in their
lifetime, or if individuals had smoked at least 100 cigarettes but were not current
smokers. These individuals were compared to individuals who reported not using 100
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cigarettes in their lifetime. Researchers reported a significant effect of additive genetic
influences (A = 0.70) and unique environmental influences (E = 0.30), but no effect due
to shared environmental influences.
Wills and colleagues used a measure of smoking status that asked twins to
report how many cigarettes they smoke in a day breaking up smoking by either 1-19
cigarettes per day or more than 20 per day 140. They also asked twins to report if they
used to or only occasionally smoke cigarettes. These groups were aggregated into a
smoking initiator category and compared against individuals who never smoked. They
reported significant genetic (A = 0.43), shared environmental (C = 0.39), and unique
environmental influences (E = 0.18) in this sample of 850 American twin pairs.
Age of Smoking Initiation. An early twin study of SI assessed the age the twins
started smoking by asking, “At what age did you start smoking?”91 Using 3,810 adult
twins from the Australian Twin Registry, Heath and colleagues reported significant
genetic effects and unique environmental influences in both a sample of young twins
(age at assessment was less than 30; A = 0.62, E = 0.38) and an older cohort (age at
assessment greater than 30; A = 0.51, E = 0.49). During the same timeframe, Kendler
and colleagues used a sample of 1,898 Virginian female twins to assess age of SI,
though they used a slightly different question 141. Kendler and colleagues asked when
they started regular smoking with regular smoking defined as a pattern of cigarette use
such that the participant smoked at least 7 cigarettes per week for one month. They
reported significant genetic (A = 0.78), shared environmental (C = 0.07), and unique
environmental influences (E = 0.15).
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Genome-Wide Association Studies of Smoking Initiation
Genome-wide association studies (GWAS) examine a series of genetic markers
across the genome. A genetic association is a single test of association which uses
genotypic data from a genetic marker to test for statistical associations between a
genetic variant (e.g., single nucleotide polymorphism, SNP) at a specific locus and CIG
initiation. A GWAS expands this test to thousands of genetic markers that test for
associations with CIG initiation with SNPs across located throughout the genome.
These designs typically genotype a number of markers (generally between 500,000 and
1 million markers) and exploit linkage disequilibrium (the non-random segregation of
alleles) to impute up to 30 million markers 142. This study design allows researchers to
identify specific genetic variants associated with phenotypes of interest. There were 12
GWAS that identified “Smoking Initiation” as an outcome and of these, 5 use data with
relatively small sample sizes (N = 1,114-8,842). A known limitation of GWAS of complex
polygenic phenotypes is that they require sample sizes of greater than 20,000 143
because the effect sizes that are often detected are very small (e.g., OR < 1.3).
Consequently, most single-sample GWAS generally do not have the statistical power
necessary to detect significant genetic associations with genome-wide data, and only
one was a single-sample study 144. In response to this limitation, seven 122,145–150 studies
used a multi-sample approach in which GWAS data was aggregated from a few
samples 147 or a GWAS was conducted in a single discovery sample and tested for
replication of results in additional samples 146,148. Many of these studies have suffered
from low power to detect statistically significant results at a genome-wide level.
Nevertheless, these single-sample studies are the foundation by which GWAS on
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tobacco use were expanded, and as such we briefly summarize published results using
these approaches in addition to study designs.

Single- and Multi- Sample GWAS
Lifetime Ever Smoking Initiation. A study of Japanese participants ages 20-89
(Biobank Japan Projects, N = 165,456) used a measure of lifetime ever smoking
initiation using an item on length of smoking in life (“How many years do/did you
smoke?”) 144. Responses to this item were categorized as ever versus never smokers.
One SNP with a genome-wide significant association was detected in men and women
(rs117036946). This SNP is located in DLC1. Two additional genome-wide significant
associations were detected in analyses of males only. These intergenic variants are
located between CXCL12 and TMEM72-AS1 (rs117097449) as well as GALR1 and
SALL3 (rs77105140) and their biological function is unclear.
Initiation of Regular Smoking. No single-sample GWAS reported results on
initiation of regular smoking. Two multi-sample GWAS have been conducted. One multisample GWAS reported results on lifetime initiation of regular smoking 145 (“Have you
ever smoked cigarettes/bidis regularly in the past?”). None of the reported results
achieved genome-wide significance (p <= 5 x 10-8). However, seven loci with suggestive
results (p < 1x10-6) were identified in men. Six of these loci were located in the
SLC39A11 region. This gene encodes a protein belonging to the ZIP, a Zinc transporter
gene which is responsible for moving zinc in and out of the cell, transporter family 151. In
women, 14 loci with suggestive results were identified. Two of these loci were located
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on the X chromosome and chromosome 15 in the region between SLCO3A1 and
ST8SIA2 genes and as such biological function is as yet unknown.
A second study used a single smoking status item and coded two different ways
to measure SI in the discovery sample (N = 8,842 Korean participants, ages 40-69). The
first SI measure was a binary trait related to lifetime regular cigarette use (i.e., never
versus having regular cigarette smoking experiences) 149.

Smoking Initiation Derived from Smoking Status. No single-sample GWAS has
reported on smoking initiation measured as smoking status. Four multi-sample studies
have reported lifetime ever smoking initiation using a measure of current smoking status
and categorized participants as “ever versus never smokers”. The first study used a
discovery sample (N = 3,497) and three additional replication samples (N = 7,863) that
measured SI in a similar fashion. No suggestive genetic associations at p ≤ 1x10-6 were
detected. Twenty-two genetic associations at p ≤ 1x10-4 were detected. Of these, the
single nucleotide polymorphisms (SNPs) with the lowest p-values were rs4423615 (p =
5.3 x 10-5). This SNP is located in GRB14, a gene involved in the tyrosine kinase
signaling pathway. It is possible that GRB14 is involved in the development type 2
diabetes 152. There was also an association with rs10794595 (p = 4.3 x10-6). This SNP
is not located in a gene nor in linkage disequilibrium with any other SNP 148.
The second study combined data from two samples using a measure of lifetime
ever use as ever versus never use (N = 4,611) 147. No suggestive genetic associations
at p ≤ 1x10-6 were detected. Seven genetic associations at p ≤ 1x10-5 were detected,
although none of the variants identified were located in known gene regions 148.
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The third study used a single smoking status item in the discovery sample (N =
8,842 Korean participants, ages 40-69) and analyzed the original four-level smoking
status, treating it as an ordinal categorical variable (i.e., “never”, “former”, “light”, and
“habitual”) 149. The replication samples assessed SI as age of smoking onset in the two
replication samples (N = 402 African American participants, N = 200 European
American participants, ages 21 and older). Although three loci located in RGS17 were
detected for SI derived from smoking status in the discovery sample, these associations
did not extend to the replication samples.
A fourth multi-sample study of US military veterans (N = 286,118, Million
Veterans Program, mean age = 64.4, 55.0% were between ages 50-69) used a
measure of smoking status for being an ever smoker (past or current) versus never
smoker as a single study and meta-analyzed their results with those from a consortium
(GSCAN) 122. Results from single study analyses identified 12 genome-wide significant
associations. Of these, eight had been identified in previous GWAS studies of SI
(rs12044362, rs1004787, rs11581459, rs1474011, rs6438208, rs11724738,
rs78875955, and rs7126748). Additionally, three were also replicated in meta-analysis
(rs11581459, rs1004787, rs6438208). These SNPs are located within or near genes
responsible whose products are responsible for regulation of gene expression
(LINC01360, long intergenic non-protein coding RNA; CAMKMT 153, calmodulin-lysine
N-methyltransferase; and ZBTB20 154, zinc finger and BTB domain containing 20).
Age of Smoking Initiation. Matoba et al. 2019 studied common variants in 30,418
Japanese participants 144. Age of smoking initiation was measured by subtracting the
number of years the participant had smoked from the age at the time the interview or
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the age at the time they quit smoking. This value was then log transformed. There were
no significant associations when data from men and women were analyzed jointly. In
females, there was a genome-wide significant association for one intergenic locus
(rs6718569, p = 3.6x10-9) between LINC01793 and MIR4432HG.
Four multi-sample GWAS have reported this outcome. The first multi-sample
GWAS used data from adults ages 44-67 (Finnish Twin Cohort Study, N = 1,114) and
reported results on four measures of age of smoking initiation (age at first puff [“How old
were you the very first time you smoked even a puff of a cigarette?”], age of first
cigarette [“How old were you the first time you smoked a whole cigarette?”], age of
onset of weekly smoking [“How old were you when you first smoked a cigarette at least
once a week for at least two months in a row?”], age of onset of daily smoking [“How old
were you when you first smoked cigarette every day or nearly every day for at least two
months in a row?”]) 146. Three SNPs located in the intergenic region between NACKAP5
and MGAT5 were associated with age of weekly smoking. However, these associations
were not detected in the replication sample (Finnish twin study [FT12], N = 869 and an
Australian twin family sample [NAG-OZALC], N = 4,425). A second study assessed as
age of smoking onset in a discovery sample (N = 8,842 Korean participants) and two
replication samples (N = 402 African American participants, N = 200 European
American participants). No suggestive genetic associations at p ≤ 1x10-6 were detected.
Results from a meta-analysis of the three samples identified 6 SNPs with genetic
associations (p ≤ 1x10-4) in males. Of these, two (rs7747583, p = 2.03x10-5 and
rs2349433, p = 3.09x10-5) were in the regulator region of RGS17 (G-protein Signaling
17) a gene whose product regulates gene expression 149.

77

The third study used data from two samples (Prostate, Lung, Colon, and Ovarian
Trial and the Nurses Health Study, N = 4,611) of adults ages 55 and above 147. No
suggestive genetic associations at p ≤ 1x10-6 were detected. However, associations
were detected with two SNPs (rs11082304, p = 6.0x10-6 and rs17050782, p = 8.4x10-6)
in genes whose products are responsible for cell proliferation and/or differentiation
(CABLES1) and gene expression (SETD7) 147.
Siedlinski et al. 2011 studied common variants in a four-cohort study of 3,397
patients of European ancestry with COPD (mean age = 65) 150. Age of initiation was
measured as using either a case Report Form or modified versions of the American
Thoracic Society /Division of Lung Diseases Respiratory Disease Questionnaire 155.
Eight loci had suggestive associations at p<1x10-6. Of these, three highly correlated
SNPs (rs9380362, rs7743060, rs769051) were in an intergenic region between BAK1
and ZBTB9.

Consortia-Based GWAS
Meta-analyses of consortia containing many individual samples with similarly
measured smoking behaviors have been used to overcome issues of low statistical
power to detect genome-side significant associations in GWAS. Consortia-based
approaches typically differ from multi-sample approaches using pre-identified data
analysis plans agreed upon by individual study teams as well as sharing and metaanalyzing results across studies within the consortium. Five consortia-based studies of
smoking initiation have been reported. These represent the largest studies of tobacco
use outcomes to date and have the strongest statistical power to detect significant
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genetic associations. Below, we detail seven consortia-based studies and the results
that were prioritized by smoking initiation phenotype. When reported, estimates of
heritability are also included.
Lifetime Ever Smoking Initiation. No consortia-based GWAS has been conducted
on a measure of lifetime ever smoking initiation.
Initiation of Regular Smoking. Five consortia-based GWAS studies measured
initiation of regular smoking by distinguishing lifetime ever use of 100 or more
cigarettes. One of the first studies to use a consortium-based used a consortium of
European ancestry-based studies (Tobacco and Genetics Consortium, 16 studies, N =
74,053). Eight genome-wide significant associations were identified 156 (Table 4.1). All
the SNPs identified were in BDNF, a gene whose product (Brain-Derived Neurotrophic
Factor) is responsible for maintaining neuronal survival and neuronal plasticity.
Although Brain-Derived Neurotrophic Factor was initially determined to function within
the striatum, it has been reported to be widely expressed in cortical and subcortical
regions of the brain 157–161.
A study of African American adults (Study of Tobacco in Minority Populations
Genetics Consortium, 13 studies, N = 32,389) ages 20-75 detected no genome-wide
significant associations for SI 162.
A study of European ancestry samples of adults (GWAS and Sequencing
Consortium of Alcohol and Nicotine Use, 29 studies, N = 1,232,091) 163 identified 378
genome-wide significant variants. Smoking initiation was harmonized across studies
from three types of measures (i.e., “Have you smoked over 100 cigarettes over the
course of your life?”; “Have you ever smoked every day for at least a month?”; and
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“Have you ever smoked regularly?”). This study reported the significant genetic variants
that were identified explained 7.8% of the variance for SI. Of the variants identified,
those with known biological function included a variant near PPP1R1B (protein
phosphatase 1 regulatory subunit 1B). The product of PPP1R1B affects synaptic
plasticity and reward-based learning in the striatum. Similarly, variants involved in the
pathways related to glutamate processes were identified. Additionally, pathways
involved in SI also included sodium-, potassium-, and calcium- voltage-gated channels
which are important for neuronal excitability and signaling. Other identified variants were
determined to be important in the pathway related to dopamine neurotransmitter
release.
A study of European and African ancestry adults (17 studies, N = 146,117)
focused on genome-wide associations with low-frequency, nonsynonymous and
putative loss-of-function exonic variants 164. A total of 93 loci associated with initiation of
regular smoking and having genome-wide significance were detected. The heritability
for initiation of regular smoking explained by all SNPs in the study was 14%. The
variation due to rare coding variants explained 2.2% of the phenotypic variance.
Therefore, rare coding variants explained 15.7% of the of the SNP heritability. Novel
variants with the strongest statistical evidence were identified in rs2232423 (ZSCAN12),
rs35891966 (NAV2), and rs6265 (BDNF). Additionally, a suggestive SNP association
and tests of gene-based association detected a significant association with HEATR5A.
BDNF is a protein coding gene which produces brain-derived neurotrophic factor
(BDNF). BDNF promotes survival and differentiation of neuronal populations during
mammalian development. It is widely expressed in the adult nervous system as well as
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in non-neural tissues, including the thymus, heart, and lung 165,166. Further, it acts as a
regulator of activity-dependent neurotransmission and plasticity in adults 157,160,161,167,168.
NAV2 is a protein coding gene whose product (neuron navigator 2) is responsible in
part for neuronal development and neurite outgrowth 169–171. It is highly expressed in the
brain (frontal cortex), kidney and liver, as well as other locations. ZSCAN12 is a protein
coding gene whose product (zinc finger and SCAN domain containing 12) is involved in
DNA binding and transcriptional regulation. It is moderately expressed throughout the
body. HEATR5A is a protein coding gene whose product (HEAT repeat containing 5A)
is moderately expressed throughout the body. Generally, a HEAT repeat refers to a
protein tandem repeat structural motif. Further, this structural motif is commonly found
in four proteins (huntingtin, elongation factor 3, protein phosphatase 2A, and yeast
kinase TOR1, HEAT) 172,173. HEAT repeats form extended super-helical structures
which are involved in intracellular transport.
One study of adults ages 18 and over focused on associations with rare coding
variants 174. This study used data from a discovery cohort and 61 replication cohorts,
consisting of three consortia (N = 346,813). The phenotypic variance explained by the
rare variants were 0.53%. Further, out of 40 variants with genome-wide significant
associations detected in a combined analysis of discovery and replication cohorts, novel
associations with three SNPs were also detected in initial analysis in the discovery
sample. These SNPs are in BORCS7 (rs7096169), SMG6 (rs216195), and TMEM182
(rs6738833). An additional non-novel association was detected in both discovery and
replication samples for a SNP (rs462779) in a gene (REV3L) that encodes a protein
which protects DNA from damage. Similarly, the products of SMG6 and TMEM182 are
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responsible for downstream regulation of gene expression for other genes. BORCS7 is
a protein coding gene and its product (BLOC-1 related complex subunit 7) is part of a
multi-subunit complex that regulates lysosome positioning and cell function related to
regulation of cell spreading and motility. Further, BORCS7 is expressed throughout the
body, including the brain. Prior studies report expression in adult neurons and
astrocytes 175.
Smoking Initiation Derived from Smoking Status. No consortia-based studies of
smoking initiation derived from smoking status were identified.
Age of Smoking Initiation. Four consortia-based GWAS measured age of
smoking initiation. All studies used self-report.
Furberg et al (TAG consortium) 2010163 studied common variants in 24,114
European ancestry participants. Age of smoking initiation measured the age the
participant started smoking cigarettes. Some studies studied the age at which the
participant first tried smoking, even one or two puffs. Others measured the age the
participant began smoking regularly. No genome-wide significant associations were
detected.
David et al. 2012 162 studied common variants in 15,547 African American
participants. Age of initiation was measured two different ways. Some studies
measured as the age at which smoking was first attempted. Other samples measured
as the age at which participants began smoking regularly. Three highly correlated SNPs
(rs1678618, rs12445577, and rs1612028) located in SPOCK2 had a suggestive
association (p < 1x10-6) with age of initiation. The product of SPOCK2 (SPARC
[Osteonectin], Cwcv And Kazal Like Domains Proteoglycan 2, also known as testican-2)
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is a protein which binds with glycosaminoglycans to form part of the extracellular matrix.
It is expressed across several tissues and has particularly high levels of expression in
the brain and lung. Further, it is expressed prominently in normal brain, and its
expression levels decrease as tumor grade in this area increases.
Liu et al 2019 163 studied common variants in 341,427 European ancestry
participants. Age of smoking initiation was measured as “At what age did you begin
smoking regularly?” Alternatively, other studies used a combination of “How long have
you smoked?” and “What is your current age?” to derive a continuous measure for age
of regular smoking initiation. Ten loci were associated at a level of genome-wide
significance. The total SNP heritability was 5%. Of the 10 loci identified, 7 were located
within intronic regions of genes (rs72853300- TEX41, rs12611472- CUL3, rs7559982WDPCP, rs11915747- CADM2, rs13136239- MAML3, rs624833- ADD1, rs1403174MAD1L1). TEX41 is a long-noncoding RNA gene.
Brazel et al 2019 164 focused on associations with rare coding variants in 124,590
adults. Age of smoking initiation was conceptualized as the age at which an individual
started smoking cigarettes regularly. Studies used items such as: “At what age did you
begin smoking regularly?” Alternatively, other studies used a combination of “How long
have you smoked?” and “What is your current age?” to derive a continuous measure for
age of regular smoking initiation. Three loci were associated at a level of genome-wide
significance (rs12493563- CADM2, rs8082191- ACCN1, rs442467- MACROD2). The
total SNP heritability was 6% and the heritability due to the detected rare variants was
1.1%. Therefore, rare variants accounted for 18% of the SNP heritability for age of
smoking initiation.
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Functional Analysis. DAVID analyses reported 15 biological pathways that were
significantly associated with genome-wide significant SNPs for SI. Five pathways were
associated with the synapse and cell junctions. These two pathways included CHRNA4
among 14 other genes (FOCAD, TENM2, GRID2, NLGN1, CADM2, NRXN1, MAGI2,
DIXDC1, GRIK4, CABP1, GRIN2B, DPP4, OLFM1, TRIM9, SDK1, GRIN2A, ADAM15,
DLC1, CTNNA2, ERC2, CBLN4, LRRC4C). Five pathways were associated with the
immune system, specifically immunoglobulins. These pathways impact the adhesion of
the immunoglobulins rendering them less effective176. In total 14 genes were associated
with this system (ROBO2, LINGO1, NEGR1, CADM2, DCC, NTM, PXDNL, SEMA3F,
PTPRF, IGSF11, PTPRD, SDK1, NCAM1, CNTN4, LRRC4C, OPCML). Two other
pathways related to transmembrane structure, proteins that span the membrane of the
cell. More than 80 genes were associated with these pathways. Seven genes, including
CHRNA4 and BDNF, were associated with a pathway that control ligand-gated ion
channels. Finally, three other pathways, with over 50 genes, involved in the nucleus and
transcription within the nucleus were associated. These genes implicate either signaling
between cells (i.e., synapse functions, cell junctions, transmembrane structure),
transcription within the nucleus, or immune system response (Table 3.1).
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Table 3.1. DAVID-Identified Gene Clusters and Biological Systems for Smoking Initiation
Category
Term
Genes
UP_KEYWORDS

Synapse

UP_KEYWORDS

Cell junction
IPR013098:
Immunoglobulin I-set
IPR003598:
Immunoglobulin
subtype 2
domain: Ig-like C2type 3

INTERPRO
INTERPRO
UP_SEQ_FEATURE
SMART

UP_KEYWORDS

SM00408: IGc2

Transmembrane helix

TENM2, GRID2, NLGN1, CHRNA4, CADM2, NRXN1, MAGI2, GRIK4,
CABP1, GRIN2B, OLFM1, TRIM9, SDK1, GRIN2A, ERC2, CBLN4,
LRRC4C
FOCAD, TENM2, GRID2, NLGN1, CHRNA4, CADM2, NRXN1, MAGI2,
DIXDC1, GRIK4, CABP1, GRIN2B, DPP4, OLFM1, TRIM9, SDK1,
GRIN2A, ADAM15, DLC1, CTNNA2, ERC2, CBLN4, LRRC4C
ROBO2, LINGO1, NEGR1, DCC, NTM, PXDNL, PTPRF, PTPRD, SDK1,
NCAM1, CNTN4, LRRC4C, OPCML
ROBO2, LINGO1, NEGR1, CADM2, DCC, NTM, PXDNL, SEMA3F,
PTPRF, IGSF11, PTPRD, SDK1, NCAM1, CNTN4, LRRC4C, OPCML
ROBO2, PTPRD, SDK1, NEGR1, DCC, NTM, NCAM1, PXDNL, CNTN4,
PTPRF, OPCML
ROBO2, LINGO1, NEGR1, CADM2, DCC, NTM, PXDNL, SEMA3F,
PTPRF, IGSF11, PTPRD, SDK1, NCAM1, CNTN4, LRRC4C, OPCML
THSD7B, GIMAP2, XYLT1, TMEM261, IGF1R, HS6ST3, EDNRA,
CHCHD3, NOMO2, ENTPD1, EPHA7, SEMA6D, VRK2, CDYL, HLA-G,
INPP4B, ADAM15, ADGRB2, ADGRB3, YME1L1, GPM6A, TMEM161B,
CHRNA4, PCDH15, CACNA1D, EFNA5, TMEM242, DPP4, RHOT2,
GRIN2A, GALR1, RNF217, CDH23, LRRC4C, ST3GAL1, BTN2A2,
BDNF, CADM2, PTCH1, ST8SIA2, EDEM1, SLC4A10, GRIN2B, IGSF11,
PTPRD, SDK1, FAM163A, TBXAS1, SLC26A7, CSPG5, FAT3, TMEM18,
XKR6, DDR1, ROBO2, ALK, RYR2, NRP1, TENM2, MCTP1, TENM3,
RNF13, TMEM110-MUSTN1, GRIK4, TMEM182, SPPL3, ELFN1,
PTPRF, CLYBL, PTPRG, IMMP2L, SGCD, GRM8, CNGA3, GRID2, EED,
TRPC4, DCC, ELOVL3, SLC39A11, ELOVL7, SORCS3, CDH12,
SMIM21, ST6GALNAC3, OR10A6, CHST3, TMEM55A, NFAT5, NLGN1,
FOCAD, SLC24A4, SLC24A3, NRXN1, TMPRSS3, PTGER3, NRXN3,
SEZ6, NRXN2, SPG7, ERBB3, HECTD4, NCAM1, CNNM2, KCNJ3,
LINGO1, PCDH9, SYT14, SLC28A3

p
0.008
0.022
0.002
0.005
0.015
0.037

0.037
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Table 3.1 (continued). DAVID-Identified Gene Clusters and Biological Systems for Smoking Initiation
Category

Term

UP_KEYWORDS

Glycoprotein
GO:0050839~cell
adhesion molecule
GOTERM_MF_DIRECT
binding
GO:0007416~synapse
GOTERM_BP_DIRECT
assembly
Ligand-gated ion
UP_KEYWORDS
channel

UP_KEYWORDS

Nucleus

Genes

p

DDR1, ROBO2, ALK, NRP1, TENM2, TENM3, ITPRIP, RNF13, THSD7B,
CPXM2, XYLT1, GRIK4, TMEM182, CLU, ELFN1, PTPRF, IGF1R,
PTPRG, HS6ST3, EDNRA, SGCD, GRM8, NOMO2, POSTN, ENTPD1,
GRID2, EPHA7, DCC, SEMA6D, ELOVL3, SORCS3, HLA-G, OLFM1,
ADAM15, ADGRB2, ADGRB3, CDH12, MAPT, ST6GALNAC3, OR10A6,
HIST1H2BD, CHST3, GPM6A, SLC24A4, TMEM161B, NLGN1, ITIH3,
SLC24A3, CHRNA4, NRXN1, NTM, TMPRSS3, PTGER3, NRXN3,
PCDH15, SEZ6, NRXN2, CACNA1D, SEMA3F, EFNA5, THBS4, DPP4,
IGSF21, GRIN2A, BRINP1, ERBB3, GALR1, SPOCK2, CDH23, NCAM1,
CNNM2, ST3GAL1, KCNJ3, OPCML, LINGO1, BTN2A2, NEGR1,
PCDH9, BDNF, CADM2, ST8SIA2, PTCH1, EDEM1, PXDNL, GRIN2B,
PTPRD, IGSF11, SDK1, CSPG5, FAT3, CNTN4, CBLN4

0.030

PTPRD, NLGN1, POSTN, TENM2, TENM3, CADM2, NRXN1, NRXN3,
NRXN2

0.004

GPM6A, SDK1, NLGN1, BDNF, NRXN1, SPOCK2, NRXN3, NRXN2

0.042

RYR2, GRIN2A, GRID2, CHRNA4, GRIK4, CNGA3, GRIN2B
ZBTB20, CLU, IKZF4, RPS6KA4, CHCHD3, PPP4R2, SALL3, GRAP2,
CHEK2, ZNF207, MACROD2, BTRC, SMARCC1, EBF1, RFX3, ARID5B,
HDGFRP2, VRK2, TNNI3K, CDYL, OVOL1, DGKZ, POU3F2, FOXP1,
CAMKMT, MAML3, TOX, MAD1L1, HIST1H2BD, KHDRBS3, CUL3,
TSHZ1, NOLC1, FOXO3, FHIT, PHF21A, ZSCAN12, ZNF789, CAMTA1,
ZNF423, IP6K2, PHC2, ZFHX3, CPSF6, SMAD3, BCL11B, BCL11A,
ZBTB16, CEP350, RANBP17, MICAL2, FOXN3, ZBTB9, ICK, DAZL,
MLLT10, MSRA, LSM8, KIF4B, TMEM18, BRWD1, RERE, BARHL2,
TENM2, BNC2, RNF13, BNC1, CELF2, SETD7, CHD3, AFF3, SMG6,
ZNF407, SIX3, REV3L, ZNF644, EED, RMI1, SLC39A11, NAV2, MED27,
MMS22L, NAV3, RARB, RBM20, NFAT5, CTDP1, ZBTB46, NOL4,
FGD2, TRA2B, POLR2F, FPGT-TNNI3K, IGF2BP2, CTNNA2, ASCC3,
RUNX1T1, MCRS1, CABLES1, WWP2, ZIC4, CHFR, REST, KANSL1

0.030

0.030
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Table 3.1 (continued). DAVID-Identified Gene Clusters and Biological Systems for Smoking Initiation
Category

Term

Genes
p
RERE, BARHL2, TENM2, BNC2, BNC1, SETD7, ZBTB20, CHD3,
AFF3, IKZF4, CHCHD3, SALL3, CHEK2, ZNF407, SIX3, ZNF644,
SMARCC1, EED, LMO3, EBF1, ARID5B, RFX3, CDYL, OVOL1,
MED27, POU3F2, FOXP1, RARB, MAML3, NFAT5, KHDRBS3,
ZBTB46, TSHZ1, FOXO3, FHIT, PHF21A, ZSCAN12, ZNF789,
POLR2F, CAMTA1, ASCC3, ZNF423, RUNX1T1, ZFHX3, SMAD3,
BCL11B, BCL11A, ZBTB16, MCRS1, FOXN3, ZBTB9, MLLT10,
UP_KEYWORDS
Transcription
REST, TMEM18, BRWD1
0.030
RERE, BARHL2, TENM2, BNC2, BNC1, SETD7, ZBTB20, CHD3,
AFF3, IKZF4, CHCHD3, SALL3, CHEK2, ZNF407, SIX3, ZNF644,
SMARCC1, EED, LMO3, EBF1, ARID5B, RFX3, CDYL, OVOL1,
MED27, POU3F2, FOXP1, RARB, MAML3, NFAT5, KHDRBS3,
ZBTB46, TSHZ1, FOXO3, FHIT, PHF21A, ZSCAN12, ZNF789,
CAMTA1, ASCC3, ZNF423, RUNX1T1, ZFHX3, SMAD3, BCL11B,
Transcription
BCL11A, ZBTB16, MCRS1, FOXN3, ZBTB9, MLLT10, REST,
UP_KEYWORDS
regulation
BRWD1
0.037
Note. Category refers to the original database or resource where the term originates. Term refers to the detailed function in
an annotation source.
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Conclusions. SI is complex, polygenic trait with many genes influencing the
phenotype. Genes that are responsible for acetylcholine receptor function (e.g.,
CHRNA4) were consistently associated via the DAVID analysis with SI.

2. Nicotine Metabolism
Almost 90% of nicotine is metabolized in the liver into six metabolites 177. Approximately
70-80% of nicotine metabolizes to cotinine (the primary nicotine metabolite) and as
such, most studies focus on this metabolite. The production of cotinine occurs in two
steps: the first is metabolizing to nicotine-Δ1′ (5′)-iminium ion with cytochrome P450 2A6
(CYP2A6), and the second step involves catalyzing the nicotine iminium ion by a
cytoplasmic aldehyde oxidase. These processes are predominately driven by the
Cytochrome P450 enzymes (e.g., CYP2A6, Figure 3.1). Cotinine is excreted through
urine, blood, and saliva. Salivary cotinine is highly correlated with blood cotinine making
salivary cotinine measurement is a less invasive and cost-effect method of measuring
cotinine 178. Urinary cotinine is generally four to six times more concentrated, making
urinary cotinine a more sensitive measure of cotinine 179. Cotinine has a half-life of
roughly 20 hours but is detectable for up to a week after exposure to nicotine. The
process of metabolizing cotinine occurs across three separate pathways (Figure 3.1).
Although there are 6 metabolites derived from nicotine, genetically-informed studies of
metabolism have focused on cotinine, 3’-hydroxycotinine and its downstream metabolite
3’-hydroxycotinine glucuronide, 5’-hydroxycotinine, and cotinine glucuronide. The first
step utilizes CYP2A6 and CYP2A13 enzymes to produce 3’-hydroxycotinine; and 5
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enzymes from the UDP-glucuronosyltransferase family (UGT1A4, UGT1A9, UGT2B7,
UGT2B4, and UGT2B15) to produce 3’-hydroxycotinine glucuronide. The highest
concentrations of this metabolite are found in urine. A third metabolite, cotinine
glucuronide, is produced when UGT1A1, UGT1A4, UGT1A9, and UGT2B10 enzymes
act on cotinine to produce cotinine glucuronide. 5’-hydroxycotinine is produced from
CYP2A6 and is frequently detected in urine. These products are all metabolites of
cotinine, which allows for an estimation of the rate of nicotine metabolism. A nicotine
metabolite ratio (NMR) is also able to be calculated as the ratio of cotinine to
3’hydroxycotinine.

Figure 3.1. Nicotine Metabolism Pathway with Enzymes Responsible for the
Pathways.
Twin Studies.
One twin study of nicotine metabolism has been published 180. This study used blood
and urine samples to assess cotinine. Additive genetic influences (A) accounted for
nearly 60% of the variance in nicotine metabolism in twins, while unique environmental
influences (E) accounted for the remaining 40% with no shared environmental
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influences. Further examination of the twin correlations (rMZ = 0.68, rDZ = 0.25) also
suggested some non-additive genetic effects, such as dominance effects (as evidenced
by the DZ twin correlation being less than half of the rMZ, or 0.34), contributing to
nicotine metabolism. This study did not have the power to detect non-additive effects
and encouraged further research to study this source of variance.

Single and Multi-Sample Genome-Wide Association Studies of Nicotine Metabolism
One single-sample GWAS was conducted using nicotine metabolism as the outcome
variable and reported 1,732 genome-wide significant associations 181. This study
examined nicotine metabolism as measured by cotinine glucuronide. Specifically, the
outcome was defined as the ratio of cotinine glucuronide to total cotinine (similar to the
NMR) which was associated with 1,241 SNPs at the genome-wide significant level. In
an effort to reduce the number of associations, researchers used the genome-wide
significant SNPs in a stepwise regression to determine which SNPs accounted for the
majority of the variance. Of the 1,241 SNPs associated with cotinine glucuronidation, 15
were associated after running stepwise regression. Four of these SNPs were in or near
UGT2B10 (on chromosome 4) which encodes for the enzyme UDPglucuronosyltransferase 2B10, which is responsible for the glucuronidation of both
nicotine and cotinine. The strongest single SNP association was for rs115765562 (p =
1.6 x 10-155), an intergenic location on chromosome 4. This SNP is highly correlated with
a UGT2B10 splice site variant, rs116294140, which together with rs6175900 (Asp67Tyr)
explains 24.3% of the variation in cotinine glucuronidation 182. Further results indicated
FAM107B (Family with Sequence Similarity 107 Member B), CERS3 (Ceramide
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Synthase 3), and SLC2A14 (Solute Carrier Family 2 Member 14) had intronic variants
associated with nicotine metabolism. All other reported results were in intergenic
regions.
In addition to cotinine glucuronidation, this study also examined nicotine
glucuronidation, which is defined as the ratio of nicotine N-glucuronide to total nicotine.
Using this definition of the outcome, 492 SNPs showed genome-wide significance. After
putting genome-wide significant SNPs into the regression model, two SNPs remained
significant after the stepwise regression procedure. Both significant SNPs were intronic
variants. The first was located on chromosome 4 in UGT2B10, the same gene
associated with cotinine glucuronidation. The other significant SNP was intronic to
SHFM1 (Split hand/foot malformation type 1), which encodes for 26S proteasome
complex subunit DSS1. It is thought this protein plays a role in the completion of the cell
cycle.
One GWAS was conducted using a multi-sample (5 studies, N = 5,185
participants) GWAS design 183. This study reported 1,267 genome-wide significant hits
for NMR, COT, and 3HC. These SNPs were all located on either chromosome 4 or
chromosome 19. Those on chromosome 4 were all located within TMPRSS11E gene
(Transmembrane Serine Protease 11E), a novel finding for nicotine metabolism.
Previous studies of this gene have indicated a role in cognition 184. The findings on
chromosome 19 were tightly linked to CYP2A6 with the most significant two SNPs being
located within this gene. Additionally, there were several highly significant SNPs either
near CYP2A6 (rs113288603) or near the CYP2B6 gene. Both CYP genes have
previously been reported to be significant with substance metabolism 37,185–189.
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Functional Analysis. No DAVID analysis was performed for nicotine metabolism
because only two studies examined the phenotype.

3. Quantitative Measures
The goal of measuring smoking quantity is to establish an estimate of the amount of
nicotine exposure. Nicotine content in typical conventional cigarettes is generally
regulated in the United States. A typical cigarette sold in the US contains approximately
11mg of nicotine 190. Consequently, one of the most common ways (5 of 5 reported
studies) of measuring regular smoking is to measure the number of cigarettes smoked
per day (CPD). This value can be transformed into the number of cigarettes consumed
during other time frames (e.g., per week, month, or year) (1 of 5 GWASs). Other studies
have also examined maximum cigarettes smoked per day when the participant was at
maximum smoking levels (1 of 5 studies). Most studies (4/5) chose to bin the CPD
measure either as a binary variable based on a threshold (e.g., smoking at least 10
cigarettes per day) or binned into other categories (e.g., 1-10 CPD, 11-20, 21-30, etc.; 1
out of 5 studies).

Twin Studies
Continuous Measures of Cigarettes per Day. To date, 7 adult twin studies have
measured CPD. In general, these studies indicate a higher proportion of variance due to
genetic factors compared to measures of smoking initiation. A study of Dutch twins ages
12-24 (mean age = 17.7, N = 1,676 twin pairs) reported a substantial estimate of
additive genetic influences (A = 0.86, 95% CI = 0.70-0.94) and a much smaller
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contribution due to shared environmental effects (C = 0.54, 95% CI 0.25-0.95) for
average number of cigarettes smoked per day 191. Similarly, in a study of Australian
twins, researchers used average number of cigarettes smoked per day as the measure
of CPD and reported significant genetic (A = 0.40) and shared environmental effects (C
= 0.12) 104. A study of US twins (N = 94 pairs) also used average number of cigarettes
smoked as the outcome; however, this study also asked twins to report their average
CPD for the year they smoked the heaviest. This study reported significant genetic (A =
0.40) but no shared environmental effects 106. Further research in a sample of AfricanAmerican adults with a mean age of 46.9 (SD = 13.9; N = 200 same-sex twin pairs)
reported a significant heritability for pack-years of smoking, though this estimate was
lower than when measured as continuous CPD (A = 0.43) (Whitfield 2007). These
results provide evidence of genetic influences on cigarette quantity using a continuous
measure.
Ordinal Measures of Cigarettes per Day. Other studies have chosen various
ways of categorizing smoking quantity twins from the Netherlands (N = 3,657 pairs;
average age 28.7 years for DZ twins and 24.7 for MZ twins) by categorizing CPD into 5
ordinal bins; the study reported significant genetic (A = 0.51) and shared environmental
effects (C =0.30) 136. Another study of Finnish twins (N = 9,880 pairs; age range 24-88)
dichotomized smoking quantity with the threshold of smoking 20 cigarettes per day. This
study reported significant genetic effects (A = 0.54) but no shared environmental effects.
A final US study examined CPD as a continuous measure from 1,078 twin pairs (aged
18-25) and reported significant genetic (A = 0.50) but not shared environmental
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influences 192. Regardless of the measure of quantity smoked, there was relatively
consistent agreement in the estimate of A with a range of roughly 0.40 to 0.54.

Single and Multi-Sample Genome-Wide Association Studies of Quantitative Measures
The earliest GWAS of smoking quantity were conducted in 2014-2015 with low sample
sizes (N ranged from ~ 500 individuals to a little over 5,000) 146,193. Unsurprisingly, these
early studies did not report any genome-wide significant associations. These studies
examined cigarettes smoked per day, the maximum number of cigarettes smoked per
day, and the average number of cigarettes smoked per day; with each measure selfreported by participants. Further, these studies were of the single-sample or multisample nature, with the multi-sample study utilizing a discovery and replication sample
(both N < 400 participants, massively underpowered).
A more recent single-sample GWAS completed in an older adult sample194 (age
range: 62-81) was also underpowered (N = 2,063) but did report genome-wide
significant associations between several variants and cigarettes per day. Three variants
(rs4300632, rs11074386, rs11074388) in the gene CLEC19A (C-Type Lectin Domain
Family 10 Containing 19A) were associated at the genome-wide level. This gene plays
a role in carbohydrate bonding (the oxidation of one or more hydroxy groups).
A multi-sample (N = 3 samples) study of middle to older adults (age range: 4481; N = 13,551) also reported genome-wide significant associations between the
number of cigarettes smoked per day with CHRNA3, CHRNA5, and CHRNB4 195. These
genes code for different subunits of the nicotinic acetylcholine receptors (nAChR).
However, all the resulting receptors react to nicotine as an acetylcholine agonist,

94

compelling the receptor to react. Additional results from this study included the
aminoglycoside phosphotransferase domain-containing protein 1 (AGPHD1), which aids
in the transferring of phosphorous-containing groups and lysine degradation. In addition,
iron responsive element binding protein 2 (IREB2) which assists in regulating the
translation and stability of mRNAs that affect iron homeostasis was significantly
associated with smoking quantity.
Another study assessed smoking quantity by asking participants the number of
cigarettes smoked and then categorized participants as never smokers, former
smokers, nondaily smokers, and daily smokers 196. This multi-sample (N = 2) study and
used data from 12,804 Hispanic participants ages 18-74. Similar to prior GWASs, this
study reported genome-wide significant associations between their measure of nicotine
use (i.e., self-reported category) and the nAChR genes, specifically CHRNA3,
CHRNA5, and CHRNB4. Importantly, this study provides convergent evidence that the
nAChR gene cluster is important when examining the molecular genetic influences on
quantitative measures of smoking 196.

Consortia-Based Genome-Wide Association Results of Quantitative Measures
One consortium has examined CPD, though the consortia was small by current
standards (N = 5,354). This study did not report any genome-wide significant results for
the CPD phenotype.

Functional Analysis. DAVID analysis identified 19 pathways with significant
association with genome-wide significant SNPs related to quantitative measures of
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nicotine (e.g., cigarettes per day). Each of these associated pathways included the
genes CHRNA3, CHRN5, and CHRNB4. PARD3 and TMC5 were also represented in
two pathways each. In general, these pathways were involved in the behavioral
response to nicotine as well as acetylcholine receptor action. These actions included ion
channel activity (i.e., transmembrane transfer of an ion via the channel that opens when
a specific ligand has been bound by the channel complex) as well as ion transport (i.e.,
directed movement of charged atoms). Genes that are involved in acetylcholine
receptor action (e.g., CHRNA2) have previously been associated with GWAS results for
quantitative measures of smoking such as CPD.
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Table 3.2. DAVID-Identified Gene Clusters and Biological Systems for Cigarettes Per Day
Category

Term

Genes

p

GO:0035095~behavioral response to
nicotine

CHRNA3, CHRNB4, CHRNA5

7.78E-04

CHRNA3, CHRNB4, CHRNA5, TMC5

0.00125425

CHRNA3, CHRNB4, CHRNA5

0.00157543

GOTERM_MF_DIRECT

GO:0004889~acetylcholine-activated
cation-selective channel activity

CHRNA3, CHRNB4, CHRNA5

9.25E-04

GOTERM_MF_DIRECT

GO:0015464~acetylcholine receptor
activity

CHRNA3, CHRNB4, CHRNA5

9.25E-04

GOTERM_CC_DIRECT

GO:0005892~acetylcholine-gated
channel complex

CHRNA3, CHRNB4, CHRNA5

0.00274975

GOTERM_MF_DIRECT

GO:0042166~acetylcholine binding

CHRNA3, CHRNB4, CHRNA5

9.25E-04

IPR027361:Nicotinic acetylcholinegated receptor, transmembrane domain

CHRNA3, CHRNB4, CHRNA5

0.00157543

GOTERM_BP_DIRECT

GO:0007271~synaptic transmission,
cholinergic

CHRNA3, CHRNB4, CHRNA5

0.00476613

GOTERM_MF_DIRECT

GO:0015276~ligand-gated ion channel
activity

CHRNA3, CHRNB4, CHRNA5

0.00134041

GOTERM_BP_DIRECT

GO:0098655~cation transmembrane
transport

CHRNA3, CHRNB4, CHRNA5

0.00603842

GOTERM_BP_DIRECT
GOTERM_BP_DIRECT
INTERPRO

INTERPRO

GO:0006811~ion transport
IPR002394:Nicotinic acetylcholine
receptor
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Table 3.2 (continued). DAVID-Identified Gene Clusters and Biological Systems for Cigarettes Per Day
Category
Term
Genes
INTERPRO

IPR018000:Neurotransmitter-gated ionchannel, conserved site

p

CHRNA3, CHRNB4, CHRNA5

0.00212964

CHRNA3, CHRNB4, CHRNA5

0.00212964

CHRNA3, CHRNB4, CHRNA5

0.00212964

INTERPRO

IPR006029:Neurotransmitter-gated ionchannel transmembrane domain
IPR006201:Neurotransmitter-gated ionchannel

INTERPRO

IPR006202:Neurotransmitter-gated ionchannel ligand-binding

CHRNA3, CHRNB4, CHRNA5

0.00212964

UP_KEYWORDS

Ion channel

CHRNA3, CHRNB4, CHRNA5, TMC5

0.02406641

UP_KEYWORDS

Ligand-gated ion channel

CHRNA3, CHRNB4, CHRNA5

0.02406641

hsa04080:Neuroactive ligand-receptor
interaction

CHRNA3, CHRNB4, CHRNA5, PARD3

0.0212414

GO:0030054~cell junction

CHRNA3, CHRNB4, CHRNA5, PARD3

0.03088171

INTERPRO

KEGG_PATHWAY
GOTERM_CC_DIRECT

Note. Category refers to the original database or resource where the term originates. Term refers to the detailed
function in an annotation source.
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4. Nicotine Dependence
Researchers have long been concerned with classification of nicotine
dependence (ND) and have several valid and reliable tools with which to do so. The
most common (2 of 5 studies) of these scales is the Fagerström Test for Nicotine
Dependence (FTND) 197, also referred to more recently as the Fagerström Test for
Cigarette Dependence (FTCD; 1 of 5 studies) 198,199. Further, researchers have also
used the time to first cigarette in the morning (TTFC) as a proxy for ND, as it is
assumed that individuals who are more dependent will need a cigarette sooner (typically
within five minutes of waking) than individuals who use but aren’t dependent (1 of 5
studies). Finally, symptoms of ND (spent a great deal of time getting, using or getting
over effects of CIG; used CIG more often or in larger amounts than intended; built up a
tolerance so that the same amount of CIGs has less effect than before; CIG use kept
you from working, going to school, taking care of children, or engaging in recreational
activities; CIG use caused emotional or psychological problems; CIG use caused health
problems; wanted or tried to stop or cut down CIG use), as defined by the American
Psychiatric Association 200 the DSM-IV-TR, binned into categories based on the sum of
symptoms has been used (1 of 5 studies) to assess ND.

Twin Studies of Nicotine Dependence
Fagerström Test for Nicotine Dependence. Three twin studies examining ND via
the FTND have most often been used to estimate A, C, and E for ND. A study of
Virginia twins (N = 6,805; age range = 20-59) reported significant genetic effects (A =
0.67) but no shared environmental effects 135. A contemporary study was completed in a
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sample of Dutch twins (N = 1,572, mean age = 30.2) and reported similar findings 201.
Specifically, this study found significant genetic effects (A = 0.75) but no influences due
to shared environmental effects 201. A study of Swedish twins (N = 5,040; age range =
22-57) reported lower, but significant effect, of additive genetic influences (A = 0.39,
95% CI = 0.29-0.49) 202. Consistent with the previous studies, there was no effect of
shared environmental influences.
DSM Symptoms. Three twin studies used the DSM definition of ND. Typically,
twin studies have examined the number of symptoms rather than using the diagnosis of
ND. Twin studies are often an initial study design employed in genetic epidemiology and
the DSM is constantly evolving. As such, twin studies may have used different versions
of the DSM to assess the symptoms. An older study of Vietnamese twins from the US
(N = 9,414; age range: 35-53) utilized the Mental Health Diagnostic Interview Schedule
III-revised (DIS-III-R) which is a standardized interview based on the DSM-III-R 138.
Nicotine dependence was assessed as an ordinal variable with 3 bins based on a sum
score of symptoms endorsed: 0-2 symptoms (no dependence), 3-4 symptoms (mild
dependence), 5-7 symptoms (high/severe dependence). This study reported significant
genetic (A = 0.55, 95% CI = 0.40-0.61) and smaller shared environmental factors (C =
0.04; 95% CI = 0.00-0.17).
More recent research transitioned to using the DSM-IV for examining nicotine
dependence. A study conducted in 2016 utilized 7,285 Australian twins with a mean age
of roughly 30 to examine ND 203. A sum score of ND items from the DSM-IV (range 0-7)
was used. This study reported significant genetic effects (A = 0.57, 95% CI = 0.43-0.71)
and nonsignificant effects of the shared environment (C = 0.02, 95% CI = -0.10-0.14).
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Another study utilizing the DSM-IV used the diagnosis of ND, which they defined as
having 3 or more symptoms (of the 7 total) in the past 12-months. Using a sample of
5,580 Australian twins (age range: 11-18), this study reported significant genetic effects
(A = 0.56, 95% CI = 0.40-0.63) but no shared environmental 204 .
Heaviness of Smoking Index. Heaviness of smoking index (HSI) is an index of
two items, the time to first cigarette and cigarettes smoked per day 205, which was used
by one twin study. The HSI showed a greater influence of genetic effects (A = 0.71) than
when ND was measured via the FTND 204. There was no significant effect of shared
environmental factors for the HSI.

Single and Multi-Sample Genome-Wide Association Studies of Nicotine Dependence
Fagerström Test for Nicotine Dependence. GWAS that have studied ND have
been multi-sample in nature (four in total), with only one single sample study employed.
The first GWAS was published in 2012 206, using the FTCD (Fagerström Test for
Cigarette Dependence) as the measure of ND. Participants (N = 3,365) were selected
from samples under the SAGE project, including the Collaborative Genetic Study of
Nicotine Dependence (COGEND), the Collaborative Study on the Genetics of
Alcoholism (COGA), and the Family Study of Cocaine Dependence (FSCD). The
authors report seven genome-wide significant associations all in or near CHRNB3 on
chromosome 8 with an additional three variants suggestive (p < 10-7). The most
significant association was rs1451240 and was protective against ND (OR = 0.65; 95%
CI = 0.56-0.76, p = 2.44 x 10-8).
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The FTND was used to quantify ND in a multi-sample (N = 2) study with 7,646
individuals 207. This study reported 67 genome-wide significant associations (Table
S3.3). Nearly all (58 number of 66 variants) of the detected variants were located on
chromosome 14. There were four significant associations on chromosome 8.
Additionally, two variants with significant associations were located on chromosome 18.
The two results on chromosome 18 were intergenic, with no known function. Other
results on chromosome 8 were all located within DLC1, Deleted in Liver Cancer 1 which
has been implicated in hepatocellular carcinomas. The majority of the associations on
chromosome 14 were located within FAM179B (most significant SNP: rs114962601, p =
6.53 x 10-10), which has been implicated in the function of primary cilia (an organelle in
eukaryotic cells which serve as sensory organelles). Three additional genes were
implicated in addition to FAM179B. KLHL28, Kelch Like Family Member 28, which
influences protein binding and has been shown to be differentially expressed in neural
tissue 208. C14orf18, chromosome 14 open reading frame 18, a gene with currently
uncharacterized function. FANCM, Fanconi anemia complementation group M, a gene
responsible for DNA repair. PRPF39, pre-mRNA processing factor 39, which is involved
in processing of RNA and mRNA.
DSM. The most current GWAS for ND as measured using DSM criteria was a
single sample study of twins from Finland using DSM-IV diagnosis as well as symptom
count 194. This study of 1,715 individuals (mean age: 55) reported 2 genome-wide
significant associations. The most significant association was detected for a SNP
located on chromosome 18 which is in the SLC14A2 gene (rs117354958, p = 3.55 x 108

). The product of this gene is the solute carrier family 14 member 2 protein. It has been
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implicated in protein binding as well as urea transport. The other significant SNP was
located in AP2A2, rs369708413, p = 6.58 X 10-8. The product of this gene, adaptor
related protein complex 2 subunit alpha 2 (AP2A2) is a protein that assists in other
protein binding and transport.

Consortia-Based Genome-Wide Association Results of Nicotine Dependence
One consortia-based based GWAS examined both the FTND and the time to first
cigarette (TTFC) in the morning 209. For the FTND, there was only one significant variant
(rs16969968) located in the CHRNA5 gene, highlighting again the important of the
nAChR genes. This study further examined gene sets (defined a priori) and reported the
CHRNA3-CHRNB4-CHRNA5 gene set was statistically associated with FTND (p = 3.96
x 10-19).
When examining the TTFC phenotype, similar results emerged. The previous
SNP from CHRNA5 (rs16969968) was also highly associated with TTF (6.21 x 10-9);
however, there were additional variants significantly associated with TTFC. These
included SNPs from SORBS2 (sorbin and SH3 domain containing 2, rs28567706;
involved in cellular structure and RNA binding), AA333164 (rs117029742, a long noncoding RNA with unknown function), and BG182718 (rs10133756, a long non-coding
RNA with unknown function). When examining gene sets, there were two sets that were
associated with TTFC. The first was the same CHRNA3-CHRNB4-CHRNA5 gene set
that was associated with the FTND (6.21 x 10-9). Also, the gene set CHRNB3-CHRNA6
was significantly associated with TTFC (8.83 x 10-8), providing further evidence for the
role of the nAChR genes.
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Functional Analysis. DAVID analyses of genome-wide significant SNPs for
nicotine dependence identified 30 significantly associated pathways (Table 3.3). Each
significant pathway was represented with several of the nAChR genes (e.g., CHRNA3,
CHRNB4). As such, it is unsurprising that the significantly associated pathways (13
pathways) overwhelmingly were involved in some sort of acetylcholine activity including
binding, ion channel activation, or gate control (all Benjamini-Hochberg p < 1.06 x 10-6).
Other associated pathways were involved with the behavioral or molecular response to
nicotine which is reasonable given that nicotine acts as an agonist of the nAChRs. This
leads to excess dopamine in the reward pathways of the brain, culminating in
pleasurable feelings, which may help explain the dependence on the drug. Further
network enrichments were found in postsynaptic cell membrane function and neural
949527

6,118 individuals from the Million Veterans Project (MVP; age range = 58-64) and

also categorized individuals as ex-smokers on the basis of self-reported questions (i.e.,
current versus former) 122. This study reported 8 genome-wide significant SNPs. 4 of
these SNPs were in intergenic regions (rs11210228, rs34735365, rs77648866,
rs112270518), 1 was in the 5’ untranslated regions (5’UTR) of CHRNA2 (rs2565060),
and the other 3 were intronic to various genes. These intronic SNPs were located on
DRD2 (rs61902807), CYP2A6 (rs56113850), and CHRNA4 (rs6011779), genes which
have been implicated in various tobacco use phenotypes.
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Table 3.3. DAVID-Identified Gene Clusters and Biological Systems for Nicotine Dependence
Category
Term
Genes

p

IPR002394:Nicotinic acetylcholine receptor

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

5.31E-09

GOTERM_MF_DIREC
T

GO:0004889~acetylcholine-activated cationselective channel activity

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

9.33E-09

GOTERM_MF_DIREC
T

GO:0015464~acetylcholine receptor activity

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

9.33E-09

GOTERM_CC_DIREC
T

GO:0005892~acetylcholine-gated channel
complex

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.74E-08

IPR027361:Nicotinic acetylcholine-gated
receptor, transmembrane domain

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.31E-08

GOTERM_MF_DIREC
T

GO:0042166~acetylcholine binding

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.21E-08

GOTERM_BP_DIRECT

GO:0007271~synaptic transmission,
cholinergic

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

3.73E-07

GOTERM_MF_DIREC
T

GO:0015276~ligand-gated ion channel
activity

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

5.15E-08

GOTERM_BP_DIRECT

GO:0098655~cation transmembrane
transport

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

7.25E-07

INTERPRO

IPR018000:Neurotransmitter-gated ionchannel, conserved site

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.71E-07

INTERPRO

IPR006029:Neurotransmitter-gated ionchannel transmembrane domain

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.71E-07

INTERPRO

IPR006201:Neurotransmitter-gated ionchannel

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.71E-07

INTERPRO

INTERPRO
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Table 3.3 (continued). DAVID-Identified Gene Clusters and Biological Systems for Nicotine Dependence
Category

Term

Genes

p

INTERPRO

IPR006202:Neurotransmitter-gated ionchannel ligand-binding

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.71E-07

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.06E-05

CHRNA3, CHRNB4, CHRNA5, CHRNA4

1.50E-05

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, DLC1, CHRNA6, SORBS2,
TMEM163, DSC3

1.65E-05

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

1.93E-04

CHRNB3, CHRNA5, CHRNA4, CHRNA6

3.43E-04

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6, TMEM163

2.81E-04

UP_KEYWORDS
GOTERM_BP_DIRECT

Ligand-gated ion channel
GO:0035095~behavioral response to
nicotine

UP_KEYWORDS

Cell junction

UP_KEYWORDS

Postsynaptic cell membrane
GO:0007274~neuromuscular synaptic
transmission

GOTERM_BP_DIRECT
UP_KEYWORDS

Synapse

GOTERM_CC_DIREC
T
GOTERM_BP_DIRECT

GO:0045211~postsynaptic membrane
GO:0035094~response to nicotine

GOTERM_BP_DIRECT

GO:0007165~signal transduction

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6
CHRNB4, CHRNB3, CHRNA4, CHRNA6
CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, DLC1, PDE2A, CHRNA6,
APOL3, VAV2

hsa04080:Neuroactive ligand-receptor
interaction

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

9.27E-04

GO:0030054~cell junction

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6, TMEM163

0.00137524

Ion channel

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

0.00321989

KEGG_PATHWAY
GOTERM_CC_DIREC
T
UP_KEYWORDS

5.57E-04
8.01E-04
8.01E-04
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Table 3.3 (continued). DAVID-Identified Gene Clusters and Biological Systems for Nicotine Dependence
Category
Term
Genes
p
KEGG_PATHWAY
GOTERM_BP_DIRECT

Cell membrane

CHRNA3, CHRNB4, CHRNA4, CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4
SLC14A2, CHRNA3, CHRNB4, CHRNB3,
CHRNA5, CHRNA4, CHRNA6, PDE2A,
SORBS2, AP2A2, RPE65, DSC3,
MFSD2A

UP_KEYWORDS

Transport

CHRNA3, CHRNB4, SLC14A2, CHRNB3,
CHRNA5, CHRNA4, CHRNA6, AP2A2,
APOL3, MFSD2A

0.02228539

UP_KEYWORDS

Ion transport

CHRNA3, CHRNB4, CHRNB3, CHRNA5,
CHRNA4, CHRNA6

0.02793515

UP_KEYWORDS

hsa04725:Cholinergic synapse
GO:0006811~ion transport

0.00736798
0.02273874

0.01730657

Note. Category refers to the original database or resource where the term originates. Term refers to the detailed
function in an annotation source.
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5. Smoking Cessation
Smoking cessation (SC) is the final point on the smoking continuum,
representing abstinence from tobacco use. As cessation is a process, it is possible for
individuals to relapse and return to regular smoking or nicotine dependence. Abstinence
is rarely achieved on the first cessation attempt. Cessation is a process and may have
several episodes of relapse or returning to regular smoking and nicotine dependence
210

.

Twin Studies
One study has examined SC in a twin study design 211. This study examined the
genetic and environmental influences on failed SC (i.e., an individual who attempted to
quit, but relapsed) attempts. This study of 4,112 twins from the Vietnam Era Registry
estimated significant genetic effects on failed smoking cessation attempts (A = 0.54,
95% CI = 0.40-0.62). Variance due to shared environmental influences did not
significantly contribute to SC.

Single and Multi-Sample Genome-Wide Association Studies of Smoking Cessation
Two GWASs have been performed using single samples. The first was from a sample
of Bangladeshi adults (N = 5,354) aged between 18 and 75 years old 145. Measuring SC
as a self-reported smoking status (i.e., current or former smoker), researchers reported
no genome-wide significant findings. The other single sample GWAS utilized 286,118
individuals from the Million Veterans Project (MVP; age range = 58-64) and also
categorized individuals as ex-smokers on the basis of self-reported questions (i.e.,
current versus former) 122. This study reported 8 genome-wide significant SNPs. 4 of
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these SNPs were in intergenic regions (rs11210228, rs34735365, rs77648866,
rs112270518), 1 was in the 5’ untranslated regions (5’UTR) of CHRNA2 (rs2565060),
and the other 3 were intronic to various genes. These intronic SNPs were located on
DRD2 (rs61902807), CYP2A6 (rs56113850), and CHRNA4 (rs6011779), genes which
have been implicated in various tobacco use phenotypes.

Consortia-Based Genome-Wide Association Results of Smoking Cessation
Three separate consortia examined SC, all categorizing former smokers using selfreport. The Tobacco and Genetic Consortium was the first to analyze smoking
cessation using data from 16 studies (N = 74,053) 156. They reported one genome-wide
significant SNP on DBH (rs3025343, p = 3.56 x 10-8). The GWAS and Sequencing
Consortium of Alcohol and Nicotine (GSCAN) also performed a GWAS on SC with a
larger sample (N = 547,219) from 24 different studies 163. GSCAN reported 24 genomewide significant SNPs for SC. Half (12) of these significant SNPs were intergenic. Two
SNPs were intronic to CHRNA4 (rs6011779, rs4809543) with another intronic to
CHRNA5 (rs518425). Additionally, there was one SNP that was intronic to CYP2A6
(rs56113850). Other genes with genome-wide significant SNPs (one each) were DBH
(rs1611124), SOX6 (rs7109376), SEMA6D (rs591143), ISL2 (rs3866543), PDE1C
(rs7778443), IRF4 (rs12203592), KLHDC8B (rs7617480), and PPP6C (rs12378015). A
final consortium used data from 61 studies (N = 622,409; N = 121,543 former smokers)
to examine smoking cessation 174. This study reported two genome-wide significant
SNPs for smoking cessation on TOB2 (transducer of ERBB2; rs202664) and CCDC141
(Coiled-Coil Domain Containing 141; rs150493199). TOB2 is involved in the regulation
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of the cell cycle progression (i.e., from cell formation to cell death), while CCDC141 is
involved with cell adhesion.
Functional Analysis. Functional analysis of five studies conducted with DAVID
indicated 41 significantly associated pathways involved in smoking cessation (Table
3.4). Similar to other tobacco use phenotypes, acetylcholine related pathways were
significantly associated. Pathways dealing with acetylcholine receptor structure and
activity were associated with CHRNA3, CHRNB4, CHRNA5, CHRNA4, and CHRNA6,
including the most associated pathway which was associated with the nicotinic
acetylcholine receptor (p = 6.11 x 10-7). A secondary pathway related to chemical
synaptic transmission was associated with CHRNA5, CHRNA4, CHRNA6, LPAR3, and
DBH. Thus, two general pathways emerged from the DAIVD analysis. Most pathways
were involved in neuronal signaling, either via receptor or ligand gate control and
synaptic functions. Another set of pathways was associated with iron and oxygen flow.
These pathways were also associated with Cytochrome P450, an enzyme encoded by
CYP2A6, previously associated with smoking cessation.
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Table 3.4. DAVID-Identified Gene Clusters and Biological Systems for Smoking Cessation
Category
Term
Genes

p

IPR002394:Nicotinic acetylcholine
receptor

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

6.11E-07

GO:0005892~acetylcholine-gated
channel complex
IPR027361:Nicotinic acetylcholinegated receptor, transmembrane
domain

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.47E-06

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.06E-06

GOTERM_MF_DIRECT

GO:0004889~acetylcholine-activated
cation-selective channel activity

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.24E-06

GOTERM_MF_DIRECT

GO:0015464~acetylcholine receptor
activity

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.24E-06

GOTERM_MF_DIRECT

GO:0042166~acetylcholine binding

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.40E-06

GOTERM_BP_DIRECT

GO:0007271~synaptic transmission,
cholinergic

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

1.80E-05

GOTERM_BP_DIRECT

GO:0035095~behavioral response to
nicotine

CHRNA3, CHRNB4, CHRNA5, CHRNA4

1.80E-05

GOTERM_MF_DIRECT

GO:0015276~ligand-gated ion
channel activity

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

4.08E-06

INTERPRO
GOTERM_CC_DIRECT
INTERPRO
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Table 3.4 (continued). DAVID-Identified Gene Clusters and Biological Systems for Smoking Cessation
Category
Term
Genes
INTERPRO
GOTERM_BP_DIRECT
INTERPRO
INTERPRO
INTERPRO
UP_KEYWORDS
GOTERM_BP_DIRECT

IPR018000:Neurotransmitter-gated
ion-channel, conserved site
GO:0098655~cation transmembrane
transport
IPR006029:Neurotransmitter-gated
ion-channel transmembrane domain
IPR006201:Neurotransmitter-gated
ion-channel
IPR006202:Neurotransmitter-gated
ion-channel ligand-binding

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

Ligand-gated ion channel

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

6.30E-06
3.05E-05
6.30E-06
6.30E-06
6.30E-06
2.34E-04

GOTERM_CC_DIRECT

GO:0045211~postsynaptic membrane

CHRNB4, CREB1, CHRNA4, CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CREB1, CHRNA4,
CHRNA6
CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

GOTERM_BP_DIRECT

GO:0007626~locomotory behavior

CHRNA3, CHRNB4, CHRNA4, DBH

0.00767406

GOTERM_BP_DIRECT

GO:0007268~chemical synaptic
transmission

CHRNA5, CHRNA4, CHRNA6, LPAR3, DBH

0.00781503

UP_KEYWORDS
KEGG_PATHWAY

GO:0035094~response to nicotine

p

Postsynaptic cell membrane
hsa04725:Cholinergic synapse

8.14E-04
0.00188089
0.00896826
0.00471956
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Table 3.4 (continued). DAVID-Identified Gene Clusters and Biological Systems for Smoking Cessation
Category

Term

Genes

p

KEGG_PATHWAY

hsa04080:Neuroactive ligand-receptor
interaction

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6, LPAR3

0.01462578

GOTERM_BP_DIRECT

GO:0007274~neuromuscular synaptic
transmission

CHRNA5, CHRNA4, CHRNA6

0.01438218

GOTERM_BP_DIRECT

GO:0006811~ion transport

CHRNA3, CHRNB4, CHRNA5, CHRNA4

0.01438218

UP_KEYWORDS

Synapse

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

0.01144954

UP_KEYWORDS

Ion channel

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6

0.01144954

CYP2A7, CYP2A6, CYP2B6, EGLN2,
ACO2

0.00106543

CYP2A7, CYP2A6, CYP2B6, EGLN2

0.00106543

CYP2A7, CYP2A6, CYP2B6, DBH

0.00377331

CYP2A7, CYP2A6, CYP2B6

0.00228772

CYP2A7, CYP2A6, CYP2B6

0.00228772

GOTERM_MF_DIRECT

GOTERM_MF_DIRECT
UP_KEYWORDS
GOTERM_MF_DIRECT

GOTERM_MF_DIRECT

GO:0005506~iron ion binding
GO:0016705~oxidoreductase activity,
acting on paired donors, with
incorporation or reduction of molecular
oxygen
Monooxygenase
GO:0008392~arachidonic acid
epoxygenase activity
GO:0016712~oxidoreductase activity,
acting on paired donors, with
incorporation or reduction of molecular
oxygen, reduced flavin or flavoprotein
as one donor, and incorporation of one
atom of oxygen
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Table 3.4 (continued). DAVID-Identified Gene Clusters and Biological Systems for Smoking Cessation
Category
GOTERM_BP_DIRECT
UP_KEYWORDS

Term

Genes

p

GO:0019373~epoxygenase P450
pathway

CYP2A7, CYP2A6, CYP2B6

0.00781503

Iron

CYP2A7, CYP2A6, CYP2B6, EGLN2,
ACO2

0.01092355

CYP2A7, CYP2A6, CYP2B6

0.00623443

CYP2A7, CYP2A6, CYP2B6

0.02314858

CYP2A7, CYP2A6, CYP2B6

0.02715231

CYP2A7, CYP2A6, CYP2B6

0.02929044

INTERPRO

GO:0008395~steroid hydroxylase
activity
IPR002401:Cytochrome P450, Eclass, group I
IPR017972:Cytochrome P450,
conserved site

INTERPRO

IPR001128:Cytochrome P450

GOTERM_MF_DIRECT
INTERPRO

signal peptide

CYP2A7, CYP2A6, CYP2B6, EGLN2,
DBH
CCDC134, CHRNA3, CHRNB4,
TNFRSF6B, HSPA5, CHRNA5, LAMB2,
CHRNA4, SEMA6D, CHRNA6, PLA2G3,
DBH, CYP2A7, CYP2B6, ENPP2, NUCB2
CCDC134, CHRNA3, CHRNB4,
TNFRSF6B, HSPA5, CHRNA5, LAMB2,
CHRNA4, SEMA6D, CHRNA6, PLA2G3,
ENPP2, NUCB2

hsa04080:Neuroactive ligand-receptor
interaction

CHRNA3, CHRNB4, CHRNA5, CHRNA4,
CHRNA6, LPAR3

UP_KEYWORDS

Oxidoreductase

UP_KEYWORDS

Signal

UP_SEQ_FEATURE
KEGG_PATHWAY

0.04642428

7.12E-04

0.03475165
0.01462578

Note. Category refers to the original database or resource where the terms orient. Term refers to a detailed item in an
annotation source.
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Conclusion. Several individual genes have been reported to be associated with
smoking cessation. However, functional analysis identified pathways relevant for
acetylcholine receptor structure and activity were significantly associated with smoking
cessation. This is consistent result as all phenotypes with DAVID analysis have
identified this gene cluster and action as relevant for smoking phenotypes.

6. Other Tobacco Product Use.
Snus
Snus are an alternative tobacco product that are popular in Europe and are similar to
chewing tobacco or dip. In contrast to chewing tobacco, snus are more finely cut with
some being in powder form inside pouches or loose for later packaging by the user.
Snus expose individuals to nicotine which may lead users to nicotine dependence and
other negative health outcomes 212. A twin study of nicotine dependence, as measured
by the FTND, was conducted using 5,040 Swedish male twins 202. This study reported
significant additive genetic (0.32; 95% CI = 0.23-0.41) and unique environmental (0.68,
95% CI = 0.59-0.77) influences. This study also evaluated the twins ND arising from
CIG use and found similar estimates of A (0.39) and E (0.61).
Another twin study of Norwegian twins (N = 3,862) asked about two phenotypes
related to snu use: initiation and quantity of use 109. Initiation was assessed as, “Have
you ever used snus regularly for at least a month?” while quantity was probed with,
“When you used snus the most, how many times per day did you use it?” Using these
definitions, researchers reported significant genetic effects for both initiation (0.51) and
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quantity used (0.55), as well as significant shared environmental influences (0.29 for
initiation and 0.23 for quantity).

Electronic Cigarettes
Electronic cigarettes (ECIG) are just beginning to be evaluated in the genetic
epidemiology literature. As of May 2020, studies of ECIGs remain sparse; however,
there have been several studies examining differing aspects of ECIG use. A recent twin
of ECIG initiation defined as self-reported ever use of ECIGs reported genetic (A = 0.25)
and shared environmental (C = 0.42) contributions to ECIG initiation as well as overlap
in these factors with CIG initiation (rg = 0.76, rc = 0.68) 213.
To date, no GWAS studies have been conducted of ECIG use. However, other
studies58,124 have used GWAS data to generate polygenic risk scores (PRS) and study
ECIG use 214. Both studies examining PRS used self-reported ever use without any
additional caveats to classify individuals as initiators or not. In addition, one study
examined the age of initiation as a secondary outcome. Both studies created PRSs for
conventional cigarette initiation (SI; and CPD in the case of Allegrini) and then applied
those scores in a secondary (target) data set to examine if genetic influences on
cigarettes could also indicate if those influences also impact ECIG ever use. While no
influence was detected for the SI PRS and ECIG ever use, there was a significant
finding between CPD PRS and ECIG ever use in the Allegrini study. In contrast, Khouja
and colleagues reported a significant effect of SI PRS and ECIG ever use (OR = 1.24),
though they did not examine CPD to generate PRS. Taken together, these results
provide an unclear answer to the genetic overlap between CIG and ECIG use.
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CONCLUSIONS AND RECOMMENDATIONS
This paper has demonstrated how measurement of tobacco phenotypes has led to
inconsistent results in GWAS and twin study designs. It was generally expected that the
same genetic association results would be identified regardless of measure, particularly
in studies of consortia or single studies with sufficiently large sample sizes. However,
this did not occur. The high variability in tobacco use measures within a specific
behavior (e.g., regular smoking, nicotine dependence) has multiple measures for
quantifying a specific form of tobacco use. It is expected that among the many other
limitations of different genetic influences than if another measure had been used.

Areas of Results Consistency
The nicotine acetylcholine receptor genes were consistently associated with
various facets of nicotine use such as quantitative measures of smoking (e.g., CPD),
nicotine dependence, and smoking cessation. Additionally, the CYP2A6 gene was
significantly associated with several nicotine use phenotypes including: nicotine
metabolism and smoking cessation. These consistent results indicate that genetic
influences are impactful; however, the inconsistent results suggest the genetic
architecture is more complex. Aggregating genetic effects may help elucidate how
genetics contribute to complex phenotypes.
Consistent findings from GWAS identify biological functions that may help explain
their repeated associations with tobacco use. Genes responsible for acetylcholine
receptor activity was associated for nearly every tobacco use phenotype. Further, ligand
gate ion-channel activity was also consistently associated. These biological pathways
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help explain the addictive properties of nicotine. Each leads to increased
neurotransmitters (such as dopamine, glutamate, and GABA) in the brain which lead to
rewarding sensations.
Genome-wide significant SNPs combined by these biological functions which
may lead to more consistent interpretations of results than seeking to replicate the same
variant. Genes, rather than SNPs, in a biological pathway are reported which help lead
to more consistent interpretation of GWAS results. For instance, while specific SNPs
may not be replicated across phenotypes, each tobacco use phenotype was associated
with cell signaling and receptor structure or function. This consistency has been
demonstrated in this paper via the use of DAVID annotation and the identification of
pathways significantly associated, or over-represented, for a similar set of genes. For
example, the nicotinic acetylcholine receptor genes were consistently associated with
DAVID pathways for most of the conceptual phenotypes examined here. However, it
should be noted that DAVID relies on published associations of genetic variants and
biological function. It is possible that the results presented here are not comprehensive
due to publishing bias.
Further, this functional annotation would allow for multiple phenotypes to be
examined in each paper. Looking at individual smoking behaviors in the continuum (i.e.,
only focusing on smoking initiation or nicotine dependence) is not logical as facets of
tobacco use build upon one another (e.g., one cannot be a regular smoker without
having initiated smoking) 215. Many biological pathways were shared across nicotine
phenotypes, such as coding for receptors which influence the transmembrane ion
channels. The nAChR genes were consistently identified with each nicotine use
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phenotype as were biological pathways for gate control and receptor binding. These
results suggest that there is biological plausibility for overlap between each nicotine
phenotype. Therefore, future GWAS should examine multiple behaviors rather than
several single tobacco use behaviors.

Limitations of GWAS in Tobacco Use
In addition to issues related to inconsistencies of tobacco measurement, there
are other general limitations in GWAS designs. These studies often suffer from weak
statistical power due to small samples (N~ 1,000) 143,216. Small sample sizes may lead
to biased estimates of effect and/or inconsistent results across studies. One solution to
increase sample sizes is through consortia and meta-analyses of substance use
phenotypes. However, studies contributing to consortia often vary slightly in how they
operationalize and measure tobacco use (e.g., studies of smoking cessation may use
differing definitions of successful cessation based on the length of time since last
smoking). This leads to challenges in the ability to test the same measures across
samples. Many consortia currently use secondary data, but as more data is collected,
especially involving novel products, it would be advantageous to utilize the same
operational definitions of tobacco use stages. To date, GWAS results have produced
inconsistent results as would be expected due to outcome measurement heterogeneity.
Many studies report genome-wide significant SNPs that have not been replicated in
other studies.
GWAS results are reported as SNP ID (e.g., rs number, or chromosome and
base pair), followed by the gene in which the SNP is present (if applicable, some
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variants may be in intergenic regions), and the measure of association (i.e., beta value
or odds ratio) with an associated p value and confidence interval. Sometimes
researchers will also choose to report the chromosome, arm, and location of the
significant SNP (e.g., Chr13p5.5). There may be an inconsistency of results when
reporting in this manner as rs numbers may change based on the build used for the
reference genome. It is also difficult to aggregate results in a meaningful manner as
direct replication of a particular SNP may be difficult. Other methods of aggregating
results are needed for determining relevance of GWAS analyses.

Recommendations for Future Studies of Tobacco Use in Genetically-Informative
Samples
Future studies should continue to examine differences between major groupings
of the population. For instance, twin studies report differing effects of additive genetic
influences based on sex. However, only two GWAS144,162 studies examined molecular
effects by sex. Likewise, twin studies have demonstrated different influences of A on
smoking phenotypes by race/ethnicity. However, two GWAS 196,207explicitly examined
racial differences. Genetic influences also change as an individual ages; however, only
6 GWAS 122,145,181,195,217,218 explicitly looked at age groups. These GWASs typically
chose older individuals (age > 45 years) as participants whereas younger individuals
were grouped in with the entire age spectrum (ages 18+). Future studies should
continue to stratify GWAS results by environmental influences that have previously
identified as associated with tobacco use whenever feasible. Lower levels of income
have been associated with greater rates of tobacco use when compared with individuals
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at higher income levels. Likewise, other SES variables (such as educational attainment)
have been associated with higher tobacco use. Other environmental variables beyond
demographic variables should also be examined, including exposure to marketing.
Individuals who receive coupons for tobacco products are more likely to use tobacco
products. Similarly, individuals who are exposed to marketing promotions are more
likely to use tobacco products compared to people who are not 219.
Further, more standardized data collection of tobacco use phenotypes is needed.
The movement to standardize phenotypic data collection in genetic studies continues to
grow. Different measures of tobacco use have led to inconsistent results in GWAS of
tobacco use. Consistently identifying the phenotype with the same operational
measures of tobacco use across studies may help increase the statistical power via
ensuring the same operational measures are used without needing to harmonize data
during analysis. This could also lead to greater phenotypic refinement in appropriate
samples, leading to a greater chance of detecting and replicating genetic influences.
Reducing the heterogeneity in measurement will allow for consortia to be built faster
and with more ease, as well as allowing meta-analyses to occur more efficiently.
Multiple measures could also be used to evaluate the phenotypes to ensure that studies
capture all variations of the phenotype.
Additional attention should be paid to phenotypes that may be missing from the
current measures of tobacco use. GWAS results of smoking cessation generally
focused on current versus former smoking status. However, no analyses have been
conducted with nicotine withdrawal as the outcome measure. Likewise, there was no
analysis for time to failure of cessation (i.e., duration of abstinence during an attempt to
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quit smoking). Future GWAS should report on multiple phenotypes in the smoking
continuum rather than focusing on very specific behaviors.

ECIG Recommendations. Results from studies of CIG use should be used to
guide future studies of ECIG use. There are four recommendations for future studies of
genetically informative samples when it comes to measuring tobacco use as administer
via ECIGs. First, biological confirmation of smoking status whenever feasible is needed,
through expired CO for CIG users and through plasma/urine cotinine levels for both CIG
and ECIG users 220,221. ECIG users may not know if their e-liquid contains nicotine or
not 222,223. Therefore, nicotine exposure would not be captured by self-report. Biological
confirmation of recent tobacco use should help distinguish those currently use versus
those who have not, leading to greater external validity of results. Future research
should examine if salivary COT levels are feasible for large scale epidemiological
studies compared to plasma/urine COT. Another important factor to consider, as
tobacco use progresses into the ECIG era, is how to handle dual use of CIG and ECIG
products. Other research has shown that dual users of CIG and ECIG are a distinct
class of tobacco user (see Chapter 5) and future research needs to appropriately model
this relationship. GWAS moving forward will need to consider this possibility. While
outcome group assignment may seem straight forward, dual users need to be
considered a distinct class of user. Future work should delineate exactly how dual users
are distinct; for example, how much time must an individual use both products to be
considered a dual user? How long after cessation of one product is one still considered
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to be a dual user? These questions need to be addressed to ensure accurate results
are generated.
Misclassifying individuals as CIG or ECIG users when they are dual users may
lead to biased estimates. Future GWAS should take this into account and run
multinomial regressions rather than logistic models. While it is possible to account for
other tobacco product use as a covariate in the regression, it is not optimal when
compared to running multinomial models. Absent running multinomial regression,
results could be stratified on tobacco use (CIG-exclusive, ECIG-exclusive, and dual
use) which would also present results for each specific tobacco use group.
ECIG research should probe participants to report at what concentration of
nicotine a participant’s e-liquid is set at to allow for greater accuracy in the estimation of
nicotine used by an individual. Though there are after-market modifications to ECIG
devices which change the amount of nicotine administered, knowing the concentration
will allow researchers to estimate how much nicotine is being used 21.
Finally, results from genetically informed studies should continue to report on
functional relevance for tobacco use. Functional relevance may be closely related to
clinical relevance which may lead to real world changes by focusing therapies on
interrupting the biological pathways from genetic influence to exposure. Continued
investigations of functional relevance with polygenic methods may help identify
pathways that significantly contribute to tobacco use.
The area of tobacco use is currently evolving as novel tobacco use devices
continue to be introduced into the market. Consequently, genetic epidemiological
studies across tobacco products are also rapidly evolving. For example, an update to

123

ECIGs involves heat-not-burn products (e.g., IQOS) which were introduced in the
United States in 2019 224. Such rapid evolution in product development has implications
for the study of nicotine dependence in genetically informative samples. ECIG remain a
highly popular product and the measures used in genetic epidemiology studies need to
keep pace. In particular, given the variability in CIG initiation results, effectively
measuring ECIG initiation should be a high priority. For example, is it enough to classify
an individual as an ECIG user if they only use a friend’s device or must they own their
own device in order to be classified as a user? Similarly, what about individuals who use
ECIG devices but use e-liquid that is nicotine-free? These are important issues as
different definitions of an ECIG user may yield differing results as happened with CIG
samples.
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CHAPTER 4: ELECTRONIC CIGARETTE GENOME-WIDE ASSOCIATION AND
POLYGENIC SCORES AMONG SELF-IDENTIFIED WHITE PARTICIPANTS: TEST
OF OVERLAPPING GENETIC INFLUENCES WITH CONVENTIONAL CIGARETTE
INITIATION

INTRODUCTION
The genetic factors that influence conventional cigarette (CIG) initiation may also
influence electronic cigarette (ECIG) initiation. Results from Chapter 2 suggest a
significant overlap in additive genetic influences between ECIG initiation and CIG
initiation in young adults. Chapter 3 summarized several previously reported genetic loci
that contribute to CIG initiation. Further, prior studies using genome-wide polygenic
scores (GPS) demonstrate the genetic overlap between CIG initiation and ECIG
initiation 58,225. This suggests that similar genes contribute to the liability of CIG as well
as ECIG initiation and encourages additional study to detect specific genetic loci
associated with ECIG initiation by taking advantage of the genetic overlap shared
between CIG and ECIG use.

The Role of Age on CIG and ECIG Initiation
The age of CIG and ECIG initiation for tobacco use is increasing, with more
individuals initiating in young adulthood as compared to adolescence 226. The proportion
of individuals who initiated CIGs in young adulthood (age 18-23) more than doubled
from 20.6% (2002) to 42.6% in 2018. Similarly, the prevalence of ECIG initiation is
increasing among adults. For example, the prevalence of ECIG initiation at age 18 was
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estimated at 8.3%. That prevalence grew to 33.8% by age 25 in analysis of the
Population Assessment of Tobacco and Health (PATH) study 227. Additionally, twin
studies report that genetic influences on CIG smoking initiation are larger at older ages
compared to younger ages (age range = 12 to 18, see Chapter 3) 95,228,229. While the
role of genetic influences on ECIG initiation in adults remains unclear (see Chapters 2
and 3), the epidemiological evidence suggests that it will be important to study adults
across the life course rather than only addressing younger users. Further, given the
trends related to increasing magnitude of genetic effects on CIG initiation as age
increases, such patterns may also apply to ECIG initiation. Therefore, although
substantial effort related to the study of CIG and ECIG initiation is focused on young
adults (ages 18-24) and adolescents (ages 12-17), study of the etiology underlying CIG
and ECIG initiation across adulthood is necessary.

Genome-Wide Association Studies Identify Specific Genetic Loci Contributing to CIG
Initiation
Prior genome-wide association studies (GWAS) have identified genetic variants in
several loci (i.e., specific locations in the genome) that are associated with CIG initiation
(see Chapter 3 for an in-depth discussion). A genetic association is a single test of
association which uses genotypic data from a genetic marker to test for statistical
associations between a genetic variant (e.g., single nucleotide polymorphism, SNP) at a
specific locus and CIG initiation. A GWAS expands this test to thousands of genetic
markers that test for associations with CIG initiation with SNPs across located
throughout the genome. Therefore, GWAS produces results that identify specific
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locations within the genome that are associated with an outcome (i.e., phenotypes such
as CIG and ECIG initiation).
To date, 12 GWASs have consistently identified significant associations between
SNPs located in the nicotinic acetylcholine receptor genes (e.g., CHRNA3, CHRNB4),
with various tobacco use behaviors, including initiation 122,144,145,147–150,162–164,174,217,230
(Chapter 3). These genes encode subunits of nicotinic acetylcholine neuronal receptors
which mediates fast signal transmission at synapses. Neuronal nicotinic acetylcholine
receptors reside on all neurons and their influences function throughout the brain 231.
Neuronal nicotinic acetylcholine receptors are activated by acetylcholine and nicotine
(and other drugs). When nicotine binds to a nicotinic acetylcholine receptor, it acts as an
agonist to potentiate receptor activation. Activation of nicotinic acetylcholine receptors
allows sodium (Na+) into the neuron and results in production of several
neurotransmitters, including dopamine, acetylcholine, glutamate, GABA, epinephrine,
norepinephrine, and serotonin (Figure 4.1) 232. Acetylcholine contributes to the reward
pathway (along with pathways relating to attention, memory, and arousal 233–235) leading
to rewarding sensations. Addiction is also enhanced through acetylcholine-mediated
craving for euphoric feelings produced by this neurotransmitter. Further, consistent
evidence has emphasized the role of dopamine, glutamate, and GABA resulting from
nicotine exposure which are responsible for information processing, memory, and
emotions232. Glutamate, which is the brain’s primary excitatory neurotransmitter 236, is
released in several brain structures such as the ventral tegmental area (VTA) after
nicotine exposure and regulates the dopaminergic neurons. Increased firing of
dopaminergic neurons in the VTA stimulates dopamine release in the nucleus
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accumbens (NAc), which leads to rewarding feelings arising from the mesolimbic
system. ECIGs contain nicotine and been reported to change glutamate and dopamine
levels in mice 237, which is expected to be mediated by nicotinic acetylcholine receptors
and the genetic variants that influence their function.

Figure 4.1. Nicotine Acts as an Agonist for Acetylcholine Receptors. Nicotine
binds to and stimulates the acetylcholine receptor (1), which allows sodium (Na+)
into the presynaptic neuronal cell (2), which stimulations the calcium ion channel
to open (3) releasing Ca2+, potentiating the cell to release neurotransmitters (4)
into the synapse. Figure adapted from Price & Martinez, 2019 238.
CYP2A6 has been associated with several CIG use behaviors including regular
smoking, nicotine dependence, and smoking cessation. CYP2A6 encodes the
Cytochrome P450 A6 enzyme. This enzyme is responsible for metabolizing nicotine and
cotinine via oxidation 189,239 (see Chapter 3: Nicotine Metabolism). Further, CYP2A6 is
necessary for moving nicotine through the body while the nAChR gene cluster is
responsible for rewarding sensations arising from tobacco use. Taken together, prior
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GWAS results have identified several important loci within genes that have biological or
psychological function associated with CIG use. However, it remains unknown if these
same genes play a role in ECIG initiation and use.

Use of Genome-Wide Polygenic Scores Addresses Limitations of GWAS
The concept of “polygenic” factors was first discussed by Sir Ronald Fisher as
the influence of many genes making small contributions to a phenotype240, has been
confirmed throughout the GWAS era142,241, and has led to the recent development and
study of genome-wide polygenic scores (GPS). A GPS reflects the average genetic
contribution for a phenotype across all measured loci. This approach was developed
because large-scale GWAS demonstrated significant associations of hundreds of
common variants that contribute small effects to many complex phenotypes 142,240,242–
245

, including CIG initiation (e.g., GWAS and Sequencing Consortium for Alcohol and

Nicotine, GSCAN, 163). Common variants of small effect are most likely the cause of
genetic variation in complex traits 142,242,246 (e.g., outcomes that are due to many genetic
and environmental influences). To date, many GWASs have been underpowered due to
small sample sizes247 which limits the ability to detect genetic influences of small effect
sizes. Therefore, GWAS may often fail to capture the variation from genes of small
effect 248. The use of GPS to aggregate genetic variants with small effects (i.e., variants
with odds ratios less than 1.3) is expected to reflect a more accurate representation of
multiple genetic influences on an outcome 249–251.
Studies of GPS use summary statistics (i.e., β values and p values) generated
from GWAS of large “discovery” samples with sample sizes that have sufficient power to
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detect genome-wide significant genetic associations (N > 100,000). Discovery samples
generally refer to single sample studies (e.g., UK BioBank) or a consortium of several
studies that have appropriate sample sizes to conduct GWAS (e.g., GSCAN). After
summary statistics are generated in the discovery sample, they can be applied in
smaller “target” samples that would otherwise be underpowered to detect genetic
effects (N ~ 1,000) 248,252. The generation of GPS from a discovery sample and its
application of summary statistics to a target sample relies on the assumption that both
samples contain participants from the same ancestral group. “Ancestral groups” refer to
populations of humans whose biological ancestors come from similar geographic
regions (e.g., Europe) and experience common evolutionary selection migration
patterns and selection pressures over several generations. Consequently, individuals
within a specific ancestral group have largely similar distributions of allele frequencies at
most loci throughout the genome. To date, most GWAS studies are conducted in
samples with European ancestry groups. Therefore, GPS generation is most often
conducted in these populations because they have reliably similar allele distributions
across discovery and target samples 253–255.
Genome-wide polygenic scores were first used to examine common genetic
variation and its influence on schizophrenia 256. Using data from the International
Schizophrenia Consortium (ISC), polygenic scores were calculated for schizophrenia
and applied in independent samples provided by the Molecular Genetics of
Schizophrenia (MGS) consortium. The polygenic scores performed adequately,
explaining roughly 3% of the variance for schizophrenia in the European sample of
MGS. However, the clinical utility of a polygenic score was deemed insufficient to
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increase diagnostic accuracy 257. More recent research has shown improvement in the
predictive probability of GPS, though not enough to warrant use in clinical settings 258.
The improvement of the predictive probability of GPS has suggested that with more
research, clinical utility could be found 258–262.

CIG GPS Influences on Psychiatric Phenotypes
Significant genetic overlap has been reported between CIG GPS for various CIG
phenotypes and other psychiatric outcomes. CIG GPS has been associated with
smoking initiation, explaining nearly 5% of the variance in one study 263. Similarly, a
GPS constructed for CPD was associated with CPD 264. GPS for CIG initiation have
also been associated with non-tobacco related phenotypes. GPS for late onset CIG
initiation has also been associated with schizophrenia. Individuals who initiated CIG use
later in life were at an increase in the odds of reporting a diagnosis of schizophrenia 265.
In addition, GPS for having ever been a regular smoker have been associated with
externalizing behaviors, with being a regular smoker associated with an increase in the
odds of reporting externalizing behaviors 266. Further, GPS for age of CIG initiation has
been associated with age of regular alcohol drinking, which suggests there may be
overlap with substance use 267. These results suggest that overlap exists between
genetic influences for CIG initiation and multiple psychiatric disorders, including other
substance use beyond CIGs. It is therefore expected that some genetic influences may
be shared between CIG and ECIG initiation.
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Associations between CIG GPS and ECIG Initiation
To date, three GPS studies have been conducted on ECIG initiation. Allegrini
and colleagues utilized the Tobacco and Alcohol Genetics (TAG) to create GPS for CIG
initiation (SI; defined as having smoked 100 or more cigarettes in an individual’s
lifetime) and cigarettes per day (CPD)124. These scores were then applied to a target
sample of Netherlands twins who used ECIGs. While the GPS for SI wasn’t significantly
associated with ECIG use, the GPS calculated from the CPD phenotype was
associated. Specifically, the GPS was significantly associated with ECIG initiation
among ex-smokers (OR = 1.43) and never smokers (OR = 1.35). These results suggest
that there may be some association between genetic influences for CIG and ECIG use;
however, the authors acknowledge their study may have been underpowered to detect
genetic effects and recommended additional studies.
More recently, GPS for CIG initiation were created from the GWAS and
Sequencing Consortium of Alcohol and Nicotine (GSCAN) and used to study their
association with ECIG initiation 58. A significant association was detected between GPS
for CIG initiation and ECIG initiation by age 24 (OR = 1.24, 95% CI = 1.14-1.34, p <
0.001). Importantly, a separate analysis was conducted to ensure that the GPS for CIG
initiation was associated with CIG initiation in their target sample (OR = 1.29, 95% CI =
1.19-1.39, p < 0.001), confirming the GPS for CIG initiation was associated with the
same phenotype in an independent sample. Taken together, these two analyses show
that the genetic influences which are important for CIG initiation are also meaningful for
ECIG initiation.
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A similar analysis was conducted in the United States utilizing a GPS for regular
CIG use and cigarettes per day calculated from GSCAN and applied to ECIG use in a
sample of college students 225. This study reported a significant associated with CIG
regular use and ECIG initiation (OR = 1.27, 95% CI = 1.19-1.36, p < 0.001) among
individuals of European descent. While this study did not model CIG initiation as a GPS,
it provides additional preliminary evidence that genetic influences of other CIG
phenotypes (quantity of use, regular cigarette use) are also shared with ECIG initiation.
This study builds on the previous results in two ways. First, the molecular genetic
variants that may contribute to ECIG initiation remain unknown. Several genome-wide
association studies (GWAS) have been conducted on the initiation of CIG use.
However, it is unknown if the same variants identified for CIG initiation will also be
significant with ECIG initiation. These analyses will first detail the molecular genetic
contribution to ECIG lifetime initiation in a sample of US adults, aged 18-93. Second,
current results suggest there may be some overlapping genetic influences in a sample
of young adults, ages 18-25 (e.g., see Chapter 2) 58,225. Analyses in this chapter build
on the prior results by using data from a community-based sample of unrelated adults
(age 18-93) to examine genetic overlap within a larger age range. Taken together these
analyses answer two research questions: 1) are there any specific variants that are
significantly associated with lifetime ECIG initiation across adulthood and 2) are the
molecular genetic influences shared between ECIG and CIG lifetime initiation?
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METHODS
Study Description
Data from the Genes for Good (G4G) study were used. The G4G study uses a
community-based sample of active Facebook users in the United States aged 18 and
older (N = 81,476). In brief, Facebook users participated in the G4G project through a
Facebook-specific application (i.e., a third-party add on to the base Facebook page).
Participants were taken through a consent process after adding the application to their
profile. Participants who used the G4G application on Facebook answered survey
questions regarding a variety of behaviors and lifestyles including: sleep, personality,
exercise, and drug use (including tobacco, alcohol, marijuana, and other illicit
substances). Surveys were divided into two broad categories: 1) health history surveys
(baseline surveys focused on behaviors prior to G4G participation) and 2) health
tracking surveys (daily behavior tracking from the previous day, such as how many
alcoholic drinks they consumed or number of cigarettes smoked). Participants
completed surveys at any time and chose the modules they wanted to answer.
Participants were recruited via “snowball recruiting”; where individuals are recruited
through their peer group (e.g., parents, friends, Facebook groups) via posts that are
shared about the participants engagement with G4G (e.g., “I just completed a health
tracking survey for Genes for Good!”).
A subset of G4G participants also volunteered to give a sample of their DNA via
a mailed saliva collection kit (N = 27,469). To be included, participants must have
answered the health history survey as well as a minimum of 15 health tracking surveys
of their choice. Participants received a free genetic ancestry report and access to their
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raw genetic data via a secure (i.e., encrypted) file transfer point (SFTP) over the
internet.
As of 18 June 2019, 81,476 individuals had signed up to use the G4G application
and completed at least one survey. Of these, 27,469 individuals had been genotyped
(33.7%). Data from 20,231 genotyped participants were available at the time of data
release. For purposes of this study, individuals were limited to self-identified ancestral
(SIA) White participants only (N = 15,881). SIA White participants reduced the influence
of possible population stratification on analyses. Population stratification is a source of
confounding in GWAS, conceptualized as a phenomenon that arises due to differing
selection pressures placed on non-random mating populations. This selection leads to
differing allele frequencies between ancestral groups 268. Different allele frequencies
may lead to spurious relationships being detected between genetic markers and
phenotypes 269.
Measures of CIG and ECIG Initiation. Two items assessed lifetime CIG and
ECIG initiation. CIG lifetime initiation was treated as a dichotomous variable, probed as,
“Have you ever tried a cigarette?” ECIG lifetime initiation was treated as a dichotomous
variable and measured as, “Do you smoke e-cigarettes?”
Genotyping. Participant DNA was genotyped across approximately 600,000
SNPs using the Illumina Infinium CoreExome-24 v1.0 or v1.1 arrays 163. Genotyping
was completed on nonsynonymous exonic variants (i.e., a mutation that alters the
protein coded for by the amino acid sequence), as well as a panel of common genomewide markers. Additional markers were also genotyped including missense (i.e.,
mutation of coding for an amino acid), loss-of-function (i.e., mutation leading to less, or
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no, function), potential lipid- and myocardial infarction-associated variants, heightassociated variants, stop-gain variants (i.e., a mutation that stops transcription
prematurely) in 96 genes with loci potentially implicated in type 2 diabetes, blood lipid
levels, Alzheimer’s disease, nicotine/alcohol metabolism, and other serious but treatable
health conditions. Additionally, Neanderthal SNPs from the 1000 Genomes Project, and
ancestry informative markers were also genotyped. Genotypes for approximately 30
million additional variants were imputed using Minimac3 270 using the 1000 Genomes
Phase 3 271 panel as a reference panel. Imputation is an important step because it
allows for additional markers to be imputed, increasing the number of genetic markers.
These additional markers allow for a more complete interrogation of the genome, above
and beyond the directly observed genotypes.
Quality Control. Standard data quality control (QC) procedures were
implemented before data analysis (Figure 4.2). This included removing individuals
which had excessive missing data (greater than 5% missing) and individuals who were
cryptically related (i.e., unknown to either researcher and/or participants that two
individuals were biologically related) to one another (p > 0.05, 0 participants removed).
Individuals with increased heterozygosity rates, defined as more than three standard
deviations from the mean were removed (0 individuals. Heterozygosity rate is the
proportion of an individual’s genome that is heterozygous (i.e., they have one copy of
the dominant and recessive allele). Only SIA White participants were used for this
study, leaving an analytic sample of 15,881 participants after per-individual QC. Further
participants were removed due to missing phenotypic data (85 missing CIG data, 86
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missing ECIG data), leaving 15,796 CIG initiators and 15,795 ECIG initiators for
analyses.
QC was also done on a per-SNP basis. SNPs were removed if they significantly
violated Hardy-Weinberg Equilibrium (HWE; p < 10-8, 395 markers removed) as were
SNPs with excessive missingness (> 5%, 125,044 markers removed). Violations of
HWE suggest that there may be influences (e.g., assortative mating, genetic drift, or
founder effects) impacting the frequency of a particular genotype 272. Two other
commonly used QC measures were not utilized: sex checking and INFO score pruning.
INFO scores were not included with the data transfer from the G4G study staff. In
general, GWAS analyses are limited to high performing SNPs (INFO score >= 0.5) to
ensure the highest possible quality of data. Additionally, information was not sent
regarding the X chromosome which would be used to check the self-reported sex
versus the biological sex of participants. Instead of genetic data regarding the
participants, self-reported sex was utilized as a covariate in subsequent GWAS
analyses. After completing the per-marker QC, 7,252.506 markers were available for
analysis.
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Figure 4.2. Flowchart of Quality Control Procedures and Number of SNPs and
Individuals Removed.
Genome-Wide Polygenic Score Calculation. GPS are calculated from a discovery, or
training, sample for CIG lifetime initiation. This sample is made up of individuals who are
unrelated to the target sample. Markers in this training sample are ranked by their
association with the phenotype, generally measured by p values 273. The measure of
association (e.g., beta values) are then summed across the markers that are associated
at a given level (e.g., all markers with p values less than 0.01, 0.05, or 0.10) as shown
in the formula below.
)

!"# = & '( !(
(

where '( is equal to the beta coefficient that is associated with genetic variant !( for the
ith person. Therefore, a GPS is the summed effect (of participants running from i to n) for
all measured genetic variants.
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GPS for this study was generated for CIG initiation from summary statistics
provided by GSCAN163. GPS were generated via PRS-CS, a freely available Pythonbased software 274. PRS-CS (Polygenic Risk Score with Continuous Shrinkage) is a
relatively new program that calculates GPS under a Bayesian regression framework
rather than the frequentist framework presented above. Using this Bayesian framework,
the SNP prior probabilities are subject to continuous shrinkage as follows:
*+ |-+ ~/00, 3-+ 4,

-+ ~5

where *+ is the effect size of the jth SNP which is contingent on a mixing distribution (g)
and the variance is multiplied by 3 a scaling parameter (10-6, 10-4, 10-2, 1, or
autoscaling). Using a known LD reference panel (in this analysis, the European sample
from 1000 Genomes), individual level regression models are able to put a posterior
probability on each SNP in the sample (assuming the SNPs are overlapping). This
continuous shrinkage removes the need for p value pruning as is commonplace in nonBayesian programs (e.g., PRSice-2, PLINK). Continuous shrinkage reduces the priors
towards the average effect for the SNP. This shrinkage is updated iteratively constantly
shrinking the priors as new information is added. For this study, the amount of variance
explained (Nagelkerke R2) was calculated for both a null model (i.e., a model that uses
all terms outside of the GPS in a logistic regression) and a model with the GPS, with the
two models then compared 275.
GSCAN summary statistics were calculated on individuals of European ancestry
only 276. The use of summary statistics to calculate GPS works best within a single
ancestral group and predicting across ancestry groups (i.e., any non-European ancestry
group) may lead to biased estimates 277,278.
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Covariates. Several covariates were included in the statistical analyses. These items
have previously been associated with CIG and ECIG use in other peer reviewed
studies. Previous research has reported a difference between males and females in
terms of ECIG use 279,280. Sex was included as a dichotomous variable (male vs.
female). Age has also been associated with ECIG use with younger ages using ECIGS
more than older individuals 281. Age was assessed as a ten-level ordinal variable with
age binned into 10 year gaps after age 21 by G4G study staff. Education has been
associated with ECIG use with individuals of higher education being less likely to use
ECIG compared to individuals with lower education 46. Education was recoded into a
four-level ordinal item with bins reflecting: 1) less than high school (HS), 2) HS
Graduate, GED, or Some College, 3) Associate’s Degree, and 4) College Graduate or
More. The analytic sample was restricted to SIA White individuals, so there was no
additional variable to denote race in the GWAS, though the first 7 Principal Components
were adjusted for (see below). To account for dual use, opposite tobacco product use
(i.e., ECIG users’ CIG use) was used as a covariate.

Analytic Strategy
Univariate GWAS was conducted using standard methodologies via PLINK v1.9 72.
GWAS involves a series of regressions wherein each measured SNP (both genotyped
and imputed) is regressed on the outcome of interest.
Ancestry Principal Components Analysis. PLINK v1.9 (--pca) was used to
calculate ancestry PCs among G4G SIA White participants to further address the
possibility of population stratification, even within SIA White individuals. Prior to running
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the PCA, SNPs were restricted to those that were overlapping with the 1KG reference
genome (NSNP = 80,104; Figure 4.3. Seven ancestry PCs were retained to account for
the majority of the variance of ECIG initiation (Figure 4.4). Seven PCs were retained
rather than the first 10 as the scree plot of PCs suggested that after 7, no significant
additional proportion of variance was explained (Figure 4.4).

Figure 4.3. Three-Dimensional Plot of the First Three Principal Components for
Self-Identified White Participants.
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Figure 4.4. Proportion of Variance (y-axis) Explained by the SIA White Principal
Components (x-axis).
Predictive Probability of GPS
The area under the curve (AUC) was generated from a receiver operator characteristic
(ROC) curve to examine the predictive probability utility of the GPS (i.e., how well does
a model with GPS accurately predict an individual’s ECIG use) 282,283. The ROC curve
was calculated by comparing a binary outcome (Y, or ECIG initiation) with a continuous
predictor (X, or GPS). In a ROC curve, each level of X is evaluated as a candidate cut
point which will discriminate an individual’s classification on the binary Y (i.e., an ECIG
user or not). These predicted classifications are then compared with the observed value
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of Y, from which the number of true positives and false positives can be computed. The
sensitivity (i.e., the probability that an observation with a positive outcome is correctly
classified as positive [sensitivity = True Positives /(True Positive + False Negatives)])
and specificity (i.e., the probability that an observation with a negative outcome is
correctly classified as negative [specificity = True Negatives/(True Negatives + False
Positives)]) may then be calculated and graphed against one another with the x-axis
being the false positive rate (1 – specificity) and the y-axis being the true positive rate
(sensitivity). The ROC then calculates the AUC, or the probability of accurate outcome
group assignment based on the regression results 250,284.

RESULTS
Sample Representativeness
In general, participants who were genotyped were less likely to have used either CIGs
or ECIGs (6.6% of those genotyped were ECIG users while 8.4% of those not
genotyped were, 68.2% of genotyped participants were CIG users while 72.3% of nongenotyped participants used CIGs; Table 4.1). Genotyped individuals differed from
ungenotyped participants in several respects: they were more likely to fall in the age 2230 age group (37.6% vs 35.7% respectively).; had a larger proportion of men (29.7% vs
22.8%); were more likely to be college graduates (18.6% vs 14.7%); and more likely to
have health insurance (92% vs 90%). All differences were significant at the p < 0.001
level. These analyses suggest there are systematic differences in participants who were
genotyped compared to those who were not.
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Table 4.1. Descriptive Statistics for Genotyped vs Not Genotyped Participants

ECIG
Yes
No
CIG
Yes
No
Sex
Male
Female
Age Range
18-21
22-30
31-40
41-50
51-60
61-70
70+

Genotyped
N (%)

Not Genotyped
N (%)

1,299 (6.6)
18,274 (93.4)

2,978 (8.4)
32,545 (91.6)

13,358 (68.2)
6,216 (31.8)

25,676 (72.3)
9,849 (27.7)

5,837 (29.7)
13,847 (70.3)

8,241 (22.8)
27,908 (77.2)

1,143 (5.8)
7,404 (37.6)
5,597 (28.4)
2,416 (12.3)
1,854 (9.4)
986 (5.0)
284 (1.4)

2,279 (6.3)
12,834 (35.7)
10,110 (28.1)
5,050 (14.0)
3,516 (9.8)
1,776 (4.9)
379 (1.1)

Education
Less than HS
387 (2.0)
HS Grad/GED/Some College
7,642 (38.8)
Associate’s Degree
7,998 (40.6)
College Graduate or More
3,656 (18.6)
Insurance Status
Covered
18,118 (92.0)
Not Covered
1,430 (7.3)
I Don’t Know
135 (0.7)
2
Note. All χ statistics significant at p < 0.001.

953 (2.6)
16,279 (45.0)
13,624 (37.7)
5,310 (14.7)
32,536 (90.0)
3,373 (9.3)
257 (0.7)

Conventional Cigarettes. The majority of participants who were asked “Have you
ever tried a cigarette?” responded “Yes” (N = 11,058; 70%; Table 4.2). Lifetime
initiators of CIG were more female (72.1%) compared to non-initiators (69%). A greater
proportion of initiators were older (34.7% were over 41) compared to non-initiators
(21.3%). Initiators also reported less education (82% of initiators had an Associate’s
Degree or lower) compared to non-initiators (78.6% had an Associate’s Degree or
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lower. Finally, initiators reported fewer participants without health insurance (7.4%)
compared to non-initiators (5.7%). All differences were significant at the p < 0.001 level.
These results suggest differences between initiators and non-initiators of CIGs across
several important variables.

Table 4.2. Descriptive Statistics of CIG Lifetime Initiation
CIG Initiation
Yes
No
N (%)
N (%)
Sex
Male
3,084 (27.9)
1,458 (31.0)
Female
7,974 (72.1)
3,281 (69.0)
Age Range
18-21
236 (2.1)
490 (10.3)
22-30
3,449 (31.2)
2,133 (45.0)
31-40
3,533 (31.9)
1,110 (23.4)
41-50
1,640 (14.8)
445 (9.4)
51-60
1,278 (11.6)
335 (7.1)
61-70
720 (6.5)
174 (3.7)
70+
292 (1.8)
52 (1.1)
Education
Less than HS
207 (1.9)
79 (1.7)
HS Grad/GED/Some College
4,391 (39.7)
1,592 (33.6)
Associate Degree
4,474 (40.5)
2,055 (43.4)
College Graduate or More
1,985 (18.0)
1,013 (21.4)
Insurance Status
Covered
10,187 (92.1)
4,437 (93.6)
Not Covered
823 (7.4)
268 (5.7)
I Don’t Know
47 (0.4)
34 (0.7)
Note. All χ2 statistics significant at p < 0.001.
Electronic Cigarette Initiation. ECIG lifetime initiation was measured with, “Do
you smoke e-cigarettes?” to which almost 7% of participants (N = 1,050; 6.6%; Table
4.3) reported they had initiated ECIGs. Most ECIG lifetime initiators were between the
ages of 22-30 (36.7%) or 31-40 (34.3). Likewise, ECIG lifetime initiators had lower
education levels (6.9% were a College Graduate) compared to non-initiators (19.8%
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had a College Degree). Finally, a greater proportion of ECIG lifetime initiators did not
have insurance coverage (11.8%) compared to participants who did not initiate ECIGs
(6.6%). All differences were significant at the p < 0.001 level. These results suggest
differences between ECIG initiators versus non-initiators across several important
variables.
Table 4.3. Descriptive Statistics of ECIG Lifetime Initiation
ECIG Initiation
Yes
No
N (%)
N (%)
Sex
Male
386 (36.8)
4,156 (28.2)
Female
664 (63.2)
10,590 (71.8)
Age Range
18-21
49 (4.7)
677 (4.6)
22-30
385 (36.7)
5,197 (35.2)
31-40
360 (34.3)
4,282 (29.0)
41-50
138 (13.1)
1,947 (13.2)
51-60
88 (8.4)
1,525 (10.3)
61-70
24 (2.3)
870 (5.9)
70+
6 (0.6)
248 (1.7)
Education
Less than HS
33 (3.1)
253 (1.7)
HS Grad/GED/Some College
590 (56.2)
5,393 (36.6)
Associate’s Degree
355 (33.8)
6,173 (41.9)
College Graduate or More
72 (6.9)
2,926 (19.8)
Insurance Status
Covered
917 (87.3)
13,706 (93.0)
Not Covered
124 (11.8)
967 (6.6)
I Don’t Know
9 (0.1)
72 (0.5)
2
Note. All χ statistics significant at p < 0.001.
Dual Use of ECIG and CIG. ECIG and CIGs are often used concurrently, known
as dual use. G4G participants were rarely ECIG-exclusive initiators (0.3%) with most
people having initiated CIGs only (63.6%; Table 4.4). Nearly 30% of participants had
tried both products. These results suggest that ECIG-exclusive initiation is rare.
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Table 4.4. Distribution of Tobacco Lifetime Initiation Among Self-Identified
White Participants with Genotypic Data
N
%
Tobacco Lifetime Initiation
No Initiation
1,008
6.4
CIG-Exclusive Initiation
10,082
63.6
ECIG-Exclusive Initiation
45
0.3
Dual Use Initiation
4,706
29.7

Main Results
CIG Initiation
There were no genome-wide significant associations (Figure 4.5). However, three SNPs
had suggestive associations (p ! 1 x 10-6). The first genome-wide suggestive SNP was
in an intergenic region on chromosome 18 (18:61021122, OR = 1.24, p = 2.5 x 10-7)
between HMGN1P31 (High Mobility Group Nucleosome Binding Domain 1 Pseudogene
31) and CDH20 (Cadherin 20). Neither of these genes has been associated with
tobacco use in prior literature. The second suggestive SNP was on chromosome 2
(chromosome identification number: base pair location- 2:84368347, OR = 0.88, p =
9.11 x 10-7) near the gene SUCLG1 (Succinyl-CoA ligase GDP/ADP-forming subunit
alpha). No significant associations between this gene and tobacco use have been
reported to date. The final genome-wide suggestive SNP was located on chromosome
11 (11:42405437, OR = 0.63, p = 7.24 x 10-7) near the LINC0240 (Long Non-Coding
RNA 2740) gene. This gene has not been associated with tobacco use in prior studies.
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Figure 4.5 Manhattan Plot of CIG Initiation Adjusted for Covariates.

ECIG Initiation
Similar to the CIG results, no SNP reached genome-wide significance in the ECIG
GWAS, though there were four SNPs reached the genome-wide suggestive threshold (p
! 1 x 10-6; Figure 4.6). The most significant SNP was on chromosome 13 located in the
N4BP2L1 gene (NEDD4 Binding Protein 2 Like 1, 13:32403784, OR = 0.62, p = 7.49 x
10-7). This gene has previously been linked to several cancers, including breast cancer
285

. One SNP located on chromosome 2 (2:115364757) in the DPP10 (Dipeptidyl

Peptidase Like 10) gene was genome-wide suggestive (OR =1.28, p = 5.19 x10-7). This
gene has previously been linked to asthma, a respiratory disease 286,287. A third SNP on
chromosome 15 (15:49010393) within the SECISBP2L (SECIS Binding Protein 2 Like)
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gene was genome-wide suggestive (OR = 0.44, p = 8.01 x 10-7). This gene has not
been associated with tobacco use or a possible health consequence of tobacco use.
Finally, a SNP on chromosome 6 (6:33902823) was genome-wide suggestive (OR =
0.79, p = 1.75 x 10-7); however, this SNP is located in an uncharacterized location
(LOC105375026).

Figure 4.6. Manhattan Plot of ECIG Initiation Adjusted for Covariates.
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GPS Results
Raw GPS values had very little variance (Figure 4.7a). Consequently, GPS were
transformed into z-scores to have adequate range of variation (Figure 4.7b) as
recommended by Choi and colleagues 252,288,289.

B
A
A
Figure 4.7. Distribution of Raw (Panel A) and Transformed (Panel B) Genome-wide
Polygenic Scores.
There was no significant association between GPS and ECIG initiation after
controlling for cross tobacco product use, insurance status, education level, income
level, gender, and the first 7 ancestry PCs before or after the transformation. A null
model was calculated wherein all predictors were added to a logistic regression except
for the GPSs (Nagelkerke R2 = 0.0595) and compared against a model with the GPSs
and all covariates (Nagelkerke R2 = 0.0596). The difference in Nagelkerke R2 between
the models was 0.0001, suggesting a very small amount of the variance was explained
with the addition of the GPS. The AUC analysis showed the model performed fairly well
(AUC = 0.75, Figure 4.8). Additionally, there was decent discrimination for ECIG
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initiation290 (AUC >= 0.70 is the threshold for acceptable discrimination). However, the
difference in Nagelkerke R2 suggests that this association is due to the covariates rather
than the GPS.

Figure 4.8. Receiver Operator Curve from the Full Model, Including Genome-wide
Polygenic Score.
DISCUSSION
This is the first GWAS of ECIG use to date. Genome-wide significant SNPs were not
detected for either CIG initiation or ECIG initiation after accounting for covariates. These
results are typical of GWAS results in small samples (this sample N = 15,881). Further,
GPS calculated from CIG initiation in a large training sample were not significantly
associated with ECIG initiation in the test sample after adjusting for covariates.
This study found phenotypic similarities to other published reports. ECIG initiation
has been reported to be near 40% in wave 4 of the Population Assessment of Tobacco
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and Health (PATH) 291. Importantly, this study did not differentiate between dual and
exclusive use, so it possible the majority of participants were dual users similar to G4G.
Similarly, Spit for Science (S4S) reported nearly 41% of participants had initiated ECIG,
though dual use was not account for. It is unsurprising that this is a higher proportion
than G4G as S4S is focused on college aged participants. Younger participants use
ECIGs more frequently than older age ranges 292. Further, these estimates of ECIG use,
when considering dual users, is in line with Khouja and colleagues estimate from
ALSPAC (ECIG initiation = 30%) 58. Further, this study reported 64% of participants had
initiated CIG use, similar to the G4G study 58. Dual use was higher in this sample with
95% of ECIG initiators also engaging in CIG initiation. Prevalence of ECIG-exclusive
initiation was reported at 0.3% in G4G, which is similar to ECIG-exclusive initiation in
PATH (0.4%) 293.

Genome-Wide Suggestive SNPs for CIG and ECIG Initiation
There were no genome-wide significant SNPs for CIG initiation; however, there
were two genome-wide suggestive SNPs. The most significant SNP was an intergenic
region of chromosome 18 (18:61021122), with the nearest gene being CDH20
(Cadherin 20). Previous research has utilized SNPs in this gene to create a genotype
score for successful smoking cessation in a clinical trial of nearly 500 smokers
examining nicotine replacement therapy 294. On the other side of this intergenic location,
this SNP is bounded by HMGN1P31 (High Mobility Group Nucleosome Binding Domain
1 Pseudogene 31), a gene with an unknown function and has not been associated with
substance use in previous research.
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Likewise, no SNP reached genome-wide significance for ECIG initiation after
accounting for covariates. However, several genes were genome-wide suggestive. The
most intriguing of these suggestive markers was 2:115364757 in the DPP10 gene.
DPP10 has previously been associated with asthma, a common respiratory disease
which is also associated with ECIG initiation 295–297. This biologically plausible gene
should be marked for further investigation, especially with the rise of EVALI (E-cigarette
or vaping associated lung injury 298,299.
That no SNP reached genome-wide significance is not unexpected in this study.
GWASs require large sample sizes due to the small effect sizes of SNPs of common
variation (MAF > 1%). While the G4G is a large sample, it is still underpowered to detect
such small effects. Post-hoc power analyses indicated that this sample had about 5%
power to detect genetic effects, with nearly 300,000 participants needed to reach 80%
power. Further, ECIG-exclusive initiation in this study was estimated at 0.3%. To detail
ECIG exclusive initiation in GWAS, using this proportion as a starting point, a sample
size of more than 39 million participants would be needed. Future research efforts
should continue to build larger data sets, ensuring greater statistical power to detect
small effects from common variation. In addition, ensuring that all ancestries are
represented in the analyses will increase sample size and increase external validity.

Association between Genome-Wide Polygenic Scores and ECIG Use
This study reported no significant association between the GPS for CIG initiation and
ECIG initiation in a community-based sample. To date, three other studies have
examined CIG GPS and ECIG initiation with inconsistent results. The initial study of CIG
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initiation GPS did not find an association overall between CIG GPS and lifetime ECIG
initiation in a small sample (N ~ 4,000) of twins from the Netherlands. When analyses
were stratified by past tobacco use, a significant association was reported for former
smokers of CIG 124. A more recent study reported a significant association between
lifetime CIG initiation GPS and ECIG initiation in a sample of young adults (age = 24)
from the UK 58. The final study did not examine a lifetime CIG initiation GPS, but did
report significant associations with other GPS built from other CIG phenotypes
(cigarettes per day, regular cigarette use) in an American college aged sample (18-25)
225

. Therefore, it would be advantageous for future studies to examine multiple facets of

the smoking rather than focusing in on one behavior.
While there was no statistical association between the GPS and ECIG initiation,
the model still performed adequately. Compared to model with only covariates and
phenotypic variables, a model with GPS altered the Nagelkerke R2 by less than 0.01%.
However, as shown in Figure 4.9, the area under the curve is sufficient to be classified
as adequately predictive of ECIG use. Most likely this association is drive by the dual
use of ECIG and CIG use. The prevalence of ECIG-exclusive use is extremely small
(0.3% of the sample) which is in line with other published research (e.g., Population
Assessment of Tobacco and Health ECIG-exclusive lifetime initiation is 0.4%
(unweighted)) 293. Additionally, all the phenotypic covariates included in the model have
previously been associated with ECIG use, leading to a model that accurately predicts
ECIG use without genotypic data.
This study has several limitations. First, the proportion of ECIG-exclusive use
was very low (0.3%). This suggests that any genetic variants may be masked by dual
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initiation of ECIG and CIGs. This was accounted for in these analyses by using the
opposite tobacco product as a covariate in regression models. Models that included
genetic risk did not significantly alter the AUC suggesting that there is no additional
information gained by using PRS in this sample. Secondly, even though the GPS takes
into account variants with small effects, it is possible that these variants were not
captured. This would lead to an incomplete picture of the genetic architecture shared
between CIG and ECIG initiation. Thirdly, these analyses were limited to SIA White
participants. Technological improvements have been made to allow for cross-ancestry
estimate of GPS via PRS-CSx 300. Future studies should continue to examine ancestral
groups other than those of European descent
This study also demonstrated several strengths in addition to the limitations. The
large sample size for GPS generation met the minimum for statistical power 273. Further,
this study replicated previous null findings of CIG GPS and ECIG lifetime initiation 124.
Lastly, the proportions of tobacco use were similar to other published reports
The DPP10 gene, a novel gene for ECIG initiation, was identified as genomewide suggestive. While this study was underpowered to detect genetic effects via
GWAS, this gene should be marked for replication in other samples with greater power.
Particular attention should be paid to this possible gene due to its previous association
with respiratory diseases. These preliminary results report that this gene is associated
with increased odds of ECIG use (OR = 1.29). This gene may play a role in the
emergence of EVALI cases and should continue to be researched.

155

CHAPTER 5: THE EFFECT OF COUPON RECEIPT ON THE RELATIONSHIP
BETWEEN INCOME AND PAST 12-MONTH ELECTRONIC AND CONVENTIONAL
CIGARETTE USE IN ADULTS

INTRODUCTION
Tobacco use is more common among individuals at lower income levels. In 2016,
approximately 32% of households with an annual income of less than $20,000 per year
used tobacco products for at least some days. In comparison, approximately 12% of
households making more than $100,000 per year used tobacco products 301. 34 million
Americans were estimated to live in poverty (e.g., annual household income of $24,339
for a family with two adults and two children) 302 in 2013-2014. Consequently, tobacco
use may affect a significant proportion of the American population who are also
financially vulnerable.

The Association between Income and Tobacco Use
CIG use creates a greater health burden and financial stress on low-income individuals
compared to individuals with higher levels of income 303. Individuals at lower income
levels spend a greater proportion of their income on tobacco products 304. Further, CIG
use as well as ECIG use, are risk factors for several chronic diseases (e.g., cancers,
cardiovascular disease), and these conditions impact individuals at lower income levels
more severely 305,306. Low-income populations are also less likely to have access to
health insurance or health care compared to individuals at higher levels of income.
Individuals who do not have health insurance tend to have worse health outcomes than
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individuals with health insurance and generally receive worse quality health care
compared to those with health insurance 307. Low-income populations are particularly
vulnerable to the negative consequences of tobacco use as a result of an increased
immediate financial burden resulting from regular tobacco expenditures. Previous
research has reported significant associations between CIG-exclusive use and dual use
such that individuals with lower incomes were more likely to be users (Friedman & Horn,
2019). There are no reported significant associations between ECIG-exclusive use and
income (Friedman & Horn, 2019).

Initial ECIG Price Point as an Obstacle to Initiation
Coupons produced by tobacco companies are a cigarette expenditure minimizing
strategy (CEMS) that can reduce immediate costs precluding tobacco initiation and use.
CEMS reduces the immediate purchase cost of various forms of tobacco use. Engaging
in coupon use as a CEMS has been associated with increased use of tobacco products
308

. For example, receipt of coupons was associated with greater odds of CIG initiation

309

, smoking relapse 310, and switching to regular smoking from experimental use 311 in

adolescents and young adults. This strategy has been more widely used in low-income
populations to reduce the cost of CIG use 312,313.
The use of coupons as a CEMS is likely to extend to ECIG use since they require
a large initial investment to purchase the device. For example, rechargeable ECIG
starter kits typically range from $25-$150 or more while the liquid refill kits cost $50-$75
monthly 314. Therefore, the cost of ECIG may prevent lower income individuals from
accessing this product 315. Receipt of ECIG coupons and marketing materials was
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associated with an increased likelihood of trying ECIGs by reducing the purchase price
of these devices 316,317. Consequently, lower income populations may use CEMS to help
defray the initial price point of initiating ECIG use. However, to date, it is unclear the
degree to which this strategy is used across all income levels or whether the receipt of
coupons moderates this association.
Although low income and use of CEMS have been associated with CIG-exclusive
and ECIG-exclusive use, it remains unclear whether receipt of coupons focused on a
particular tobacco delivery system is also associated with the dual use of ECIG and CIG
in adults. Likewise, it is unclear if income is associated with dual use. It is unclear
whether receipt of coupons is associated with specific patterns of ECIG and CIG use
(i.e., exclusive product use or dual ECIG and CIG use). This study has two aims: (1)
describe the relationship between income and tobacco use, as categorized by productexclusive use or dual use of ECIG and CIGs, and (2) detail how this relationship varies
with receipt of coupons for ECIGs or CIGs. We anticipate that (1) the relationship
between income and tobacco use will be similar to previously reported associations
(Freidman & Horn, 2019), a significant association will be noted for all modalities of
tobacco use (CIG/ECIG-exclusive and dual use) and (2) the association between
tobacco use and income will receipt be stronger in low income groups and nonsignificant in higher income groups.
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METHODS
Study Population
Data for this study were drawn from the publicly available files from Wave 3 of the
Population Assessment of Tobacco and Health (PATH; N = 28,148) 318. Described in
detail elsewhere 319, PATH is a nationally representative longitudinal study of tobacco
use and health. Our analytic sample consisted of adults aged 18-99 who had complete
data on tobacco use, income, and coupon receipt. Most participants were White
(77.7%) and Female (52.0%, Table 5.1).

Variables
Tobacco Use. Tobacco use, the outcome variable, was recoded into a 4-level
variable. If a participant reported not using ECIGs or CIGs in the past 12-months, they
were coded as a non-user. If an individual marked they had used CIGs in the past 12months, but not ECIGs, they were coded as a CIG-exclusive user. The reverse is also
true, reporting that one had used ECIGs in the past 12-months but not CIGs returned an
ECIG-exclusive user. Finally, if the participant reported using both ECIGs and CIGs in
the past 12-months, they were coded as a dual user.
Income. Income was divided into a 5-level ordinal variable, using the following
prompt, “Which of the following categories best describes your total household income
in the past 12 months?” Responses included: less than $10,000, $10,000-$24,999,
$25,000-$49,999, $50,000-$99,999, and $100,000 or more as defined by the PATH
study staff.
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Receipt of Coupons. Coupon and promotion materials were probed with the
following items: “In the past 12 months, received discounts or coupons for any of the
following products: Cigarettes?” to which participants could endorse or not endorse and
“In the past 12 months, received discounts or coupons for any of the following products:
E-cigarettes or other electronic nicotine products (including e-liquid)?” to which
individuals could endorse or not endorse. Each of these items was treated as binary
with response options of yes or no.
Covariates. Several demographic factors (age, gender, race, education), which
have previously been associated with ECIG as well as CIG use 320 were included as
covariates. Gender was included as a PATH derived binary variable, representing male
and female response options. Education was recoded into a four-level ordinal variable
defined as less than high school, high school graduate or GED, some college, and
bachelor’s degree or higher. The race was captured as a three-level, PATH-defined
nominal variable defined as White, Black, or Other. Age was measured in PATH as a
seven-level ordinal variable: 18-24, 25-34, 35-44, 45-54, 55-64, 65-74, and 75+.

Statistical Analysis
Descriptive statistics were used to summarize the characteristic of the study
participants. Multinomial regression was used to assess the association between
income and past 12-month tobacco use. ECIG and CIG use do not necessarily occur
independently of one another and dual use of these products is common 321–323.
McMillian and colleagues (2015) reported about a third of daily and non-daily smokers
or CIGs reported they were also using ECIGs 113. Consistent with other research, dual
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users of these delivery systems may represent a distinct group from delivery system
specific groups 324, and as such, this study applied multinomial modeling to take this
unique group into account.
Moderation Analysis
To assess whether receiving coupons modifies the relation between income and
tobacco use, preliminary moderation analysis was performed. To date, it remains
unclear how coupons may influence the income and tobacco use association. One
possible avenue for investigation is to test whether or not coupons moderate the
association. Conceptually, a moderation analysis tests whether the moderating variable
(M, coupon receipt) influences the direct relationship between the independent variable
(X, income) and dependent variable (Y, tobacco use; Figure 5.1). M can moderate the
relationship by either increasing or decreasing the magnitude of the pathway, between
variables X and Y as shown in Figure 5.1, via pathway b from M to the relationship of X
and Y. Previous research has reported that redeeming coupons was associated with a
reduction in the odds of past 30-day abstinence of CIG use 325. Though researchers did
not explicitly model moderation, this may suggest that using coupons may influence the
pathway by creating a situation where lower income is not prohibitive of CIG use.
Explicitly modeling the moderation by coupons may reveal additional insight into why
individuals with lower incomes disproportionately use tobacco products. It is
conceivable that using a CEMS, such as coupons, may lead to greater uptake or
continued use of a tobacco product. They may also influence an individual to switch
administration routes or use both products simultaneously. CEMS seeks to minimize the
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amount of money spent on a tobacco product; therefore, a moderating relationship may
exist between income and tobacco use coupons.
Coupon
Receipt
(M)

b
Income
(X)

a

Tobacco
Use
(Y)

Figure 5.1. Conceptual Model for Moderation Analysis.
Multinomial regression approach allows the separation of the outcome variable
into groups of CIG-exclusive users, ECIG-exclusive users, dual users, and non-users
and allows for comparisons to be made between unordered groups. Multinomial
regression reduces the possibility of misclassification bias by separating the delivery
systems used by participants, including those participants who dual used both systems
so dual users are not represented as both ECIG and CIG-exclusive users. All models
were run in SAS 9.4 (SAS Inc., Cary, NC) and accounted for the complex survey design
with PROC SURVEYLOGISTIC. Additionally, these analyses were adjusted for age,
race, gender, and education level as these have been previously associated with ECIG
and CIG use 326. Replicate weights were estimated using Fay’s variant of balanced
repeated replication 327 as detailed in the PATH User Guide. Additionally, preliminary
moderation analyses, with coupons as the moderator variable, were conducted to
determine how coupon receipt may influence the tobacco use and income relationship.
Moderation was tested in SAS by the addition of an interaction term between income
and coupon receipt as well as through stratification of results based on coupon receipt.
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RESULTS
Descriptive Statistics
Table 5.1. Summary Statistics for PATH Wave 3
Variable
N
Weighted %
Tobacco Use
Non-User
14,548
72.4
CIG-exclusive
8,171
17.5
ECIG-exclusive
1,373
2.6
Dual User
4,056
7.5
Income
< $10,000
4,634
11.6
$10,000-$24,999
5,686
19.1
$25,000-$49,999
5,975
22.8
$50,000-$99,999
5,866
26.7
> $100,000
3,917
19.8
ECIG Coupon Receipt
Yes
1,078
3.4
No
26,962
96.6
CIG Coupon Receipt
Yes
4,869
12.2
No
23,171
87.8
Gender
Male
13,788
48.0
Female
14,334
52.0
Race
White
19,899
77.7
Black
4,494
12.5
Other
2,951
9.89
Education
< HS
3,714
11.1
HS Grad/GED
8,547
28.2
Some College
9,724
31.7
College grad or higher
6,025
28.0
Age
18-24
8,453
12.4
25-34
5,824
17.5
35-44
3,972
16.1
45-54
3,804
17.2
55-64
3,389
17.2
65-74
1,891
12.3
75+
813
7.3
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Approximately 27.6% of all participants engaged in some form of lifetime tobacco
use. Of these, 9,544 (20.1%) used CIG or ECIG in the last 12 months. Most participants
engaged in CIG-exclusive use (17.5%). Most participants had an annual household
income of $50,000- $99,999 per year (26.7%). Approximately 3.4% of participants
received ECIG coupons and 12.2% received CIG coupons (Table 5.1). 328,329
Table 5.2 Description of Participants Receiving Coupons
Any Coupon Receipt
Yes
No
Variable
N (Row %)
N (Row %)
Tobacco Use
Non-User
1,085 (7.5)
13,432 (92.5)
CIG
2,573 (31.7)
5,551 (68.3)
ECIG
177 (13.0)
1,189 (87.0)
Dual User
1,442 (35.8)
2,591 (64.2)
Income
< $10,000
1,050 (22.8)
3,565 (77.2)
$10,000 - $24,999
1,301 (23.0)
4,367 (77.0)
$25,000 - $49,999
1,287 (21.6)
4,678 (78.4)
$50,000 - $99,999
1,020 (17.4)
4,842 (82.6)
> $100,000
411 (10.5)
3,501 (89.5)
Sex
Male
2,360 (17.2)
11,357 (82.8)
Female
2,912 (20.4)
11,385 (79.6)
Race
White
4,010 (20.2)
15,832 (79.8)
Black
727 (16.3)
3,742 (83.7)
Other
462 (15.7)
2,474 (84.3)
Age
18-24
981 (11.6)
7,449 (88.4)
25-34
1,377 (23.7)
4,429 (76.3)
35-44
948 (24.0)
3,009 (76.0)
45-54
962 (25.4)
2,821 (74.6)
55-64
738 (21.9)
2,632 (78.1)
65-74
225 (12.0)
1,656 (88.0)
75+
46 (5.7)
765 (94.3)
Education
< HS
762 (20.6)
2,932 (79.4)
HS Grad/GED
1,814 (21.3)
6,704 (78.7)
Some College
2,013 (20.7)
7,692 (79.3)
College grad or higher
681 (11.3)
5,335 (88.7)

p-value
< 0.001

< 0.001

< 0.001
< 0.001

< 0.001

< 0.001
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Individuals with household incomes of $50,000 and higher comprised nearly half
of non-tobacco users (46.6%). Participants in the lowest income category (less than
$10,000) represented 22.7% of all tobacco users. The second highest income group
(those making between $50,000 and $99,999; Table 5.3) had the lowest frequency of
tobacco use. Receipt of coupons, either for ECIG or CIG products, was well spread out
with nearly equal distributions among the four lowest income categories. Individuals in
the highest income category reported the lowest prevalence of coupon receipt (Table
5.3).
Table 5.3. Distribution of Tobacco Use and Coupon Receipt by Income Category
Less than
$10,000$25,000$50,000$100,000
$10,000
$24,999
$49,999
$99,999
or more
Variable
N
%
N
%
N
%
N
%
N
%
Tobacco Use
Non-Use
1,734
13.0 2,365 17.8 3,016 22.6 3,474 26.1 2,737 20.5
CIG-Exclusive
1,874
24.4 2,068 27.0 1,717 22.4 1,392 18.2
617
8.1
ECIG-Exclusive
192
24.4
265
21.2
299
23.9
287
22.9
209
16.7
Dual Use
834
21.8
988
25.8
943
24.6
713
18.6
354
9.2
Coupon Receipt
ECIG
144
13.9
224
21.6
260
25.1
258
24.9
151
14.6
CIG
1,012
21.6 1,231 26.3 1,202 25.7
911
19.5
325
6.9

Modeling Results
CIG-Exclusive Use. Relative to non-tobacco users, income was significantly
associated with CIG-exclusive use across all income levels after adjusting for
covariates. Lower levels of household income were more strongly associated with past
12-month CIG use, with decreasing but still significant ORs for higher income levels
relative to those making more than $100,000 (aOR<10k = 4.01, 95% CI = 3.38-4.76;
aOR50-99k = 1.43, 95% CI = 1.24-1.65; Table 5.4). for addition to this significant
association, CIG coupon receipt was associated with a roughly 25% decrease in the
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odds of CIG use (aORCoupons = 0.74 95% CI = 0.59-0.92; Table 5.4). The association
between income and CIG use also remained significant after also estimating the effect
of ECIG coupon receipt (OR= 5.69, 95% CI = 5.08-6.38; Table 5.4). Lower levels of
income were more strongly associated with past 12-month CIG use, and attenuated but
still significant increases in the odds as the income level rose (aOR<10k = 3.60, 95% CI =
3.02-4.29; aOR50-99k = 1.30, 95% CI = 1.12-1.51; aORECIGCoupons = 5.69, 95% CI = 5.086.38; Table 5.4)
ECIG-Exclusive Use. Relative to non-tobacco users, income was not significantly
associated with ECIG-exclusive use across all income levels (Table 5.4). This
association remained non-significant after adjusting for covariates and ECIG coupon
receipt. However, there was a statistically significant association between CIG coupon
receipt and ECIG-exclusive past 12-month use (aORCoupons = 2.32, 95% CI = 1.74-3.10;
Table 5.4). Likewise, there was no significant association between income and ECIG
use after accounting for covariates and ECIG coupon receipt, though there was a
significant association between ECIG past 12-month use and ECIG coupons
(aORECIGCoupons = 1.40, 95% CI = 1.05-1.88; Table 5.4).
Dual Use. Relative to non-tobacco users, income was significantly associated
with dual use across all income levels after adjusting for covariates. Similar to CIG use,
the magnitude of the association was the highest as the lowest income level and
attenuated, but remained significant, as the income level increased (aOR<10k = 3.65,
95% CI = 2.97-4.48; aOR50-99k = 1.51, 95% CI = 1.23-1.86; Table 5.4). This association
remained significant after adjusting for CIG coupon (OR = 2.62, 95% CI = 2.10-3.28;
Table 5.4) or ECIG coupon receipt (OR =7.61, 95% CI = 6.75-8.58; Table 5.4).
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Table 5.4. Parameter Estimates for Association between income and Past 12-Month
Tobacco Use by ECIG and CIG Coupon Receipt
CIG User
ECIG User
Dual User
aOR (95% CI)
aOR (95% CI)
aOR (95% CI)
CIG Coupon Receipt
Income
> $100,000
Reference
Reference
Reference
< $10,000
4.01 (3.38-4.76)
1.00 (0.73-1.26)
3.65 (2.97-4.48)
$10,000-$24,999
3.02 (2.57-3.53)
1.10 0.82-1.47)
3.13 (2.61-3.75)
$25,000-$49,999
2.00 (1.70-2.26)
1.03 (0.77-1.37)
2.34 (1.95-2.82)
$50,000-$99,999
1.43 (1.24-1.65)
0.88 (0.68-1.15)
1.51 (1.23-1.86)
Coupon Receipt
No
Reference
Reference
Reference
Yes
0.74 (0.59-0.92)
2.32 (1.74-3.10)
2.62 (2.10-3.28)
ECIG Coupon Receipt
Income
> $100,000
Reference
Reference
Reference
< $10,000
3.60 (3.02-4.29)
0.98 (0.72-1.33)
3.23 (2.62-3.99)
$10,000-$24,999
2.73 (2.33-3.21)
1.10 (0.82-1.47)
2.77 (2.29-3.34)
$25,000-$49,999
1.77 (1.53-2.05)
1.02 (0.77-1.36)
2.07 (1.71-2.51)
$50,000-$99,999
1.30 (1.12-1.51)
0.88 (0.68-1.15)
1.34 (1.08-1.67)
Coupon Receipt
No
Reference
Reference
Reference
Yes
5.69 (5.08-6.38)
1.40 (1.05-1.88)
7.61 (6.75-8.58)
Note. The outcome reference group is Non-User; all estimates adjusted for age, race, gender,
education level, and complex survey design; bolded values indicate p < 0.05
Moderation. No statistically significant moderation of CIG coupon receipt was
detected for associations between income and any tobacco product (F(12, 100) = 1.73,
p > 0.05). However, there was evidence of moderation by ECIG coupon receipt on the
relationship between income and CIG use (F(12,100) = 2.73, p < 0.001). Stratified
analyses revealed a weak statistically significant relationship (aOR = 2.51, 95% CI =
1.50-4.16) for those who smoked CIG and received ECIG coupons for participants
making between $50,000 and $99,999 (Table 5.5).
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Table 5.5. Parameter Estimates of Past 12-Month CIG Use by ECIG Coupon Receipt Stratified
by Income Level
< $10,000
$10,00-$24,999
$25,000$50,000> $100,000
$49,999
$99,999
b (SE)
b (SE)
b (SE)
b (SE)
b (SE)
aOR (95% CI)
aOR (95% CI)
aOR (95% CI)
aOR (95% CI)
aOR (95% CI)
Receipt
No
Reference
Reference
Reference
Reference
Reference
Yes
-0.11 (0.34)
0.38 (0.27)
0.05 (0.23)
0.91 (0.26)
0.18 (0.26)
0.89 (0.46-1.75) 1.46 (0.85-2.50) 1.05 (0.67-1.65) 2.51 (1.50-4.16) 1.19 (0.71-2.00)
Note. The outcome reference group is Non-User; all estimates adjusted for age, race, gender,
education level, and complex survey design; bolded values indicate p < 0.05
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$25,000-$49,999

Coupons Received
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> $100,000

Coupons Not Received

Figure 5.2. Proportion of CIG-Exclusive Users by Income Level and ECIG Coupon
Receipt.
DISCUSSION
This study evaluated whether receipt of product-specific coupons influences the
association between tobacco use and income in a nationally-representative sample.
The results from this study indicate that the patterns of association between income and
tobacco use vary across products. Further, receipt of coupons was independently
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associated with tobacco use, with receipt of ECIG coupons associated with a reduction
in the odds of CIG and dual use.
The prevalence of CIG-exclusive use in this sample (17.5%) was similar to that of other
studies (approximately 14%) 330. Additionally, the estimated prevalence of ECIG
exclusive use in Wave 3 PATH was 2.6%, which was similar to those previously
reported in other nationally representative samples (1.3% in 2014-2016 NHIS; 4.5%
2016 BRFSS) 52,326. There was also a higher prevalence of dual use (7%) compared to
previous reports (2.7% from Friedman & Horn, 2019), but similar to other nationally
representative samples (7.0% 2016 BRFSS; 52). The difference in the prevalence of
ECIG-exclusive use and dual use may be due to the more recent collection for Wave 3
of PATH (2016-2017) compared to previous analyses (National Health Information
Survey 2014-2016; Friedman & Horn, 2019) as ECIG-exclusive use has become more
common over time in adults 18-25 113. Further, ECIG use among existing CIG users
(dual use) has also been increasing 331.

Associations between Income and CIG-Exclusive Use and Dual Use
Participants with incomes of less than $10,000 were at greater odds of past 12-month
CIG use compared to individuals making more than $100,000. as income increased the
magnitude of the association was reduced. These results are similar to previous studies
of income and tobacco use 61,113. Tobacco is thusly used disproportionately by
individuals with fewer means to indulge. One method promoted for reducing tobacco
use is via raising taxes 332,333. Therefore, monetary restrictions (e.g., raising taxes) may
disproportionately affect more individuals of lower income.
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Participants making less than $100,000 per year had a greater odds of past 12month dual use of ECIG and CIG, compared to participants making more than $100,000
per year. These results are similar to the pattern previously reported for CIG-exclusive
use 61,326. This pattern of association may be due to individuals adding ECIG use to their
existing CIG use 334. As CIG users experiment with ECIGs, it is likely that their patterns
of tobacco use should most resemble CIG-exclusive users because they likely continue
to engage in CIG use.
There was no significant association between ECIG-exclusive use and income,
as has been reported in other studies 326. ECIG use is generally perceived as a
“healthier alternative” to CIG use 335. Prior literature has also reported individuals with
lower income are less likely to engage in positive health behaviors (e.g., smoking
cessation) compared to individuals with higher income 336–338. ECIGs have been
marketed products to reduce harmful exposure to the carcinogens in CIG 339 although it
is unclear whether these products have been successful for this purpose. Nevertheless,
many CIG users perceive ECIG to be safer than CIG 340. Therefore, among CIG users,
ECIG use may be considered a positive health behavior. However, it is possible that
lower income smokers do not use ECIGs as harm reduction tools because this belief
does not offset the initial higher price of ECIGs. Preferably, individuals would choose
not to use tobacco at all; however, using a less harmful product may result in the
reduction of lost time and money due to illness attributable to tobacco use. This study
provides some initial evidence that reducing the price point of ECIGs via coupons is
associated with greater use of ECIGs.
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Receipt of Coupons Associated with Varying Patterns Nicotine Use
Receipt of CIG coupons was associated with greater odds of ECIG-exclusive and dual
use; however, receipt of CIG coupons was associated with a 26% reduction in the odds
of CIG-exclusive use (Table 3). It is possible that providing consumers with coupons
means providing them with coupons for all products, including ECIGs, from the
manufacturer. In this sample, 62% of participants who received CIG coupons also
received ECIG coupons. Thus, individuals may be encouraged to switch to dual or
ECIG-exclusive use through the receipt of coupons in manufacturer packs rather than
for a specific product. Further research should continue to examine how coupons are
received and utilized by consumers.
Receipt of ECIG coupons was associated with greater odds of all forms of
tobacco use: ECIG-exclusive use, CIG-exclusive, and dual use. Previous research has
reported that individuals who receive coupons from tobacco companies are more likely
to report that tobacco companies care about their health and try to make cigarettes as
safe as possible 341. Exposure to tobacco marketing materials and coupon receipt has
been associated with an increased willingness of an individual to try ECIGs or CIGs 342,
thus increasing the odds of initiation of these tobacco delivery systems. Despite this, the
prevalence of CIG use is decreasing 343 while ECIG use is increasing 344. Further
analysis should focus on how coupon receipt influences transitions from productexclusive use to dual use, though the long-term health benefits or risks of ECIGs have
yet to be detailed 345.
The receipt of ECIG coupons was showing an association with greater odds of all
tobacco use, additional models were tested to investigate whether ECIG coupons
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moderated the relationship between income and tobacco use. Significant statistical
evidence of a weak interaction between income and ECIG coupons was detected.
Further investigation showed that the moderating effect was driven by individuals
making $50,000-$99,999 such that receipt of ECIG coupons was associated with a
decrease in CIG use. Participants at lower incomes may have transitioned into a higher
income category, but remained in the opt-in group for coupons (i.e., they continued to
receive coupons). Individuals may also transition from user to non-user as they move
into different income groups, thus rendering a negative effect of coupon receipt. Future
studies should examine how transitioning between income groups impacts tobacco use.
Previous research has reported on the possibility that receipt of coupons may
contribute to the disparity in smoking by socioeconomic status. Other studies have
shown that tobacco companies use direct marketing to target individuals, specifically
women of low SES 329,346. Tobacco companies have used strategies such as coupons to
market their products for over 40 years. More recent research has shown that coupon
saving is considerably high among adolescents and young adults, creating another
barrier to smoking cessation for these populations 347. Though these analyses do not
allow for any conclusions to be drawn about the potential for targeting individuals with
low income, future research should examine possible disparities in the receipt of ECIG
coupons and determine if ECIG couponing resembles traditional CIG couponing.

Limitations
One major limitation of this study is the inability to distinguish who redeemed and
who simply received coupons or promotional items. Previously reported research has
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demonstrated that individuals who receive coupons are different from those who do not
348

. Coupon receivers tend to be white, middle aged (25-44), sexual minority females

with higher levels of nicotine dependence 348. Couponing, in the United States, is limited
to an “opt-in” situation whereby individuals must agree to receive coupons which may
indicate significant differences between those who do and do not receive coupons346,349.
Future studies should continue to examine those individuals who receive coupons and
how these coupons (particularly those for ECs) may influence tobacco use, especially in
terms of tobacco use maintenance, tobacco product switching, and tobacco use
cessation. Studies should also focus on the receipt of promotional material that takes
place where individuals do not need to opt-in. These places may be bars, restaurants,
or other private spaces where brand ambassadors are distributing promotional materials
(e.g., t-shirts, keychains), samples, or coupons.
These analyses were conducted cross-sectionally, using only wave 3 of PATH.
Future studies should probe how coupons influence transitions from product-specific
use to dual use or vice versa. The moderation analysis is likely underpowered to detect
a significant statistical interaction due to the small sample size since only 3.4% of the
sample had received ECIG coupons 350. As receipt of coupons becomes more common,
it may be the case that larger sample sizes will be available to replicate and confirm this
preliminary finding. There is also a causal assumption in moderation analysis such that
the exposure of interest causes the outcome of interest (pathway a in Figure 5.1); future
research should expand on these findings by modeling moderation in a longitudinal
analysis. Finally, future studies should continue to study the possible moderation by
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using more refined exposure group assignments, such as detailing if the participants
actually used the coupons or merely received them.

Strengths
This study also has several strengths along with the above limitations. First, this study
used data from a nationally representative sample of non-institutionalized individuals
living in the United States. Appropriate statistical modeling allowed for all individuals
who completed the questions regarding income, couponing, and tobacco use to be
included while also accounting for the complex sampling design of PATH. Therefore,
the results from the current study is more generalizable to broader population.
Secondly, we used a multinomial logistic regression approach which allowed the
outcome groups to be separated by using patterns to avoid misclassification and bias of
model estimates. The use of multinomial logistic regression allowed for the groups of
users to be modeled simultaneously and allowed for more accurate estimates of current
(past 12-month) CIG-exclusive, ECIG-exclusive, and dual use prevalence in the United
States. Lastly, these analyses accounted for the product-specific couponing and
produced interesting results: ECIG coupons had a competing effect on the past 12month CIG-exclusive use, and may represent an opportunity for individuals to
experiment with ECIGs and possible switch products. Future studies need to account
for the product being advertised and not just general advertisements or coupons and
better understand the influence of the coupons on the potential switching between CIGexclusive and ECIG or dual use.
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Measuring income on an ordinal scale is an additional strength that builds upon
previous research. Utilizing the PATH derived income variable allows for a more
nuanced view of income rather than the more common use of a percentage of the
federal poverty level (FPL). Previous research around income and tobacco use has
focused on FPL as the level of measurement for income 113,326,351. By focusing on the
level of income (e.g., less than $10,000 versus greater than $100,000) rather than the
percentage of FPL, a clearer picture of the association between income and tobacco
use emerges. Regardless of the level of measurement for income, the same pattern is
clear: lower levels of income are associated with greater odds of tobacco use relative to
individuals with higher income. Specifically, relative to the highest income group, each
income group shows an association with tobacco use suggesting that no income group
is being targeted for tobacco use though this targeting may be present in targeting of
communities rather than individuals 352. Further research should continue to resolve the
association between income and tobacco use by measuring income as a continuous
measure as well as modeling individual income within the context of the larger
neighborhood environment.

Public Health Implications
Since the Tobacco Master Settlement Agreement of 1998, tobacco companies have
reduced, or ceased, their public advertising practices; however, direct mail marketing
remains a primary means for tobacco companies to communicate with their consumers
353

. Previous research has shown individuals who receive coupons for tobacco products

are less likely to successfully cease tobacco use 325 as well as increase the odds of
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progression of smoking to regular or daily smoking from experimental use 354. These
results may suggest that advertising of ECIGs may result in fewer individuals using
CIGs exclusively and might foster switching to dual use. For those who are considering
ECIG use as a harm reduction tool to CIG use 355, exposure to advertising may offer an
opportunity to engage in ECIG use. However, effort should continue to be expended on
promoting the notion that there is no safe tobacco product when compared to no
product use.
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CHAPTER 6: DISCUSSION

This chapter summarizes and synthesizes the results from the research previously
detailed in Chapters 2 through 5. It is divided into two sections that address the major
knowledge gaps of this dissertation as identified in Chapter 1 (Introduction). The first
knowledge gap set out to quantify the relative degree to which genetic and
environmental influences impact ECIG lifetime initiation and to what degree are those
factors shared with CIG initiation. While there was statistical evidence of genetic overlap
there was no detection of genome-wide significant molecular genetic effect in the
GWAS. The second knowledge gap was addressed by examining specific genetic and
environmental factors associated with CIG and ECIG initiation. Specific genes and
biological pathways were found to associated with several CIG phenotypes. Income (a
specific environmental influence) was associated with CIG and dual use, but not ECIGexclusive use, suggesting dual users represent a distinct class of tobacco user.

Knowledge Gap 1 Results: Preliminary Evidence of Genetic and Environmental Overlap
for CIG and ECIG Initiation
This dissertation estimated the degree to which there were overlapping genetic and
environmental factors shared between CIG and ECIG initiation. Chapter 2 used a twin
study of adolescents and young adults and detected significant overlap in additive
genetic (rg = 0.76, p = 1), shared environmental influences (rc = 0.68, p = 0.32), and
unique environmental influences (rE = 0.87, p = 0.01) between CIG and ECIGs. While
these estimates were non-significant, dropping these parameters resulted in worse
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model fit, suggesting that these parameters cannot be excluded in bivariate models of
ECIG and CIG initiation. Chapter 4 extended twin study results by examining genetic
overlap using a genome-wide polygenic score (GPS) for CIG initiation to determine
whether there was significant genetic overlap in measured genetic variants with ECIG
initiation. Analyses did not identify any significant specific genetic variants that
contributed to both phenotypes. However, power analyses showed this study did not
have adequate power to detect genetic effects. Nevertheless, prior studies have
reported significant association between a GPS for CIG use and ECIG initiation in a
sample of young adults (age = 24) from the UK. Additional studies have reported
significant associations with GPS for other CIG use behaviors (e.g., regular cigarette
use) and ECIG initiation 58,124,225. Therefore, additional research is needed in
appropriate samples to probe the overlapping genetic influences of CIG and ECIG
initiation. Additionally, these studies reported prevalence rates of ECIG initiation similar
to those identified in Genes for Good (Genes for Good = 30.0%, other samples = 4.7%,
Netherlands Twin Registry – 37.3%, S4S-EUR). Further study is recommended in
significantly larger samples (N~ 300,000) with appropriate power to verify the genetic
effects that are shared between ECIG and CIG initiation 356.
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Translating Results from Knowledge Gap 1 for Public Health: Advancing Future Public
Health Strategies to Influence ECIG Initiation by Characterizing Genetic and
Environmental Overlap with CIG Initiation

Results addressing Knowledge Gap 1 suggest that factors influencing CIG initiation may
also impact ECIG initiation. Consequently, it is possible that previous smoking
prevention efforts may also impact ECIG use. For example, previous research has
shown an association between peer group attitudes and CIG and ECIG use67,357. Peers
have previously been targeted by public health prevention efforts for CIG use 358–360.
These strategies may be modified to target ECIG use rather than CIG. Therefore,
exploring the degree to which strategies that limit CIG initiation may also limit ECIG
initiation because similar genetic and environmental influences impact ECIG initiation as
CIG.

Knowledge Gap 2 Results: Income and Coupon Receipt
Chapter 5 assessed the association between a specific environmental factor
(income) on CIG and ECIG use. These results reflected other published results of
income and CIG or ECIG use 46. Specifically, those with lower income had greater odds
of CIG use. However, there was no significant association with ECIG use. Additionally,
moderation was tested to determine if the receipt of coupons influenced the association
between income and tobacco use. There was a statistically weak, but significant,
interaction between ECIG coupons and income and the odds of past 12-month CIG use;
receiving ECIG coupons led to a two and half time increase in the odds of using CIGs in
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the past 12 months. However, the sample size was quite small which necessitates
further research into this possible association with larger samples 350.

Translating Income and Moderation of Coupon Results for Public Health.
Coupon receipt was associated with greater odds of all forms of tobacco use
(product-exclusive and dual use). Cross-product coupon receipt was associated with an
increase in the odds of being a user of the other product (CIG users who received ECIG
coupons OR = 5.69, 95% CI = 5.08-6.38; ECIG users who received CIG coupons OR =
2.32, 95% CI = 1.74-3.10). Individuals who received ECIG coupons were more likely to
use CIGs as well as ECIGs. This could be due to several reasons. First, tobacco
coupon receipt is an opt-in scenario in the United States. People must willingly sign up
to receive coupons and marketing materials from tobacco companies. Second, coupon
receipt of any tobacco product may prime an individual to use tobacco regardless of the
delivery form 361,362. This priming effect has been established for CIG use and is used in
state-sponsored counter programming to tobacco marketing initiatives 363. Further
research is needed to understand coupon receipt (i.e., what makes individuals opt-in to
coupons), if individuals are being target, and the effect coupon receipt has on switching
from a product exclusive users to a dual user.
The trend of coupon receipt increasing the odds of tobacco use did not hold true
for receipt of CIG coupons and past 12-month CIG use. Receipt of CIG coupons was
associated with a roughly 25% reduction in the odds of past 12-month CIG-exclusive
use (OR = 0.74, 95% CI = 0.59-0.92). All other coupon receipt was associated with
increased odds of tobacco use (Chapter 5, Table 5.4). It is possible that individuals are
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being pushed from CIG-exclusive use to dual use as receipt of CIG coupons was
associated with a more than two and half fold increase in the odds of dual use. This
may happen as consumers are given coupons for all products for a particular
manufacturer when they agree to receive marketing (i.e., signing up for Marlboro
marketing may also expose the consumer to marketing for JUUL and IQOS, as all are
manufactured by Philip Morris). Further research is needed to understand how
individuals are receiving and using coupons from tobacco companies.

Translation for Public Health
Public health professionals are interested in preventing the morbidity and
premature mortality associated with tobacco use. Detailing this specific environment
(knowledge gap 2) has led to two innovations, one for prevention and one for research,
that may be utilized by public health professionals. First, individuals who receive
coupons may be priming themselves for additional tobacco use 361,362. Prevention efforts
could focus on negating this priming effect by including material for smoking cessation
along with the marketing material. Second, smoking cessation studies should consider
how individuals transition from ECIG-exclusive user to non-user and the similarities this
trajectory may have with CIG use. Additional research should also consider how dual
users move toward smoking cessation: how can individuals quickly cease use of both
products? Perhaps it is easier to cease use of one product compared to the other, which
would inform future cessation efforts as to which product to focus on first. Further
research is needed to understand the dynamics of CIG and ECIG use.
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Knowledge Gap 2 Results: Genome-Wide Association Study
Chapter 4 used GWAS to determine whether there were specific genetic variants
that were associated with ECIGs. No GWAS results reached genome-wide significance,
but there were several variants that were genome-wide suggestive. Further, one SNP in
these suggestive results was in a biologically plausible pathway linked to respiratory
disease. Therefore, further investigation of this variant is encouraged in samples that
are adequately powered to detect genetic effects. Additionally, as the prevalence of
ECIG use is low, oversampling for ECIG-exclusive users is encouraged to further
investigate. Similar to other published GWAS of CIG initiation (see Chapter 3 for further
detail), there were no genome-wide significant associations detected in this small
sample.

Translating Genetic Association Results for Public Health.
A suggestive SNP in DPP10 was reported from the univariate GWAS. This gene
should be marked for further investigation with ECIG use. This gene has previously
been associated with asthma, a respiratory disease364–366. EVALI (ECIG or Vaping
Associated Lung Injury) has become a health concern for individuals using ECIGs298.
This gene may contribute to EVALI as DPP10 is already active within the respiratory
system. Further research with adequately powered samples is encouraged, especially
as EVALI prevalence increases and the rate of initiation of ECIGs continues to increase.
These results suggest that novel methods of aggregating GWAS results may
lead to more actionable findings (Chapter 3). GWAS was aggregated by biological
function via DAVID in this dissertation. This aggregation show consistency among
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GWAS results that were otherwise somewhat inconsistent. Aggregating in this fashion
provides biological insights which may lead to novel treatment development for nicotine
use.

Additional Results and Lessons for Future Research and Public Health
The following sections summarize additional insights that were established from
this work to advance genetic epidemiological research of ECIGs and tobacco more
broadly: 1) inconsistent GWAS results may be due, in part to inconsistent measurement
of tobacco use phenotypes and, 2) modeling of tobacco use must consider how dual
users impact the results so as to not report biased estimates of effect.

Inconsistent Genetic Epidemiological Studies of CIG Use Encourages Careful
Measurement of ECIG Use for Similar Study Designs.
Chapter 3 demonstrated how measures that operationalize a conceptual variable
for tobacco use may lead to different results. For example, an adult sample (18 and
older) using DSM symptom count reported a significant association with AP2A2 for ND
194

. In contrast, another adult sample (18 and older) using the FTCD identified an

association between ND and a different gene, CHRNB3206. These results show that the
measure may influence the results even though both of these studies were mostly likely
underpowered. These results encourage thoughtful consideration of the measures
needed to study a phenotype of interest in the study design phase. In addition, using
more than one measure for a particularly important phenotype may be necessary for
future study aggregation for meta-analysis or for comparisons against other published
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results. While measurement may not address all limitation of GWAS, this is an important
facet that is correctable.
Future studies of ECIG use should pay attention to the lessons learned from
genetic epidemiological studies of CIG use, particularly as measurement of ECIG use is
under active development. For instance, a standardized definition of ECIG initiation is
strongly encouraged. Individuals may be misclassified as never users if they are
required to meet a threshold (e.g., owning a vape, or using one container of e-liquid).
Chapter 3 discusses how the inconsistency of results are due, in part, to differing
definitions of smoking initiation. For example, DLC1 was significantly associated with SI
when asking individuals to classify themselves as ever versus never smoker 144.
However, when smoking initiation was defined as smoking more than 100 cigarettes in
one’s lifetime, this gene was not associated with SI164. ECIG researchers are advised to
not repeat these mistakes to increase the consistency of results. Several measures
have been developed to measure ECIG-related nicotine dependence including the Penn
State Electronic Cigarette Dependence Index (PS-ECDI) and the e-cigarette Wisconsin
Inventory of Smoking Dependence Motives (e-WISDM) among others 367. As multiple
instruments are developed in parallel, there is risk of future inconsistencies for
genetically-informed ECIG research. It is impossible to stop the development of multiple
measures of ECIG use especially as this area of study is in its infancy. Given this
reality, future studies may need to consider the progression of genetic epidemiology
studies of CIG use and the related inconsistency of results. Further, researchers must
pay careful attention to the operationalization of their variables and ensure they are
captured the conceptualized variable adequately if multiple measures are developed.
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Measurement, as detailed in Chapter 3, is a key component that requires more
thorough thought in the study design phase. Moving forward, it would be best to
standardize operational measures of conceptual tobacco behaviors, especially as it
applies to ECIG use. ECIGs represent a novel tobacco product that appears to share
similar genetic and environmental influences with CIG use. Therefore, ECIG
researchers should take heed of the lessons learned from years of CIG research and
agree to common items that could be used to assess various facets of ECIG use. There
are currently fewer measures of ND arising from ECIG use 368 compared to ND from
CIG use. Reducing these measures to a single instrument may be advantageous in
future studies of ECIG use, particularly in genetic epidemiology. Which measure
researchers choose to assess ND arising from ECIGs with may lead to inconsistent
results.
Environmental factors, like genetic factors, have been consistently identified with
tobacco use. For instance, having peers who use CIG increases the likelihood that one
will use CIGs themselves 357. Similarly, policies impact the expression of nicotine
dependence. The proliferation and ease of access to pharmacological treatments (e.g.,
the patch, nicotine gum) have led to a decrease in nicotine dependence, though
additional avenues should also be examined 369. These environmental factors present
ways for modifying the risk of tobacco use in a low-risk, high-reward fashion (i.e.,
Changing a policy or ensuring one’s child is not associating with those who use could
drastically reduce tobacco use). However, the measures of nicotine use may be slightly
different, compared to genetic research, as environmental studies may have the time
and ability to dig further into tobacco use. Though beyond the scope of this dissertation,

185

additional time and consideration should be placed into the measurement of
environments during the study design phase. Measurement of environmental influences
is also an important step in genetically informed studies, although beyond the scope of
this paper. Environmental measures should also be given as much attention as how the
outcome and genetics are measured.

The Importance of Modeling Tobacco Use Carefully
Chapter 5 showed how dual users are phenotypically similar to CIG-exclusive
users as it pertains to income level and tobacco use. Specifically, the magnitude of
associations between of income and CIG-exclusive use (OR<10k = 4.01, 95% CI= 3.384.76) was similar that of dual users (OR<10k = 3.65, 95% CI = 2.97-4.48). Generally,
lower income levels were significantly associated with higher odds of dual and CIGexclusive use compared to individuals making $100,000 or more per year. In contrast,
no statistically significant association between ECIG-exclusive use and income and use
was detected (OR<10k = 1.00, 95% CI =0.73-1.26). These results suggest CIG users that
dual users are adding ECIG use to their existing behaviors. The patterns of association
with income differed by class of CIG/ECIG user: 1) Non-users, 2) CIG-exclusive users,
3) ECIG-exclusive users, and 4) dual users. These results agree with previously
published results of CIG and ECIG use and income. Further, ECIG use was not
associated with income 46. Therefore, it is important to include dual use as a category of
tobacco user as the pattern of association changes between tobacco use categories.
Examining CIG or ECIG use needs to include cross product use in the statistical
analysis due to exposure to nicotine via two avenues, which may be used in concert.
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This is of particular concern over other tobacco forms due to the high prevalence of dual
use among CIG and ECIG users. Dual use was estimated to be 7.5% (weighted) in
chapter 5. Therefore, there are many users who engage in both product use. Use of
other tobacco products should be used as a covariate in any regression (i.e., ECIG use
should be a covariate for models of CIG use) to account for dual use. Multinomial
regression should be preferred whenever possible.

Recommendations for Future Work
Future studies should continue to explore the genetic overlap between CIG and
ECIG use. While no statistically significant genetic overlap was detected between CIG
and ECIG initiation using GPS in Chapter 4, there is still a suggestion of genetic effects
for both CIG and ECIG use using a twin study in Chapter 2. However, there remains
inconsistencies when comparing measured genetic effects to estimates of heritability
from twin studies. This may be due to two reasons. First, the parameter estimates of the
magnitude of associations generated from GWAS may be biased. This would lead to
differences in estimates of heritability from GWAS compared to those generated from
twin studies. In general, these molecular genetic estimates are well short of the
heritability estimated by twin studies 370. There are several reasons as to why this
occurs. It may be that the genetic liability is not inherited in an additive fashion but may
be the result of non-additive genetic effects (e.g., epistasis or gene-environment
interaction). Further, epigenetic processes (the influence of environmental factors that
do not involve actual alterations in the DNA, but are involved with differential expression
of the genes) rather than genetic effects may influence the heritability of certain
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phenotypes 371. Second, heterogeneity in outcome measurement may lead to
inconsistent results across GWAS. Further, this would lead to an inability to replicate
GWAS results. It is also possible that the traits are misclassified (i.e., labeling one an
ECIG user, when they are actually a dual user) leading to measurement error which
would produce inconsistent results 372,373. Tobacco use is more complex and difficult to
assess than other clinical phenotypes that have reported many significant GWAS
results (e.g., height). Height is a phenotype that is unmistakable (i.e., height can be
accurately ascertained) and unable to be hidden. Tobacco use is more covert compared
to height, relies on self-report, and is subject to social desirability bias. Therefore, it may
be more difficult to detect and measure though both phenotypes are polygenic and
complex 374.

Final Conclusions of Dissertation
There were three conclusions that could be applied to future genetic epidemiologic
studies of ECIG initiation and use. First, latent genetic effects were established through
a twin study. While this study was small, the results suggest that there are significant
genetic influences on ECIG initiation. Therefore, genetic association studies should
continue to be investigated for its association with ECIG initiation and use. A second
study probed molecular measured genetic effects that were both unique to ECIG and
shared with CIG initiation. While this study did not report significant effects, there was a
genome-wide suggestive association that was detected in univariate analysis of ECIG.
This SNP resides in a gene with biological plausibility related to nicotine function which
should be investigated further. These two study designs provided convergent evidence
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that genetic influences are important for ECIG initiation. More research is required to
understand the precise nature of these genetic effects. ECIGs expose individuals to
nicotine creating the possibility of nicotine dependence arising in ECIG users. Nicotine
has been linked to many negative health outcomes 375. ECIG use is growing in
popularity 281,376. Therefore, understanding how individuals initiate use may help
prevention efforts for ECIGs, stopping the possible exposure to nicotine and possible
development of nicotine dependence.
This dissertation also showed consistency in GWAS results. A DAVID analysis of
results from a scoping review of the literature provided consistency of results. These
consistencies arose from gene- and biological pathway levels rather than SNPs. The
results suggest that aggregating GWAS results would result in more replication of
results (i.e., rather than replicating SNPs, replicating genes or biological pathways).
Aggregating genetic effects in this manner may guide future research target specific
genes and pathways which will lead to creating understanding of the biological and
potential prevention and cessation targets.
This dissertation also probed an environmental influence in addition to genetic
effects. These results suggest that modeling of CIG and ECIG use needs to account for
cross-product use. Future studies of CIG and ECIG also need to account for this dual
use, otherwise the study results will be biased.
Therefore, although these results are limited by the sample sizes and prevalence
of ECIG initiation, they provide preliminary evidence that genetic influences are
associated with ECIG use. Further, specific environmental influences may not impact
ECIG users in the same manner as CIG users. Further genetic epidemiologic
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investigation is warranted and encouraged from these results. However, future results
should attempt to aggregate genetic effects with plausible biological pathways. These
results also encourage additional study of ECIG use to increase the health and wellness
of society. ECIG use is increasing and continues to expose users to nicotine and the
negative health effects associated with this exposure. It is possible other specific
environments will be identified that influence CIG and ECIG use in the same manner.
Prevention and cessation efforts built around these environments for CIG could be
modified and applied to ECIG use.
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APPENDIX A. Supplementary Tables for Chapter 3.

Due to the large tables created from Chapter 3, supplementary tables S3.1 to S3.5 are
available online at:
https://osf.io/nzgf9/?view_only=23911760b4ad4188aa2e4024b5a9090c
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STATISTICAL CODE
### ANALYSIS FOR CHAPTER 2
.#####--------------------####
##### Equating Sexes Elelctronic Cigarettes ####
#####--------------------####
#rm(list=ls())
#source('http://openmx.psyc.virginia.edu/getOpenMx.R')
setwd('C:/Users/cliffordjs/Desktop/Research Projects/Adolescent and Young Adult Twin
Study/6. Liz Edits')
#rm(list = ls(all = TRUE))
source("C:/Users/cliffordjs/Desktop/Super wicked important R
files/GenEpiHelperFunctions.R")
source("C:/Users/cliffordjs/Desktop/Super wicked important R files/miFunctions.R")
#source('http://openmx.ssri.psu.edu/getOpenMx.R')
#omxGetNPSOL()
require(MASS)
require(OpenMx)
require(psych)
require(polycor)
mxOption( NULL, "Default optimizer","CSOLNP" )
# Call data, NAs = NA
setwd('C:/Users/cliffordjs/Desktop/Research Projects/Adolescent and Young Adult Twin
Study/0. Raw Data')
# was twindata2019.csv
data2<-read.csv("TwinData4.csv", header=T,na.strings=c("9999", "NA"))
names(data2)
table(data2$zyg2)
###----------------------------------------------------###
###
UNIVARIATE FOR EC
###
###----------------------------------------------------###
# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
vars
<- c("ecigEver3")
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#vars
<- c("cccigEver3", "ecigEver3") #reverse order of variables to see if same
results emerge
nv
<- 1
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for binary data)
# Subset the data to only the things I need
twinDatauni <- data2[,c(selVars,'zyg2')]
describe(twinDatauni)
summary(twinDatauni)
dim(twinDatauni)
#twinData2<-na.omit(twinData)
#summary(twinData2)
#dim(twinData2)
twinDataBin <-twinDatauni
dim(twinDataBin)
table(twinDataBin$zyg2)
# Factorize Ordinal Variables using the mxFactor option
twinDataBin[,c(1,2)] <- mxFactor(twinDataBin[,c(1,2)], levels = c(0:nth))
# 1=MZM, 2= MZF, 3=DZM, 4=DZF, 5=ODZ
#Vars
<- c("cccigEver3")
#nv
<- 1
# number of variables
#ntv
<- nv*2
# number of total variables
#selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #males = T1, females = T2
polychor(mzfData$ecEver3_T1,mzfData$ecEver3_T2, std.err=T)
polychor(mzmData$ecEver3_T1,mzmData$ecEver3_T2, std.err=T)
polychor(dzfData$ecEver3_T1,dzfData$ecEver3_T2, std.err=T)
polychor(dzmData$ecEver3_T1,dzmData$ecEver3_T2, std.err=T)
polychor(dzoData$ecEver3_T1,dzoData$ecEver3_T2, std.err=T)
# Set Starting Values /
svLTh <- 0.8 # start value for first threshold
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svITh <- 1
# start value for increments
#svTh
<- c(0.7,1,0.7,1)
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=ntv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=ntv) # lower bounds
for thresholds
#svTh
<- c(1,1)
# start value for thresholds
svPa
<- .4
# start value for path coefficient
svPaD <- vech(diag(svPa,nv,nv)) # start values for diagonal of covariance matrix
svPe
<- .8
# start value for path coefficient for e
svPeD <- vech(diag(svPe,nv,nv)) # start values for diagonal of covariance matrix
lbPa
<- .00001
# start value for lower bounds
lbPaD <- diag(lbPa,nv,nv)
# lower bounds for diagonal of covariance matrix
lbPaD[lower.tri(lbPaD)] <- -2
# lower bounds for below diagonal elements
lbPaD[upper.tri(lbPaD)] <- NA
# lower bounds for above diagonal elements
# Set Starting Values
aLabs <- paste("a",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
cLabs <- paste("c",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
eLabs <- paste("e",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
var1thM <- paste("var1M","_th",1:nth, sep="")
var2thM <- paste("var2M","_th",1:nth, sep="")
var1thF <- paste("var1F","_th",1:nth, sep="")
var2thF <- paste("var2F","_th",1:nth, sep="")
thUB

<- 2

# -----------------------------------------------------------------------------# PREPARE MODEL
# ACE Model
# Create Algebra for expected Mean Matrices to include differing thresholds for males
and females
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
threGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values= svTh,
labels=c(var1thM,var2thM), name="threGm",lbound=-2, ubound=2 )
threGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thF,var2thF), name="threGf",lbound=-2, ubound=2 )
threGmf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thM,var2thM,var1thF,var2thF), name="threGmf", lbound=2, ubound=2 )
# Create Matrices for Path Coefficients
pathA <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE, values=c(0.2),
#replacing svPaD
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pathC
pathE

label=aLabs, lbound=lbPaD, name="a" )
<- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE, values=c(0.4),
label=cLabs, lbound=lbPaD, name="c" )
<- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE,
values=0.4, label=eLabs, lbound=lbPaD, name="e" )

# Create Algebra for Variance Comptwonts
covA
<- mxAlgebra( expression=a %*% t(a), name="A" )
covC
<- mxAlgebra( expression=c %*% t(c), name="C" )
covE
<- mxAlgebra( expression=e %*% t(e), name="E" )
# Create Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
covP
<- mxAlgebra( expression= A+C+E, name="V" )
covMZ <- mxAlgebra( expression= A+C, name="cMZ" )
covDZ <- mxAlgebra( expression= 0.5%x%A+ C, name="cDZ" )
expCovMZ <- mxAlgebra( expression= rbind( cbind(V, cMZ), cbind(t(cMZ), V)),
name="expCovMZ" )
expCovDZ <- mxAlgebra( expression= rbind( cbind(V, cDZ), cbind(t(cDZ), V)),
name="expCovDZ" )
# Create Algebra for Standardization
matI
<- mxMatrix( type="Iden", nrow=nv, ncol=nv, name="I")
invSD <- mxAlgebra( expression=solve(sqrt(I*V)), name="iSD")
# Calculate genetic and environmental correlations
corA
<- mxAlgebra( expression=solve(sqrt(I*A))%&%A, name ="rA" ) #cov2cor()
corC
<- mxAlgebra( expression=solve(sqrt(I*C))%&%C, name ="rC" )
corE
<- mxAlgebra( expression=solve(sqrt(I*E))%&%E, name ="rE" )
## Calculate Phenotypic Correlation ##
corP
<- mxAlgebra (expression=solve(sqrt(I*V)) %*% V %*% solve(sqrt(I*V)),
name="rP")
## Calculate Standardized Covariances ##
stCovA <- mxAlgebra (solve(sqrt(I*V)) %*% A %*% solve(sqrt(I*V)), name="stCovA")
stCovC <- mxAlgebra (solve(sqrt(I*V)) %*% C %*% solve(sqrt(I*V)), name="stCovC")
stCovE <- mxAlgebra (solve(sqrt(I*V)) %*% E %*% solve(sqrt(I*V)), name="stCovE")
# Constrain Variance of Binary Variables
matUnv <- mxMatrix( type="Unit", nrow=nv, ncol=1, name="Unv1" )
var1
<- mxConstraint( expression=diag2vec(V)==Unv1, name="Var1" )
# Create Algebra for Variance Components
rowVC <- rep('VC',nv)
colVC <- rep(c('A','C','E','SA','SC','SE'),each=nv)
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estVC <- mxAlgebra( expression=cbind(A,C,E,A/V,C/V,E/V), name="VC",
dimnames=list(rowVC,colVC))
# Create Confidence Interval Objects
ciACE <- mxCI(c("stCovA","stCovC", "stCovE"))#
"VC[1,seq(1,3*nv,nv),(2,seq(1,3*nv,nv)),(2,seq(2,3*nv,nv)))]" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGf")
expDZf <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGf" )
expMZm <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZm <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZo <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGmf" )
funML <- mxFitFunctionML()
# Combine Groups
parsZf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGf, matI, invSD, matUnv )
parsZm <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGm, matI, invSD, matUnv )
parsZmf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGmf, matI, invSD, matUnv )
modelMZf <- mxModel( parsZf, meanG, covMZ, expCovMZ, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanG, covDZ, expCovDZ, dataDZf, expDZf, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanG, covMZ, expCovMZ, dataMZm, expMZm,
funML, name="MZm" )
modelDZm <- mxModel( parsZm, meanG, covDZ, expCovDZ, dataDZm, expDZm,
funML, name="DZm" )
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modelDZo <- mxModel( parsZmf, meanG, covDZ, expCovDZ,dataDZo, expDZo,
funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
EcUniAceModel <- mxModel( "EcUniAce", parsZf, parsZm, parsZmf,
modelMZf, modelDZf, modelMZm, modelDZm, modelDZo, multi,
estVC, ciACE)
EcUniAceFit <-mxRun(EcUniAceModel, intervals = F)
EcUniAceFit <-mxTryHardOrdinal(EcUniAceFit, intervals = F)
EcUniAceFit$algebras
#tableFitStatistics(QualAceFit, EcUniAceFit)
# Confidence Intervals
EcUniAceFit2 <-mxTryHardOrdinal(EcUniAceFit, intervals = T)
summary(EcUniAceFit2, verbose=T)
# Test of A
EcUniNoA <- EcUniAceFit2
EcUniNoAModel<- omxSetParameters(EcUniNoA, labels=c( "a11"), free=FALSE,
values=0 )
EcUniNoAfit<- mxTryHardOrdinal(EcUniNoAModel, intervals = T)
tableFitStatistics(EcUniAceFit, EcUniNoAfit)
# Test of C
EcUniNoC <- EcUniAceFit2
EcUniNoCModel<- omxSetParameters(EcUniNoC, labels=c( "c11"), free=FALSE,
values=0 )
EcUniNoCFit<- mxTryHardOrdinal(EcUniNoCModel, intervals = F)
tableFitStatistics(EcUniAceFit, EcUniNoCFit)
EcUniNoC2 <- EcUniNoCFit
EcUniNoCModel2<- omxSetParameters(EcUniNoC2, labels=c( "c11"), free=FALSE,
values=0 )
EcUniNoCFit2<- mxTryHardOrdinal(EcUniNoCModel2, intervals = F)
tableFitStatistics(EcUniAceFit, EcUniNoCFit2)

# Test of E
EcUniNoE <- EcUniAceFit2
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EcUniNoEModel<- omxSetParameters(EcUniNoE, labels=c("a11", "c11"),
free=FALSE, values=0 )
EcUniNoEModelFit<- mxTryHardOrdinal(EcUniNoEModel, intervals = F)
tableFitStatistics(EcUniAceFit, EcUniNoEModelFit)
ECallmodels<-list(EcUniNoAfit,EcUniNoCFit,EcUniNoEModelFit)
tableFitStatistics(EcUniAceFit, ECallmodels)

###---------------------------------------------------###
###
Testing model assumptions for EC
###---------------------------------------------------###

###

# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
Vars
<- c("ecigEver3")
nv
<- 1
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for ordinal data)
mzData_1 <- subset(twinDataBin, zyg2 %in% c(1,2), select = selVars)
dzData_1 <- subset(twinDataBin, zyg2 %in% c(3,4,5), select = selVars)
# Set Starting Values
svLTh <- -1.5 # start value for first threshold
svITh <- 1
# start value for increments
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=nv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv) # lower bounds
for thresholds
svCor <- .5
# start value for correlations
lbCor <- -0.99 # lower bounds for correlations
ubCor <- 0.99 # upper bounds for correlations
labThMZ <- c(paste("t",1:nth,"MZ1",sep=""),paste("t",1:nth,"MZ2",sep=""))
labThDZ <- c(paste("t",1:nth,"DZ1",sep=""),paste("t",1:nth,"DZ2",sep=""))
# -----------------------------------------------------------------------------# PREPARE MODEL
# Saturated Model
# Algebra for expected Mean & Threshold Matrices in MZ & DZ twins
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
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thinMZ <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=TRUE, values=svTh,
lbound=lbTh, labels=labThMZ, name="thinMZ" )
thinDZ <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=TRUE, values=svTh,
lbound=lbTh, labels=labThDZ, name="thinDZ" )
inc
<- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=FALSE, values=1,
name="inc" )
threMZ <- mxAlgebra( expression= inc %*% thinMZ, name="threMZ" )
threDZ <- mxAlgebra( expression= inc %*% thinDZ, name="threDZ" )
# Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
corMZ <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels="rMZ", name="corMZ" )
corDZ <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels="rDZ", name="corDZ" )
# Data objects for Multiple Groups
dataMZ <-mxData( observed=mzData_1, type="raw" )
dataDZ <-mxData( observed=dzData_1, type="raw" )
# Objective objects for Multiple Groups
expMZ <- mxExpectationNormal( covariance="corMZ", means="meanG",
dimnames=selVars, thresholds="threMZ" )
expDZ <- mxExpectationNormal( covariance="corDZ", means="meanG",
dimnames=selVars, thresholds="threDZ" )
funML <- mxFitFunctionML()
# Combine Groups
modelMZ <- mxModel( "MZ", meanG, corMZ, thinMZ, inc, threMZ, dataMZ, expMZ,
funML )
modelDZ <- mxModel( "DZ", meanG, corDZ, thinDZ, inc, threDZ, dataDZ, expDZ,
funML )
multi <- mxFitFunctionMultigroup( c("MZ","DZ") )
ciCor <- mxCI( c('MZ.corMZ','DZ.corDZ' ))
ciThre <- mxCI( c('MZ.threMZ','DZ.threDZ' ))
twinSatOrdModel <- mxModel( "EC Cigs", modelMZ, modelDZ, multi, ciCor, ciThre )
# -----------------------------------------------------------------------------# RUN MODEL
# Run Saturated Model
twinSatOrdFit <- mxRun( twinSatOrdModel, intervals=T )
twinSatOrdSum <- summary( twinSatOrdFit )
twinSatOrdSum
round(twinSatOrdFit$output$estimate,4)
# Generate Saturated Model Output
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rMZ
rDZ
tMZ
tDZ

<- twinSatOrdFit$MZ.corMZ$values[2,1]
<- twinSatOrdFit$DZ.corDZ$values[2,1]
<- twinSatOrdFit$MZ.threMZ$result
<- twinSatOrdFit$DZ.threDZ$result

twinSatOrdOS
twinSatOrdDF
twinSatOrdNP
twinSatOrdLLL
twinSatOrdAIC

<- twinSatOrdSum$observedStatistics
<- twinSatOrdSum$degreesOfFreedom
<- length(twinSatOrdSum$parameters[[1]])
<- twinSatOrdFit$output$Minus2LogLikelihood
<- twinSatOrdSum$AIC

mxCompare(twinSatOrdFit)
# -----------------------------------------------------------------------------# RUN SUBMODELS
# Constrain expected Thresholds to be equal across twin order
eqThresTwinModel <- mxModel(twinSatOrdFit, name="eqThresTwin" )
eqThresTwinModel <- omxSetParameters( eqThresTwinModel,
label=c("t1MZ1","t1MZ2"), free=TRUE, values=svLTh, newlabels='t1MZ' )
eqThresTwinModel <- omxSetParameters( eqThresTwinModel,
label=c("t1DZ1","t1DZ2"), free=TRUE, values=svLTh, newlabels='t1DZ' )
eqThresTwinFit
<- mxRun( eqThresTwinModel, intervals=F )
eqThresTwinSum
<- summary( eqThresTwinFit )
eqThresTwinLLL
<- eqThresTwinFit$output$Minus2LogLikelihood
mxCompare(twinSatOrdFit, eqThresTwinFit)
# Constrain expected Thres to be equal across twin order and zygosity
eqThresZygModel <- mxModel(eqThresTwinModel, name="eqThresZyg" )
eqThresZygModel <- omxSetParameters( eqThresZygModel,
label=c("t1MZ","t1DZ"), free=TRUE, values=svLTh, newlabels='t1Z' )
eqThresZygFit
<- mxRun( eqThresZygModel, intervals=F )
eqThresZygSum
<- summary( eqThresZygFit )
eqThresZygLLL
<- eqThresZygFit$output$Minus2LogLikelihood
mxCompare(eqThresTwinFit, eqThresZygFit)
# -----------------------------------------------------------------------------# Print Comparative Fit Statistics
SatNested <- list(eqThresTwinFit, eqThresZygFit)
mxCompare(twinSatOrdFit, SatNested)
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tableFitStatistics(twinSatOrdFit, SatNested)

###---------------------------------------------------###
###
Testing Sex Difference EC
###
###---------------------------------------------------###
# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #fm
# Set Starting Values
svLTh <- -1.5 # start value for first threshold
svITh <- 1
# start value for increments
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=nv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv) # lower bounds
for thresholds
svCor <- .5
# start value for correlations
lbCor <- -0.99 # lower bounds for correlations
ubCor <- 0.99 # upper bounds for correlations
labThMZ <- c(paste("t",1:nth,"MZ1",sep=""),paste("t",1:nth,"MZ2",sep=""))
labThDZ <- c(paste("t",1:nth,"DZ1",sep=""),paste("t",1:nth,"DZ2",sep=""))
mvar1th <- paste("mvar1","_th",1:nth, sep="")
mvar2th <- paste("mvar2","_th",1:nth, sep="")
fvar1th <- paste("fvar1","_th",1:nth, sep="")
fvar2th <- paste("fvar2","_th",1:nth, sep="")
dzvar1th <- paste("dzvar1","_th",1:nth, sep="")
dzvar2th <- paste("dzvar2","_th",1:nth, sep="")
thUB
<- 2
# -----------------------------------------------------------------------------# PREPARE MODEL
# General non-scalar ACE Model
# Matrices declared to store a, c, and e Path Coefficients
pathAf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="af11", name="af" )
pathCf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="cf11", name="cf" )
pathEf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="ef11", name="ef" )
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pathAm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="am11", name="am" )
pathCm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="cm11", name="cm" )
pathEm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="em11", name="em" )
pathRa <- mxMatrix( "Lower", nrow=1, ncol=1, free=TRUE, values=1, label="ra11",
name="ra", ubound=1, lbound=0 )
# Matrices generated to hold A, C, and E computed Variance Components
covAf <- mxAlgebra( af %*% t(af), name="Af" )
covCf <- mxAlgebra( cf %*% t(cf), name="Cf" )
covEf <- mxAlgebra( ef %*% t(ef), name="Ef" )
covAm <- mxAlgebra( am %*% t(am), name="Am" )
covCm <- mxAlgebra( cm %*% t(cm), name="Cm" )
covEm <- mxAlgebra( em %*% t(em), name="Em" )
# Algebra to compute total variances and standard deviations (diagonal only)
covPf <- mxAlgebra( Af+Cf+Ef, name="Vf" )
covPm <- mxAlgebra( Am+Cm+Em, name="Vm" )
# Algebras generated to hold Parameter Estimates and Derived Variance Components
colVarsZf <- c('Af','Cf','Ef','SAf','SCf','SEf')
estVarsZf <- mxAlgebra( cbind(Af,Cf,Ef,Af/Vf,Cf/Vf,Ef/Vf), name="VarsZf",
dimnames=list(NULL,colVarsZf))
colVarsZm <- c('Am','Cm','Em','SAm','SCm','SEm')
estVarsZm <- mxAlgebra( cbind(Am,Cm,Em,Am/Vm,Cm/Vm,Em/Vm),
name="VarsZm", dimnames=list(NULL,colVarsZm))
# Algebra for expected Mean and Variance/Covariance Matrices in MZ & DZ twins
meanGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanf", name="expMeanGf" )
meanGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanm", name="expMeanGm" )
meanGfm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label=c("meanf","meanm"), name="expMeanGfm" )
covMZf <- mxAlgebra( expression= rbind( cbind(Vf, Af+Cf), cbind(Af+Cf, Vf)),
name="expCovMZf" )
covDZf <- mxAlgebra( expression= rbind( cbind(Vf, 0.5%x%Af+Cf),
cbind(0.5%x%Af+Cf, Vf)), name="expCovDZf" )
covMZm <- mxAlgebra( expression= rbind( cbind(Vm, Am+Cm), cbind(Am+Cm,
Vm)), name="expCovMZm" )
covDZm <- mxAlgebra( expression= rbind( cbind(Vm, 0.5%x%Am+Cm),
cbind(0.5%x%Am+Cm, Vm)), name="expCovDZm" )
CVfm
<- mxAlgebra( expression= ra%x%(af%*%t(am))+cf%*%t(cm), name="CVfm"
)

230

CVmf

<- mxAlgebra( expression= ra%x%(am%*%t(af))+cm%*%t(cf), name="CVmf"

)
covDZo <- mxAlgebra( expression= rbind( cbind(Vf, CVfm), cbind(CVmf, Vm)),
name="expCovDZo" )
Inc <- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=F, values=1, name="Inc" )
# MALES
ThreM <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(mvar1th, mvar2th), lbound=-2, ubound=thUB, name="ThreM")
ExpThreM <- mxAlgebra( expression= cbind( ( Inc %*% ThreM ),
( Inc %*% ThreM ) ), name="ExpThreM" )
# FEMALES
ThreF <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(fvar1th, fvar2th), lbound=-2, ubound=thUB, name="ThreF")
ExpThreF <- mxAlgebra( expression= cbind( ( Inc %*% ThreF ),
( Inc %*% ThreF ) ), name="ExpThreF" )
## OS
ThreOS <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(dzvar1th, dzvar2th), lbound=-2, ubound=thUB, name="ThreOS")
ExpThreOS <- mxAlgebra( expression= cbind( ( Inc %*% ThreOS ),
( Inc %*% ThreOS ) ), name="ExpThreOS" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expDZf <- mxExpectationNormal( covariance="expCovDZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expMZm <- mxExpectationNormal( covariance="expCovMZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZm <- mxExpectationNormal( covariance="expCovDZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZo <- mxExpectationNormal( covariance="expCovDZo",
means="expMeanGfm", dimnames=selVars, thresholds = "ExpThreOS" )
funML <- mxFitFunctionML()
# Combine Groups
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parsZf <- list( pathAf, pathCf, pathEf, covAf, covCf, covEf, covPf, estVarsZf, ThreF,
ExpThreF, Inc )
parsZm <- list( pathAm, pathCm, pathEm, covAm, covCm, covEm, covPm,
estVarsZm, ThreM, ExpThreM, Inc )
parsZfm <- list( pathRa, CVfm, CVmf, ExpThreOS, Inc, ThreOS)
modelMZf <- mxModel( parsZf, meanGf, covMZf, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanGf, covDZf, dataDZf, expDZf, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanGm, covMZm, dataMZm, expMZm, funML,
name="MZm" )
modelDZm <- mxModel( parsZm, meanGm, covDZm, dataDZm, expDZm, funML,
name="DZm" )
modelDZo <- mxModel( parsZf, parsZm, parsZfm, meanGfm, covDZo, dataDZo,
expDZo, funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
QualAceModel <- mxModel( "QualACE", modelMZf, modelDZf, modelMZm,
modelDZm, modelDZo, multi )
QualAceFit <-mxTryHardOrdinal(QualAceModel, intervals = F)
summary(QualAceFit)
## Coerce threshold to be equal
eqthres <-mxModel(QualAceFit, name = "Equal Threshold")
eqthres <-omxSetParameters( eqthres, label="mvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthres <-omxSetParameters( eqthres, label="fvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthres <-omxSetParameters( eqthres, label="dzvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthresfit<-mxTryHardOrdinal(eqthres, intervals = F)
summary(eqthresfit)
tableFitStatistics(QualAceFit, eqthresfit)
## Coerce males and females to be equal
eqsex <-mxModel(QualAceFit, name = "Equal sexes")
eqsex <-omxSetParameters( eqsex, label="am11", free=TRUE, values=0.04,
newlabels="a11")
eqsex <-omxSetParameters( eqsex, label="af11", free=TRUE, values=0.04,
newlabels="a11")
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eqsex <-omxSetParameters( eqsex, label="cm11", free=TRUE, values=0.5,
newlabels="c11")
eqsex <-omxSetParameters( eqsex, label="cf11", free=TRUE, values=0.5,
newlabels="c11")
eqsex <-omxSetParameters( eqsex, label="em11", free=TRUE, values=0.3,
newlabels="e11")
eqsex <-omxSetParameters( eqsex, label="ef11", free=TRUE, values=0.3,
newlabels="e11")
eqsexfit<-mxTryHardOrdinal(eqsex, intervals = F)
tableFitStatistics(QualAceFit, eqsexfit)
## NO sex
nosex <- omxSetParameters(eqsex, labels="ra11", name="No Sex Effects",
free=FALSE, values=0.5 )
nosexfit<- mxTryHardOrdinal(nosex, intervals = F)
nested <-list(eqthresfit, eqsexfit, nosexfit)
tableFitStatistics(QualAceFit, nested)
###----------------------------------------------------###
###
UNIVARIATE FOR CC
###
###----------------------------------------------------###
mxOption(NULL, "Default optimizer", "CSOLNP")
# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
vars
<- c("cccigEver3")
#vars
<- c("cccigEver3", "ecigEver3") #reverse order of variables to see if same
results emerge
nv
<- 1
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for binary data)
# Subset the data to only the things I need
twinDatauni <- data2[,c(selVars,'zyg2')]
describe(twinDatauni)
summary(twinDatauni)
dim(twinDatauni)
#twinData2<-na.omit(twinData)
#summary(twinData2)
#dim(twinData2)
twinDataBin <-twinDatauni
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dim(twinDataBin)
table(twinDataBin$zyg2)
# Factorize Ordinal Variables using the mxFactor option
twinDataBin[,c(1,2)] <- mxFactor(twinDataBin[,c(1,2)], levels = c(0:nth))
# 1=MZM, 2= MZF, 3=DZM, 4=DZF, 5=ODZ
#Vars
<- c("cccigEver3")
#nv
<- 1
# number of variables
#ntv
<- nv*2
# number of total variables
#selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #males = T1, females = T2
polychor(mzfData$cccever3_T1,mzfData$cccever3_T2, std.err=T)
polychor(mzmData$cccever3_T1,mzmData$cccever3_T2, std.err=T)
polychor(dzfData$cccever3_T1,dzfData$cccever3_T2, std.err=T)
polychor(dzmData$cccever3_T1,dzmData$cccever3_T2, std.err=T)
polychor(dzoData$cccever3_T1,dzoData$cccever3_T2, std.err=T)
# Set Starting Values /
svLTh <- 0.8 # start value for first threshold
svITh <- 1
# start value for increments
#svTh
<- c(0.7,1,0.7,1)
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=ntv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=ntv) # lower bounds
for thresholds
#svTh
<- c(1,1)
# start value for thresholds
svPa
<- .4
# start value for path coefficient
svPaD <- vech(diag(svPa,nv,nv)) # start values for diagonal of covariance matrix
svPe
<- .8
# start value for path coefficient for e
svPeD <- vech(diag(svPe,nv,nv)) # start values for diagonal of covariance matrix
lbPa
<- .00001
# start value for lower bounds
lbPaD <- diag(lbPa,nv,nv)
# lower bounds for diagonal of covariance matrix
lbPaD[lower.tri(lbPaD)] <- -2
# lower bounds for below diagonal elements
lbPaD[upper.tri(lbPaD)] <- NA
# lower bounds for above diagonal elements
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# Set Starting Values
aLabs <- paste("a",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
cLabs <- paste("c",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
eLabs <- paste("e",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
var1thM <- paste("var1M","_th",1:nth, sep="")
var2thM <- paste("var2M","_th",1:nth, sep="")
var1thF <- paste("var1F","_th",1:nth, sep="")
var2thF <- paste("var2F","_th",1:nth, sep="")
thUB

<- 2

# -----------------------------------------------------------------------------# PREPARE MODEL
# ACE Model
# Create Algebra for expected Mean Matrices to include differing thresholds for males
and females
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
threGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values= svTh,
labels=c(var1thM,var2thM), name="threGm",lbound=-2, ubound=2 )
threGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thF,var2thF), name="threGf",lbound=-2, ubound=2 )
threGmf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thM,var2thM,var1thF,var2thF), name="threGmf",
lbound=-2, ubound=2 )
# Create Matrices for Path Coefficients
pathA <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE, values=c(0.2),
#replacing svPaD
label=aLabs, lbound=lbPaD, name="a" )
pathC <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE, values=c(0.4),
label=cLabs, lbound=lbPaD, name="c" )
pathE <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE,
values=0.4, label=eLabs, lbound=lbPaD, name="e" )
# Create Algebra for Variance Comptwonts
covA
<- mxAlgebra( expression=a %*% t(a), name="A" )
covC
<- mxAlgebra( expression=c %*% t(c), name="C" )
covE
<- mxAlgebra( expression=e %*% t(e), name="E" )
# Create Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
covP
<- mxAlgebra( expression= A+C+E, name="V" )
covMZ <- mxAlgebra( expression= A+C, name="cMZ" )
covDZ <- mxAlgebra( expression= 0.5%x%A+ C, name="cDZ" )
expCovMZ <- mxAlgebra( expression= rbind( cbind(V, cMZ), cbind(t(cMZ), V)),
name="expCovMZ" )
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expCovDZ <- mxAlgebra( expression= rbind( cbind(V, cDZ), cbind(t(cDZ), V)),
name="expCovDZ" )
# Create Algebra for Standardization
matI
<- mxMatrix( type="Iden", nrow=nv, ncol=nv, name="I")
invSD <- mxAlgebra( expression=solve(sqrt(I*V)), name="iSD")
# Calculate genetic and environmental correlations
corA
<- mxAlgebra( expression=solve(sqrt(I*A))%&%A, name ="rA" ) #cov2cor()
corC
<- mxAlgebra( expression=solve(sqrt(I*C))%&%C, name ="rC" )
corE
<- mxAlgebra( expression=solve(sqrt(I*E))%&%E, name ="rE" )
## Calculate Phenotypic Correlation ##
corP
<- mxAlgebra (expression=solve(sqrt(I*V)) %*% V %*% solve(sqrt(I*V)),
name="rP")
## Calculate Standardized Covariances ##
stCovA <- mxAlgebra (solve(sqrt(I*V)) %*% A %*% solve(sqrt(I*V)), name="stCovA")
stCovC <- mxAlgebra (solve(sqrt(I*V)) %*% C %*% solve(sqrt(I*V)), name="stCovC")
stCovE <- mxAlgebra (solve(sqrt(I*V)) %*% E %*% solve(sqrt(I*V)), name="stCovE")
# Constrain Variance of Binary Variables
matUnv <- mxMatrix( type="Unit", nrow=nv, ncol=1, name="Unv1" )
var1
<- mxConstraint( expression=diag2vec(V)==Unv1, name="Var1" )
# Create Algebra for Variance Components
rowVC <- rep('VC',nv)
colVC <- rep(c('A','C','E','SA','SC','SE'),each=nv)
estVC <- mxAlgebra( expression=cbind(A,C,E,A/V,C/V,E/V), name="VC",
dimnames=list(rowVC,colVC))
# Create Confidence Interval Objects
ciACE <- mxCI(c("stCovA","stCovC", "stCovE"))#
"VC[1,seq(1,3*nv,nv),(2,seq(1,3*nv,nv)),(2,seq(2,3*nv,nv)))]" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGf")
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expDZf

<- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGf" )
expMZm <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZm <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZo <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGmf" )
funML <- mxFitFunctionML()
# Combine Groups
parsZf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGf, matI, invSD, matUnv )
parsZm <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGm, matI, invSD, matUnv )
parsZmf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGmf, matI, invSD, matUnv )
modelMZf <- mxModel( parsZf, meanG, covMZ, expCovMZ, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanG, covDZ, expCovDZ, dataDZf, expDZf, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanG, covMZ, expCovMZ, dataMZm, expMZm,
funML, name="MZm" )
modelDZm <- mxModel( parsZm, meanG, covDZ, expCovDZ, dataDZm, expDZm,
funML, name="DZm" )
modelDZo <- mxModel( parsZmf, meanG, covDZ, expCovDZ,dataDZo, expDZo,
funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
CcUniAceModel <- mxModel( "CcUniAce", parsZf, parsZm, parsZmf,
modelMZf, modelDZf, modelMZm, modelDZm, modelDZo, multi,
estVC, ciACE)
CcUniAceFit <-mxRun(CcUniAceModel, intervals = F)
CcUniAceFit <-mxTryHardOrdinal(CcUniAceFit, intervals = F)
CcUniAceFit$algebras
# Confidence Intervals
CcUniAceFitCIs <- mxTryHardOrdinal(CcUniAceFit, intervals = T)
summary(CcUniAceFitCIs, verbose=T)
#CcUniAceFitCIs$algebras
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# Test of A
CcUniNoA <- CcUniAceFit
CcUniNoAModel<- omxSetParameters(CcUniNoA, labels=c( "a11"), free=FALSE,
values=0 )
CcUniNoAfit<- mxTryHardOrdinal(CcUniNoAModel, intervals = T)
tableFitStatistics(CcUniAceFit, CcUniNoAfit)
# Test of C
CcUniNoC <- CcUniAceFit
CcUniNoCModel<- omxSetParameters(CcUniNoC, labels=c( "c11"), free=FALSE,
values=0 )
CcUniNoCFit<- mxTryHardOrdinal(CcUniNoCModel, intervals = F)
tableFitStatistics(CcUniAceFit, CcUniNoCFit)
# Test of E Only Model
CcUniNoE <- CcUniAceFit
CcUniNoEModel<- omxSetParameters(CcUniNoE, labels=c("a11","c11"), free=FALSE,
values=0 )
CcUniNoEModelFit<- mxTryHardOrdinal(CcUniNoEModel, intervals = F)
tableFitStatistics(CcUniAceFit, CcUniNoEModelFit)
CCallmodels<-list(CcUniNoAfit,CcUniNoCFit,CcUniNoEModelFit)
tableFitStatistics(CcUniAceFit, CCallmodels)

###---------------------------------------------------###
###
Testing model assumptions for CC
###---------------------------------------------------###

###

# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
Vars
<- c("cccigEver3")
nv
<- 1
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for ordinal data)
mzData_1 <- subset(twinDataBin, zyg2 %in% c(1,2), select = selVars)
dzData_1 <- subset(twinDataBin, zyg2 %in% c(3,4,5), select = selVars)
# Set Starting Values
svLTh <- -1.5 # start value for first threshold
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svITh <- 1
# start value for increments
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=nv) # start value for
thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv) # lower bounds
for thresholds
svCor <- .5
# start value for correlations
lbCor <- -0.99 # lower bounds for correlations
ubCor <- 0.99 # upper bounds for correlations
labThMZ <- c(paste("t",1:nth,"MZ1",sep=""),paste("t",1:nth,"MZ2",sep=""))
labThDZ <- c(paste("t",1:nth,"DZ1",sep=""),paste("t",1:nth,"DZ2",sep=""))
# -----------------------------------------------------------------------------# PREPARE MODEL
# Saturated Model
# Algebra for expected Mean & Threshold Matrices in MZ & DZ twins
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
thinMZ <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=TRUE, values=svTh,
lbound=lbTh, labels=labThMZ, name="thinMZ" )
thinDZ <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=TRUE, values=svTh,
lbound=lbTh, labels=labThDZ, name="thinDZ" )
inc
<- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=FALSE, values=1,
name="inc" )
threMZ <- mxAlgebra( expression= inc %*% thinMZ, name="threMZ" )
threDZ <- mxAlgebra( expression= inc %*% thinDZ, name="threDZ" )
# Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
corMZ <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels="rMZ", name="corMZ" )
corDZ <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels="rDZ", name="corDZ" )
# Data objects for Multiple Groups
dataMZ <-mxData( observed=mzData_1, type="raw" )
dataDZ <-mxData( observed=dzData_1, type="raw" )
# Objective objects for Multiple Groups
expMZ <- mxExpectationNormal( covariance="corMZ", means="meanG",
dimnames=selVars, thresholds="threMZ" )
expDZ <- mxExpectationNormal( covariance="corDZ", means="meanG",
dimnames=selVars, thresholds="threDZ" )
funML <- mxFitFunctionML()
# Combine Groups
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modelMZ <- mxModel( "MZ", meanG, corMZ, thinMZ, inc, threMZ, dataMZ, expMZ,
funML )
modelDZ <- mxModel( "DZ", meanG, corDZ, thinDZ, inc, threDZ, dataDZ, expDZ,
funML )
multi <- mxFitFunctionMultigroup( c("MZ","DZ") )
ciCor <- mxCI( c('MZ.corMZ','DZ.corDZ' ))
ciThre <- mxCI( c('MZ.threMZ','DZ.threDZ' ))
twinSatOrdModel <- mxModel( "CC Cigs", modelMZ, modelDZ, multi, ciCor, ciThre )
# -----------------------------------------------------------------------------# RUN MODEL
# Run Saturated Model
twinSatOrdFit <- mxRun( twinSatOrdModel, intervals=T )
twinSatOrdSum <- summary( twinSatOrdFit )
twinSatOrdSum
round(twinSatOrdFit$output$estimate,4)
# Generate Saturated Model Output
rMZ
<- twinSatOrdFit$MZ.corMZ$values[2,1]
rDZ
<- twinSatOrdFit$DZ.corDZ$values[2,1]
tMZ
<- twinSatOrdFit$MZ.threMZ$result
tDZ
<- twinSatOrdFit$DZ.threDZ$result
twinSatOrdOS
twinSatOrdDF
twinSatOrdNP
twinSatOrdLLL
twinSatOrdAIC

<- twinSatOrdSum$observedStatistics
<- twinSatOrdSum$degreesOfFreedom
<- length(twinSatOrdSum$parameters[[1]])
<- twinSatOrdFit$output$Minus2LogLikelihood
<- twinSatOrdSum$AIC

mxCompare(twinSatOrdFit)
# -----------------------------------------------------------------------------# RUN SUBMODELS
# Constrain expected Thresholds to be equal across twin order
eqThresTwinModel <- mxModel(twinSatOrdFit, name="eqThresTwin" )
eqThresTwinModel <- omxSetParameters( eqThresTwinModel,
label=c("t1MZ1","t1MZ2"), free=TRUE, values=svLTh, newlabels='t1MZ' )
eqThresTwinModel <- omxSetParameters( eqThresTwinModel,
label=c("t1DZ1","t1DZ2"), free=TRUE, values=svLTh, newlabels='t1DZ' )
eqThresTwinFit
<- mxRun( eqThresTwinModel, intervals=F )
eqThresTwinSum
<- summary( eqThresTwinFit )
eqThresTwinLLL
<- eqThresTwinFit$output$Minus2LogLikelihood
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mxCompare(twinSatOrdFit, eqThresTwinFit)
# Constrain expected Thres to be equal across twin order and zygosity
eqThresZygModel <- mxModel(eqThresTwinModel, name="eqThresZyg" )
eqThresZygModel <- omxSetParameters( eqThresZygModel, label=c("t1MZ","t1DZ"),
free=TRUE, values=svLTh, newlabels='t1Z' )
eqThresZygFit
<- mxRun( eqThresZygModel, intervals=F )
eqThresZygSum
<- summary( eqThresZygFit )
eqThresZygLLL
<- eqThresZygFit$output$Minus2LogLikelihood
mxCompare(eqThresTwinFit, eqThresZygFit)
# -----------------------------------------------------------------------------# Print Comparative Fit Statistics
SatNested <- list(eqThresTwinFit, eqThresZygFit)
mxCompare(twinSatOrdFit, SatNested)
tableFitStatistics(twinSatOrdFit, SatNested)
#####--------------------####
##### Equating Sexes CC ####
#####--------------------####
# 1=MZM, 2= MZF, 3=DZM, 4=DZF, 5=ODZ
Vars
<- c("cccigEver3")
nv
<- 1
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Subset the data to only the things I need
twinDatauni <- data2[,c(selVars,'zyg2')]
describe(twinDatauni)
summary(twinDatauni)
dim(twinDatauni)
#twinData2<-na.omit(twinData)
#summary(twinData2)
#dim(twinData2)
twinDataBin <-twinDatauni
dim(twinDataBin)
table(twinDataBin$zyg2)
# Factorize Ordinal Variables using the mxFactor option
twinDataBin[,c(1,2)] <- mxFactor(twinDataBin[,c(1,2)], levels = c(0:nth))
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# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #fm
# Set Starting Values
svLTh <- -1.5 # start value for first threshold
svITh <- 1
# start value for increments
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=nv) # start value for
thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv) # lower bounds
for thresholds
svCor <- .5
# start value for correlations
lbCor <- -0.99 # lower bounds for correlations
ubCor <- 0.99 # upper bounds for correlations
labThMZ <- c(paste("t",1:nth,"MZ1",sep=""),paste("t",1:nth,"MZ2",sep=""))
labThDZ <- c(paste("t",1:nth,"DZ1",sep=""),paste("t",1:nth,"DZ2",sep=""))
var1th <- paste("var1","_th",1:nth, sep="")
var2th <- paste("var2","_th",1:nth, sep="")
thUB
<- 2
# -----------------------------------------------------------------------------# PREPARE MODEL
# General non-scalar ACE Model
# Matrices declared to store a, c, and e Path Coefficients
pathAf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label="af11", name="af" )
pathCf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label="cf11", name="cf" )
pathEf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label="ef11", name="ef" )
pathAm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="am11", name="am" )
pathCm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="cm11", name="cm" )
pathEm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label="em11", name="em" )
pathRa <- mxMatrix( "Lower", nrow=1, ncol=1, free=TRUE, values=1, label="ra11",
name="ra", ubound=1, lbound=0 )
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# Matrices generated to hold A, C, and E computed Variance Components
covAf <- mxAlgebra( af %*% t(af), name="Af" )
covCf <- mxAlgebra( cf %*% t(cf), name="Cf" )
covEf <- mxAlgebra( ef %*% t(ef), name="Ef" )
covAm <- mxAlgebra( am %*% t(am), name="Am" )
covCm <- mxAlgebra( cm %*% t(cm), name="Cm" )
covEm <- mxAlgebra( em %*% t(em), name="Em" )
# Algebra to compute total variances and standard deviations (diagonal only)
covPf <- mxAlgebra( Af+Cf+Ef, name="Vf" )
covPm <- mxAlgebra( Am+Cm+Em, name="Vm" )
# Algebras generated to hold Parameter Estimates and Derived Variance Components
colVarsZf <- c('Af','Cf','Ef','SAf','SCf','SEf')
estVarsZf <- mxAlgebra( cbind(Af,Cf,Ef,Af/Vf,Cf/Vf,Ef/Vf), name="VarsZf",
dimnames=list(NULL,colVarsZf))
colVarsZm <- c('Am','Cm','Em','SAm','SCm','SEm')
estVarsZm <- mxAlgebra( cbind(Am,Cm,Em,Am/Vm,Cm/Vm,Em/Vm), name="VarsZm",
dimnames=list(NULL,colVarsZm))
# Algebra for expected Mean and Variance/Covariance Matrices in MZ & DZ twins
meanGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanf", name="expMeanGf" )
meanGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanm", name="expMeanGm" )
meanGfm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label=c("meanf","meanm"), name="expMeanGfm" )
covMZf <- mxAlgebra( expression= rbind( cbind(Vf, Af+Cf), cbind(Af+Cf, Vf)),
name="expCovMZf" )
covDZf <- mxAlgebra( expression= rbind( cbind(Vf, 0.5%x%Af+Cf),
cbind(0.5%x%Af+Cf, Vf)), name="expCovDZf" )
covMZm <- mxAlgebra( expression= rbind( cbind(Vm, Am+Cm), cbind(Am+Cm, Vm)),
name="expCovMZm" )
covDZm <- mxAlgebra( expression= rbind( cbind(Vm, 0.5%x%Am+Cm),
cbind(0.5%x%Am+Cm, Vm)), name="expCovDZm" )
CVfm
<- mxAlgebra( expression= ra%x%(af%*%t(am))+cf%*%t(cm), name="CVfm" )
CVmf
<- mxAlgebra( expression= ra%x%(am%*%t(af))+cm%*%t(cf), name="CVmf" )
covDZo <- mxAlgebra( expression= rbind( cbind(Vf, CVfm), cbind(CVmf, Vm)),
name="expCovDZo" )
Inc <- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=F, values=1, name="Inc" )
# MALES
ThreM <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(mvar1th, mvar2th), lbound=-2, ubound=thUB, name="ThreM")
ExpThreM <- mxAlgebra( expression= cbind( ( Inc %*% ThreM ),
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( Inc %*% ThreM ) ), name="ExpThreM" )
# FEMALES
ThreF <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(fvar1th, fvar2th), lbound=-2, ubound=thUB, name="ThreF")
ExpThreF <- mxAlgebra( expression= cbind( ( Inc %*% ThreF ),
( Inc %*% ThreF ) ), name="ExpThreF" )
## OS
ThreOS <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(dzvar1th, dzvar2th), lbound=-2, ubound=thUB, name="ThreOS")
ExpThreOS <- mxAlgebra( expression= cbind( ( Inc %*% ThreOS ),
( Inc %*% ThreOS ) ), name="ExpThreOS" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expDZf <- mxExpectationNormal( covariance="expCovDZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expMZm <- mxExpectationNormal( covariance="expCovMZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZm <- mxExpectationNormal( covariance="expCovDZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZo <- mxExpectationNormal( covariance="expCovDZo", means="expMeanGfm",
dimnames=selVars, thresholds = "ExpThreOS" )
funML <- mxFitFunctionML()
# Combine Groups
parsZf <- list( pathAf, pathCf, pathEf, covAf, covCf, covEf, covPf, estVarsZf, ThreF,
ExpThreF, Inc )
parsZm <- list( pathAm, pathCm, pathEm, covAm, covCm, covEm, covPm,
estVarsZm, ThreM, ExpThreM, Inc )
parsZfm <- list( pathRa, CVfm, CVmf, ExpThreOS, Inc, ThreOS)
modelMZf <- mxModel( parsZf, meanGf, covMZf, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanGf, covDZf, dataDZf, expDZf, funML, name="DZf"
)
modelMZm <- mxModel( parsZm, meanGm, covMZm, dataMZm, expMZm, funML,
name="MZm" )
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modelDZm <- mxModel( parsZm, meanGm, covDZm, dataDZm, expDZm, funML,
name="DZm" )
modelDZo <- mxModel( parsZf, parsZm, parsZfm, meanGfm, covDZo, dataDZo,
expDZo, funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
QualAceModel <- mxModel( "QualACE", modelMZf, modelDZf, modelMZm,
modelDZm, modelDZo, multi )
QualAceFit <-mxTryHardOrdinal(QualAceModel, intervals = F)
summary(QualAceFit)
## Coerce threshold to be equal
eqthres <-mxModel(QualAceFit, name = "Equal Threshold")
eqthres <-omxSetParameters( eqthres, label="mvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthres <-omxSetParameters( eqthres, label="fvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthres <-omxSetParameters( eqthres, label="dzvar1_th1", free=TRUE, values=0.5,
newlabels="var1_th1")
eqthresfit<-mxTryHardOrdinal(eqthres, intervals = F)
summary(eqthresfit)
tableFitStatistics(QualAceFit, eqthresfit)
## Coerce males and females to be equal
eqsex <-mxModel(QualAceFit, name = "Equal sexes")
eqsex <-omxSetParameters( eqsex, label="am11", free=TRUE, values=0.04,
newlabels="a11")
eqsex <-omxSetParameters( eqsex, label="af11", free=TRUE, values=0.04,
newlabels="a11")
eqsex <-omxSetParameters( eqsex, label="cm11", free=TRUE, values=0.5,
newlabels="c11")
eqsex <-omxSetParameters( eqsex, label="cf11", free=TRUE, values=0.5,
newlabels="c11")
eqsex <-omxSetParameters( eqsex, label="em11", free=TRUE, values=0.3,
newlabels="e11")
eqsex <-omxSetParameters( eqsex, label="ef11", free=TRUE, values=0.3,
newlabels="e11")
eqsexfit<-mxTryHardOrdinal(eqsex, intervals = F)
tableFitStatistics(QualAceFit, eqsexfit)
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## NO sex
nosex <- omxSetParameters(eqsex, labels="ra11", free=FALSE, values=0.5,
name="No sex Effects" )
nosexfit<- mxTryHardOrdinal(nosex, intervals = F)
nested <-list(eqthresfit,eqsexfit, nosexfit)
tableFitStatistics(QualAceFit, nested)

###----------------------------------------------------###
###
BIVARIATE ANALYSIS
###
###----------------------------------------------------###
# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
vars
<- c("ecigEver3", "cccigEver3")
#vars
<- c("cccigEver3", "ecigEver3") #reverse order of variables to see if same
results emerge
nv
<- 2
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for binary data)
# Subset the data to only the things I need
twinData <- data2[,c(selVars,'zyg2')]
describe(twinData)
summary(twinData)
dim(twinData)
#twinData2<-na.omit(twinData)
#summary(twinData2)
#dim(twinData2)
twinDataBin <-twinData
dim(twinDataBin)
table(twinDataBin$zyg2)
# Factorize Ordinal Variables using the mxFactor option
twinDataBin[,c(1,3)] <- mxFactor(twinDataBin[,c(1,3)], levels = c(0:nth))
twinDataBin[,c(2,4)] <- mxFactor(twinDataBin[,c(2,4)], levels = c(0:nth))
# Twin correlations
mzdat <- subset(twinDataBin, zyg2==c(1) | zyg2 ==2, selVars)
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dzdat <- subset(twinDataBin, zyg2==c(3) | zyg2 ==4 | zyg2==5, selVars)
polychor(mzdat$ecEver3_T1, mzdat$ecEver3_T2,std.err = T)
.65+(1.96*.12)
.65-(1.96*.12)
polychor(mzdat$cccever3_T1, mzdat$cccever3_T2,std.err = T)
.62+(1.96*.12)
.62-(1.96*.12)
polychor(dzdat$ecEver3_T1, dzdat$ecEver3_T2,std.err = T)
.55+(1.96*.11)
.55-(1.96*.11)
polychor(dzdat$cccever3_T1, dzdat$cccever3_T2,std.err = T)
.52+(1.96*.11)
.52-(1.96*.11)
# 1=MZM, 2= MZF, 3=DZM, 4=DZF, 5=ODZ
#Vars
<- c("cccigEver3")
#nv
<- 1
# number of variables
#ntv
<- nv*2
# number of total variables
#selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #males = T1, females = T2
# Set Starting Values /
svLTh <- 0.8 # start value for first threshold
svITh <- 1
# start value for increments
#svTh
<- c(0.7,1,0.7,1)
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=ntv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=ntv) # lower bounds
for thresholds
#svTh
<- c(1,1)
# start value for thresholds
svPa
<- .4
# start value for path coefficient
svPaD <- vech(diag(svPa,nv,nv)) # start values for diagonal of covariance matrix
svPe
<- .8
# start value for path coefficient for e
svPeD <- vech(diag(svPe,nv,nv)) # start values for diagonal of covariance matrix
lbPa
<- .00001
# start value for lower bounds
lbPaD <- diag(lbPa,nv,nv)
# lower bounds for diagonal of covariance matrix
lbPaD[lower.tri(lbPaD)] <- 0
# lower bounds for below diagonal elements
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lbPaD[upper.tri(lbPaD)] <- NA

# lower bounds for above diagonal elements

# Set Starting Values
aLabs <- paste("a",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
cLabs <- paste("c",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
eLabs <- paste("e",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
var1thM <- paste("var1M","_th",1:nth, sep="")
var2thM <- paste("var2M","_th",1:nth, sep="")
var1thF <- paste("var1F","_th",1:nth, sep="")
var2thF <- paste("var2F","_th",1:nth, sep="")
thUB

<- 2

# -----------------------------------------------------------------------------# PREPARE MODEL
# ACE Model
# Create Algebra for expected Mean Matrices to include differing thresholds for males
and females
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
threGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values= svTh,
labels=c(var1thM,var2thM), name="threGm",lbound=-2, ubound=2 )
threGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thF,var2thF), name="threGf",lbound=-2, ubound=2 )
threGmf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thM,var2thM,var1thF,var2thF), name="threGmf", lbound=2, ubound=2 )
# Create Matrices for Path Coefficients
pathA <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE,
values=c(0.7,0.5,0), #replacing svPaD
label=aLabs, lbound=lbPaD, name="a" )
pathC <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE,
values=c(0.8,0.6,0.8),
label=cLabs, lbound=lbPaD, name="c" )
pathE <- mxMatrix( type="Lower", nrow=nv, ncol=nv, free=TRUE,
values=svPeD, label=eLabs, lbound=lbPaD, name="e" )
# Create Algebra for Variance Comptwonts
covA
<- mxAlgebra( expression=a %*% t(a), name="A" )
covC
<- mxAlgebra( expression=c %*% t(c), name="C" )
covE
<- mxAlgebra( expression=e %*% t(e), name="E" )
# Create Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
covP
<- mxAlgebra( expression= A+C+E, name="V" )
covMZ <- mxAlgebra( expression= A+C, name="cMZ" )
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covDZ <- mxAlgebra( expression= 0.5%x%A+ C, name="cDZ" )
expCovMZ <- mxAlgebra( expression= rbind( cbind(V, cMZ), cbind(t(cMZ), V)),
name="expCovMZ" )
expCovDZ <- mxAlgebra( expression= rbind( cbind(V, cDZ), cbind(t(cDZ), V)),
name="expCovDZ" )
# Create Algebra for Standardization
matI
<- mxMatrix( type="Iden", nrow=nv, ncol=nv, name="I")
invSD <- mxAlgebra( expression=solve(sqrt(I*V)), name="iSD")
# Calculate genetic and environmental correlations
corA
<- mxAlgebra( expression=solve(sqrt(I*A))%&%A, name ="rA" ) #cov2cor()
corC
<- mxAlgebra( expression=solve(sqrt(I*C))%&%C, name ="rC" )
corE
<- mxAlgebra( expression=solve(sqrt(I*E))%&%E, name ="rE" )
## Calculate Phenotypic Correlation ##
corP
<- mxAlgebra (expression=solve(sqrt(I*V)) %*% V %*% solve(sqrt(I*V)),
name="rP")
## Calculate Standardized Covariances ##
stCovA <- mxAlgebra (solve(sqrt(I*V)) %*% A %*% solve(sqrt(I*V)), name="stCovA")
stCovC <- mxAlgebra (solve(sqrt(I*V)) %*% C %*% solve(sqrt(I*V)), name="stCovC")
stCovE <- mxAlgebra (solve(sqrt(I*V)) %*% E %*% solve(sqrt(I*V)), name="stCovE")
# Constrain Variance of Binary Variables
matUnv <- mxMatrix( type="Unit", nrow=nv, ncol=1, name="Unv1" )
var1
<- mxConstraint( expression=diag2vec(V)==Unv1, name="Var1" )
# Create Algebra for Variance Components
rowVC <- rep('VC',nv)
colVC <- rep(c('A','C','E','SA','SC','SE'),each=nv)
estVC <- mxAlgebra( expression=cbind(A,C,E,A/V,C/V,E/V), name="VC",
dimnames=list(rowVC,colVC))
# Create Confidence Interval Objects
ciACE <- mxCI(c("rA", "rC", "rE", "stCovA","stCovC", "stCovE"))#
"VC[1,seq(1,3*nv,nv),(2,seq(1,3*nv,nv)),(2,seq(2,3*nv,nv)))]" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
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# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGf")
expDZf <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGf" )
expMZm <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZm <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZo <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGmf" )
funML <- mxFitFunctionML()
# Combine Groups
parsZf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGf, matI, invSD, matUnv )
parsZm <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGm, matI, invSD, matUnv )
parsZmf <- list( pathA, pathC, pathE,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGmf, matI, invSD, matUnv )
modelMZf <- mxModel( parsZf, meanG, covMZ, expCovMZ, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanG, covDZ, expCovDZ, dataDZf, expDZf, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanG, covMZ, expCovMZ, dataMZm, expMZm,
funML, name="MZm" )
modelDZm <- mxModel( parsZm, meanG, covDZ, expCovDZ, dataDZm, expDZm,
funML, name="DZm" )
modelDZo <- mxModel( parsZmf, meanG, covDZ, expCovDZ,dataDZo, expDZo,
funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
BivBinAceModel <- mxModel( "BivBinACE", parsZf, parsZm, parsZmf,
modelMZf, modelDZf, modelMZm, modelDZm, modelDZo, multi,
estVC, ciACE)
BivBinAceFit <-mxRun(BivBinAceModel, intervals = F)
BivBinAceFit <-mxTryHardOrdinal(BivBinAceFit, intervals = F)
BivBinAceFit2 <- mxTryHardOrdinal(BivBinAceFit, intervals = F)
BivBinAceFit3 <- mxTryHardOrdinal(BivBinAceFit2, intervals = F)
BivBinAceFit4 <- mxTryHardOrdinal(BivBinAceFit3, intervals = F)
BivBinAceFit5 <- mxTryHardOrdinal(BivBinAceFit4, intervals = F)
BivBinAceFit6 <- mxTryHardOrdinal(BivBinAceFit, intervals = F)
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summary(BivBinAceFit6, verbose = T)
BivBinAceFit6$algebras
#BivBinAceFit7 <- mxBootstrap(BivBinAceFit6)
#summary(BivBinAceFit7)
#BivBinAceFit7b <- mxBootstrap(BivBinAceFit7, replications = 1000)
#summary(BivBinAceFit7b)
#BivBinAceFit7b$algebras
#BivBinAceFit7c <- mxBootstrap(BivBinAceFit7b, replications = 1500)
#summary(BivBinAceFit7c)
#BivBinAceFit7c$algebras
#BivBinAceFit7d <- mxBootstrap(BivBinAceFit7c, replications = 2000)
#summary(BivBinAceFit7d)
#BivBinAceFit7d$algebras
# Confidence Interval calculation below
# Test of covA
BivBinAceModel8 <- BivBinAceFit6
BivBinAceModel8<- omxSetParameters(BivBinAceModel8, labels=c( "a21"),
free=FALSE, values=0 )
BivBinAceFit8<- mxTryHardOrdinal(BivBinAceModel8, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit8)
#BivBinAceFit8a <- omxRunCI(BivBinAceFit8)
summary(BivBinAceFit8, verbose=F)
#BivBinAceFit8$algebras
# Test of covC
BivBinAceModel9 <- BivBinAceFit6
BivBinAceModel9<- omxSetParameters(BivBinAceModel9, labels=c( "c21"),
free=FALSE, values=0 )
BivBinAceFit9<- mxRun(BivBinAceModel9, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit9)
# Test of covE
BivBinAceModel10 <- BivBinAceFit6
BivBinAceModel10<- omxSetParameters(BivBinAceModel10, labels=c("e21"),
free=FALSE, values=0 )
BivBinAceFit10<- mxTryHardOrdinal(BivBinAceModel10, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit10)
# Test of rP

251

BivBinAceModel11 <- BivBinAceFit6
BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="a21",
free=FALSE, values=0 )
BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="c21",
free=FALSE, values=0 )
#BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="e21",
free=FALSE, values=0 )
BivBinAceFit11<- mxTryHardOrdinal(BivBinAceModel11, intervals = F)
tableFitStatistics(BivBinAceFit6, c(BivBinAceFit8, BivBinAceFit9, BivBinAceFit10,
BivBinAceFit11))
# Test of covA/A
#BivBinAceModel12 <- BivBinAceFit7a
#BivBinAceModel12<- omxSetParameters(BivBinAceModel12, labels="a22",
free=FALSE, values=0 )
#BivBinAceFit12<- mxTryHardOrdinal(BivBinAceModel12, intervals = F)
# Confidence Intervals
mxOption(NULL, "Default optimizer", "CSOLNP")
BivBinAceFit7a <- omxRunCI(BivBinAceFit7d)
summary(BivBinAceFit7a, verbose=T)
BivBinAceFit7a$algebras
# Test of CE model
BivBinAceModel12 <- BivBinAceFit6
BivBinAceModel12<- omxSetParameters(BivBinAceModel12, labels=c( "a11","a21",
"a22"), free=FALSE, values=0, name = "CE model" )
BivBinAceFit12<- mxTryHardOrdinal(BivBinAceModel12, intervals = F)
summary(BivBinAceFit12, verbose=T)
tableFitStatistics(BivBinAceFit6, BivBinAceFit12)
# Test of AE Model
BivBinAceModel13 <- BivBinAceFit6
BivBinAceModel13<- omxSetParameters(BivBinAceModel13, labels=c( "c11","c21",
"c22"), free=FALSE, values=0, name = "AE model" )
BivBinAceFit13<- mxTryHardOrdinal(BivBinAceModel13, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit13)
# Test of E Model
BivBinAceModel16 <- BivBinAceFit6

252

BivBinAceModel16<- omxSetParameters(BivBinAceModel16,
labels=c("a11","a21","a22", "c11","c21", "c22"), free=FALSE, values=0, name = "E
model" )
BivBinAceFit16<- mxTryHardOrdinal(BivBinAceModel16, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit16)
bivnested <-list(BivBinAceFit12, BivBinAceFit13,BivBinAceFit16)
tableFitStatistics(BivBinAceFit6, bivnested)

# Test of E crosspaths Model
BivBinAceModel17 <- BivBinAceFit6
BivBinAceModel17<- omxSetParameters(BivBinAceModel17, labels=c("a21","c21"),
free=FALSE, values=0, name = "E model" )
BivBinAceFit17<- mxTryHardOrdinal(BivBinAceModel17, intervals = T)
summary(BivBinAceFit17, verbose=T)
tableFitStatistics(BivBinAceFit6, BivBinAceFit17)
BivBinAceModel18 <- BivBinAceFit17
BivBinAceFit18<- mxTryHardOrdinal(BivBinAceModel18, intervals = T)
summary(BivBinAceFit18, verbose=T)
BivBinAceModel19 <- BivBinAceFit18
BivBinAceFit19<- mxTryHardOrdinal(BivBinAceModel19, intervals = T)
summary(BivBinAceFit19, verbose=T)
# Using CE model, testing of C21
BivBinAceModel14 <- BivBinAceModel12
BivBinAceModel14<- omxSetParameters(BivBinAceModel14, labels=c( "c21"),
free=FALSE, values=0, name = "CE model No C21" )
BivBinAceFit14<- mxTryHardOrdinal(BivBinAceModel14, intervals = F)
tableFitStatistics(BivBinAceFit12, BivBinAceFit14)
# Using CE model, testing of E21
BivBinAceModel15 <- BivBinAceModel14
BivBinAceModel15<- omxSetParameters(BivBinAceModel15, labels=c( "e21"),
free=FALSE, values=0, name = "CE model No Cross Paths" )
BivBinAceFit15<- mxTryHardOrdinal(BivBinAceModel15, intervals = F)
tableFitStatistics(BivBinAceFit14, BivBinAceFit15)
tableFitStatistics(BivBinAceFit12, BivBinAceFit15)
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###------------------------------------------###
###
Correlated Factors Model ###
###------------------------------------------###
mxOption( NULL, "Default optimizer","CSOLNP" )
# Create Functions to assign labels
laLower <- function(la,nv) { paste(la,rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="_")
}
laSdiag <- function(la,nv) { paste(la,rev(nv+1-sequence(1:(nv-1))),rep(1:(nv-1),(nv1):1),sep="_") }
laFull <- function(la,nv) { paste(la,1:nv,rep(1:nv,each=nv),sep="_") }
laDiag <- function(la,nv) { paste(la,1:nv,1:nv,sep="_") }
laSymm <- function(la,nv) { paste(la,rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="_")
}
# Create Algebra for expected Mean Matrices to include differing thresholds for males
and females
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
threGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values= svTh,
labels=c(var1thM,var2thM), name="threGm",lbound=-2, ubound=2 )
threGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thF,var2thF), name="threGf",lbound=-2, ubound=2 )
threGmf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=svTh,
labels=c(var1thM,var2thM,var1thF,var2thF), name="threGmf", lbound=2, ubound=2 )
# Matrices a, c, and e to store a, c, and e path coefficients
pathA <- mxMatrix( type="Diag", nrow=nv, ncol=nv, free=TRUE, values=.5,
label=laDiag("a",nv), lbound=.0001, name="a" )
pathC <- mxMatrix( type="Diag", nrow=nv, ncol=nv, free=TRUE, values=.5,
label=laDiag("c",nv), lbound=.0001, name="c" )
pathE <- mxMatrix( type="Diag", nrow=nv, ncol=nv, free=TRUE, values=.5,
label=laDiag("e",nv), lbound=.0001, name="e" )
pathRa <- mxMatrix( type="Stand", nrow=nv, ncol=nv, free=TRUE, values=.4,
label=laSdiag("ra",nv), lbound=-1, ubound=1, name="Ra" )
pathRc <- mxMatrix( type="Stand", nrow=nv, ncol=nv, free=TRUE, values=.4,
label=laSdiag("rc",nv), lbound=-1, ubound=1, name="Rc" )
pathRe <- mxMatrix( type="Stand", nrow=nv, ncol=nv, free=TRUE, values=.4,
label=laSdiag("re",nv), lbound=-1, ubound=1, name="Re" )
# Matrices A, C, and E compute variance components
covA

<- mxAlgebra( expression=a %*% (Ra) %*% t(a), name="A" )
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covC
covE

<- mxAlgebra( expression=c %*% (Rc) %*% t(c), name="C" )
<- mxAlgebra( expression=e %*% (Re) %*% t(e), name="E" )

# Create Algebra for expected Variance/Covariance Matrices in MZ & DZ twins
covP
<- mxAlgebra( expression= A+C+E, name="V" )
covMZ <- mxAlgebra( expression= A+C, name="cMZ" )
covDZ <- mxAlgebra( expression= 0.5%x%A+ C, name="cDZ" )
expCovMZ <- mxAlgebra( expression= rbind( cbind(V, cMZ), cbind(t(cMZ), V)),
name="expCovMZ" )
expCovDZ <- mxAlgebra( expression= rbind( cbind(V, cDZ), cbind(t(cDZ), V)),
name="expCovDZ" )
matI
<- mxMatrix( type="Iden", nrow=nv, ncol=nv, name="I" )
invSDm <- mxAlgebra( expression=solve(sqrt(I*V)), name="iSD" )
## Calculate Standardized Covariances ##
stCovA <- mxAlgebra (solve(sqrt(I*V)) %*% A %*% solve(sqrt(I*V)), name="stCovA")
stCovC <- mxAlgebra (solve(sqrt(I*V)) %*% C %*% solve(sqrt(I*V)), name="stCovC")
stCovE <- mxAlgebra (solve(sqrt(I*V)) %*% E %*% solve(sqrt(I*V)), name="stCovE")
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
expMZf <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGf")
expDZf <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGf" )
expMZm <- mxExpectationNormal( covariance="expCovMZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZm <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGm" )
expDZo <- mxExpectationNormal( covariance="expCovDZ", means="meanG",
dimnames=selVars, thresholds = "threGmf" )
funML <- mxFitFunctionML()
# Algebras generated to hold Parameter Estimates and Derived Variance Components
colVarsZ <- paste(selVars,rep(c('A','C','E','SA','SC','SE'),each=nv),sep="")
estVarsZ <- mxAlgebra( cbind(A,C,E,A/V,C/V,E/V), name="VarsZ",
dimnames=list(NULL,colVarsZ))
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# Combine Groups
makeModel <- function(name) {
parsZf <- list( pathA, pathC, pathE, pathRa, pathRc, pathRe, covA, covC, covE,
covP, estVarsZ )
parsZm <- list( pathA, pathC, pathE, pathRa, pathRc, pathRe, covA, covC, covE,
covP, estVarsZ )
modelMZf <- mxModel( parsZf ,meanG, covMZ, dataMZf, expCovMZ, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanG, covDZ, dataDZf, expCovDZ, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanG, covMZ, dataMZm, expCovMZ, funML,
name="MZm" )
modelDZm <- mxModel( parsZm, meanG, covDZ, dataDZf, expCovDZ, funML,
name="DZm" )
modelDZo <- mxModel( parsZmf, meanG, covDZ, expCovDZ,dataDZo, expCovDZ,
funML, name="DZo" )
minus2ll <- mxAlgebra( MZf.objective+ DZf.objective+ MZm.objective+ DZm.objective,
name="m2LL" )
name
<- mxModel( name, parsZf, parsZm, modelMZf, modelDZf, modelMZm,
modelDZm, minus2ll)
}
corrfactormodel <- makeModel("Correlated Factor Model")

# Combine Groups
parsZf <- list( pathA, pathC, pathE, pathRa, pathRc, pathRe,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGf, matI, invSD, matUnv )
parsZm <- list( pathA, pathC, pathE, pathRa, pathRc, pathRe,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGm, matI, invSD, matUnv )
parsZmf <- list( pathA, pathC, pathE, pathRa, pathRc, pathRe,
covA, covC, covE, covP, corA, corC, corE, corP, stCovA, stCovC, stCovE,
meanG, threGmf, matI, invSD, matUnv )
modelMZf <- mxModel( parsZf, meanG, covMZ, expCovMZ, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanG, covDZ, expCovDZ, dataDZf, expDZf, funML,
name="DZf" )
modelMZm <- mxModel( parsZm, meanG, covMZ, expCovMZ, dataMZm, expMZm,
funML, name="MZm" )
modelDZm <- mxModel( parsZm, meanG, covDZ, expCovDZ, dataDZm, expDZm,
funML, name="DZm" )
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modelDZo <- mxModel( parsZmf, meanG, covDZ, expCovDZ,dataDZo, expDZo,
funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
corrfactormodel <- mxModel( "Correlated Factors", parsZf, parsZm, parsZmf,
modelMZf, modelDZf, modelMZm, modelDZm, modelDZo, multi,
estVC, ciACE)
# -----------------------------------------------------------------------------# RUN MODEL
#
corrfactorfit <- mxRun(corrfactormodel)
summary(corrfactorfit)
corrfactorfit$algebras
corrfactorfit2<-mxTryHardOrdinal(corrfactorfit)
summary(corrfactorfit2)
corrfactorfit2$algebras
corrfactornoc <-corrfactorfit
corrfactornoc <-omxSetParameters(corrfactornoc, labels = "rc_2_1", free=F, values=0)
corrfactornocfit <-mxTryHardOrdinal(corrfactornoc, intervals = F)
tableFitStatistics(corrfactorfit2, corrfactornocfit)
corrfactornoa <-corrfactorfit
corrfactornoa <-omxSetParameters(corrfactornoa, labels = "ra_2_1", free=F, values=0)
corrfactornoafit <-mxTryHardOrdinal(corrfactornoa, intervals = F)
tableFitStatistics(corrfactorfit2, corrfactornoafit)
# Confidence Intervals
corrfactorfit3 <- omxRunCI(corrfactorfit2)
summary(corrfactorfit3, verbose=T)
corrfactorfit3$algebras

corrfactorfit4 <- omxRunCI(corrfactorfit3)
summary(corrfactorfit4, verbose=T)

###--------------------------------------------------------###
###
Bivariate Model Assumptions
###
###--------------------------------------------------------###
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# --------------------------------------------------------------------------------------------------------------------# PREPARE DATA
# Select Variables for Analysis
Vars
<- c('ecigEver3', 'cccigEver3')
nv
<- 2
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Specify Thresholds for Ordinal Variables
## nth: number of thresholds; fcat: first category; lcat: last category; ncat: number of
categories;
nth1
<- 1 ; fcat1 <- 0 ; lcat1 <- fcat1+nth1 ; ncat1 <- nth1+1
nth
<- max(nth1)
# Specify Arguments for Threshold Matrices
## lth: lowest threshold; ith: increment;
lth1
<- 0 ; ith1
<- 0 ;
lth2
<- 0 ; ith2
<- 0 ;
thFree <- c(rep(T,nth1),rep(F,nth-nth1))
#thValues <- matrix(rep(c(lth1,(rep(ith1,nth-1)),lth2,(rep(ith2,nth-1)),lth3,(rep(ith3,nth1))),nv),nrow=nth,ncol=nv)
thValues <- matrix(c(lth1,(rep(ith1,nth-1)),lth2,(rep(ith2,nth-1))),nrow=nth,ncol=nv)
thLBound <- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv)
#thLBound <- matrix(c(-3,0, -3,0, -3,0),nrow=nth,ncol=nv)
# Select Data for Analysis
twinData <- data2[,c(selVars,'zyg2')]
#twinData <- FTall[,c(selVars,'zygroup5')]
describe(twinData)
twinDataBin <- twinData
# Factorize Ordinal Variables
twinDataBin[,c(1,nv+1)] <- mxFactor(twinDataBin[,c(1,nv+1)], levels = c(0:nth1))
twinDataBin[,c(2,nv+2)] <- mxFactor(twinDataBin[,c(2,nv+2)], levels = c(0:nth1))
#twinDataBin[,c(3,nv+3)] <- mxFactor(twinDataBin[,c(3,nv+3)], levels = c(0:nth3))
# Create Datasets by Zygosity- 5 group
dataBinMZm <- subset(twinDataBin, zyg2==1, selVars)
dataBinMZf <- subset(twinDataBin, zyg2==2, selVars)
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dataBinDZm <- subset(twinDataBin, zyg2==3, selVars)
dataBinDZf <- subset(twinDataBin, zyg2==4, selVars)
dataBinDZo <- subset(twinDataBin, zyg2==5, selVars)
# Set Starting Values
svLTh <- -1.5 # start value for first threshold
svITh <- 1 # start value for increments
svTh <- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=nv) # start value for
thresholds
lbTh <- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=nv) # lower bounds for
thresholds
svCor <- .5 # start value for correlations
lbCor <- -0.99 # lower bound for correlations
ubCor <- 0.99 # upper bound for correlations
# Create Labels
labThMZM <- labTh("MZM",selVars,nth)
labThDZM <- labTh("DZM",selVars,nth)
labThMZF <- labTh("MZF",selVars,nth)
labThDZF <- labTh("DZF",selVars,nth)
labThDZO <- labTh("DZO",selVars,nth)
labThZ <- labTh("Z",selVars,nth)
labCrMZM <- labSdiag("corMZM",ntv)
labCrDZM <- labSdiag("corDZM",ntv)
labCrMZF <- labSdiag("corMZF",ntv)
labCrDZF <- labSdiag("corDZF",ntv)
labCrDZO <- labSdiag("corDZO",ntv)
labCrZ <- labSdiag("corZ",ntv)
# --------------------------------------------------------------------------------------------------------------------# PREPARE MODEL
# Create Algebra for expected Mean & Threshold Matrices
meanG <- mxMatrix( type="Zero", nrow=1, ncol=ntv, name="meanG" )
thinMZM <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=thFree, values=svTh,
lbound=lbTh, labels=labThMZM, name="thinMZM" )
thinDZM <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=thFree, values=svTh,
lbound=lbTh, labels=labThDZM, name="thinDZM" )
thinMZF <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=thFree, values=svTh,
lbound=lbTh, labels=labThMZF, name="thinMZF" )
thinDZF <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=thFree, values=svTh,
lbound=lbTh, labels=labThDZF, name="thinDZF" )
thinDZO <- mxMatrix( type="Full", nrow=nth, ncol=ntv, free=thFree, values=svTh,
lbound=lbTh, labels=labThDZO, name="thinDZO" )
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inc <- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=FALSE, values=1, name="inc"
)
threMZM <- mxAlgebra( expression= inc %*% thinMZM, name="threMZM" )
threDZM <- mxAlgebra( expression= inc %*% thinDZM, name="threDZM" )
threMZF <- mxAlgebra( expression= inc %*% thinMZF, name="threMZF" )
threDZF <- mxAlgebra( expression= inc %*% thinDZF, name="threDZF" )
threDZO <- mxAlgebra( expression= inc %*% thinDZO, name="threDZO" )
# Create Algebra for expected Correlation Matrices
corMZM <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels=labCrMZM,
name="corMZM" )
corDZM <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels=labCrDZM,
name="corDZM" )
corMZF <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels=labCrMZF,
name="corMZF" )
corDZF <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels=labCrDZF,
name="corDZF" )
corDZO <- mxMatrix( type="Stand", nrow=ntv, ncol=ntv, free=TRUE, values=svCor,
lbound=lbCor, ubound=ubCor, labels=labCrDZO,
name="corDZO" )
# Create Data Objects for Multiple Groups
dataMZM <- mxData( observed=dataBinMZm, type="raw" )
dataDZM <- mxData( observed=dataBinDZm, type="raw" )
dataMZF <- mxData( observed=dataBinMZf, type="raw" )
dataDZF <- mxData( observed=dataBinDZf, type="raw" )
dataDZO <- mxData( observed=dataBinDZo, type="raw" )
# Create Expectation Objects for Multiple Groups
# Note- Means are set to zero and the thresholds change. So,everyone can have the
same meanG but the thresholds vary.
expMZM <- mxExpectationNormal( covariance="corMZM", means="meanG",
dimnames=selVars, thresholds="threMZM" )
expDZM <- mxExpectationNormal( covariance="corDZM", means="meanG",
dimnames=selVars, thresholds="threDZM" )
expMZF <- mxExpectationNormal( covariance="corMZF", means="meanG",
dimnames=selVars, thresholds="threMZF" )
expDZF <- mxExpectationNormal( covariance="corDZF", means="meanG",
dimnames=selVars, thresholds="threDZF" )
expDZO <- mxExpectationNormal( covariance="corDZO", means="meanG",
dimnames=selVars, thresholds="threDZO" )
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funML <- mxFitFunctionML()
# Create Model Objects for Multiple Groups
modelMZM <- mxModel( meanG, corMZM, thinMZM, inc, threMZM, dataMZM, expMZM,
funML, name="MZM" )
modelDZM <- mxModel( meanG, corDZM, thinDZM, inc, threDZM, dataDZM, expDZM,
funML, name="DZM" )
modelMZF <- mxModel( meanG, corMZF, thinMZF, inc, threMZF, dataMZF, expMZF,
funML, name="MZF" )
modelDZF <- mxModel( meanG, corDZF, thinDZF, inc, threDZF, dataDZF, expDZF,
funML, name="DZF" )
modelDZO <- mxModel( meanG, corDZO, thinDZO, inc, threDZO, dataDZO, expDZO,
funML, name="DZO" )
multi <- mxFitFunctionMultigroup( c("MZM", "DZM", "MZF", "DZF", "DZO") )
# Create Confidence Interval Objects
ciCor <- mxCI( c('MZM.corMZM','DZM.corDZM', 'MZF.corMZF','DZF.corDZF',
'DZO.corDZO' ))
#ciThre <- mxCI( c('MZ.threMZ','DZ.threDZ' ))
# Build Saturated Model with Confidence Intervals
modelSAT <- mxModel( "BivSAT", modelMZM, modelDZM, modelMZF, modelDZF,
modelDZO, multi, ciCor )
modelSAT <- mxOption(modelSAT, "mvnRelEps", 1e-3)
# --------------------------------------------------------------------------------------------------------------------# RUN MODEL
# Run Saturated Model
mxOption( NULL, "Default optimizer","CSOLNP" )
fitSAT <- mxRun( modelSAT, intervals=FALSE)
fitSAT <- mxTryHardOrdinal(fitSAT, intervals=FALSE, scale=0.5 )
sumSAT <- summary( fitSAT )
# Print Goodness-of-fit Statistics & Parameter Estimates
fitGofs(fitSAT)
fitEsts(fitSAT)
mxGetExpected( fitSAT, c("thresholds","covariance"))
options("max.print"=1100)
summary(fitSAT, verbose =TRUE)
# --------------------------------------------------------------------------------------------------------------------# RUN SUBMODELS
# Constrain expected Thresholds
# to be equal across Twin Order
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modelETO <- mxModel( fitSAT, name="threeETOo" )
## CIGS
modelETO <- omxSetParameters( modelETO,
label=c("t1MZMcccigEver3_T2","t1MZMcccigEver3_T1"), free=T, values=svLTh,
newlabels='t1MZMcccigEver3', strict=F )
modelETO <- omxSetParameters( modelETO,
label=c("t1DZMcccigEver3_T2","t1DZMcccigEver3_T1"), free=T, values=svLTh,
newlabels="t1DZMcccigEver3" , strict=F)
modelETO <- omxSetParameters( modelETO,
label=c("t1MZFcccigEver3_T2","t1MZFcccigEver3_T1"), free=T, values=svLTh,
newlabels="t1MZFcccigEver3" , strict=F)
modelETO <- omxSetParameters( modelETO,
label=c("t1DZFcccigEver3_T2","t1DZFcccigEver3_T1"), free=T, values=svLTh,
newlabels="t1DZFcccigEver3", strict=F )
modelETO <- omxSetParameters( modelETO,
label=c("t1DZOcccigEver3_T2","t1DZOcccigEver3_T1"), free=T, values=svLTh,
newlabels="t1DZOcccigEver3", strict=F )
## ECIGS
modelETO <- omxSetParameters( modelETO, label=c("t1MZMecigEver3_T1",
"t1MZMecigEver3_T2"), free=T, values=svITh, newlabels="t1MZMecigEver3", strict=F )
modelETO <- omxSetParameters( modelETO, label=c("t1DZMecigEver3_T1",
"t1DZMecigEver3_T2"), free=T, values=svITh, newlabels="t1DZMecigEver3", strict=F )
modelETO <- omxSetParameters( modelETO, label=c("t1MZFecigEver3_T1",
"t1MZFecigEver3_T2"), free=T, values=svITh, newlabels="t1MZFecigEver3", strict=F )
modelETO <- omxSetParameters( modelETO, label=c("t1DZFecigEver3_T1",
"t1DZFecigEver3_T2"), free=T, values=svITh, newlabels="t1DZFecigEver3", strict=F )
modelETO <- omxSetParameters( modelETO, label=c("t1DZOecigEver3_T1",
"t1DZOecigEver3_T2"), free=T, values=svITh, newlabels="t1DZOecigEver3", strict=F )
modelETO <- mxOption(modelETO, "mvnRelEps", 1e-3)
fitETO <- mxTryHardOrdinal( modelETO, intervals=F)
fitGofs(fitETO); fitEsts(fitETO)
# Constrain expected Thresholds to be equal across Twin Order and Zygosity
modelETZ <- mxModel( fitETO, name="twoETZo" )
modelETZ<- omxSetParameters(modelETZ, label=c("t1MZMcccigEver3",
"t1MZFcccigEver3", "t1DZFcccigEver3","t1DZMcccigEver3", "t1DZOcccigEver3"), free =
T, values=svITh, newlabels="t1cccigEver3", strict=F)
modelETZ<- omxSetParameters(modelETZ, label=c("t1MZMecigEver3",
"t1MZFecigEver3", "t1DZFecigEver3","t1DZMecigEver3", "t1DZOecigEver3"), free = T,
values=svITh, newlabels="t1ecigEver3", strict=F)
fitETZ <- mxTryHardOrdinal( modelETZ, intervals=F )
fitGofs(fitETZ); fitEsts(fitETZ)
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# Print Comparative Fit Statistics
satNested <- list(fitETO,fitETZ)
tableFitStatistics(fitSAT, satNested)
#####--------------------####
##### Equating Sexes ####
#####--------------------####
# set the number of variables per twin (nv) and total variables per twin pair (ntv) for
automation
vars
<- c("ecigEver3", "cccigEver3")
#vars
<- c("cccigEver3", "ecigEver3") #reverse order of variables to see if same
results emerge
nv
<- 2
# number of variables
ntv
<- nv*2
# number of total variables
selVars <- paste(vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
nth <- 1 # Number of thresholds per variable (only for binary data)
# Subset the data to only the things I need
twinData <- data2[,c(selVars,'zyg2')]
describe(twinData)
summary(twinData)
dim(twinData)
#twinData2<-na.omit(twinData)
#summary(twinData2)
#dim(twinData2)
twinDataBin <-twinData
dim(twinDataBin)
table(twinDataBin$zyg2)
# Factorize Ordinal Variables using the mxFactor option
twinDataBin[,c(1,3)] <- mxFactor(twinDataBin[,c(1,3)], levels = c(0:nth))
twinDataBin[,c(2,4)] <- mxFactor(twinDataBin[,c(2,4)], levels = c(0:nth))
# Twin correlations
mzdat <- subset(twinDataBin, zyg2==c(1) | zyg2 ==2, selVars)
dzdat <- subset(twinDataBin, zyg2==c(3) | zyg2 ==4 | zyg2==5, selVars)
# 1=MZM, 2= MZF, 3=DZM, 4=DZF, 5=ODZ
#Vars
<- c("ecigEver3", "cccigEver3")
#nv
<- 2
# number of variables
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#ntv
<- nv*2
# number of total variables
#selVars <- paste(Vars,c(rep("_T1",nv),rep("_T2",nv)),sep="")
# Select Data for Analysis
mzfData <- subset(twinDataBin, zyg2==2, selVars)
dzfData <- subset(twinDataBin, zyg2==4, selVars)
mzmData <- subset(twinDataBin, zyg2==1, selVars)
dzmData <- subset(twinDataBin, zyg2==3, selVars)
dzoData <- subset(twinDataBin, zyg2==5, selVars) #males = T1, females = T2
# Set Starting Values /
svLTh <- 0.8 # start value for first threshold
svITh <- 1
# start value for increments
#svTh
<- c(0.7,1,0.7,1)
svTh
<- matrix(rep(c(svLTh,(rep(svITh,nth-1)))),nrow=nth,ncol=ntv) # start value
for thresholds
lbTh
<- matrix(rep(c(-3,(rep(0.001,nth-1))),nv),nrow=nth,ncol=ntv) # lower bounds
for thresholds
#svTh
<- c(1,1)
# start value for thresholds
svPa
<- .4
# start value for path coefficient
svPaD <- vech(diag(svPa,nv,nv)) # start values for diagonal of covariance matrix
svPe
<- .8
# start value for path coefficient for e
svPeD <- vech(diag(svPe,nv,nv)) # start values for diagonal of covariance matrix
lbPa
<- .00001
# start value for lower bounds
lbPaD <- diag(lbPa,nv,nv)
# lower bounds for diagonal of covariance matrix
lbPaD[lower.tri(lbPaD)] <- 0
# lower bounds for below diagonal elements
lbPaD[upper.tri(lbPaD)] <- NA
# lower bounds for above diagonal elements
# Set Starting Values
aLabs <- paste("a",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
cLabs <- paste("c",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
eLabs <- paste("e",rev(nv+1-sequence(1:nv)),rep(1:nv,nv:1),sep="")
mvar1th <- paste("mvar1","_th",1:nth, sep="")
mvar2th <- paste("mvar2","_th",1:nth, sep="")
fvar1th <- paste("fvar1","_th",1:nth, sep="")
fvar2th <- paste("fvar2","_th",1:nth, sep="")
#dzvar1th <-paste("var1DZ", "_th", 1:nth, sep="")
#dzvar2th <-paste("var2DZ", "_th", 1:nth, sep="")
thUB

<- 2

# -----------------------------------------------------------------------------# PREPARE MODEL
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# General non-scalar ACE Model
# Matrices declared to store a, c, and e Path Coefficients
pathAf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label=c("af11", "af21", "af22"), name="af" )
pathCf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label=c("cf11", "cf21", "cf22"), name="cf" )
pathEf <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound =
-0.99, values=.6, label=c("ef11", "ef21", "ef22"), name="ef" )
pathAm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label=c("am11", "am21", "am22"), name="am" )
pathCm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label=c("cm11", "cm21", "cm22"), name="cm" )
pathEm <- mxMatrix( "Lower", nrow=nv, ncol=nv, free=TRUE, ubound = 0.99, lbound
= -0.99, values=.6, label=c("em11", "em21", "em22"), name="em" )
pathRa <- mxMatrix( "Lower", nrow=1, ncol=1, free=TRUE, values=1, label="ra11",
name="ra", ubound=1, lbound=0 )
# Matrices generated to hold A, C, and E computed Variance Components
covAf <- mxAlgebra( af %*% t(af), name="Af" )
covCf <- mxAlgebra( cf %*% t(cf), name="Cf" )
covEf <- mxAlgebra( ef %*% t(ef), name="Ef" )
covAm <- mxAlgebra( am %*% t(am), name="Am" )
covCm <- mxAlgebra( cm %*% t(cm), name="Cm" )
covEm <- mxAlgebra( em %*% t(em), name="Em" )
# Algebra to compute total variances and standard deviations (diagonal only)
covPf <- mxAlgebra( Af+Cf+Ef, name="Vf" )
covPm <- mxAlgebra( Am+Cm+Em, name="Vm" )
# Algebras generated to hold Parameter Estimates and Derived Variance Components
colVarsZf <- c('Af','Cf','Ef','SAf','SCf','SEf')
estVarsZf <- mxAlgebra( cbind(Af,Cf,Ef,Af/Vf,Cf/Vf,Ef/Vf), name="VarsZf",
dimnames=list(NULL,colVarsZf))
colVarsZm <- c('Am','Cm','Em','SAm','SCm','SEm')
estVarsZm <- mxAlgebra( cbind(Am,Cm,Em,Am/Vm,Cm/Vm,Em/Vm), name="VarsZm",
dimnames=list(NULL,colVarsZm))
# Algebra for expected Mean and Variance/Covariance Matrices in MZ & DZ twins
#meanGf <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanf", name="expMeanGf" )
#meanGm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label="meanm", name="expMeanGm" )
#meanGfm <- mxMatrix( type="Full", nrow=1, ncol=ntv, free=TRUE, values=20,
label=c("meanf","meanm"), name="expMeanGfm" )
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meanGf <- mxMatrix( type="Zero", nrow=1, ncol=ntv, label="meanf",
name="expMeanGf" )
meanGm <- mxMatrix( type="Zero", nrow=1, ncol=ntv, label="meanm",
name="expMeanGm" )
meanGfm <- mxMatrix( type="Zero", nrow=1, ncol=ntv, label=c("meanf","meanm"),
name="expMeanGfm" )
covMZf <- mxAlgebra( expression= rbind( cbind(Vf, Af+Cf), cbind(Af+Cf, Vf)),
name="expCovMZf" )
covDZf <- mxAlgebra( expression= rbind( cbind(Vf, 0.5%x%Af+Cf),
cbind(0.5%x%Af+Cf, Vf)), name="expCovDZf" )
covMZm <- mxAlgebra( expression= rbind( cbind(Vm, Am+Cm), cbind(Am+Cm, Vm)),
name="expCovMZm" )
covDZm <- mxAlgebra( expression= rbind( cbind(Vm, 0.5%x%Am+Cm),
cbind(0.5%x%Am+Cm, Vm)), name="expCovDZm" )
CVfm
<- mxAlgebra( expression= ra%x%(af%*%t(am))+cf%*%t(cm), name="CVfm" )
CVmf
<- mxAlgebra( expression= ra%x%(am%*%t(af))+cm%*%t(cf), name="CVmf" )
covDZo <- mxAlgebra( expression= rbind( cbind(Vf, CVfm), cbind(CVmf, Vm)),
name="expCovDZo" )
Inc <- mxMatrix( type="Lower", nrow=nth, ncol=nth, free=F, values=1, name="Inc" )
# MALES
ThreM <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(mvar1th, mvar2th), lbound=-2, ubound=thUB, name="ThreM")
ExpThreM <- mxAlgebra( expression= cbind( ( Inc %*% ThreM ),
( Inc %*% ThreM ) ), name="ExpThreM" )
# FEMALES
ThreF <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(fvar1th, fvar2th), lbound=-2, ubound=thUB, name="ThreF")
ExpThreF <- mxAlgebra( expression= cbind( ( Inc %*% ThreF ),
( Inc %*% ThreF ) ), name="ExpThreF" )
## OS
ThreOS <-mxMatrix( type="Full", nrow=nth, ncol=nv, free=c(T, T), values=,
labels=cbind(mvar1th ,fvar2th), lbound=-2, ubound=thUB, name="ThreOS")
ExpThreOS <- mxAlgebra( expression= cbind( ( Inc %*% ThreOS ),
( Inc %*% ThreOS ) ), name="ExpThreOS" )
# Data objects for Multiple Groups
dataMZf <- mxData( observed=mzfData, type="raw" )
dataDZf <- mxData( observed=dzfData, type="raw" )
dataMZm <- mxData( observed=mzmData, type="raw" )
dataDZm <- mxData( observed=dzmData, type="raw" )
dataDZo <- mxData( observed=dzoData, type="raw" )
# Expectation objects for Multiple Groups
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expMZf <- mxExpectationNormal( covariance="expCovMZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expDZf <- mxExpectationNormal( covariance="expCovDZf", means="expMeanGf",
dimnames=selVars, thresholds = "ExpThreF" )
expMZm <- mxExpectationNormal( covariance="expCovMZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZm <- mxExpectationNormal( covariance="expCovDZm",
means="expMeanGm", dimnames=selVars, thresholds = "ExpThreM" )
expDZo <- mxExpectationNormal( covariance="expCovDZo", means="expMeanGfm",
dimnames=selVars, thresholds = "ExpThreOS" )
funML <- mxFitFunctionML()
# Combine Groups
parsZf <- list( pathAf, pathCf, pathEf, covAf, covCf, covEf, covPf, estVarsZf, ThreF,
ExpThreF, Inc )
parsZm <- list( pathAm, pathCm, pathEm, covAm, covCm, covEm, covPm,
estVarsZm, ThreM, ExpThreM, Inc )
parsZfm <- list( pathRa, CVfm, CVmf, ExpThreOS, Inc, ThreOS)
modelMZf <- mxModel( parsZf, meanGf, covMZf, dataMZf, expMZf, funML,
name="MZf" )
modelDZf <- mxModel( parsZf, meanGf, covDZf, dataDZf, expDZf, funML, name="DZf"
)
modelMZm <- mxModel( parsZm, meanGm, covMZm, dataMZm, expMZm, funML,
name="MZm" )
modelDZm <- mxModel( parsZm, meanGm, covDZm, dataDZm, expDZm, funML,
name="DZm" )
modelDZo <- mxModel( parsZf, parsZm, parsZfm, meanGfm, covDZo, dataDZo,
expDZo, funML, name="DZo" )
multi <- mxFitFunctionMultigroup( c("MZf","DZf","MZm","DZm","DZo") )
QualAceModel <- mxModel( "QualACE", modelMZf, modelDZf, modelMZm,
modelDZm, modelDZo, multi )
QualAceFit <-mxTryHardOrdinal(QualAceModel, intervals = F)
summary(QualAceFit)
## Coerce threshold to be equal across variables, see around line 500
eqthres <-mxModel(QualAceFit, name = "Equal Thresholds")
#eqthres <-omxSetParameters( eqthres, label=c("mvar1_th1", "mvar2_th1"),
free=TRUE, values=0.5, newlabels="var_th1")
#eqthres <-omxSetParameters( eqthres, label=c("fvar1_th1", "fvar2_th1"), free=TRUE,
values=0.5, newlabels="var_th1")
eqthres <-omxSetParameters( eqthres, label=c("mvar1_th1", "fvar1_th1"), free=TRUE,
values=0.5, newlabels="var1_th")
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eqthres <-omxSetParameters( eqthres, label=c("mvar2_th1", "fvar2_th1"), free=TRUE,
values=0.5, newlabels="var2_th")
eqthresfit<-mxTryHardOrdinal(eqthres, intervals=F)
satNested <- list(eqthresfit)
tableFitStatistics(QualAceFit, satNested)
## Coerce males and females to be equal
eqsex <-mxModel(eqthresfit, name = "Equal sexes")
eqsex <-omxSetParameters( eqsex, label=c("am11", "am21", "am22"), free=TRUE,
values=0.04, newlabels=c("a11", "a21", "a22") )
eqsex <-omxSetParameters( eqsex, label=c("af11", "af21", "af22"), free=TRUE,
values=0.04, newlabels=c("a11", "a21", "a22") )
eqsex <-omxSetParameters( eqsex, label=c("cm11", "cm21", "cm22"), free=TRUE,
values=0.5, newlabels=c("c11", "c21", "c22"))
eqsex <-omxSetParameters( eqsex, label=c("cf11", "cf21", "cf22"), free=TRUE,
values=0.5, newlabels=c("c11", "c21", "c22"))
eqsex <-omxSetParameters( eqsex, label=c("em11", "em21", "em22"), free=TRUE,
values=0.3, newlabels=c("e11", "e21", "e22") )
eqsex <-omxSetParameters( eqsex, label=c("ef11", "ef21", "ef22"), free=TRUE,
values=0.3, newlabels=c("e11", "e21", "e22") )
eqsexfit<-mxTryHardOrdinal(eqsex, intervals = F)
tableFitStatistics(QualAceFit, eqsexfit)
## NO sex
nosex <- omxSetParameters(eqsex, labels="ra11", free=FALSE, values=0.5,
name="No sex Effects" )
#nosex <- omxSetParameters(eqsex, labels="meanf", free=T, values=0,
newlabels="meanm", name="No sex Effects" )
nosexfit<- mxTryHardOrdinal(nosex, intervals = F)
nested <-list(eqthresfit,eqsexfit, nosexfit)
tableFitStatistics(QualAceFit, nested)
parameterSpecifications(nosexfit)

# Check BivBinACEFIT is equal to nosex model
testmodel<-omxSetParameters(BivBinAceFit6, labels=c("var1M_th1", "var1F_th1"), free
=T, values = 0.3, newlabels="var1_th", name="Testing Model")

268

testmodel<-omxSetParameters(testmodel, labels=c("var2M_th1", "var2F_th1"), free =T,
values = 0.2, newlabels="var2_th")
testfit<-mxTryHardOrdinal(testmodel, intervals=F)
tableFitStatistics(nosexfit, testfit)
# Test of covA
BivBinAceModel8 <- BivBinAceFit6
BivBinAceModel8<- omxSetParameters(BivBinAceModel8, labels=c( "a21"),
free=FALSE, values=0 , name = "Test of CovA")
BivBinAceFit8<- mxTryHardOrdinal(BivBinAceModel8, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit8)
#BivBinAceFit8a <- omxRunCI(BivBinAceFit8)
#summary(BivBinAceFit8, verbose=F)
#BivBinAceFit8$algebras
# Test of covC
BivBinAceModel9 <- BivBinAceFit6
BivBinAceModel9<- omxSetParameters(BivBinAceModel9, labels=c( "c21"),
free=FALSE, values=0, name = "Test of CovC" )
BivBinAceFit9<- mxTryHardOrdinal(BivBinAceModel9, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit9)
# Test of covE
BivBinAceModel10 <- BivBinAceFit6
BivBinAceModel10<- omxSetParameters(BivBinAceModel10, labels=c("e21"),
free=FALSE, values=0, name="Test of CovE" )
BivBinAceFit10<- mxTryHardOrdinal(BivBinAceModel10, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit10)
# Test of rP
BivBinAceModel11 <- BivBinAceFit6
BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="a21",
free=FALSE, values=0, name = "Test of rP" )
BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="c21",
free=FALSE, values=0 )
#BivBinAceModel11<- omxSetParameters(BivBinAceModel11, labels="e21",
free=FALSE, values=0 )
BivBinAceFit11<- mxTryHardOrdinal(BivBinAceModel11, intervals = F)
tableFitStatistics(BivBinAceFit6, c(BivBinAceFit8, BivBinAceFit9, BivBinAceFit10,
BivBinAceFit11))
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# Test of CE model
BivBinAceModel12 <- BivBinAceFit6
BivBinAceModel12<- omxSetParameters(BivBinAceModel12, labels=c( "a11","a21",
"a22"), free=FALSE, values=0, name = "CE model" )
BivBinAceFit12<- mxTryHardOrdinal(BivBinAceModel12, intervals = F)
summary(BivBinAceFit12, verbose=T)
tableFitStatistics(BivBinAceFit6, BivBinAceFit12)
# Test of AE Model
BivBinAceModel13 <- BivBinAceFit6
BivBinAceModel13<- omxSetParameters(BivBinAceModel13, labels=c( "c11","c21",
"c22"), free=FALSE, values=0, name = "AE model" )
BivBinAceFit13<- mxTryHardOrdinal(BivBinAceModel13, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit13)
# Test of E Model
BivBinAceModel16 <- BivBinAceFit6
BivBinAceModel16<- omxSetParameters(BivBinAceModel16,
labels=c("a11","a21","a22", "c11","c21", "c22"), free=FALSE, values=0, name = "E
model" )
BivBinAceFit16<- mxTryHardOrdinal(BivBinAceModel16, intervals = F)
tableFitStatistics(BivBinAceFit6, BivBinAceFit16)
bivnested <-list(BivBinAceFit12, BivBinAceFit13,BivBinAceFit16)
tableFitStatistics(BivBinAceFit6, bivnested)

# Test of E crosspaths Model
BivBinAceModel17 <- BivBinAceFit6
BivBinAceModel17<- omxSetParameters(BivBinAceModel17, labels=c("a21","c21"),
free=FALSE, values=0, name = "E model" )
BivBinAceFit17<- mxTryHardOrdinal(BivBinAceModel17, intervals = T)
summary(BivBinAceFit17, verbose=T)
tableFitStatistics(BivBinAceFit6, BivBinAceFit17)
BivBinAceModel18 <- BivBinAceFit17
BivBinAceFit18<- mxTryHardOrdinal(BivBinAceModel18, intervals = T)
summary(BivBinAceFit18, verbose=T)
BivBinAceModel19 <- BivBinAceFit18
BivBinAceFit19<- mxTryHardOrdinal(BivBinAceModel19, intervals = T)
summary(BivBinAceFit19, verbose=T)
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# Using CE model, testing of C21
BivBinAceModel14 <- BivBinAceModel12
BivBinAceModel14<- omxSetParameters(BivBinAceModel14, labels=c( "c21"),
free=FALSE, values=0, name = "CE model No C21" )
BivBinAceFit14<- mxTryHardOrdinal(BivBinAceModel14, intervals = F)
tableFitStatistics(BivBinAceFit12, BivBinAceFit14)
# Using CE model, testing of E21
BivBinAceModel15 <- BivBinAceModel14
BivBinAceModel15<- omxSetParameters(BivBinAceModel15, labels=c( "e21"),
free=FALSE, values=0, name = "CE model No Cross Paths" )
BivBinAceFit15<- mxTryHardOrdinal(BivBinAceModel15, intervals = F)
tableFitStatistics(BivBinAceFit14, BivBinAceFit15)
tableFitStatistics(BivBinAceFit12, BivBinAceFit15)
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## ANALYSIS FOR CHAPTER 4
## Title: Genes for Good phenotypic data cleaning and analysis
## Author: James Clifford (cliffordjs@vcu.edu)
require(car)
require(polycor)
require(gmodels)
setwd("~/Desktop/G4G_Data")
getwd()
samp <- read.table("masked-id-pass-samples.txt", header = F)
samp[,1] <- as.character(samp[,1])
dim(samp)
## Read in the main outcome data
## Tobacco use
tobdata<-read.csv("~/Desktop/G4G_Data/G4G_tobacco.csv", header=T, na.strings = "")
dim(tobdata)
names(tobdata)
tobdata<-subset(tobdata, user_id %in% samp[,1])
dim(tobdata)
table(tobdata[,9], useNA = 'always')
table(tobdata[,22], useNA = 'always')
newtobdat<-subset(tobdata, user_id %in% samp[,1])
dim(newtobdat)
table(newtobdat[,6])
table(newtobdat[,22])
table(newtobdat[,6], newtobdat[,22])
ans<-polychor(newtobdat[,6], newtobdat[,22])
pchisq(ans$chisq, ans$df, lower.tail=T)
## Get the EC data into a format with just ID and EC ever use
ecdata <-tobdata[,c(1,22)]
names(ecdata)
## Add in column for family id (user ID) as this column is required for PLINK
ecdata2<-cbind(famid=ecdata$user_id, ecdata)
head(ecdata2)
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## Recode from string variables into numeric
## 1 = No, 2 = Yes. This is consistent with PLINK pheno file notation
ecdata2$e_cigs<-recode(ecdata2$e_cigs, "'No' = 1; 'Yes'= 2")
head(ecdata2)
table(ecdata2[,3])
## Write EC phenotype file to space delimited text
#write.table(ecdata2, file = "G4G_ecuse.txt", sep = " ", col.names=F, row.names=F,
quote=F)
## Repeating previous steps but with CC ever use
ccdata <-tobdata[,c(1,6)]
head(ccdata)
## Add in column for family id (user ID) as this column is required for PLINK
ccdata2<-cbind(famid=ccdata$user_id, ccdata)
head(ccdata2)
## Recode from string variables into numeric
## 1 = No, 2 = Yes. This is consistent with PLINK pheno file notation
ccdata2$ever_tried_cig<-recode(ccdata2$ever_tried_cig, "'No' = 1; 'Yes'= 2")
head(ccdata2)
table(ccdata2[,3])
## Write CC phenotype file to space delimited text
#write.table(ccdata2, file = "G4G_ccuse2.txt", sep = " ", col.names=F, row.names=F,
quote = F)
## Create new R object for phenotypic analyses
phenodat<-tobdata[,c(1,6,22,28,29,30)]
names(phenodat)
# Recode tobacco varaibles
phenodat$ever_tried_cig<-recode(phenodat$ever_tried_cig, "'No' = 1; 'Yes'= 2")
phenodat$e_cigs<-recode(phenodat$e_cigs, "'No' = 1; 'Yes'= 2")
table(phenodat[,2])
table(phenodat[,3])
## Parents smoke
table(phenodat[,4])
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phenodat$parents_smoke<-recode(phenodat$parents_smoke, "'Neither
smokes/smoked'=1; 'Yes, both'=2;'Yes, one of them' =2")
table(phenodat[,4])
## Friends smoke
table(phenodat[,5])
phenodat$friends_smoke<-recode(phenodat$friends_smoke, "'None of them smoke'=1;
'Yes, a few' = 2; 'Yes, most of them'=2")
table(phenodat[,5])
## Friends smoke under 18
table(phenodat[,6])
phenodat$friends_smoke_under_18<-recode(phenodat$friends_smoke_under_18,
"'None of them smoked'=1; 'Yes, a few' = 2; 'Yes, most of them'=2")
table(phenodat[,6])

## Read in the demographic data, note there are two separate demo files
demodata<-read.csv("~/Desktop/G4G_Data/G4G_demos_a.csv", header=T, na.strings
= "")
dim(demodata)
names(demodata)
demodatasmall<-demodata[,c(1,3,4,28,38,39,41)]
dim(demodatasmall)
names(demodatasmall)
# recode Health insurance, 1= Yes, 2 = No, 3 = I don't know
demodatasmall$insure_r <-recode (demodatasmall[,7], "'I do not know' = 3; 'No'=2;
'Yes'=1")
table(demodatasmall$insure_r )
# recode gender, male = 1, female =2
demodatasmall$gender_r <-recode(demodatasmall[,2], "'female'=2; 'male'=1")
table(demodatasmall$gender_r)
# Recode education
demodatasmall$education_r<-recode(demodatasmall[,5], "'No high school diploma or
GED'=1;'Some college but no degree'=2;'High school graduate or GED'=2;
'Associates degree'=3; 'Bachelors degree (such as BA, AB, BS,
or BBA)'=3;'Masters degree or higher (such as MA, MS, MBA, PhD, MD, and so on)'=4
")
table(demodatasmall$education_r)
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demodata2<-read.csv("~/Desktop/G4G_Data/G4G_demos2.csv", header=T, na.strings
= "")
dim(demodata2)
names(demodata2)
demodata2small<-demodata2[,c(1,3,4,19, 14,15,13)]
dim(demodata2small)
names(demodata2small)
# recode Health insurance, 1= Yes, 2 = No, 3 = I don't know
demodata2small$insure_r <-recode (demodata2small[,7], "'I do not know' = 3; 'No'=2;
'Yes'=1")
table(demodata2small$insure_r )
# recode gender, male = 1, female =2
demodata2small$gender_r <-recode(demodata2small[,2], "'female'=2; 'male'=1")
table(demodata2small$gender_r)
# Recode education, < HS, some college, college degree, master or higher
demodata2small$education_r<-recode(demodata2small[,5], "'No high school diploma or
GED'=1;'Some college but no degree'=2;'High school graduate or GED'=2;
'Associate degree'=3; 'Bachelor degree (like a BA, AB, BS, or
BBA)'=3;'Master degree or higher (such as MA, MS, MBA, PhD, MD, and so on)'=4
")
table(demodata2small$education_r)

totaldemo<-rbind(demodatasmall, demodata2small)
dim(totaldemo)
names(totaldemo)
## recode age range
totaldemo$age_range_r<-recode(totaldemo[,3], "'18-21' =1; '21-30'=2;'30-40'=3;'4050'=4;
'50-60'=5;'60-70'=6; '70+'=7")
table(totaldemo[,11])
### Filter out individuals without Genetic data
demofilt<-subset(totaldemo, user_id %in% samp[,1])
dim(demofilt)
# Remove phenotypic duplicates
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finaldemo<-subset(demofilt, !duplicated(demofilt[,1]))
table(finaldemo[,2], useNA = 'always')
dim(finaldemo)
# filter pheno data to Whte only data
racedemo<-totaldemo[totaldemo$race == "White" | totaldemo$race=="White or
European",]
dim(racedemo)
whiteIDs<-(racedemo[,1])
head(whiteIDs)
whiteIDs<-as.data.frame(whiteIDs)
head(whiteIDs)
whitepheno<-subset(finaldemo, user_id %in% whiteIDs[,1])
dim(whitepheno)
# 15,927 individuals
# Find out dual users in Whites
whitetob<-subset(phenodat, user_id %in% whiteIDs[,1])
table(whitetob$e_cigs, whitetob$ever_tried_cig)
# 1008 never users
# 45 ECIG exclusive
# 4706 dual users
# 10082 CIG exclusive
# Find genotyped participants' tobacco use
tobuse<-subset(phenodat, user_id %in%finaldemo[,1])
dim(tobuse)
names(tobuse)
table(tobuse$e_cigs, tobuse$ever_tried_cig)
## Add in PCs
setwd("/Users/jamesclifford/Desktop/G4G/PCA")
pca<-read.table("plink_pca_test_white.eigenvec")
# remove extra column
pca <-pca[,-1]
# set names
names(pca)[1] <- "IID"
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names(pca)[2:ncol(pca)] <- paste0("PC", 1:(ncol(pca)-1))
head(pca)
dim(pca)
names(pca)
## remove individuals who aren't present
finalgen<-subset(pca, IID %in% finaldemo[,1])
dim(finalgen)
# 15881
## Take only first 7 PCs
finalgen<-finalgen[,c(1:8)]
names(finalgen)
# Combine PCs with phenotypic data
names(whitepheno)[1]<-"IID"
whitefinal<-merge(whitepheno, finalgen, by ="IID")
dim(whitefinal)
# 15,881 individuals
names(whitefinal)
## Write Covariate file with only white participants
# write.table(finalcovars, "G4G_white_covars.txt", quote=F, row.names=F,
col.names=F)
# test<-read.table("G4G_white_covars.txt")
# head(test)
## Write covariate file with ECIG use
names(whitetob)[1] <- "IID"
ecigtest<-whitetob[,c(1,3)]
whiteecigfinal<-merge(whitefinal, ecigtest, by = "IID")
dim(whiteecigfinal)
names(whiteecigfinal)
# 15798
whiteecigfinal<-whiteecigfinal[,c(1,1,8:19)]
# write.table(whiteecigfinal, "G4G_white_ECIG_covars.txt", quote=F, row.names=F,
col.names=F)
# test2<-read.table("G4G_white_ECIG_covars.txt")
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# head(test2)
## Write covar file with CIG use
cigtest<-whitetob[,c(1,2)]
whitecigfinal<-merge(whitefinal, cigtest, by = "IID")
dim(whitecigfinal)
names(whitecigfinal)
# 15798
whitecigfinal<-whitecigfinal[,c(1,1,8:19)]
# write.table(whitecigfinal, "G4G_white_CIG_covars.txt", quote=F, row.names=F,
col.names=F)
# test3<-read.table("G4G_white_CIG_covars.txt")
# head(test3)
## Add in ECIG and CIG data
tobdata2<-merge(ecdata2, ccdata2, by = "user_id")
dim(tobdata2)
# 20105
names(tobdata2)
tobdata2<-subset(tobdata2, select = c("user_id", "e_cigs", "ever_tried_cig"))
head(tobdata2)
tobdata3<-subset(tobdata2, user_id %in%whitefinal[,1])
dim(tobdata3)
#15798
names(tobdata3)[1]<-"IID"
## Merge phenotypic/PC data with tobacco data
finaldata<-merge(tobdata3, whitefinal, by = "IID")
dim(finaldata)
# 15798
names(finaldata)
### Create Table 1
require(table1)
finaldata$age_range_r <- factor(finaldata$age_range_r, levels = 1:7,
labels=c("18-21", "22-30", "31-40", "41-50", "51-60",
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"61-70", "70+"))
finaldata$education_r <-factor(finaldata$education_r, levels=1:4, labels=c("Less than
HS",
"HS Grad/GED/Some College",
"Associates Degree", "College Graduate or More"))
finaldata$insure_r <-factor(finaldata$insure_r, levels=1:3, labels=c("Covered", "Not
Covered", "I Dont Know"))
finaldata$gender_r
"Female"))

<-factor(finaldata$gender_r, levels = 1:2, labels=c("Male",

finaldata$ever_tried_cig<-factor(finaldata$ever_tried_cig, levels = 1:2, labels=c("No",
"Yes"))
finaldata$e_cigs<-factor(finaldata$e_cigs, levels = 1:2, labels=c("No", "Yes"))
label(finaldata$age_range_r)
<- "Age Range"
label(finaldata$education_r)
<- "Education Level"
label(finaldata$insure_r)
<- "Insurance Status"
label(finaldata$gender_r)
<- "Sex"
table1(~ gender_r+age_range_r+ education_r+ insure_r|ever_tried_cig, data=finaldata,
overall=F)
table1(~ gender_r+age_range_r+ education_r+ insure_r|e_cigs, data=finaldata,
overall=F)
table(finaldata$e_cigs)
table(finaldata$ever_tried_cig)
## Bivariate
### CIG
CrossTable(finaldata$gender_r, finaldata$ever_tried_cig, chisq=T)
## p < 0.0001
CrossTable(finaldata$age_range_r, finaldata$ever_tried_cig,chisq=T)
## p < 0.0001
CrossTable(finaldata$education_r, finaldata$ever_tried_cig,chisq=T)
## p < 0.0001
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CrossTable(finaldata$insure_r, finaldata$ever_tried_cig,chisq=T)
## p < 0.0001
### ECIG
CrossTable(finaldata$gender_r, finaldata$e_cigs,chisq=T)
## p < 0.0001
CrossTable(finaldata$age_range_r, finaldata$e_cigs, chisq=T)
## p < 0.0001
CrossTable(finaldata$education_r, finaldata$e_cigs, chisq=T)
## p < 0.0001
CrossTable(finaldata$insure_r, finaldata$e_cigs, chisq=T)
## p < 0.0001
### CIG x ECIG
finaldata$ever_tried_cig<-factor(finaldata$ever_tried_cig, levels = 1:2, labels=c("No",
"Yes"))
finaldata$e_cigs<-factor(finaldata$e_cigs, levels = 1:2, labels=c("No", "Yes"))
CrossTable(finaldata$e_cigs, finaldata$ever_tried_cig, chisq=T)
(4694*1005)/(45*100052)
## Crude OR = 1.048; those who smoke cigarettes are ~4% more likely to use ECIGs
than
## non-smokers
## create genotype or not and rerun bivaraite with that
totaldemo$geno<-ifelse(totaldemo$user_id %in% samp[,1], 2, 1)
# Remove phenotypic duplicates
totaldemo<-subset(totaldemo, !duplicated(totaldemo[,1]))
#table(totaldemo[,2], useNA = 'always')
dim(totaldemo)
table(totaldemo$geno)
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## Label for easy readin'
totaldemo$age_range_r <- factor(totaldemo$age_range_r, levels = 1:7,
labels=c("18-21", "22-30", "31-40", "41-50", "51-60",
"61-70", "70+"))
totaldemo$education_r <-factor(totaldemo$education_r, levels=1:4, labels=c("Less than
HS",
"HS Grad/GED/Some College",
"Associates Degree", "College Graduate or More"))
totaldemo$insure_r <-factor(totaldemo$insure_r, levels=1:3, labels=c("Covered", "Not
Covered", "I Dont Know"))
totaldemo$gender_r
"Female"))
totaldemo$geno
"Genotyped"))

<-factor(totaldemo$gender_r, levels = 1:2, labels=c("Male",
<-factor(totaldemo$geno, levels=1:2, labels = c("Not Genotyped",

CrossTable(totaldemo$gender_r, totaldemo$geno, chisq=T)
## p < 0.0001
CrossTable( totaldemo$age_range_r,totaldemo$geno, chisq=T)
## p < 0.0001
CrossTable(totaldemo$education_r, totaldemo$geno, chisq=T)
## p < 0.0001
CrossTable(totaldemo$insure_r,totaldemo$geno, chisq=T)
## p < 0.0001
tobdata_geno<-read.csv("~/Desktop/G4G_Data/G4G_tobacco.csv", header=T,
na.strings = "")
## Get the EC data into a format with just ID and EC ever use
genoecdata <-tobdata_geno[,c(1,22)]
names(genoecdata)
## Recode from string variables into numeric
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## 1 = No, 2 = Yes. This is consistent with PLINK pheno file notation
genoecdata$e_cigs<-recode(genoecdata$e_cigs, "'No' = 1; 'Yes'= 2")
head(genoecdata)
table(genoecdata[,2])
## Repeating previous steps but with CC ever use
genoccdata <-tobdata_geno[,c(1,6)]
head(genoccdata)
## Recode from string variables into numeric
## 1 = No, 2 = Yes. This is consistent with PLINK pheno file notation
genoccdata$ever_tried_cig<-recode(genoccdata$ever_tried_cig, "'No' = 1; 'Yes'= 2")
head(genoccdata)
table(genoccdata[,2])
newtobgen<-merge(genoccdata, genoecdata, by = "user_id")
dim(newtobgen)
genodat<-merge(newtobgen, totaldemo, by = "user_id")
dim(genodat)
# 55,104
genodat$ever_tried_cig<-factor(genodat$ever_tried_cig, levels = 1:2, labels=c("No",
"Yes"))
genodat$e_cigs<-factor(genodat$e_cigs, levels = 1:2, labels=c("No", "Yes"))
CrossTable(genodat$e_cigs,genodat$geno, chisq=T)
CrossTable( genodat$ever_tried_cig,genodat$geno, chisq=T)

## Overlap of ECIG and CIG use
names(genodat)
dim(genodat)
table(genodat$ever_tried_cig, genodat$e_cigs)
CrossTable(genodat$ever_tried_cig, genodat$e_cigs, chisq=T)

### COMMAND LINE CODES AND BASH SCRIPTS
## Plink QC for Genes for Good (G4G)
## Using 1000 Genomes (1KG) as reference panel
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## Note that though this is written in R, there are very few R commands
## Author: James Clifford (cliffordjs@vcu.edu) with special thanks/acknowledgments
## to Dr Roseann Peterson
## Remove duplicate SNPs
/vcu_gpfs2/home/cliffordjs/bin/./plink --bfile
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged --list-duplicate-vars --suppress-first
--make-bed --out /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged_pruned
## Merge reference and data
/vcu_gpfs2/home/cliffordjs/bin/./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg -bmerge /vcu_gpfs2/home/cliffordjs/g4g_geno --allow-no-sex --geno 0.05 --make-bed -out /vcu_gpfs2/home/GfG/refgenome/1kg_merged
## 2504 individuals in 1KG
## 20231 in G4G
## 1.28.21 this is throwing several errors: multiple variants for rs #, multiple
chromosomes for variant,
## variant '.'?
## variants with multiple positions: rs9442277, rs571228985
## rs6658405
## SNPs with multiple chromosomes: rs2789523, rs554199249, .
# Tried flipping on .missnp file, no good
## How many SNPs overlap 1KG and G4G
## Genotyping rate
/vcu_gpfs2/home/cliffordjs/bin/./plink --bfile
/vcu_gpfs2/home/GfG/refgenome/1kg_merged
-- freq --out merge_genoRate
## Total genotyping rate is
# Light QC on overlapping SNPs
# limit 1KG to overlapping SNPs
/vcu_gpfs2/home/cliffordjs/bin/./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg
--extract /vcu_gpfs2/home/GfG/refgenome/1kg_merged --allow-no-sex --make-bed --out
/vcu_gpfs2/home/GfG/refgenome/1kg_g4gsnps
# Light QC --mind 0.05 --geno 0.5 --maf 0.01 --hwe 0.0000000005 (5xe-10)
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/vcu_gpfs2/home/cliffordjs/bin/./plink --bfile
/vcu_gpfs2/home/GfG/refgenome/1kg_g4gsnps
--mind 0.05 --geno 0.05 --maf 0.01 --hwe 0.0000000005 --allow-no-sex --make-bed
--out /vcu_gpfs2/home/GfG/refgenome/1kg_g4gsnps_qc
## PCA
setwd("/vcu_gpfs2/home/cliffordjs")
data1<-read.table("chr22_illumina.txt")
data2<-read.table("chr22_g4g.txt")
test<-merge(data1, data2)
head(test)
dim(test)
# 5130 SNPs
data1<-read.table("chr21_illumina.txt")
#4407 SNPs
data2<-read.table("chr21_g4g.txt")
# 7027 SNPs
test<-merge(data1, data2)
head(test)
dim(test)
# 4345 SNPs
data1<-read.table("illumina_snp_ids.txt")
# 547667
data2<-read.table("G4G_snpids2.txt")
# 313085
test<-merge(data1, data2)
head(test)
dim(test)
# 308,985 SNPs
## Looking at G4G and 1KG
require(data.table)
require(dplyr)
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data1<-fread("1kg_snpids.txt", header=F)
#data1<-as.data.frame(data1)
# 84,358,431
#data2<-read.table("G4G_snpids2.txt")
data2<-fread("G4G_snpids2.txt", header=F)
# 313085 SNPs
test<-inner_join(data1, data2)
head(test)
dim(test)
# 312,304 SNPs
## Create list of new snp ids for 1 kg
# awk '{print $2,$1":"$4":"$6":"$5}' 1kg.bim >> 1kg_ids2.txt
# Remove Duplicates
#
# --allow-extra-chr
# --bfile /vcu_gpfs2/home/GfG/refgenome/1kg
# --exclude /vcu_gpfs2/home/GfG/refgenome/1kg_dups_id.txt
# --make-bed
# --out /vcu_gpfs2/home/GfG/refgenome/1kg_dupsremoved
# update SNP namesta
# --allow-extra-chr
# --bfile /vcu_gpfs2/home/GfG/refgenome/1kg_dupsremoved
# --make-bed
# --out 1kg_updated_ids
# --update-name /vcu_gpfs2/home/GfG/refgenome/1kg_ids.txt
# Run in plink
#./plink --bfile /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged3 --extract
# /vcu_gpfs2/home/cliffordjs/overlapping_gfg_1kg.txt --make-bed --out
1KG_G4G_merge
# --allow-no-sex
# Genotyping rate
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# ./plink --bfile /vcu_gpfs2/home/GfG/cleangenetic/Filtered/1KG_G4G_merge --freq -out
# /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merge_genoRate

# Limit 1KG to overlapping SNPs
# ./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg_update_ids \
# --extract /vcu_gpfs2/home/GfG/cleangenetic/Filtered/1KG_G4G_merge.bim --allowno-sex --make-bed
# --out /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps --allow-extra-chr
# 229,934 variants and 2504 people pass filters and QC.
# Light QC --mind 0.05 --geno 0.05 --maf 0.01 --hwe 0.0000000005 (5.0xe-10)
# ./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps --mind 0.05 --geno 0.05
--maf 0.01 --hwe 0.0000000005
# --keep-allele-order --chr 1-22 \
# --allow-no-sex --make-bed --out /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps_qc
# 27,618 removed due to HWE
# 3,978 removed due to MAF
# 198,338 variants and 2504 people pass filters and QC.
# Prune SNps
# ./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps_qc
# --indep-pairwise 1500 150 0.2 --allow-no-sex --keep-allele-order
# --out /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps_qc_prune02
# after pruning: 118,224 of 198,338 variants removed
### Quick check G4G quality overlap SNPs
# Light QC --mind 0.05 --geno 0.05 --maf 0.01 --hwe 0.0000000005 (5.0xe-10)
# ./plink --bfile /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged3 --extract
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/1KG_G4G_merge.bim --mind 0.05 --geno
0.05 --maf 0.01 --hwe 0.0000000005 --keep-allele-order --chr 1-22 \
# --allow-no-sex --make-bed --out
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/G4G_1kgSNPs_qc
# 0 removed to missing genotype data
# 0 removed due to HWE
# 8 removed due to MAF
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# 229,924 variants and 20231 people pass filters and QC
## Create 1KGP-G4G bed file on pruned 0.2
#./plink --bfile /vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps --extract
/vcu_gpfs2/home/GfG/refgenome/1kg_G4Gsnps_qc_prune02.prune.in
# --allow-no-sex --keep-allele-order --make-bed --out
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/G4G_1kgSNPs_qc_pruned
# 80,114 variants and 2504 people pass filters and QC.
### Create Pedind file
setwd('/Users/jamesclifford/Desktop/G4G/PCA/')
# add row number to make sure order has not changed
#awk '{print $0 "\t" NR}' G4G_1kgSNPs_qc_pruned_newids.fam >
G4G_1kgSNPs_qc_pruned_fam_NR.txt
#scp
cliffordjs@fenn.vcu.edu:/vcu_gpfs2/home/GfG/refgenome/G4G_1kgSNPs_qc_pruned_f
am_NR.txt /Users/jamesclifford/Desktop/G4G/PCA
fam<-read.table('/Users/jamesclifford/Desktop/G4G/PCA/Old
files/G4G_1kgSNPs_qc_pruned_fam_NR.txt', header=F)
colnames(fam)<-c("FID", "IID", "V3" ,"V4" ,"V5" ,"V6" ,"Index")
head(fam)
dim(fam)
# Add G4G IDs
#awk '{print $1 "\t" $2 "\t" "G4G"}' G4G_1kgSNPs_qc.fam > G4G_ID.txt
#scp cliffordjs@fenn.vcu.edu:/vcu_gpfs2/home/GfG/cleangenetic/Filtered/G4G_ID.txt
/Users/jamesclifford/Desktop/G4G/PCA
g4g<-read.table('/Users/jamesclifford/Desktop/G4G/PCA/Old files/G4G_ID.txt', header =
F)
colnames(g4g)<-c("FID", "IID", "pop")
head(g4g)
dim(g4g)
# 1KGP IDs
kgp<-read.table('/Users/jamesclifford/Desktop/G4G/PCA/Old files/1KGP_pop.txt',
header = T)
colnames(kgp)
#"IID" "fam" "pop"
kgpID<-subset(kgp, select=c(fam, IID, pop))
colnames(kgpID)<-c("FID","IID", "pop")
# merge here to remove extra samples from 1kgp_pop.txt
table(kgpID$pop)
# 3500 ppl
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dim(fam)
require(dplyr)
test<-inner_join(fam, kgpID, by =c("IID", "FID"))
dim(test)
# returns 824 people, should be 2504
test<-merge(fam, kgpID, by=c("IID", "FID"),all.x=T, no.dups = T)
dim(test)
table(test$pop, useNA="always")
#1680 NAs?
testIDS<-subset(test, select=c(FID, IID, pop))
dim(testIDS)
## new ID file from website
## https://github.com/WeiYang-BAI/Impu-Reference-PanelReconstruction/blob/master/1000GP_Phase3.sample
kgp2<-read.table('1kg_pops.txt', header=T)
dim(kgp2)
names(kgp2)
kgp2IDS<-subset(kgp2, select=c("ID", "ID", "POP"))
colnames(kgp2IDS)<-c("FID","IID", "pop")
dim(kgp2IDS)
names(kgp2IDS)
table(kgp2IDS$pop)
test<-merge(fam, kgp2IDS, by=c("IID", "FID"),all.x=T, no.dups = T)
dim(test)
head(test)
table(test$pop, useNA="always")
testIDS<-subset(test, select=c(FID, IID, pop))
dim(testIDS)
table(testIDS$pop, useNA = 'always')
# Merge 1KGP pop data
pops<-rbind(testIDS,g4g)
dim(pops)
names(pops)
table(pops$pop, useNA = 'always')
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# Do a merge and keep all x
#fam_pops<-merge(fam, pops, all.x=T, by=c("IID"))
fam_pops<-merge(fam, pops, all.y=T, by=c("IID"))
table(fam_pops$pop)
table(is.na(fam_pops$pop))
colnames(fam_pops)
pedindI<-subset(fam_pops, select=c(FID.y, IID, V3, V4, V5, pop, Index))
#write.table(pedindI,
file="/Users/jamesclifford/Desktop/G4G/PCA/1KGP_G4G_pop_index.txt", row.names =
T, col.names = T, quote=F)
# Confirmed Index
pedind<-subset(fam_pops, select=c(FID.y, IID, V3, V4, V5, pop))
#write.table(pedind,
file="/Users/jamesclifford/Desktop/G4G/PCA/1KGP_G4G_qc_pruned.pedind",
row.names = F, col.names = F, quote=F)
## GWAS
CIG
PLINK v1.90b6.18 64-bit (16 Jun 2020)
Options in effect:
--allow-no-sex
--bfile /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged3
--covar /vcu_gpfs2/home/cliffordjs/G4G_white_ECIG_covars.txt
--keep /vcu_gpfs2/home/cliffordjs/G4G_white_ids.txt
--logistic hide-covar
--out
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/Adjust_Assoc/ECIG_adjusted_hidecovar_
White_CC_phenocovars_pc
s
--pheno /vcu_gpfs2/home/GfG/cleanphenotypic/G4G_ccuse2.txt
ECIG
PLINK v1.90b6.18 64-bit (16 Jun 2020)
Options in effect:
--allow-no-sex
--bfile /vcu_gpfs2/home/GfG/cleangenetic/Filtered/merged3
--covar /vcu_gpfs2/home/cliffordjs/G4G_white_CIG_covars.txt
--keep /vcu_gpfs2/home/cliffordjs/G4G_white_ids.txt
--logistic hide-covar
--out
/vcu_gpfs2/home/GfG/cleangenetic/Filtered/Adjust_Assoc/CIG_adjusted_hidecovar_Wh
ite_ECIG_phenocovars_p
cs

289

--pheno /vcu_gpfs2/home/GfG/cleanphenotypic/G4G_ecuse.txt

## Manhattan
require(data.table)
require(qqman)
setwd("/vcu_gpfs2/home/GfG/cleangenetic/Filtered/Adjust_Assoc/")
ccdatadj<fread("ECIG_adjusted_hidecovar_White_CC_phenocovars_pcs.assoc.logistic", header
= T)
head(ccdatadj)
tiff("cc_adj_forECIG_withwhitepcs.tiff")
manhattan(ccdatadj, chr = "CHR", bp = "BP", snp = "SNP", p = "P", main = "Manhat
tan Plot for CIG-Adjusted Analyses, White Only PCs",ylim=c(0,11),
col = c("red", "blue4"), suggestiveline=-log10(1e-05), genomewideline
= -log10(1e-08), annotatePval = -log10(1e-07),
chrlabs = c(1:22))
dev.off()
# Manhattan plot without annotation
tiff("cc_noannotation_adj_forECIG_withwhitepcs_3302022.tiff")
manhattan(ccdatadj, chr = "CHR", bp = "BP", snp = "SNP", p = "P", main =
"",ylim=c(0,11),
col = c("red", "blue4"), suggestiveline=-log10(1e-05), genomewideline
= -log10(1e-08), annotateTop=F,
chrlabs = c(1:22))
dev.off()
## Find Suggestive/Significant Variants
ccSNPS<-subset(ccdatadj, P <= 1e-6)
ccSNPS
# CHR
SNP
BP A1 TEST NMISS OR STAT
P
# 10 10:122876485 122876485 A ADD 15796 1.771 5.005 5.574e-07 Gene:
FAM24B-CUZD1
# 18 18:61024122 61024122 T ADD 15796 1.234 5.158 2.500e-07 Intergenic:
HMGN1P31, CDH20
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# ECIG Adjusted results
# 2 2:84368347 84368347 T ADD 15795 0.8810 -4.910 9.114e-07 #SUCLG1
# 11 11:42405437 42405437 A ADD 15795 0.6264 -4.955 7.243e-07 # LINC02740
# 18 18:61024122 61024122 T ADD 15795 1.2370 5.142 2.715e-07 Intergenic:
HMGN1P31, CDH20
ecdatadj<fread("CIG_adjusted_hidecovar_White_ECIG_phenocovars_pcs.assoc.logistic", header
= T)
head(ecdatadj)
tiff("ec_adj_forCIG_withwhitepcs.tiff")
manhattan(ecdatadj, chr = "CHR", bp = "BP", snp = "SNP", p = "P", main = "Manhat
tan Plot for ECIG-Adjusted Analyses", ylim = c(0,11),
col = c("red", "blue4"), suggestiveline=-log10(1e-05), genomewideline
= -log10(1e-08), annotatePval = -log10(1e-08),
chrlabs = c(1:22))
dev.off()
## No annotation manhattan
tiff("ec_noannotation_adj_forCIG_withwhitepcs3302022.tiff")
manhattan(ecdatadj, chr = "CHR", bp = "BP", snp = "SNP", p = "P", main = "", ylim =
c(0,11),
col = c("red", "blue4"), suggestiveline=-log10(1e-05), genomewideline
= -log10(1e-08), annotateTop= F,
chrlabs = c(1:22))
dev.off()

## Find Suggestive/Significant Variants
ecSNPs<-subset(ecdatadj, P <= 1e-6)
ecSNPs
dim(ecSNPs)
# CHR
SNP
BP A1 TEST NMISS OR STAT
P
# 2 2:216131813 216131813 A ADD 15795 0.6215 -4.929 8.276e-07 Gene: XRCC5
# 2 2:216131851 216131851 G ADD 15795 0.6172 -5.038 4.706e-07 Gene: XRCC5
# 2 2:216132049 216132049 A ADD 15795 0.6195 -4.942 7.736e-07 Gene: XRCC5
# 2 2:216133672 216133672 C ADD 15795 0.6237 -4.899 9.657e-07 Gene: XRCC5
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# 6 6:33902823 33902823 T ADD 15795 0.7852 -5.224 1.752e-07 Gene:
LOC105375026
# 8 8:25281329 25281329 G ADD 15795 0.6349 -4.995 5.895e-07 Gene: DOCK5
# 13 13:32403784 32403784 T ADD 15795 0.6188 -5.379 7.494e-07 Gene:N4BP2L1
# 13 13:47437096 47437096 C ADD 15795 0.5112 -4.918 8.761e-07 Intergenic:
GNGSP5, RN7SL700P
# CIG ADJUSTED
# CHR
SNP
BP A1 TEST NMISS OR STAT
P
# 2 2:115364757 115364757 C ADD 15795 1.2840 5.019 5.192e-07 Gene: DPP10
# 6 6:33902823 33902823 T ADD 15795 0.7881 -5.079 3.801e-07 Gene:
LOC105375026
# 13 13:32403784 32403784 T ADD 15795 0.6207 -5.252 1.508e-07 Gene:N4BP2L1
# 15 15:49010393 49010393 T ADD 15795 0.4387 -4.935 8.009e-07 Gene:
SECISBP2L
## PCA PLOTS
#scp cliffordjs@fenn.vcu.edu:/vcu_gpfs2/home/cliffordjs/bin/*white.eigenval .
#scp cliffordjs@fenn.vcu.edu:/vcu_gpfs2/home/cliffordjs/bin/*white.eigenvec .
setwd("/Users/jamesclifford/Desktop/G4G/PCA")
require(tidyverse)
pca <- read_table2("plink_pca_test_white.eigenvec", col_names = FALSE)
eigenval <- scan("plink_pca_test_white.eigenval")
# remove extra column
pca <-pca[,-1]
# set names
names(pca)[1] <- "ind"
names(pca)[2:ncol(pca)] <- paste0("PC", 1:(ncol(pca)-1))
pca <- as_tibble(data.frame(pca))
# first convert to percentage variance explained
pve <- data.frame(PC = 1:20, pve = eigenval/sum(eigenval)*100)
# make plot of variance explained
png("PLINK_var_exp_white_3Aug2021.tiff")
a <- ggplot(pve, aes(PC, pve)) + geom_bar(stat = "identity")
a + ylab("Percentage variance explained") + theme_light()
dev.off()
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pca2<-data.frame(pca)
dim(pca2)
firstten<-pca2[,1:11]
dim(firstten)
head(firstten)
# Examine PC1 vs PC2
png("PLINK_pca_white_3Aug21.tiff")
plot(firstten$PC1,firstten$PC2, main = "First 2 PCs with PLINK method, White Only",
xlab="First PC",
ylab = "Second PC")
dev.off()
require(scatterplot3d)
# Examine PC1, PC2, and PC3
png("PLINK_pca_3d_white_3Aug21.tiff")
scatterplot3d(firstten$PC1
, firstten$PC2, firstten$PC3, main = "3D Plot of First 3 PCs via PLINK, White
Only")
dev.off()

### PRS
### CREATE PRS
Rscript /vcu_gpfs2/home/cliffordjs/bin/PRSice.R \
--prsice /vcu_gpfs2/home/cliffordjs/bin/PRSice_linux \
--base /vcu_gpfs2/home/GfG/sumstats/noheaderfinalSIsumstats.txt \
--target /vcu_gpfs2/home/GfG/cleangentic/Filtered/SIA_White \
--binary-target T \
--pheno /vcu_gpfs2/home/GfG/cleanphenotypic/G4G_ecuse.txt \
--cov /vcu_gpfs2/home/GfG/cleanphenotypic/White_covars.txt \
--chr-id c:l \
--base-maf MAF:0.01 \
--stat BETA \
--beta \
setwd("~/Desktop/PRS-Reg")
require(data.table)
require(tidyverse)
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require(fmsb)
p.threshold <- c(0.001,0.05,0.1,0.2,0.3,0.4,0.5)
# Read in the phenotype file
phenotype <- fread("G4G_ecuse.txt", header=F)
ccuse<-fread("G4G_ccuse2.txt", header = F)
# Read in the covariates
covariate <- fread("White_G4G_covars_pcs.txt", header=F)
head(covariate)
# make column names for p and c
colnames(phenotype)<- c("IID", "FID", "EC")
covariate<-covariate[,c(1:6, 8:14)] # Remove the extra 3 PCs
head(covariate)
colnames(covariate)<- c("IID", "FID", "insure", "gender", "education", "age_range",
"PC1","PC2","PC3","PC4","PC5","PC6","PC7")
head(covariate)
colnames(ccuse)<- c("IID", "FID", "CC")
head(ccuse)
# Now merge the files
pheno <- merge(phenotype, covariate, by=c("IID", "FID"))
table(pheno$EC, useNA = 'always')
phenocc<-merge (pheno, ccuse, by =c("IID", "FID"))
phenonomiss<-na.omit(phenocc)
# Recode ECs to 1 and 0, no missing data
phenonomiss$EC <-ifelse(phenonomiss$EC == 1, 1, 0)
# Recode CCs to 1 and 0, no missing data
phenonomiss$CC <-ifelse(phenonomiss$CC == 1, 1, 0)
# We can then calculate the null model (model without PRS) using a logistic regression
prs <- fread("SI_CIG_PRScs.profile", header=T)
pheno.prs<-merge(phenonomiss, prs[,c("IID","FID", "SCORE")], by=c("IID", "FID"))
head(pheno.prs)
## Histogram of PRS Scores
#tiff("Unnormalized_GPS.tiff")
#hist(pheno.prs$SCORE, xlab= "GPS", main ="")
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#dev.off()
# Table of covars
table(pheno.prs$insure)
table(pheno.prs$gender)
table(pheno.prs$education)
table(pheno.prs$age_range)
table(pheno.prs$EC)
pheno.prs$EC<-factor(pheno.prs$EC, levels = c(0:1))
pheno.prs$CC<-factor(pheno.prs$CC, levels = c(0:1) )
table(pheno.prs$CC)
pheno.prs$gender<-factor(pheno.prs$gender, levels = c(1:2))
table(pheno.prs$gender)
pheno.prs$insure<-factor(pheno.prs$insure, levels =c(1:3))
table(pheno.prs$insure)
pheno.prs$education<-factor(pheno.prs$education, levels = c(1:4))
table(pheno.prs$education)
pheno.prs$age_range<-factor(pheno.prs$age_range, levels=c(1:7))
table(pheno.prs$age_range)
null.model <glm(EC~CC+insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC5+PC6+
PC7, family=binomial, data=pheno.prs)
# And the R2 of the null model is
null.r2 <- NagelkerkeR2(null.model)
model <glm(EC~SCORE+CC+insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC
5+PC6+PC7, family=binomial, data=pheno.prs)
# model R2 is obtained as
model.r2 <- NagelkerkeR2(model)
# R2 of PRS is simply calculated as the model R2 minus the null R2
prs.r2 <- model.r2$R2-null.r2$R2
# We can also obtain the coeffcient and p-value of association of PRS as follow
prs.coef <- summary(model)$coeff
prs.beta <- as.numeric(prs.coef[1])
prs.se <- as.numeric(prs.coef[2])
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prs.p <- as.numeric(prs.coef[4])
# We can then store the results
prs.result <- rbind(data.frame(R2=prs.r2, P=prs.p, BETA=prs.beta,SE=prs.se))
#write.file(prs.result, "/vcu_gpfs2/home/cliffordjs/PRS_out.txt", quote=F, row.names=F)
### AUC
predprob <- predict(model, type = "response")
library(pROC)
rocCurve <- roc(EC ~ predprob, data = pheno.prs)
tiff("roccurve3302022.tiff")
plot(rocCurve)
dev.off()
auc(rocCurve)
#write.file(rocCurve,"/vcu_gpfs2/home/cliffordjs/AUC_out.txt", quote=F, row.names=F)
## normalized GPS
pheno.prs$scaled<-scale(pheno.prs$SCORE)
## Histogram of PRS Scores
tiff("Normalized_GPS.tiff")
hist(pheno.prs$scaled, xlab= "GPS", main ="")
dev.off()
model2 <glm(EC~scaled+insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC5+PC
6+PC7, family=binomial, data=pheno.prs)
summary(model2)
prs.coef <- summary(model2)$coeff
prs.beta <- as.numeric(prs.coef[1])
prs.se <- as.numeric(prs.coef[2])
prs.p <- as.numeric(prs.coef[4])
# model R2 is obtained as
model.r2 <- NagelkerkeR2(model)
# R2 of PRS is simply calculated as the model R2 minus the null R2
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prs.r2 <- model.r2$R2-null.r2$R2
exp(cbind(coef(model), confint(model)))
prs.result <- rbind(data.frame(R2=prs.r2, P=prs.p, BETA=prs.beta,SE=prs.se))
predprob <- predict(model, type = "response")
## Create ROC and AUC figure
library(pROC)
rocCurve <- roc(EC ~ predprob, data = pheno.prs)
tiff("roccurve.tiff")
plot(rocCurve)
dev.off()
auc(rocCurve)

###--------------------------------------------###
###
CIG USE AND PRS
###
###--------------------------------------------###
ccuse<-fread("G4G_ccuse2.txt", header = F)
# Read in the covariates (here, it is sex)
covariate <- fread("White_G4G_covars_pcs.txt", header=F)
head(covariate)
# make column names for p and c
colnames(ccuse)<- c("IID", "FID", "CC")
head(ccuse)
covariate<-covariate[,c(1:6, 8:14)] # Remove the extra 3 PCs
head(covariate)
colnames(covariate)<- c("IID", "FID", "insure", "gender", "education", "age_range",
"PC1","PC2","PC3","PC4","PC5","PC6","PC7")
head(covariate)
# Now merge the files
ccpheno <- merge(ccuse, covariate, by=c("IID", "FID"))
table(ccpheno$CC, useNA = 'always')
ccphenonomiss<-na.omit(ccpheno)
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# Recode CIGs to 1 and 0, no missing data
ccphenonomiss$CC <-ifelse(ccphenonomiss$CC == 1, 1, 0)
# We can then calculate the null model (model without PRS) using a logistic regression
prs <- fread("SI_CIG_PRScs.profile", header=T)
ccpheno.prs<-merge(ccphenonomiss, prs[,c("IID","FID", "SCORE")], by=c("IID", "FID"))
head(ccpheno.prs)
table(ccpheno.prs$insure)
table(ccpheno.prs$gender)
table(ccpheno.prs$education)
table(ccpheno.prs$age_range)
table(ccpheno.prs$CC)
ccpheno.prs$CC<-factor(ccpheno.prs$CC, levels = c(0:1))
ccpheno.prs$gender<-factor(ccpheno.prs$gender, levels = c(1:2))
table(ccpheno.prs$gender)
ccpheno.prs$insure<-factor(ccpheno.prs$insure, levels =c(1:3))
table(pheno.prs$insure)
ccpheno.prs$education<-factor(ccpheno.prs$education, levels = c(1:4))
table(ccpheno.prs$education)
ccpheno.prs$age_range<-factor(ccpheno.prs$age_range, levels=c(1:7))
table(ccpheno.prs$age_range)
null.model <glm(CC~insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC5+PC6+PC7,
family=binomial, data=ccpheno.prs)
# And the R2 of the null model is
null.r2 <- NagelkerkeR2(null.model)
model <glm(CC~SCORE+insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC5+P
C6+PC7, family=binomial, data=ccpheno.prs)
# model R2 is obtained as
model.r2 <- NagelkerkeR2(model)
# R2 of PRS is simply calculated as the model R2 minus the null R2
prs.r2 <- model.r2$R2-null.r2$R2
# We can also obtain the coeffcient and p-value of association of PRS as follow
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prs.coef <- summary(model)$coeff["scaled",]
prs.beta <- as.numeric(prs.coef[1])
prs.se <- as.numeric(prs.coef[2])
prs.p <- as.numeric(prs.coef[4])
# We can then store the results
prs.result <- rbind(data.frame(R2=prs.r2, P=prs.p, BETA=prs.beta,SE=prs.se))
ccpheno.prs$scaled<-scale(ccpheno.prs$SCORE)
model2 <glm(CC~scaled+insure+gender+education+age_range+PC1+PC2+PC3+PC4+PC5+PC
6+PC7, family=binomial, data=ccpheno.prs)
summary(model2)
prs.coef <- summary(model2)$coeff["scaled",]
prs.beta <- as.numeric(prs.coef[1])
prs.se <- as.numeric(prs.coef[2])
prs.p <- as.numeric(prs.coef[4])
# model R2 is obtained as
model.r2 <- NagelkerkeR2(model)
# R2 of PRS is simply calculated as the model R2 minus the null R2
prs.r2 <- model.r2$R2-null.r2$R2
exp(cbind(coef(model2), confint(model2)))
## Power calcualtion
require(genpwr)
pw<-genpwr.calc(calc="ss", model = "logistic", Case.Rate = 0.066, OR = 1.02,
True.Model = "Additive",
Test.Model = "Additive", Alpha= 0.05, Power = 0.8, MAF =0.1)
pw
pw2<-genpwr.calc(calc="Power", model = "logistic", Case.Rate = 0.066, OR = 1.02,
True.Model = "Additive",
Test.Model = "Additive", Alpha= 0.05, N=15881, MAF =0.1)
pw2
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## CHAPTER 5 - SAS
* Do an import wizard of SPSS data file;
* Do an import wizard of SPSS weights;
proc contents data = weights;
run;
data path3;
merge path3 weights;
by PERSONID;
run;
data path3;
set path3;
use=.;
ec = 0;
cc = 0;
if R03_AV1002_12M = 1 or R03_AV1004 = 1 then ec = 1; * recodes any past 12-month
use into yes/no;
if R03_AC1002_12M = 1 or R03_AC1004 =1 then cc = 1; * recodes any past 12-month
use into yes/no;
if ec = 1 and cc =1 then use = 3;
if ec = 0 and cc = 1 then use = 2;
if ec = 1 and cc = 0 then use = 1;
if ec = 0 and cc = 0 then use = 0;
run;
* NOte for use, 1 = EC user, 2 = CC user, 3 = Dual user, 0 = non-user;
proc format;
value use
1 = 'EC user'
2 = 'CC user'
3 = 'Dual user'
0 = 'Non-user';
run;
proc format;
value single
1 = 'User'
0 = 'Non-user';
run;
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proc freq data = path3;
table R03_AC1002_12M R03_AC1004;
run;
proc freq data = path3;
table R03R_A_AM0030 * use;
format use use.;
run;
proc freq data = path3;
table R03R_A_AM0030*R03_AX0708_02;
run;
proc freq data = path3;
table R03R_A_AM0030*R03_AX0708_01;
run;
proc freq data =path3;
table use ;
format use use. ;
run;
proc freq data= path3;
table R03R_A_AM0030;
run;
proc freq data = path3;
table ec*cc ec2*cc2;
run;
proc freq data = path3;
table use2;
format use2 use.;
run;
proc freq data = path3;
table R03_AV1002_12M * R03_AC1002_12M;
run;
proc freq data = path3;
table R03R_A_SEX R03R_A_AGECAT7 R03R_A_RACECAT3 R03R_A_AM0018;
run;
* create new data set with truncated education, less than hs, hs, some college, college
degree;
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data path4;
set path3;
education = .;
if R03R_A_AM0018 = 1 then education = 1;
if R03R_A_AM0018 = 2 or R03R_A_AM0018 = 3 then education =2;
if R03R_A_AM0018 = 4 then education = 3;
if R03R_A_AM0018 = 5 or R03R_A_AM0018 = 6 then education = 4;
run;
proc format;
value edu
1 = 'less than HS'
2 = 'hs'
3 = 'some college'
4 = 'bs or higher'
;
run;
proc surveyfreq data=path4 varmethod=BRR (fay=0.3);
table use;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;

proc surveyfreq data=path4 varmethod=BRR (fay=0.3);
table cc ec;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format ec single. cc single.;
run;
quit;
proc surveyfreq data=path4 varmethod=BRR (fay=0.3);
table R03R_A_AM0030 R03_AX0708_01 R03_AX0708_02;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
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* Multinomial regression of income and tobacco use;
proc surveylogistic data=path4 varmethod=BRR (fay=0.3);
class use (ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')R03R_A_SEX
(ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;
* Multinomial regression code, note that link = glogit;
* EC coupons;
proc surveylogistic data=path3 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_02 (ref='2 = Not Marked')/ param=ref;
model use = R03R_A_AM0030 R03_AX0708_02/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;

* adjusted for age, sex, race, education;
proc surveylogistic data=path3 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_02 (ref='2 = Not Marked')
R03R_A_SEX (ref = '1 = Male') R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old')
R03R_A_RACECAT3 (ref = '1 = White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03_AX0708_02 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
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run;
quit;
** Moderation model for EC coupons;
proc surveylogistic data=path4 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_02 (ref='2 = Not Marked')
R03R_A_SEX (ref = '1 = Male') R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old')
R03R_A_RACECAT3 (ref = '1 = White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03_AX0708_02 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education R03R_A_AM0030*R03_AX0708_02/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;
** Stratified model for EC coupons;
proc sort data=path4 out=path5;
by R03_AX0708_02;
run;
proc freq data=path5;
table R03_AX0708_02;
run;
proc surveylogistic data=path5 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03R_A_SEX (ref = '1 = Male') R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old')
R03R_A_RACECAT3 (ref = '1 = White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education /link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
domain R03_AX0708_02; * this allows for multiple results from regression, not where or
by;
run;
quit;
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* CC Coupons;
proc surveylogistic data=path3 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_01 (ref='2 = Not Marked')/ param=ref;
model use= R03R_A_AM0030 R03_AX0708_01/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;
proc surveylogistic data=path4 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_01 (ref='2 = Not Marked')
R03R_A_SEX (ref = '1 = Male') R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old')
R03R_A_RACECAT3 (ref = '1 = White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03_AX0708_01 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;
** Moderation CIG coupons;
proc surveylogistic data=path4 varmethod=BRR (fay=0.3);
class use(ref='Non-user') R03R_A_AM0030(ref='5 = $100,000 or more')
R03_AX0708_01 (ref='2 = Not Marked')
R03R_A_SEX (ref = '1 = Male') R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old')
R03R_A_RACECAT3 (ref = '1 = White alone')
education (ref = '4')/ param=ref;
model use = R03R_A_AM0030 R03_AX0708_01 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education R03R_A_AM0030*R03_AX0708_01/link=glogit;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
format use use.;
run;
quit;
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** Logistic regressions;
** EC Coupons;
proc surveylogistic data = path3 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more')/ param=ref;
model ec (event='User') = R03R_A_AM0030/link=logit;
format ec single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
* adjusted analyses;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model ec (event='User') = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education/link=logit;
format ec single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more') R03_AX0708_02 (ref='2 = Not
Marked')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model ec (event='User')= R03R_A_AM0030 R03_AX0708_02 R03R_A_SEX
R03R_A_AGECAT7 R03R_A_RACECAT3 education/link=logit;
format ec single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;

** CC Coupons;
proc surveylogistic data = path3 varmethod=BRR (fay=0.3);
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class R03R_A_AM0030(ref='5 = $100,000 or more')/ param=ref;
model cc (event='User') = R03R_A_AM0030/link=logit;
format cc single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
proc surveylogistic data = path3 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more') R03_AX0708_01 (ref='2 = Not
Marked')/ param=ref;
model cc (event='User')= R03R_A_AM0030 R03_AX0708_01/link=logit;
format cc single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
* adjusted analyses;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more')R03R_A_AM0030(ref='5 =
$100,000 or more')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model cc (event='User') = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education/link=logit;
format cc single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more') R03_AX0708_02 (ref='2 = Not
Marked')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model cc (event='User')= R03R_A_AM0030 R03_AX0708_02 R03R_A_SEX
R03R_A_AGECAT7 R03R_A_RACECAT3 education/link=logit;
format cc single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
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quit;
proc surveyfreq data=path4 varmethod=BRR (fay=0.3);
table R03R_A_SEX R03R_A_AGECAT7 R03R_A_RACECAT3 education;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
* Interaction model;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more') R03_AX0708_02 (ref='2 = Not
Marked')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4')/ param=ref;
model cc (event='User')= R03R_A_AM0030 R03_AX0708_02 R03R_A_SEX
R03R_A_AGECAT7 R03R_A_RACECAT3 education
R03R_A_AM0030*R03_AX0708_02/link=logit;
format cc single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
**** Covariate MODEL;
** CC outcome first, adding EC use as a covariate;
* adjusted analyses;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more')R03R_A_AM0030(ref='5 =
$100,000 or more')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4') ec (ref='1')/ param=ref;
model cc (event='User') = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education ec/link=logit;
format cc single. ec single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
** EC outcome second, adding CC use as a covariate;
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* adjusted analyses;
proc surveylogistic data = path4 varmethod=BRR (fay=0.3);
class R03R_A_AM0030(ref='5 = $100,000 or more')R03R_A_AM0030(ref='5 =
$100,000 or more')R03R_A_SEX (ref = '1 = Male')
R03R_A_AGECAT7 (ref = '1 = 18 to 24 years old') R03R_A_RACECAT3 (ref = '1 =
White alone')
education (ref = '4') cc (ref='User')/ param=ref;
model ec (event='User') = R03R_A_AM0030 R03R_A_SEX R03R_A_AGECAT7
R03R_A_RACECAT3 education cc/link=logit;
format cc single. ec single.;
weight R03_A_SWGT;
repweights R03_A_SWGT1 - R03_A_SWGT100;
run;
quit;
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